data_5lcs_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5lcs _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.496 HG12 ' HG3' ' A' ' 46' ' ' ARG . 41.9 mt . . . . . 0 N--CA 1.465 0.287 0 CA-C-O 121.415 0.626 . . . . 4.46 112.23 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.541 ' O ' HG22 ' A' ' 30' ' ' ILE . 17.0 m-20 -103.37 165.62 10.92 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.128 -0.942 . . . . 3.25 110.069 175.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.425 ' C ' ' H ' ' A' ' 12' ' ' ARG . 25.0 p -83.53 -176.34 6.25 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.843 -0.617 . . . . 2.2000000000000002 110.375 173.167 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.581 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 25.4 t -58.01 1.58 0.05 OUTLIER 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 122.789 0.436 . . . . 1.3 112.081 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.425 ' H ' ' C ' ' A' ' 10' ' ' THR . 8.3 ptt180 -54.56 -35.44 63.26 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 109.86 -0.422 . . . . 4.8099999999999996 109.86 170.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.406 ' O ' HD11 ' A' ' 30' ' ' ILE . 11.1 mp -85.41 97.82 10.22 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 107.278 -1.379 . . . . 3.0499999999999998 107.278 165.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.648 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 19.0 tpt180 -107.41 168.57 9.14 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 112.22 0.452 . . . . 7.7800000000000002 112.22 -164.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.648 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 6.1 t30 72.57 69.63 0.13 Allowed 'General case' 0 CA--C 1.513 -0.48 0 CA-C-N 114.859 -1.064 . . . . 4.9500000000000002 111.219 172.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.726 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -130.45 -47.17 0.14 Allowed Glycine 0 N--CA 1.435 -1.369 0 C-N-CA 119.891 -1.147 . . . . 1.7 111.273 167.146 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.726 HG12 ' O ' ' A' ' 16' ' ' GLY . 15.9 mm -164.86 146.51 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 124.415 1.086 . . . . 1.6299999999999999 108.685 164.162 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -113.92 111.4 21.64 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.32 -0.622 . . . . 1.28 109.32 165.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.463 ' CE1' HG23 ' A' ' 17' ' ' ILE . 44.3 m-85 -94.27 139.91 22.62 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 116.38 -0.373 . . . . 0.84999999999999998 111.17 -176.754 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -84.98 98.52 0.68 Allowed 'Trans proline' 0 N--CA 1.445 -1.356 0 C-N-CA 121.819 1.68 . . . . 0.55000000000000004 109.139 163.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 123.51 -131.13 7.97 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 110.373 -1.091 . . . . 0.58999999999999997 110.373 -166.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 36.4 pt -136.95 156.67 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.532 0.682 . . . . 1.6499999999999999 112.228 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . 0.529 ' SG ' ' HB2' ' A' ' 29' ' ' TRP . 0.2 OUTLIER -81.17 130.59 35.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.876 -1.057 . . . . 1.4399999999999999 110.428 174.73 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.739 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 14.8 ptp180 -119.14 -39.98 2.87 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 119.461 -0.896 . . . . 5.6399999999999997 112.701 176.494 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.739 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 12.9 mmt180 176.43 140.45 0.22 Allowed Pre-proline 0 N--CA 1.482 1.158 0 C-N-CA 123.32 0.648 . . . . 4.3700000000000001 110.557 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.406 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 1.7 Cg_endo -91.24 100.46 0.22 Allowed 'Cis proline' 0 N--CA 1.455 -0.765 0 C-N-CA 123.646 -1.398 . . . . 1.6899999999999999 109.968 -13.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.757 ' HH ' ' HE ' ' A' ' 43' ' ' ARG . 83.7 m-85 -160.84 133.03 5.98 Favored 'General case' 0 CA--C 1.503 -0.834 0 N-CA-C 108.816 -0.809 . . . . 1.1100000000000001 108.816 -174.065 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.519 ' CD1' ' HB3' ' A' ' 46' ' ' ARG . 19.1 p90 -108.3 129.54 55.22 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.003 -0.544 . . . . 1.1499999999999999 109.582 -179.019 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' TRP . . . . . 0.529 ' HB2' ' SG ' ' A' ' 23' ' ' CYS . 90.0 t90 -66.8 112.77 4.43 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.34 -0.845 . . . . 0.57999999999999996 110.746 -178.538 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.581 ' O ' ' HB2' ' A' ' 11' ' ' CYS . 5.3 pt -119.2 93.41 2.53 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 115.021 -0.99 . . . . 1.3200000000000001 108.985 173.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 68.7 177.22 13.52 Favored Glycine 0 C--N 1.316 -0.544 0 C-N-CA 120.821 -0.704 . . . . 0.51000000000000001 112.715 -179.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.471 HG21 ' O ' ' A' ' 38' ' ' GLY . 0.1 OUTLIER -97.71 164.53 12.37 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 122.323 -0.516 . . . . 1.1799999999999999 111.19 -175.99 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 10.5 t -136.26 179.57 6.27 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.355 -0.98 . . . . 1.0700000000000001 108.355 175.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.419 ' ND2' ' HA3' ' A' ' 38' ' ' GLY . 83.9 m-20 53.34 27.65 6.49 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 120.722 0.296 . . . . 1.54 111.106 -175.072 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 2.8 t30 64.54 22.16 12.61 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 123.36 0.664 . . . . 3.2200000000000002 111.586 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 136.3 -36.04 2.05 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 119.911 -1.137 . . . . 1.4399999999999999 114.021 175.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.418 HG13 ' CB ' ' A' ' 34' ' ' ASN . 0.9 OUTLIER -82.57 -23.55 8.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 112.597 0.591 . . . . 1.8700000000000001 112.597 -175.835 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.471 ' O ' HG21 ' A' ' 32' ' ' THR . . . -103.53 -167.93 25.54 Favored Glycine 0 N--CA 1.426 -1.991 0 N-CA-C 110.37 -1.092 . . . . 1.0 110.37 -177.794 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.529 ' HB2' ' SG ' ' A' ' 41' ' ' CYS . 23.6 p -144.77 119.87 10.09 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.478 0.656 . . . . 1.6499999999999999 111.75 -173.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.49 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 41.8 t -74.42 104.2 5.06 Favored 'General case' 0 N--CA 1.442 -0.86 0 N-CA-C 107.073 -1.454 . . . . 0.87 107.073 172.076 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.529 ' SG ' ' HB2' ' A' ' 39' ' ' SER . 14.1 m -139.26 111.16 7.27 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.361 -0.607 . . . . 1.02 109.361 -176.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.545 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -80.7 143.39 33.03 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.871 0.367 . . . . 1.1799999999999999 110.87 -172.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.757 ' HE ' ' HH ' ' A' ' 27' ' ' TYR . 39.7 ttm180 -62.53 114.07 3.33 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.432 -0.804 . . . . 4.46 111.096 -176.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 139.17 -152.56 22.38 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 114.676 -1.147 . . . . 1.54 111.263 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 38.3 t-105 -145.12 130.39 18.6 Favored 'General case' 0 N--CA 1.443 -0.806 0 C-N-CA 119.957 -0.697 . . . . 1.98 112.048 179.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.519 ' HB3' ' CD1' ' A' ' 28' ' ' TYR . 1.9 tpp180 -125.33 117.32 23.49 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 115.092 -0.958 . . . . 4.2199999999999998 110.312 174.093 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.426 ' HB2' HD12 ' A' ' 8' ' ' ILE . 44.4 m . . . . . 0 C--O 1.248 1.014 0 CA-C-N 114.067 -1.424 . . . . 4.0099999999999998 111.704 -176.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 2.2 mp . . . . . 0 N--CA 1.453 -0.277 0 CA-C-O 121.296 0.57 . . . . 4.46 111.259 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -91.37 165.24 13.52 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.295 -0.866 . . . . 3.25 109.464 177.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.425 ' C ' ' H ' ' A' ' 12' ' ' ARG . 6.5 p -89.27 -175.83 4.89 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 116.264 -0.426 . . . . 2.2000000000000002 110.825 176.07 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.453 ' H ' ' HA3' ' A' ' 31' ' ' GLY . 19.0 t -64.41 11.37 0.05 OUTLIER 'General case' 0 N--CA 1.47 0.549 0 CA-C-O 121.317 0.58 . . . . 1.3 112.088 -172.242 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.425 ' H ' ' C ' ' A' ' 10' ' ' THR . 18.3 ptt85 -57.96 -25.69 61.32 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.851 -0.796 . . . . 4.8099999999999996 108.851 161.526 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.6 HD23 ' NH2' ' A' ' 46' ' ' ARG . 5.4 mp -74.71 153.19 38.97 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 115.554 -0.748 . . . . 3.0499999999999998 109.518 169.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.66 98.99 6.41 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 114.611 1.337 . . . . 7.7800000000000002 114.611 -167.156 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 66.5 t30 31.18 61.74 0.24 Allowed 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 124.181 0.992 . . . . 4.9500000000000002 113.335 156.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.667 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -77.24 -43.54 16.01 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 118.811 -1.661 . . . . 1.7 112.824 -172.176 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.667 HG12 ' O ' ' A' ' 16' ' ' GLY . 20.3 mm -163.18 128.33 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 124.896 1.278 . . . . 1.6299999999999999 108.273 165.685 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 8.2 m -94.89 110.54 22.41 Favored 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 120.407 -0.517 . . . . 1.28 110.785 173.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.527 ' CZ ' HG22 ' A' ' 17' ' ' ILE . 43.8 m-85 -102.52 131.68 22.16 Favored Pre-proline 0 CA--C 1.51 -0.59 0 CA-C-N 116.036 -0.529 . . . . 0.84999999999999998 110.82 177.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -74.48 97.8 1.07 Allowed 'Trans proline' 0 N--CA 1.448 -1.165 0 C-N-CA 121.104 1.202 . . . . 0.55000000000000004 109.316 169.03 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.448 ' H ' ' HA2' ' A' ' 38' ' ' GLY . . . 128.92 -122.56 3.96 Favored Glycine 0 N--CA 1.442 -0.927 0 CA-C-N 115.217 -0.901 . . . . 0.58999999999999997 111.204 -169.155 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -146.6 147.15 18.2 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 121.115 0.483 . . . . 1.6499999999999999 111.567 -178.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . 0.452 ' HB3' ' HB2' ' A' ' 27' ' ' TYR . 0.0 OUTLIER -71.65 127.69 33.39 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.367 -0.833 . . . . 1.4399999999999999 110.424 173.759 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.701 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 25.8 ptt180 -116.09 -38.11 3.69 Favored 'General case' 0 C--N 1.322 -0.628 0 C-N-CA 120.14 -0.624 . . . . 5.6399999999999997 111.537 175.555 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.701 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 14.7 mmt180 175.7 143.93 0.23 Allowed Pre-proline 0 N--CA 1.477 0.899 0 C-N-CA 123.361 0.664 . . . . 4.3700000000000001 110.932 177.218 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.416 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 1.2 Cg_endo -93.94 100.4 0.18 OUTLIER 'Cis proline' 0 N--CA 1.457 -0.62 0 C-N-CA 123.878 -1.301 . . . . 1.6899999999999999 110.756 -14.464 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.614 ' CE1' HG13 ' A' ' 17' ' ' ILE . 63.1 m-85 -161.5 139.56 9.29 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.726 -0.842 . . . . 1.1100000000000001 108.726 -175.203 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 42' ' ' ALA . 26.1 p90 -107.85 131.74 54.17 Favored 'General case' 0 C--N 1.312 -1.027 0 C-N-CA 120.306 -0.558 . . . . 1.1499999999999999 110.348 177.689 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 86.9 t90 -67.02 112.58 4.44 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.642 -1.163 . . . . 0.57999999999999996 110.92 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.546 HG12 ' O ' ' A' ' 40' ' ' CYS . 0.6 OUTLIER -120.11 93.62 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 CA-C-O 121.957 0.884 . . . . 1.3200000000000001 109.404 170.398 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.453 ' HA3' ' H ' ' A' ' 11' ' ' CYS . . . 70.75 178.63 26.72 Favored Glycine 0 CA--C 1.523 0.559 0 CA-C-N 115.544 -0.753 . . . . 0.51000000000000001 113.482 -177.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.525 HG22 ' O ' ' A' ' 38' ' ' GLY . 0.0 OUTLIER -97.87 162.9 13.02 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.066 0.46 . . . . 1.1799999999999999 111.137 -177.534 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 15.7 t -135.36 -177.22 4.56 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.374 -0.973 . . . . 1.0700000000000001 108.374 175.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.416 ' ND2' ' HA3' ' A' ' 38' ' ' GLY . 92.5 m-20 59.63 -160.82 0.28 Allowed 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 109.905 -0.406 . . . . 1.54 109.905 -173.138 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -83.21 42.21 0.8 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.113 0.482 . . . . 3.2200000000000002 110.113 174.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 89.72 11.61 63.58 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 121.069 -0.586 . . . . 1.4399999999999999 112.487 -178.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 8.1 pt -120.25 14.09 6.51 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.351 0 CA-C-O 121.219 0.533 . . . . 1.8700000000000001 112.013 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.525 ' O ' HG22 ' A' ' 32' ' ' THR . . . -133.12 170.4 22.21 Favored Glycine 0 N--CA 1.424 -2.109 0 N-CA-C 110.082 -1.207 . . . . 1.0 110.082 178.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 57.2 p -120.51 126.04 49.38 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 121.022 0.439 . . . . 1.6499999999999999 110.584 -177.253 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.546 ' O ' HG12 ' A' ' 30' ' ' ILE . 38.5 t -82.67 91.05 6.91 Favored 'General case' 0 C--O 1.211 -0.967 0 N-CA-C 107.346 -1.353 . . . . 0.87 107.346 175.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.433 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 3.0 m -100.66 -176.52 3.21 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.791 -0.818 . . . . 1.02 108.791 -177.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.598 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -142.32 138.76 31.5 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.909 -0.316 . . . . 1.1799999999999999 110.479 166.018 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.473 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 34.8 ttp180 -59.81 110.4 1.15 Allowed 'General case' 0 C--O 1.234 0.287 0 O-C-N 123.957 0.786 . . . . 4.46 110.876 -178.822 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 138.65 -154.86 23.34 Favored Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 114.909 -1.041 . . . . 1.54 111.215 -177.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 32.5 t-105 -145.25 146.03 31.52 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 121.222 0.534 . . . . 1.98 111.353 177.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.6 ' NH2' HD23 ' A' ' 13' ' ' LEU . 10.5 ttm180 -130.69 127.28 38.54 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.484 -0.78 . . . . 4.2199999999999998 110.523 176.047 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 45.8 m . . . . . 0 C--O 1.25 1.107 0 O-C-N 124.605 1.191 . . . . 4.0099999999999998 111.859 179.161 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 2.5 mp . . . . . 0 N--CA 1.454 -0.231 0 CA-C-O 121.302 0.572 . . . . 4.46 110.26 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -100.1 169.2 9.33 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.329 -0.85 . . . . 3.25 110.295 -174.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.518 ' C ' ' H ' ' A' ' 12' ' ' ARG . 16.9 p -91.03 -176.43 4.62 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.795 -0.639 . . . . 2.2000000000000002 111.106 -177.299 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.598 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 47.7 t -59.56 8.67 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 121.291 0.567 . . . . 1.3 111.797 177.01 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.518 ' H ' ' C ' ' A' ' 10' ' ' THR . 0.0 OUTLIER -53.28 -38.42 63.06 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.555 -0.535 . . . . 4.8099999999999996 109.555 167.84 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.466 HD12 ' HG3' ' A' ' 12' ' ' ARG . 8.6 mp -77.22 126.08 30.37 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 109.07 -0.715 . . . . 3.0499999999999998 109.07 172.075 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.598 ' HD3' ' SG ' ' A' ' 11' ' ' CYS . 17.3 mmm180 -134.31 171.75 13.83 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 113.077 0.769 . . . . 7.7800000000000002 113.077 -171.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 64.42 20.1 12.04 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 114.357 -1.292 . . . . 4.9500000000000002 110.849 -177.217 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.739 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -85.85 -51.59 3.56 Favored Glycine 0 N--CA 1.438 -1.201 0 C-N-CA 118.824 -1.655 . . . . 1.7 111.377 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.739 HG12 ' O ' ' A' ' 16' ' ' GLY . 25.5 mm -168.4 143.71 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 C-N-CA 125.903 1.681 . . . . 1.6299999999999999 107.824 157.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.6 m -109.46 99.62 8.81 Favored 'General case' 0 C--N 1.321 -0.669 0 O-C-N 121.774 -0.579 . . . . 1.28 110.084 166.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.483 ' HD1' ' SG ' ' A' ' 41' ' ' CYS . 44.8 m-85 -88.19 135.02 33.63 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.72 -0.673 . . . . 0.84999999999999998 110.938 -178.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.626 ' HB3' HD22 ' A' ' 34' ' ' ASN . 96.7 Cg_endo -88.16 97.85 0.41 Allowed 'Trans proline' 0 N--CA 1.442 -1.558 0 C-N-CA 121.452 1.435 . . . . 0.55000000000000004 109.729 164.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.55 -115.07 1.3 Allowed Glycine 0 N--CA 1.444 -0.819 0 N-CA-C 110.666 -0.973 . . . . 0.58999999999999997 110.666 -170.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 22.2 pt -146.26 152.16 13.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-O 121.277 0.56 . . . . 1.6499999999999999 111.94 179.262 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -86.27 142.52 28.49 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.219 -0.901 . . . . 1.4399999999999999 108.735 170.391 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.9 ptt180 -131.98 -39.21 1.08 Allowed 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 119.542 -0.863 . . . . 5.6399999999999997 112.251 173.218 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 4.8 mtt85 174.24 145.17 0.2 Allowed Pre-proline 0 N--CA 1.474 0.745 0 N-CA-C 112.033 0.383 . . . . 4.3700000000000001 112.033 173.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -88.41 99.47 0.22 Allowed 'Cis proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.996 -1.669 . . . . 1.6899999999999999 110.851 -9.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.601 ' CE1' HG13 ' A' ' 17' ' ' ILE . 68.7 m-85 -162.21 135.66 6.23 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.339 -0.986 . . . . 1.1100000000000001 108.339 -176.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -108.42 129.76 55.25 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.973 -0.691 . . . . 1.1499999999999999 110.194 176.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 85.4 t90 -66.81 113.45 4.9 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.684 -1.144 . . . . 0.57999999999999996 111.193 -177.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.587 ' O ' ' HB3' ' A' ' 40' ' ' CYS . 10.9 pt -121.62 92.4 2.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-N 115.548 -0.751 . . . . 1.3200000000000001 109.559 172.752 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 66.9 -171.61 30.83 Favored Glycine 0 CA--C 1.527 0.819 0 C-N-CA 121.281 -0.485 . . . . 0.51000000000000001 113.159 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.6 p -107.66 168.54 9.18 Favored 'General case' 0 CA--C 1.533 0.299 0 O-C-N 122.381 -0.482 . . . . 1.1799999999999999 111.503 -177.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.576 ' O ' ' HA3' ' A' ' 38' ' ' GLY . 42.7 t -160.38 105.31 1.47 Allowed 'General case' 0 C--N 1.334 -0.098 0 N-CA-C 110.277 -0.268 . . . . 1.0700000000000001 110.277 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.626 HD22 ' HB3' ' A' ' 20' ' ' PRO . 13.6 m-20 163.67 39.58 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.586 1.554 . . . . 1.54 109.845 176.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 57.12 37.82 28.72 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.104 -0.498 . . . . 3.2200000000000002 111.283 -175.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 136.19 -64.93 0.57 Allowed Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 111.442 -0.663 . . . . 1.4399999999999999 111.442 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.479 HG13 ' HB3' ' A' ' 34' ' ' ASN . 2.7 pt -80.27 -162.09 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.677 -0.261 . . . . 1.8700000000000001 110.339 174.533 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.576 ' HA3' ' O ' ' A' ' 33' ' ' CYS . . . 85.49 179.4 50.5 Favored Glycine 0 N--CA 1.422 -2.249 0 C-N-CA 120.497 -0.859 . . . . 1.0 111.538 177.265 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.9 m -141.25 111.9 7.04 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.015 -0.593 . . . . 1.6499999999999999 109.532 -178.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.587 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 47.2 t -79.02 111.57 15.36 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 107.26 -1.385 . . . . 0.87 107.26 175.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.483 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 2.2 m -129.2 156.5 43.85 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.815 -0.809 . . . . 1.02 108.815 -176.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.583 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -118.29 130.62 56.14 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 119.817 -0.753 . . . . 1.1799999999999999 110.301 174.008 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.503 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 1.5 tmt_? -55.12 109.86 0.59 Allowed 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 115.275 -0.875 . . . . 4.46 110.521 -177.561 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 137.4 -162.78 25.43 Favored Glycine 0 N--CA 1.442 -0.959 0 CA-C-N 115.256 -0.884 . . . . 1.54 111.85 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 31.0 t-105 -141.59 118.51 11.18 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.033 0.445 . . . . 1.98 110.597 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 12.9 ttm180 -96.68 139.55 32.58 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.032 -0.531 . . . . 4.2199999999999998 111.565 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.3 t . . . . . 0 C--O 1.247 0.943 0 CA-C-N 114.477 -1.238 . . . . 4.0099999999999998 110.976 -179.375 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.454 ' HA ' ' CD ' ' A' ' 46' ' ' ARG . 81.3 mt . . . . . 0 N--CA 1.45 -0.451 0 CA-C-O 121.524 0.678 . . . . 4.46 111.322 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.442 ' O ' HG23 ' A' ' 30' ' ' ILE . 71.4 m-20 -81.75 165.3 21.06 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 114.843 -1.071 . . . . 3.25 111.026 -176.243 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.488 ' C ' ' H ' ' A' ' 12' ' ' ARG . 21.4 p -79.56 -175.49 4.81 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 114.949 -1.023 . . . . 2.2000000000000002 110.906 173.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.413 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 19.4 t -57.12 4.52 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 123.595 0.758 . . . . 1.3 112.617 -179.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.488 ' H ' ' C ' ' A' ' 10' ' ' THR . 34.1 ptt180 -61.27 -29.91 70.14 Favored 'General case' 0 CA--C 1.531 0.239 0 O-C-N 122.018 -0.426 . . . . 4.8099999999999996 110.86 174.08 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -88.56 97.86 11.33 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 107.319 -1.363 . . . . 3.0499999999999998 107.319 167.041 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.665 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 12.7 tpp85 -101.43 163.97 12.0 Favored 'General case' 0 N--CA 1.428 -1.538 0 N-CA-C 113.349 0.87 . . . . 7.7800000000000002 113.349 -161.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.665 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 92.9 m-20 70.34 69.61 0.21 Allowed 'General case' 0 CA--C 1.514 -0.432 0 CA-C-N 114.421 -1.263 . . . . 4.9500000000000002 112.321 168.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.665 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -125.27 -46.79 0.23 Allowed Glycine 0 N--CA 1.439 -1.154 0 C-N-CA 119.385 -1.388 . . . . 1.7 111.576 169.095 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.665 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.1 mt -168.86 131.53 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 124.523 1.129 . . . . 1.6299999999999999 109.648 156.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 1.8 m -94.04 113.09 25.0 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.908 0.385 . . . . 1.28 110.213 170.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.594 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 64.7 m-85 -95.49 140.68 22.47 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.343 -0.389 . . . . 0.84999999999999998 110.077 178.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.513 ' HA ' ' ND2' ' A' ' 34' ' ' ASN . 74.9 Cg_endo -86.71 96.39 0.5 Allowed 'Trans proline' 0 N--CA 1.443 -1.49 0 C-N-CA 121.356 1.37 . . . . 0.55000000000000004 109.787 167.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.56 -109.2 0.89 Allowed Glycine 0 N--CA 1.441 -0.968 0 CA-C-N 115.339 -0.846 . . . . 0.58999999999999997 111.523 -171.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.9 pt -146.17 145.47 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 112.386 0.513 . . . . 1.6499999999999999 112.386 -176.309 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.89 126.7 32.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.609 -0.723 . . . . 1.4399999999999999 109.195 172.634 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 37.4 ptt180 -115.98 -40.04 3.37 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 118.619 -1.232 . . . . 5.6399999999999997 112.521 176.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 172.75 152.53 0.23 Allowed Pre-proline 0 N--CA 1.473 0.691 0 CA-C-N 118.112 0.414 . . . . 4.3700000000000001 111.642 172.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -87.15 100.91 0.27 Allowed 'Cis proline' 0 C--N 1.347 0.45 0 C-N-CA 123.216 -1.577 . . . . 1.6899999999999999 110.797 -12.418 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.559 ' CE1' HD12 ' A' ' 17' ' ' ILE . 89.1 m-85 -160.88 141.92 11.72 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 108.178 -1.045 . . . . 1.1100000000000001 108.178 -175.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 7.6 p90 -107.76 128.96 55.04 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 120.437 -0.505 . . . . 1.1499999999999999 109.641 177.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 92.1 t90 -66.71 113.83 5.14 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.988 -1.005 . . . . 0.57999999999999996 110.365 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.553 ' O ' ' HB3' ' A' ' 40' ' ' CYS . 11.2 pt -120.15 93.25 2.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-N 115.271 -0.877 . . . . 1.3200000000000001 109.318 175.171 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 62.31 -172.96 8.87 Favored Glycine 0 CA--C 1.526 0.736 0 C-N-CA 121.047 -0.597 . . . . 0.51000000000000001 112.93 -176.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.4 p -102.1 165.53 11.11 Favored 'General case' 0 C--N 1.324 -0.523 0 O-C-N 122.173 -0.604 . . . . 1.1799999999999999 111.631 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 20.6 t -137.5 -178.18 5.12 Favored 'General case' 0 C--O 1.216 -0.696 0 N-CA-C 108.334 -0.988 . . . . 1.0700000000000001 108.334 178.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.513 ' ND2' ' HA ' ' A' ' 20' ' ' PRO . 87.7 m-20 67.12 1.42 2.37 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 118.28 0.491 . . . . 1.54 111.753 -177.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 49.8 m-80 65.94 85.46 0.14 Allowed 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.611 0.764 . . . . 3.2200000000000002 111.846 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 110.76 -62.46 0.29 Allowed Glycine 0 CA--C 1.511 -0.174 0 N-CA-C 111.709 -0.556 . . . . 1.4399999999999999 111.709 175.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.427 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 0.2 OUTLIER -88.76 -142.43 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.753 -0.832 . . . . 1.8700000000000001 108.753 173.424 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.427 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 60.4 175.29 1.19 Allowed Glycine 0 N--CA 1.447 -0.602 0 CA-C-O 122.009 0.783 . . . . 1.0 114.485 169.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.594 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 87.6 p -142.32 119.89 11.75 Favored 'General case' 0 N--CA 1.433 -1.278 0 N-CA-C 109.599 -0.519 . . . . 1.6499999999999999 109.599 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.553 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 46.0 t -82.63 116.8 22.18 Favored 'General case' 0 C--N 1.313 -1.018 0 N-CA-C 107.127 -1.435 . . . . 0.87 107.127 174.218 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.584 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -133.67 169.03 17.62 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 108.31 -0.996 . . . . 1.02 108.31 -178.322 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.618 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -136.73 142.14 43.05 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.669 -0.812 . . . . 1.1799999999999999 110.744 172.089 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.465 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 57.0 ttp180 -61.42 116.65 4.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 114.973 -1.012 . . . . 4.46 110.909 -176.222 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 134.24 -149.84 19.88 Favored Glycine 0 CA--C 1.497 -1.044 0 CA-C-N 115.162 -0.926 . . . . 1.54 111.658 176.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 31.4 t-105 -152.7 123.88 7.58 Favored 'General case' 0 C--N 1.317 -0.843 0 C-N-CA 120.581 -0.448 . . . . 1.98 111.189 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.454 ' CD ' ' HA ' ' A' ' 8' ' ' ILE . 21.2 ttm180 -104.79 139.91 38.88 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.912 -0.585 . . . . 4.2199999999999998 110.23 169.753 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.7 t . . . . . 0 C--O 1.253 1.243 0 O-C-N 124.289 0.993 . . . . 4.0099999999999998 110.538 -179.684 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.588 ' HA ' ' HD3' ' A' ' 46' ' ' ARG . 3.5 mp . . . . . 0 C--O 1.235 0.297 0 CA-C-O 121.194 0.521 . . . . 4.46 111.465 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -89.04 164.02 15.25 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 108.943 -0.762 . . . . 3.25 108.943 170.021 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.495 ' C ' ' H ' ' A' ' 12' ' ' ARG . 38.4 p -72.75 -175.8 1.81 Allowed 'General case' 0 C--N 1.314 -0.965 0 CA-C-N 116.504 -0.317 . . . . 2.2000000000000002 110.867 176.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.417 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 11.4 t -57.51 6.23 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 123.36 0.664 . . . . 1.3 112.054 178.816 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.495 ' H ' ' C ' ' A' ' 10' ' ' THR . 38.4 ptt180 -65.89 -33.2 75.3 Favored 'General case' 0 C--N 1.33 -0.268 0 O-C-N 122.107 -0.371 . . . . 4.8099999999999996 110.939 172.484 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -97.11 97.48 9.24 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 108.472 -0.936 . . . . 3.0499999999999998 108.472 172.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.709 ' HD3' ' SG ' ' A' ' 40' ' ' CYS . 2.7 mmm-85 -110.24 -170.71 1.7 Allowed 'General case' 0 N--CA 1.438 -1.028 0 N-CA-C 113.338 0.866 . . . . 7.7800000000000002 113.338 -166.463 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.9 m-80 69.02 53.45 0.47 Allowed 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 114.678 -1.146 . . . . 4.9500000000000002 111.154 -178.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.723 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -120.46 -50.02 0.28 Allowed Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 119.445 -1.36 . . . . 1.7 112.119 172.113 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.723 HG12 ' O ' ' A' ' 16' ' ' GLY . 25.1 mm -166.65 147.02 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 C-N-CA 125.337 1.455 . . . . 1.6299999999999999 108.149 161.112 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 31.5 t -111.12 104.03 12.52 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 121.654 -0.654 . . . . 1.28 109.426 168.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.563 ' CE1' HG23 ' A' ' 17' ' ' ILE . 17.0 m-85 -93.17 124.13 58.84 Favored Pre-proline 0 C--N 1.329 -0.287 0 N-CA-C 112.404 0.52 . . . . 0.84999999999999998 112.404 -175.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -82.23 97.4 0.9 Allowed 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 121.833 1.689 . . . . 0.55000000000000004 109.473 165.339 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.64 -134.0 7.12 Favored Glycine 0 N--CA 1.443 -0.84 0 N-CA-C 110.884 -0.886 . . . . 0.58999999999999997 110.884 -170.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 23.7 pt -129.17 147.8 33.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.285 0.564 . . . . 1.6499999999999999 112.006 -178.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 93.9 m -94.77 139.62 31.02 Favored 'General case' 0 N--CA 1.437 -1.094 0 CA-C-N 115.488 -0.778 . . . . 1.4399999999999999 109.797 173.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.485 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 7.1 ptt180 -143.56 -37.1 0.35 Allowed 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 118.904 -0.569 . . . . 5.6399999999999997 112.532 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.485 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 10.8 mtt180 175.54 145.68 0.24 Allowed Pre-proline 0 N--CA 1.476 0.827 0 N-CA-C 112.067 0.395 . . . . 4.3700000000000001 112.067 170.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -88.74 99.25 0.2 Allowed 'Cis proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.839 -1.734 . . . . 1.6899999999999999 110.611 -10.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.45 ' CE1' HG13 ' A' ' 17' ' ' ILE . 96.2 m-85 -161.55 138.51 8.55 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 108.919 -0.771 . . . . 1.1100000000000001 108.919 -175.405 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.506 ' CZ ' ' HB2' ' A' ' 42' ' ' ALA . 35.8 p90 -113.09 127.93 56.35 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 109.245 -0.65 . . . . 1.1499999999999999 109.245 178.001 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' TRP . . . . . 0.564 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 90.1 t90 -73.74 117.0 14.99 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.625 -0.716 . . . . 0.57999999999999996 110.971 -175.419 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.447 HG13 ' O ' ' A' ' 30' ' ' ILE . 26.6 pt -121.35 95.03 3.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 121.524 0.678 . . . . 1.3200000000000001 110.259 176.309 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 63.39 -170.97 14.86 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 121.12 -0.562 . . . . 0.51000000000000001 113.041 -178.147 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 23.2 p -108.96 148.19 31.1 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 112.928 0.714 . . . . 1.1799999999999999 112.928 -173.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.477 ' O ' ' HA3' ' A' ' 38' ' ' GLY . 18.4 t -116.74 -175.83 2.85 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.583 -1.266 . . . . 1.0700000000000001 107.583 174.308 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.428 ' HB2' ' HA3' ' A' ' 38' ' ' GLY . 84.0 m-20 64.62 -97.44 0.06 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 118.315 0.507 . . . . 1.54 111.266 179.738 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 52.0 t30 -177.05 85.77 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.762 0.315 . . . . 3.2200000000000002 110.868 -178.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 94.09 -57.42 2.11 Favored Glycine 0 CA--C 1.503 -0.695 0 N-CA-C 110.122 -1.191 . . . . 1.4399999999999999 110.122 178.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.416 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 0.8 OUTLIER -78.51 -148.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 108.063 -1.088 . . . . 1.8700000000000001 108.063 164.997 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.477 ' HA3' ' O ' ' A' ' 33' ' ' CYS . . . 76.97 111.42 0.14 Allowed Glycine 0 N--CA 1.441 -0.976 0 C-N-CA 120.245 -0.979 . . . . 1.0 113.02 173.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.5 m -90.49 99.34 12.38 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 121.162 0.506 . . . . 1.6499999999999999 109.899 176.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.709 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 40.3 t -76.05 103.35 6.06 Favored 'General case' 0 C--O 1.218 -0.597 0 N-CA-C 107.65 -1.241 . . . . 0.87 107.65 173.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.564 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 24.3 m -128.93 178.11 6.62 Favored 'General case' 0 C--N 1.311 -1.085 0 C-N-CA 120.634 -0.426 . . . . 1.02 110.473 -178.087 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.532 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -134.19 139.89 46.14 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 116.207 -0.451 . . . . 1.1799999999999999 109.983 173.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.439 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 70.9 ttt180 -62.22 111.61 2.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.659 -0.701 . . . . 4.46 111.633 -174.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.95 -153.01 20.72 Favored Glycine 0 N--CA 1.443 -0.844 0 CA-C-N 115.188 -0.915 . . . . 1.54 112.36 178.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 28.4 t-105 -144.75 118.6 9.3 Favored 'General case' 0 N--CA 1.441 -0.916 0 CA-C-O 121.143 0.497 . . . . 1.98 110.483 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.588 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 1.0 OUTLIER -89.9 127.23 35.97 Favored 'General case' 0 N--CA 1.44 -0.945 0 CA-C-N 115.592 -0.731 . . . . 4.2199999999999998 110.087 176.27 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 19.9 m . . . . . 0 C--O 1.252 1.196 0 O-C-N 123.865 0.728 . . . . 4.0099999999999998 110.846 -179.271 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.41 ' HA ' ' HG2' ' A' ' 46' ' ' ARG . 2.6 mp . . . . . 0 N--CA 1.456 -0.172 0 CA-C-O 120.708 0.29 . . . . 4.46 110.674 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -110.02 164.72 12.35 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.113 0.482 . . . . 3.25 110.001 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.452 ' C ' ' H ' ' A' ' 12' ' ' ARG . 70.7 p -89.18 -175.35 4.76 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.508 -0.769 . . . . 2.2000000000000002 109.852 171.682 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.517 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 31.2 t -55.5 -1.06 0.03 OUTLIER 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.877 0.471 . . . . 1.3 112.079 178.263 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.452 ' H ' ' C ' ' A' ' 10' ' ' THR . 9.3 ptm180 -52.52 -40.52 62.54 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 122.676 0.39 . . . . 4.8099999999999996 111.615 175.011 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 10.6 mp -87.31 96.04 10.21 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 107.838 -1.171 . . . . 3.0499999999999998 107.838 170.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.718 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 8.1 tpt180 -99.97 172.11 7.42 Favored 'General case' 0 N--CA 1.431 -1.42 0 CA-C-N 116.032 -0.531 . . . . 7.7800000000000002 111.98 -165.238 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.718 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 34.0 t-20 71.18 57.5 0.2 Allowed 'General case' 0 CA--C 1.514 -0.409 0 CA-C-N 114.973 -1.012 . . . . 4.9500000000000002 110.417 170.409 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.634 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -117.04 -48.27 0.45 Allowed Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 119.389 -1.386 . . . . 1.7 111.244 171.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.634 HG13 ' O ' ' A' ' 16' ' ' GLY . 2.3 mt -170.02 133.67 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 124.571 1.149 . . . . 1.6299999999999999 109.564 154.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 11.4 m -96.8 112.36 24.14 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 120.897 -0.321 . . . . 1.28 110.19 170.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.571 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 43.3 m-85 -95.68 126.34 45.69 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.495 -0.32 . . . . 0.84999999999999998 110.24 177.068 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -80.65 96.96 1.0 Allowed 'Trans proline' 0 N--CA 1.445 -1.335 0 C-N-CA 121.027 1.151 . . . . 0.55000000000000004 109.133 166.174 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.5 -113.08 1.06 Allowed Glycine 0 N--CA 1.448 -0.527 0 N-CA-C 111.266 -0.734 . . . . 0.58999999999999997 111.266 -170.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.7 pt -142.79 156.43 18.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-O 121.062 0.458 . . . . 1.6499999999999999 111.87 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . 0.458 ' HB3' ' HB2' ' A' ' 27' ' ' TYR . 5.8 m -107.04 132.08 53.36 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 108.679 -0.86 . . . . 1.4399999999999999 108.679 172.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 10.6 ptm180 -118.12 -41.1 2.9 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 118.976 -1.09 . . . . 5.6399999999999997 111.315 175.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.512 ' HA ' ' H ' ' A' ' 27' ' ' TYR . 0.0 OUTLIER 173.78 158.61 0.31 Allowed Pre-proline 0 CA--C 1.533 0.303 0 C-N-CA 122.644 0.377 . . . . 4.3700000000000001 111.44 168.449 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.442 ' HA ' ' HB2' ' A' ' 25' ' ' ARG . 2.5 Cg_endo -86.8 99.07 0.22 Allowed 'Cis proline' 0 N--CA 1.458 -0.594 0 C-N-CA 122.652 -1.811 . . . . 1.6899999999999999 110.681 -6.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.512 ' H ' ' HA ' ' A' ' 25' ' ' ARG . 64.2 m-85 -162.9 134.75 5.19 Favored 'General case' 0 CA--C 1.504 -0.79 0 N-CA-C 108.116 -1.068 . . . . 1.1100000000000001 108.116 -175.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 13.0 p90 -108.68 128.33 54.76 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 120.289 -0.564 . . . . 1.1499999999999999 109.769 177.17 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' TRP . . . . . 0.71 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 89.2 t90 -65.0 114.73 4.77 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.053 -0.976 . . . . 0.57999999999999996 110.877 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.517 ' O ' ' HB2' ' A' ' 11' ' ' CYS . 20.7 pt -122.15 95.88 3.75 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.048 -0.978 . . . . 1.3200000000000001 109.783 173.658 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 62.84 -161.22 32.77 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 120.991 -0.623 . . . . 0.51000000000000001 113.089 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 19.7 p -117.17 170.1 8.94 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 112.842 0.682 . . . . 1.1799999999999999 112.842 -175.01 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 19.7 t -143.59 -174.98 4.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.875 -1.057 . . . . 1.0700000000000001 108.839 -175.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.449 ' O ' ' HB2' ' A' ' 35' ' ' ASN . 75.1 m-20 68.68 -85.02 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 122.692 0.397 . . . . 1.54 110.763 -178.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.449 ' HB2' ' O ' ' A' ' 34' ' ' ASN . 21.8 t-20 169.24 78.55 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.285 0 C-N-CA 123.799 0.84 . . . . 3.2200000000000002 109.212 -179.591 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 105.41 -56.47 0.53 Allowed Glycine 0 N--CA 1.453 -0.221 0 N-CA-C 111.123 -0.791 . . . . 1.4399999999999999 111.123 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.443 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 0.4 OUTLIER -84.41 -137.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.885 -0.783 . . . . 1.8700000000000001 108.885 170.503 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.443 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 67.07 115.99 0.02 OUTLIER Glycine 0 C--N 1.339 0.732 0 C-N-CA 120.881 -0.676 . . . . 1.0 114.045 175.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.571 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 77.5 p -93.64 98.91 11.46 Favored 'General case' 0 N--CA 1.434 -1.241 0 N-CA-C 109.006 -0.739 . . . . 1.6499999999999999 109.006 173.294 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 44.5 t -69.91 108.41 3.99 Favored 'General case' 0 CA--C 1.507 -0.707 0 N-CA-C 107.97 -1.122 . . . . 0.87 107.97 176.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.71 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 80.2 m -130.44 173.88 10.41 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 109.297 -0.631 . . . . 1.02 109.297 179.036 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.573 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -135.58 142.74 45.36 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 120.381 -0.528 . . . . 1.1799999999999999 110.264 172.217 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.446 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 74.4 ttt180 -62.37 112.19 2.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.259 -0.882 . . . . 4.46 111.484 -173.615 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.88 -151.71 21.06 Favored Glycine 0 N--CA 1.446 -0.649 0 CA-C-N 114.712 -1.131 . . . . 1.54 111.797 -179.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 32.8 t-105 -149.43 119.86 7.39 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.045 0.45 . . . . 1.98 111.004 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.41 ' HG2' ' HA ' ' A' ' 8' ' ' ILE . 0.3 OUTLIER -77.19 138.83 39.69 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.782 -0.645 . . . . 4.2199999999999998 110.015 175.55 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 31.1 p . . . . . 0 C--O 1.251 1.14 0 O-C-N 124.314 1.009 . . . . 4.0099999999999998 111.594 -178.267 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.523 ' HA ' ' HD2' ' A' ' 46' ' ' ARG . 2.6 mp . . . . . 0 N--CA 1.453 -0.309 0 CA-C-O 121.035 0.445 . . . . 4.46 111.02 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.479 ' O ' HG23 ' A' ' 30' ' ' ILE . 65.9 m-20 -98.8 165.93 11.55 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.443 -0.798 . . . . 3.25 109.777 176.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.428 ' C ' ' H ' ' A' ' 12' ' ' ARG . 26.9 p -79.6 -175.68 4.93 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.117 -0.492 . . . . 2.2000000000000002 111.071 175.332 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.406 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 12.5 t -55.74 -0.85 0.04 OUTLIER 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 123.68 0.792 . . . . 1.3 112.209 179.552 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.428 ' H ' ' C ' ' A' ' 10' ' ' THR . 12.9 ptm180 -54.74 -41.84 70.87 Favored 'General case' 0 C--O 1.234 0.237 0 C-N-CA 122.812 0.445 . . . . 4.8099999999999996 111.446 173.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -86.29 96.41 9.95 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 106.991 -1.485 . . . . 3.0499999999999998 106.991 171.338 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.71 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 18.2 tpp85 -100.31 157.44 16.61 Favored 'General case' 0 N--CA 1.429 -1.507 0 N-CA-C 114.041 1.126 . . . . 7.7800000000000002 114.041 -157.45 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.71 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 64.7 t30 70.04 69.67 0.22 Allowed 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 113.822 -1.535 . . . . 4.9500000000000002 112.348 164.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.667 ' HA3' ' HA ' ' A' ' 42' ' ' ALA . . . -108.01 -43.82 1.26 Allowed Glycine 0 N--CA 1.432 -1.63 0 N-CA-C 109.659 -1.376 . . . . 1.7 109.659 165.055 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.613 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.1 mt -165.89 132.87 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.349 1.06 . . . . 1.6299999999999999 109.258 157.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 21.5 t -91.88 109.3 20.64 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.109 -0.33 . . . . 1.28 110.109 175.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.412 ' CD1' ' SG ' ' A' ' 23' ' ' CYS . 15.4 m-85 -96.13 122.39 58.19 Favored Pre-proline 0 CA--C 1.516 -0.346 0 N-CA-C 112.125 0.417 . . . . 0.84999999999999998 112.125 -177.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -81.92 96.47 0.91 Allowed 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 121.513 1.475 . . . . 0.55000000000000004 109.816 167.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 136.26 -119.87 2.09 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 111.067 -0.813 . . . . 0.58999999999999997 111.067 -171.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.8 pt -138.14 154.4 28.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 117.131 0.466 . . . . 1.6499999999999999 111.735 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . 0.412 ' SG ' ' CD1' ' A' ' 19' ' ' PHE . 69.0 m -101.43 139.85 36.53 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 115.622 -0.717 . . . . 1.4399999999999999 109.813 173.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.736 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 13.6 ptm180 -135.5 -39.42 0.73 Allowed 'General case' 0 C--N 1.321 -0.646 0 C-N-CA 119.733 -0.787 . . . . 5.6399999999999997 112.612 179.028 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.736 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 12.0 mmt180 176.88 140.17 0.23 Allowed Pre-proline 0 N--CA 1.476 0.86 0 C-N-CA 123.104 0.561 . . . . 4.3700000000000001 110.827 178.245 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -90.42 99.94 0.21 Allowed 'Cis proline' 0 N--CA 1.456 -0.681 0 C-N-CA 123.44 -1.483 . . . . 1.6899999999999999 110.371 -13.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.482 ' CD1' ' HA ' ' A' ' 43' ' ' ARG . 96.7 m-85 -161.01 131.4 5.15 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 108.829 -0.804 . . . . 1.1100000000000001 108.829 -176.535 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -109.2 127.51 54.28 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 109.081 -0.711 . . . . 1.1499999999999999 109.081 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' TRP . . . . . 0.594 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 86.6 t90 -70.56 117.18 11.76 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.067 -0.969 . . . . 0.57999999999999996 110.985 -175.19 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.479 HG23 ' O ' ' A' ' 9' ' ' ASP . 16.2 pt -120.75 95.6 3.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.328 -0.851 . . . . 1.3200000000000001 110.019 176.213 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 61.12 -164.64 17.9 Favored Glycine 0 CA--C 1.524 0.65 0 C-N-CA 121.284 -0.484 . . . . 0.51000000000000001 113.24 -179.574 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.2 p -111.57 151.98 28.1 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 113.073 0.768 . . . . 1.1799999999999999 113.073 -175.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 49.9 t -122.17 -177.07 3.5 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 107.154 -1.425 . . . . 1.0700000000000001 107.154 175.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 58.54 -161.44 0.25 Allowed 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 118.866 0.757 . . . . 1.54 110.506 -178.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 92.0 m-20 -109.49 78.16 1.11 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.793 0.33 . . . . 3.2200000000000002 111.104 -179.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 108.69 -52.18 0.66 Allowed Glycine 0 CA--C 1.509 -0.31 0 N-CA-C 111.149 -0.78 . . . . 1.4399999999999999 111.149 176.035 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.407 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 8.6 pt -77.46 -143.14 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 114.849 -0.676 . . . . 1.8700000000000001 109.474 170.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.407 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 76.04 103.58 0.13 Allowed Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.442 -0.885 . . . . 1.0 113.031 168.399 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 38.2 m -84.04 98.71 10.0 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.898 -0.779 . . . . 1.6499999999999999 108.898 172.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 42.7 t -72.65 106.08 4.53 Favored 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 107.884 -1.154 . . . . 0.87 107.884 175.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.594 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 37.0 m -126.9 174.56 8.72 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 121.12 0.486 . . . . 1.02 109.771 178.191 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.667 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -130.17 139.47 50.85 Favored 'General case' 0 N--CA 1.432 -1.332 0 C-N-CA 120.132 -0.627 . . . . 1.1799999999999999 109.849 172.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.482 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 61.3 ttp180 -61.34 110.96 1.57 Allowed 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.567 -0.742 . . . . 4.46 111.29 -173.349 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 135.76 -158.93 24.04 Favored Glycine 0 N--CA 1.437 -1.237 0 CA-C-N 114.771 -1.104 . . . . 1.54 111.952 -178.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.429 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 28.7 t-105 -143.71 116.98 9.0 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.867 -0.419 . . . . 1.98 109.867 -179.13 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.523 ' HD2' ' HA ' ' A' ' 8' ' ' ILE . 12.5 ttm180 -88.63 136.99 32.72 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.458 -0.337 . . . . 4.2199999999999998 110.265 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.1 t . . . . . 0 C--O 1.249 1.065 0 O-C-N 123.948 0.78 . . . . 4.0099999999999998 110.042 -177.663 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.463 ' HA ' ' CD ' ' A' ' 46' ' ' ARG . 56.8 mt . . . . . 0 N--CA 1.451 -0.399 0 CA-C-O 121.292 0.568 . . . . 4.46 111.678 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 57.4 m-20 -84.3 163.28 19.71 Favored 'General case' 0 CA--C 1.513 -0.461 0 CA-C-N 115.462 -0.79 . . . . 3.25 109.503 177.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.464 ' C ' ' H ' ' A' ' 12' ' ' ARG . 11.2 p -84.01 -175.69 5.92 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.626 -0.715 . . . . 2.2000000000000002 110.593 176.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.426 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 37.0 t -56.05 1.62 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 122.878 0.471 . . . . 1.3 112.153 178.468 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.464 ' H ' ' C ' ' A' ' 10' ' ' THR . 14.5 ptt180 -55.79 -34.97 65.77 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 120.577 0.227 . . . . 4.8099999999999996 110.842 171.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -89.78 97.53 11.25 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 107.797 -1.186 . . . . 3.0499999999999998 107.797 168.324 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.759 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 8.3 tpt180 -109.71 171.59 7.36 Favored 'General case' 0 N--CA 1.433 -1.306 0 CA-C-O 120.971 0.415 . . . . 7.7800000000000002 112.007 -166.501 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.759 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 92.1 m-20 72.04 51.92 0.21 Allowed 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 115.215 -0.902 . . . . 4.9500000000000002 111.052 173.525 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.651 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -109.17 -47.75 0.86 Allowed Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.619 -1.277 . . . . 1.7 110.87 170.419 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.651 HG13 ' O ' ' A' ' 16' ' ' GLY . 3.3 mt -168.99 138.58 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 124.548 1.139 . . . . 1.6299999999999999 109.56 156.001 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 15.4 t -99.74 104.18 15.88 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.967 -0.382 . . . . 1.28 109.967 170.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.573 ' HD1' ' SG ' ' A' ' 23' ' ' CYS . 33.4 m-85 -92.37 131.45 34.46 Favored Pre-proline 0 CA--C 1.514 -0.424 0 CA-C-N 116.53 -0.305 . . . . 0.84999999999999998 110.903 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -87.5 96.12 0.45 Allowed 'Trans proline' 0 N--CA 1.443 -1.466 0 C-N-CA 121.171 1.247 . . . . 0.55000000000000004 109.744 165.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.75 -114.52 0.91 Allowed Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.638 -0.71 . . . . 0.58999999999999997 111.75 -173.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -140.28 141.75 32.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 121.25 0.547 . . . . 1.6499999999999999 112.111 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . 0.573 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 79.4 m -95.55 134.88 37.91 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-N 115.533 -0.758 . . . . 1.4399999999999999 109.604 172.359 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.452 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 15.0 ptm180 -136.38 -37.92 0.69 Allowed 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 120.046 -0.662 . . . . 5.6399999999999997 112.597 178.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.452 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 8.2 mtt180 176.32 146.48 0.26 Allowed Pre-proline 0 N--CA 1.47 0.573 0 N-CA-C 112.295 0.48 . . . . 4.3700000000000001 112.295 175.043 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -86.83 98.52 0.21 Allowed 'Cis proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.455 -1.894 . . . . 1.6899999999999999 110.049 -11.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.624 ' CE1' HD13 ' A' ' 17' ' ' ILE . 89.4 m-85 -162.53 133.47 4.94 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.658 -0.867 . . . . 1.1100000000000001 108.658 -174.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -109.1 127.36 54.09 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 109.229 -0.656 . . . . 1.1499999999999999 109.229 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' TRP . . . . . 0.597 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 76.4 t90 -68.66 114.24 6.86 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 114.955 -1.021 . . . . 0.57999999999999996 110.155 -178.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.426 ' O ' ' HB2' ' A' ' 11' ' ' CYS . 18.1 pt -120.98 93.71 2.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.669 0.747 . . . . 1.3200000000000001 109.981 176.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 65.08 -172.46 21.2 Favored Glycine 0 CA--C 1.524 0.621 0 CA-C-N 115.799 -0.637 . . . . 0.51000000000000001 113.049 -175.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 19.8 p -105.46 159.41 15.95 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.091 0.472 . . . . 1.1799999999999999 111.989 -174.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.407 ' SG ' ' N ' ' A' ' 34' ' ' ASN . 48.7 t -121.92 -178.37 3.83 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.36 -0.607 . . . . 1.0700000000000001 109.36 177.258 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.454 ' ND2' ' HA3' ' A' ' 38' ' ' GLY . 7.6 m-20 57.84 -145.53 0.58 Allowed 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.451 -0.574 . . . . 1.54 109.451 -172.403 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 35.0 m-80 -83.31 -1.09 52.42 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.617 0.246 . . . . 3.2200000000000002 111.11 175.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 153.63 -35.73 0.74 Allowed Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 119.817 -1.182 . . . . 1.4399999999999999 114.54 176.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -80.15 -32.34 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 113.033 0.753 . . . . 1.8700000000000001 113.033 -172.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.454 ' HA3' ' ND2' ' A' ' 34' ' ' ASN . . . -68.83 172.03 37.22 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 120.441 -0.885 . . . . 1.0 111.697 177.086 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.451 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 68.5 p -117.69 124.07 47.62 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.224 0.535 . . . . 1.6499999999999999 111.252 -174.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 42.0 t -83.9 104.26 13.84 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 107.592 -1.262 . . . . 0.87 107.592 172.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.597 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 29.6 m -127.38 174.77 8.72 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 109.852 -0.425 . . . . 1.02 109.852 178.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.623 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -136.37 143.01 43.82 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 119.923 -0.711 . . . . 1.1799999999999999 111.077 173.186 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.46 ' HD3' ' C ' ' A' ' 43' ' ' ARG . 3.4 tmt_? -61.54 112.13 2.09 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.062 -0.972 . . . . 4.46 110.466 -177.376 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 141.36 -159.33 26.7 Favored Glycine 0 N--CA 1.439 -1.116 0 CA-C-N 115.11 -0.95 . . . . 1.54 111.112 178.252 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.458 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 31.9 t-105 -148.0 119.15 7.74 Favored 'General case' 0 C--N 1.314 -0.942 0 C-N-CA 120.47 -0.492 . . . . 1.98 111.002 -179.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.463 ' CD ' ' HA ' ' A' ' 8' ' ' ILE . 23.8 ttm180 -107.63 145.62 33.07 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 115.787 -0.642 . . . . 4.2199999999999998 110.007 172.267 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 17.1 t . . . . . 0 C--O 1.249 1.028 0 O-C-N 124.372 1.045 . . . . 4.0099999999999998 110.02 -176.342 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 71.0 mt . . . . . 0 N--CA 1.447 -0.58 0 N-CA-C 109.921 -0.4 . . . . 4.46 109.921 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -130.36 165.9 21.56 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.401 -0.363 . . . . 3.25 110.136 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 7.7 p -57.95 -176.93 0.03 OUTLIER 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 112.743 0.645 . . . . 2.2000000000000002 112.743 177.202 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.427 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 22.9 t -58.03 4.04 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.528 1.131 . . . . 1.3 113.294 -171.212 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.469 ' HG3' HD21 ' A' ' 13' ' ' LEU . 5.0 ptp180 -57.6 -31.22 65.98 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 108.735 -0.839 . . . . 4.8099999999999996 108.735 167.454 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.718 ' O ' HD11 ' A' ' 30' ' ' ILE . 3.7 mm? -88.78 122.08 31.81 Favored 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 106.789 -1.559 . . . . 3.0499999999999998 106.789 161.663 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.734 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 13.0 tpt180 -131.21 170.54 14.43 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 112.707 0.632 . . . . 7.7800000000000002 112.707 -168.737 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . 0.734 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 94.3 m-20 72.35 66.4 0.13 Allowed 'General case' 0 CA--C 1.512 -0.512 0 CA-C-N 114.775 -1.102 . . . . 4.9500000000000002 112.86 169.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.689 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -130.67 -47.91 0.13 Allowed Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 119.632 -1.27 . . . . 1.7 111.551 167.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.689 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.3 mt -169.13 133.98 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.465 1.106 . . . . 1.6299999999999999 109.9 159.663 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 6.3 t -96.94 124.04 40.81 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.978 -0.379 . . . . 1.28 109.978 172.023 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.513 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 23.3 m-85 -105.93 127.71 27.85 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 116.471 -0.331 . . . . 0.84999999999999998 111.009 179.499 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.481 ' HA ' HD22 ' A' ' 34' ' ' ASN . 57.6 Cg_endo -74.48 97.95 1.08 Allowed 'Trans proline' 0 N--CA 1.452 -0.957 0 C-N-CA 121.3 1.333 . . . . 0.55000000000000004 109.591 167.055 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.495 ' H ' ' HA2' ' A' ' 38' ' ' GLY . . . 133.04 -124.34 3.73 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.489 -0.778 . . . . 0.58999999999999997 111.259 -171.415 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -142.85 146.95 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-N 117.069 0.434 . . . . 1.6499999999999999 111.523 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . 0.45 ' SG ' ' CD1' ' A' ' 19' ' ' PHE . 22.6 m -86.18 147.19 26.24 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 115.94 -0.573 . . . . 1.4399999999999999 111.455 177.163 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.617 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 16.3 ptm180 -141.55 -37.34 0.42 Allowed 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 112.551 0.574 . . . . 5.6399999999999997 112.551 176.281 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.617 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 10.2 mmt180 177.32 142.19 0.25 Allowed Pre-proline 0 N--CA 1.478 0.96 0 C-N-CA 122.737 0.415 . . . . 4.3700000000000001 111.193 178.658 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.576 ' HD2' ' CE2' ' A' ' 27' ' ' TYR . 24.2 Cg_endo -91.35 98.35 0.16 OUTLIER 'Cis proline' 0 C--N 1.349 0.593 0 C-N-CA 122.792 -1.753 . . . . 1.6899999999999999 111.704 -10.403 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.576 ' CE2' ' HD2' ' A' ' 26' ' ' PRO . 80.9 m-85 -161.53 143.89 11.94 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.695 -0.854 . . . . 1.1100000000000001 108.695 -172.194 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 11.0 p90 -111.07 127.76 55.65 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 109.008 -0.738 . . . . 1.1499999999999999 109.008 175.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 84.6 t90 -68.5 113.35 5.96 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.144 -0.935 . . . . 0.57999999999999996 110.126 -178.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.718 HD11 ' O ' ' A' ' 13' ' ' LEU . 12.1 pt -119.27 94.35 3.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 109.242 -0.651 . . . . 1.3200000000000001 109.242 174.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 65.24 -173.2 20.21 Favored Glycine 0 CA--C 1.524 0.612 0 CA-C-N 115.962 -0.563 . . . . 0.51000000000000001 113.079 -177.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.1 p -108.57 161.78 14.75 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 122.27 -0.547 . . . . 1.1799999999999999 112.047 -176.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 39.1 t -130.98 178.97 6.27 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 116.102 -0.499 . . . . 1.0700000000000001 110.299 -177.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.481 HD22 ' HA ' ' A' ' 20' ' ' PRO . 1.7 m-20 63.8 -82.48 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.313 1.045 . . . . 1.54 110.791 -174.251 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 54.5 m-80 -151.57 26.67 0.66 Allowed 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.364 -0.606 . . . . 3.2200000000000002 109.364 -178.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 107.8 -20.34 31.75 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.752 -0.737 . . . . 1.4399999999999999 112.944 179.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.505 ' H ' HD12 ' A' ' 37' ' ' ILE . 0.2 OUTLIER -81.09 -58.4 3.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 O-C-N 122.511 -0.405 . . . . 1.8700000000000001 111.293 -177.791 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.495 ' HA2' ' H ' ' A' ' 21' ' ' GLY . . . -69.18 174.9 33.19 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.966 -0.635 . . . . 1.0 112.198 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.513 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 77.3 p -108.54 125.74 52.16 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-O 121.392 0.615 . . . . 1.6499999999999999 111.499 -173.24 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 41.4 t -82.54 113.35 20.2 Favored 'General case' 0 N--CA 1.442 -0.86 0 N-CA-C 106.67 -1.604 . . . . 0.87 106.67 169.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.48 ' HA ' HG12 ' A' ' 30' ' ' ILE . 28.2 m -132.0 177.24 7.7 Favored 'General case' 0 C--N 1.311 -1.085 0 CA-C-O 121.421 0.629 . . . . 1.02 110.703 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.617 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -135.53 137.6 42.23 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.513 -0.767 . . . . 1.1799999999999999 109.618 167.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.505 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 4.3 tmt_? -60.7 113.41 2.46 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 115.378 -0.828 . . . . 4.46 110.778 -174.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 134.62 -150.99 20.23 Favored Glycine 0 N--CA 1.438 -1.183 0 CA-C-N 115.252 -0.886 . . . . 1.54 112.072 176.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 26.0 t-105 -145.51 124.74 12.95 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.369 -0.604 . . . . 1.98 109.369 179.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 19.5 ttm180 -102.42 128.75 48.88 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 120.978 0.418 . . . . 4.2199999999999998 110.929 176.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 18.5 m . . . . . 0 C--O 1.249 1.075 0 CA-C-N 114.145 -1.388 . . . . 4.0099999999999998 112.289 178.171 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.559 ' HA ' ' HD2' ' A' ' 46' ' ' ARG . 61.9 mt . . . . . 0 N--CA 1.451 -0.425 0 CA-C-O 121.203 0.525 . . . . 4.46 111.974 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 36.2 m-20 -81.14 166.15 20.93 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.19 -0.913 . . . . 3.25 109.732 174.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.525 ' C ' ' H ' ' A' ' 12' ' ' ARG . 37.0 p -85.86 -171.24 3.49 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.183 -0.673 . . . . 2.2000000000000002 109.183 174.03 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.558 ' O ' ' HG2' ' A' ' 14' ' ' ARG . 58.4 m -50.9 -1.52 0.01 OUTLIER 'General case' 0 CA--C 1.549 0.938 0 CA-C-O 121.076 0.465 . . . . 1.3 110.742 166.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.525 ' H ' ' C ' ' A' ' 10' ' ' THR . 12.0 ttt180 -32.74 -43.19 0.09 Allowed 'General case' 0 N--CA 1.463 0.176 0 C-N-CA 124.942 1.297 . . . . 4.8099999999999996 110.834 163.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 8.8 mp -114.96 111.35 21.02 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 115.184 -0.917 . . . . 3.0499999999999998 108.644 174.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ARG . . . . . 0.662 ' HD2' ' SG ' ' A' ' 40' ' ' CYS . 1.6 mmp_? -116.9 -171.19 1.98 Allowed 'General case' 0 CA--C 1.507 -0.682 0 N-CA-C 113.167 0.802 . . . . 7.7800000000000002 113.167 -175.438 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 70.7 42.87 0.79 Allowed 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 114.492 -1.231 . . . . 4.9500000000000002 109.63 -172.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.664 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -106.43 -51.48 0.81 Allowed Glycine 0 N--CA 1.441 -0.971 0 C-N-CA 119.233 -1.46 . . . . 1.7 111.956 173.277 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.701 HD11 ' CE1' ' A' ' 27' ' ' TYR . 2.7 mt -173.33 150.77 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 C-N-CA 125.112 1.365 . . . . 1.6299999999999999 108.914 157.14 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 9.2 t -110.89 108.28 18.02 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.263 -0.643 . . . . 1.28 109.263 166.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.618 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 46.9 m-85 -94.36 132.99 27.85 Favored Pre-proline 0 CA--C 1.513 -0.47 0 CA-C-O 120.881 0.372 . . . . 0.84999999999999998 111.184 -177.53 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -85.54 95.83 0.61 Allowed 'Trans proline' 0 N--CA 1.438 -1.793 0 N-CA-C 108.349 -1.443 . . . . 0.55000000000000004 108.349 158.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.93 -130.6 5.53 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.26 -0.882 . . . . 0.58999999999999997 110.973 -168.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.1 pt -135.87 148.48 27.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.521 0.677 . . . . 1.6499999999999999 112.606 -176.527 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -87.78 123.35 32.49 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.053 -0.976 . . . . 1.4399999999999999 109.308 169.2 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.468 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 12.3 ptm180 -123.59 -38.24 2.55 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 119.579 -0.849 . . . . 5.6399999999999997 112.335 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.468 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 11.5 mtt180 175.02 141.86 0.2 Allowed Pre-proline 0 N--CA 1.475 0.795 0 O-C-N 123.385 0.428 . . . . 4.3700000000000001 111.88 171.154 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -88.55 99.84 0.23 Allowed 'Cis proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.715 -1.785 . . . . 1.6899999999999999 110.567 -10.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.701 ' CE1' HD11 ' A' ' 17' ' ' ILE . 75.7 m-85 -161.74 128.54 3.86 Favored 'General case' 0 CA--C 1.506 -0.729 0 N-CA-C 108.883 -0.784 . . . . 1.1100000000000001 108.883 -177.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' TYR . . . . . 0.472 ' CZ ' ' HB3' ' A' ' 42' ' ' ALA . 27.0 p90 -107.83 130.13 55.01 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-O 121.208 0.528 . . . . 1.1499999999999999 110.205 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 86.4 t90 -65.67 113.82 4.53 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.49 -1.232 . . . . 0.57999999999999996 111.122 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.473 HD11 HH21 ' A' ' 14' ' ' ARG . 4.7 pt -120.32 92.68 2.21 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.852 0 CA-C-N 115.66 -0.7 . . . . 1.3200000000000001 109.383 171.728 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 66.18 -164.87 39.87 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 120.711 -0.757 . . . . 0.51000000000000001 113.292 -177.389 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -114.46 160.11 19.56 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 112.518 0.562 . . . . 1.1799999999999999 112.518 -174.693 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 49.6 t -127.92 -176.37 3.76 Favored 'General case' 0 C--O 1.22 -0.485 0 N-CA-C 107.808 -1.182 . . . . 1.0700000000000001 107.808 175.034 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.4 ' HB3' ' H ' ' A' ' 35' ' ' ASN . 92.9 m-20 61.23 -155.87 0.35 Allowed 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 118.891 0.769 . . . . 1.54 109.884 -177.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.4 ' H ' ' HB3' ' A' ' 34' ' ' ASN . 45.4 m-80 -111.05 88.54 2.81 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.806 0.336 . . . . 3.2200000000000002 111.064 179.739 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 92.04 -47.86 2.7 Favored Glycine 0 CA--C 1.506 -0.49 0 N-CA-C 110.892 -0.883 . . . . 1.4399999999999999 110.892 175.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ILE . . . . . 0.462 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 4.7 pt -77.74 -147.7 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 114.397 -0.901 . . . . 1.8700000000000001 109.79 170.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.462 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 73.44 161.76 7.01 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 121.171 -0.538 . . . . 1.0 113.459 169.211 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.772 ' HB2' ' SG ' ' A' ' 41' ' ' CYS . 4.7 p -139.74 113.2 8.43 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-O 121.928 0.87 . . . . 1.6499999999999999 111.4 177.638 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' CYS . . . . . 0.662 ' SG ' ' HD2' ' A' ' 14' ' ' ARG . 36.5 t -77.95 98.12 5.56 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 106.957 -1.497 . . . . 0.87 106.957 172.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . 0.772 ' SG ' ' HB2' ' A' ' 39' ' ' SER . 12.3 m -132.72 141.86 48.76 Favored 'General case' 0 C--N 1.32 -0.687 0 O-C-N 121.946 -0.471 . . . . 1.02 109.832 -174.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.48 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -100.69 139.8 35.87 Favored 'General case' 0 C--N 1.316 -0.848 0 C-N-CA 120.258 -0.577 . . . . 1.1799999999999999 111.495 -176.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.514 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 4.0 tmt_? -62.04 107.99 0.97 Allowed 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 115.258 -0.883 . . . . 4.46 110.245 179.11 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 138.5 -170.77 23.77 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.417 -0.81 . . . . 1.54 111.293 -178.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.525 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 23.9 t-105 -135.3 118.67 16.75 Favored 'General case' 0 N--CA 1.442 -0.842 0 C-N-CA 120.271 -0.571 . . . . 1.98 110.898 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ARG . . . . . 0.559 ' HD2' ' HA ' ' A' ' 8' ' ' ILE . 15.7 ttm180 -112.6 144.83 41.42 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 115.789 -0.641 . . . . 4.2199999999999998 110.338 176.012 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 16.3 t . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.06 -0.971 . . . . 4.0099999999999998 110.652 -179.103 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.683 0 CA-C-O 120.392 0.139 . . . . 6.6399999999999997 111.262 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.1 -45.3 0.22 Allowed 'Trans proline' 0 N--CA 1.461 -0.431 0 C-N-CA 122.447 2.098 . . . . 6.8499999999999996 109.681 173.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.553 ' O ' ' HD3' ' A' ' 5' ' ' PRO . 5.5 p90 -81.39 164.99 21.71 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 114.834 -1.075 . . . . 6.21 108.488 171.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.471 ' O ' HG21 ' A' ' 4' ' ' ILE . 6.7 tp -86.22 108.64 18.25 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-O 120.94 0.4 . . . . 6.9800000000000004 110.254 176.091 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.593 ' HB3' ' H ' ' A' ' 47' ' ' SER . 87.5 Cg_exo -50.03 114.54 1.43 Allowed 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 122.602 2.202 . . . . 4.5899999999999999 113.055 178.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.477 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 21.4 mmm180 -79.4 178.42 2.32 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 115.083 -0.962 . . . . 7.54 108.605 176.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.477 ' HD2' ' HB3' ' A' ' 6' ' ' ARG . 98.1 Cg_exo -46.61 135.34 16.64 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 121.936 1.757 . . . . 5.6900000000000004 112.329 174.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.496 HG12 ' HG3' ' A' ' 46' ' ' ARG . 41.9 mt -60.29 129.47 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 121.415 0.626 . . . . 4.46 112.23 -177.157 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.541 ' O ' HG22 ' A' ' 30' ' ' ILE . 17.0 m-20 -103.37 165.62 10.92 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.128 -0.942 . . . . 3.25 110.069 175.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.425 ' C ' ' H ' ' A' ' 12' ' ' ARG . 25.0 p -83.53 -176.34 6.25 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.843 -0.617 . . . . 2.2000000000000002 110.375 173.167 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.581 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 25.4 t -58.01 1.58 0.05 OUTLIER 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 122.789 0.436 . . . . 1.3 112.081 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.425 ' H ' ' C ' ' A' ' 10' ' ' THR . 8.3 ptt180 -54.56 -35.44 63.26 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 109.86 -0.422 . . . . 4.8099999999999996 109.86 170.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.406 ' O ' HD11 ' A' ' 30' ' ' ILE . 11.1 mp -85.41 97.82 10.22 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 107.278 -1.379 . . . . 3.0499999999999998 107.278 165.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.648 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 19.0 tpt180 -107.41 168.57 9.14 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 112.22 0.452 . . . . 7.7800000000000002 112.22 -164.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.648 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 6.1 t30 72.57 69.63 0.13 Allowed 'General case' 0 CA--C 1.513 -0.48 0 CA-C-N 114.859 -1.064 . . . . 4.9500000000000002 111.219 172.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.726 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -130.45 -47.17 0.14 Allowed Glycine 0 N--CA 1.435 -1.369 0 C-N-CA 119.891 -1.147 . . . . 1.7 111.273 167.146 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.726 HG12 ' O ' ' A' ' 16' ' ' GLY . 15.9 mm -164.86 146.51 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 124.415 1.086 . . . . 1.6299999999999999 108.685 164.162 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -113.92 111.4 21.64 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.32 -0.622 . . . . 1.28 109.32 165.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.463 ' CE1' HG23 ' A' ' 17' ' ' ILE . 44.3 m-85 -94.27 139.91 22.62 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 116.38 -0.373 . . . . 0.84999999999999998 111.17 -176.754 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -84.98 98.52 0.68 Allowed 'Trans proline' 0 N--CA 1.445 -1.356 0 C-N-CA 121.819 1.68 . . . . 0.55000000000000004 109.139 163.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 123.51 -131.13 7.97 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 110.373 -1.091 . . . . 0.58999999999999997 110.373 -166.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 36.4 pt -136.95 156.67 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.532 0.682 . . . . 1.6499999999999999 112.228 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . 0.529 ' SG ' ' HB2' ' A' ' 29' ' ' TRP . 0.2 OUTLIER -81.17 130.59 35.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.876 -1.057 . . . . 1.4399999999999999 110.428 174.73 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.739 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 14.8 ptp180 -119.14 -39.98 2.87 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 119.461 -0.896 . . . . 5.6399999999999997 112.701 176.494 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.739 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 12.9 mmt180 176.43 140.45 0.22 Allowed Pre-proline 0 N--CA 1.482 1.158 0 C-N-CA 123.32 0.648 . . . . 4.3700000000000001 110.557 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.406 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 1.7 Cg_endo -91.24 100.46 0.22 Allowed 'Cis proline' 0 N--CA 1.455 -0.765 0 C-N-CA 123.646 -1.398 . . . . 1.6899999999999999 109.968 -13.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.757 ' HH ' ' HE ' ' A' ' 43' ' ' ARG . 83.7 m-85 -160.84 133.03 5.98 Favored 'General case' 0 CA--C 1.503 -0.834 0 N-CA-C 108.816 -0.809 . . . . 1.1100000000000001 108.816 -174.065 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.519 ' CD1' ' HB3' ' A' ' 46' ' ' ARG . 19.1 p90 -108.3 129.54 55.22 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.003 -0.544 . . . . 1.1499999999999999 109.582 -179.019 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' TRP . . . . . 0.529 ' HB2' ' SG ' ' A' ' 23' ' ' CYS . 90.0 t90 -66.8 112.77 4.43 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.34 -0.845 . . . . 0.57999999999999996 110.746 -178.538 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.581 ' O ' ' HB2' ' A' ' 11' ' ' CYS . 5.3 pt -119.2 93.41 2.53 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 115.021 -0.99 . . . . 1.3200000000000001 108.985 173.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 68.7 177.22 13.52 Favored Glycine 0 C--N 1.316 -0.544 0 C-N-CA 120.821 -0.704 . . . . 0.51000000000000001 112.715 -179.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.471 HG21 ' O ' ' A' ' 38' ' ' GLY . 0.1 OUTLIER -97.71 164.53 12.37 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 122.323 -0.516 . . . . 1.1799999999999999 111.19 -175.99 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 10.5 t -136.26 179.57 6.27 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.355 -0.98 . . . . 1.0700000000000001 108.355 175.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.419 ' ND2' ' HA3' ' A' ' 38' ' ' GLY . 83.9 m-20 53.34 27.65 6.49 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 120.722 0.296 . . . . 1.54 111.106 -175.072 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 2.8 t30 64.54 22.16 12.61 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 123.36 0.664 . . . . 3.2200000000000002 111.586 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 136.3 -36.04 2.05 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 119.911 -1.137 . . . . 1.4399999999999999 114.021 175.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.418 HG13 ' CB ' ' A' ' 34' ' ' ASN . 0.9 OUTLIER -82.57 -23.55 8.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 112.597 0.591 . . . . 1.8700000000000001 112.597 -175.835 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.471 ' O ' HG21 ' A' ' 32' ' ' THR . . . -103.53 -167.93 25.54 Favored Glycine 0 N--CA 1.426 -1.991 0 N-CA-C 110.37 -1.092 . . . . 1.0 110.37 -177.794 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.529 ' HB2' ' SG ' ' A' ' 41' ' ' CYS . 23.6 p -144.77 119.87 10.09 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.478 0.656 . . . . 1.6499999999999999 111.75 -173.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.49 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 41.8 t -74.42 104.2 5.06 Favored 'General case' 0 N--CA 1.442 -0.86 0 N-CA-C 107.073 -1.454 . . . . 0.87 107.073 172.076 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.529 ' SG ' ' HB2' ' A' ' 39' ' ' SER . 14.1 m -139.26 111.16 7.27 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.361 -0.607 . . . . 1.02 109.361 -176.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.545 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -80.7 143.39 33.03 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.871 0.367 . . . . 1.1799999999999999 110.87 -172.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.757 ' HE ' ' HH ' ' A' ' 27' ' ' TYR . 39.7 ttm180 -62.53 114.07 3.33 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.432 -0.804 . . . . 4.46 111.096 -176.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 139.17 -152.56 22.38 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 114.676 -1.147 . . . . 1.54 111.263 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 38.3 t-105 -145.12 130.39 18.6 Favored 'General case' 0 N--CA 1.443 -0.806 0 C-N-CA 119.957 -0.697 . . . . 1.98 112.048 179.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.519 ' HB3' ' CD1' ' A' ' 28' ' ' TYR . 1.9 tpp180 -125.33 117.32 23.49 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 115.092 -0.958 . . . . 4.2199999999999998 110.312 174.093 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.593 ' H ' ' HB3' ' A' ' 5' ' ' PRO . 44.4 m . . . . . 0 C--O 1.248 1.014 0 CA-C-N 114.067 -1.424 . . . . 4.0099999999999998 111.704 -176.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.795 0 CA-C-O 120.39 0.138 . . . . 6.6399999999999997 110.906 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -76.4 -29.46 6.09 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.581 2.187 . . . . 6.8499999999999996 109.991 175.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 4.0 p90 -119.1 165.18 14.48 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-N 114.463 -1.244 . . . . 6.21 107.973 173.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.415 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 7.0 tp -83.35 112.39 38.73 Favored Pre-proline 0 C--N 1.322 -0.6 0 C-N-CA 121.069 -0.252 . . . . 6.9800000000000004 110.634 178.374 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 6.5 Cg_endo -48.9 111.18 0.43 Allowed 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 123.332 2.688 . . . . 4.5899999999999999 113.409 -178.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.479 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 13.4 mtm180 -106.94 167.49 9.4 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 115.348 -0.842 . . . . 7.54 108.908 176.405 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.479 ' HD2' ' HB3' ' A' ' 6' ' ' ARG . 3.5 Cg_endo -48.55 140.53 21.56 Favored 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.103 1.869 . . . . 5.6900000000000004 110.586 171.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 2.2 mp -60.01 119.18 3.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.296 0.57 . . . . 4.46 111.259 -172.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -91.37 165.24 13.52 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.295 -0.866 . . . . 3.25 109.464 177.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.425 ' C ' ' H ' ' A' ' 12' ' ' ARG . 6.5 p -89.27 -175.83 4.89 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 116.264 -0.426 . . . . 2.2000000000000002 110.825 176.07 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.453 ' H ' ' HA3' ' A' ' 31' ' ' GLY . 19.0 t -64.41 11.37 0.05 OUTLIER 'General case' 0 N--CA 1.47 0.549 0 CA-C-O 121.317 0.58 . . . . 1.3 112.088 -172.242 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.425 ' H ' ' C ' ' A' ' 10' ' ' THR . 18.3 ptt85 -57.96 -25.69 61.32 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.851 -0.796 . . . . 4.8099999999999996 108.851 161.526 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.6 HD23 ' NH2' ' A' ' 46' ' ' ARG . 5.4 mp -74.71 153.19 38.97 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 115.554 -0.748 . . . . 3.0499999999999998 109.518 169.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.66 98.99 6.41 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 114.611 1.337 . . . . 7.7800000000000002 114.611 -167.156 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 66.5 t30 31.18 61.74 0.24 Allowed 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 124.181 0.992 . . . . 4.9500000000000002 113.335 156.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.667 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -77.24 -43.54 16.01 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 118.811 -1.661 . . . . 1.7 112.824 -172.176 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.667 HG12 ' O ' ' A' ' 16' ' ' GLY . 20.3 mm -163.18 128.33 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 124.896 1.278 . . . . 1.6299999999999999 108.273 165.685 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 8.2 m -94.89 110.54 22.41 Favored 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 120.407 -0.517 . . . . 1.28 110.785 173.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.527 ' CZ ' HG22 ' A' ' 17' ' ' ILE . 43.8 m-85 -102.52 131.68 22.16 Favored Pre-proline 0 CA--C 1.51 -0.59 0 CA-C-N 116.036 -0.529 . . . . 0.84999999999999998 110.82 177.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -74.48 97.8 1.07 Allowed 'Trans proline' 0 N--CA 1.448 -1.165 0 C-N-CA 121.104 1.202 . . . . 0.55000000000000004 109.316 169.03 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.448 ' H ' ' HA2' ' A' ' 38' ' ' GLY . . . 128.92 -122.56 3.96 Favored Glycine 0 N--CA 1.442 -0.927 0 CA-C-N 115.217 -0.901 . . . . 0.58999999999999997 111.204 -169.155 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -146.6 147.15 18.2 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 121.115 0.483 . . . . 1.6499999999999999 111.567 -178.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . 0.452 ' HB3' ' HB2' ' A' ' 27' ' ' TYR . 0.0 OUTLIER -71.65 127.69 33.39 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.367 -0.833 . . . . 1.4399999999999999 110.424 173.759 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.701 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 25.8 ptt180 -116.09 -38.11 3.69 Favored 'General case' 0 C--N 1.322 -0.628 0 C-N-CA 120.14 -0.624 . . . . 5.6399999999999997 111.537 175.555 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.701 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 14.7 mmt180 175.7 143.93 0.23 Allowed Pre-proline 0 N--CA 1.477 0.899 0 C-N-CA 123.361 0.664 . . . . 4.3700000000000001 110.932 177.218 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.416 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 1.2 Cg_endo -93.94 100.4 0.18 OUTLIER 'Cis proline' 0 N--CA 1.457 -0.62 0 C-N-CA 123.878 -1.301 . . . . 1.6899999999999999 110.756 -14.464 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.614 ' CE1' HG13 ' A' ' 17' ' ' ILE . 63.1 m-85 -161.5 139.56 9.29 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.726 -0.842 . . . . 1.1100000000000001 108.726 -175.203 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 42' ' ' ALA . 26.1 p90 -107.85 131.74 54.17 Favored 'General case' 0 C--N 1.312 -1.027 0 C-N-CA 120.306 -0.558 . . . . 1.1499999999999999 110.348 177.689 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 86.9 t90 -67.02 112.58 4.44 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.642 -1.163 . . . . 0.57999999999999996 110.92 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.546 HG12 ' O ' ' A' ' 40' ' ' CYS . 0.6 OUTLIER -120.11 93.62 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 CA-C-O 121.957 0.884 . . . . 1.3200000000000001 109.404 170.398 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.453 ' HA3' ' H ' ' A' ' 11' ' ' CYS . . . 70.75 178.63 26.72 Favored Glycine 0 CA--C 1.523 0.559 0 CA-C-N 115.544 -0.753 . . . . 0.51000000000000001 113.482 -177.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.525 HG22 ' O ' ' A' ' 38' ' ' GLY . 0.0 OUTLIER -97.87 162.9 13.02 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.066 0.46 . . . . 1.1799999999999999 111.137 -177.534 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 15.7 t -135.36 -177.22 4.56 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.374 -0.973 . . . . 1.0700000000000001 108.374 175.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.416 ' ND2' ' HA3' ' A' ' 38' ' ' GLY . 92.5 m-20 59.63 -160.82 0.28 Allowed 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 109.905 -0.406 . . . . 1.54 109.905 -173.138 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -83.21 42.21 0.8 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.113 0.482 . . . . 3.2200000000000002 110.113 174.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 89.72 11.61 63.58 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 121.069 -0.586 . . . . 1.4399999999999999 112.487 -178.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 8.1 pt -120.25 14.09 6.51 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.351 0 CA-C-O 121.219 0.533 . . . . 1.8700000000000001 112.013 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.525 ' O ' HG22 ' A' ' 32' ' ' THR . . . -133.12 170.4 22.21 Favored Glycine 0 N--CA 1.424 -2.109 0 N-CA-C 110.082 -1.207 . . . . 1.0 110.082 178.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 57.2 p -120.51 126.04 49.38 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 121.022 0.439 . . . . 1.6499999999999999 110.584 -177.253 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.546 ' O ' HG12 ' A' ' 30' ' ' ILE . 38.5 t -82.67 91.05 6.91 Favored 'General case' 0 C--O 1.211 -0.967 0 N-CA-C 107.346 -1.353 . . . . 0.87 107.346 175.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.433 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 3.0 m -100.66 -176.52 3.21 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.791 -0.818 . . . . 1.02 108.791 -177.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.598 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -142.32 138.76 31.5 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.909 -0.316 . . . . 1.1799999999999999 110.479 166.018 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.473 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 34.8 ttp180 -59.81 110.4 1.15 Allowed 'General case' 0 C--O 1.234 0.287 0 O-C-N 123.957 0.786 . . . . 4.46 110.876 -178.822 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 138.65 -154.86 23.34 Favored Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 114.909 -1.041 . . . . 1.54 111.215 -177.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 32.5 t-105 -145.25 146.03 31.52 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 121.222 0.534 . . . . 1.98 111.353 177.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.6 ' NH2' HD23 ' A' ' 13' ' ' LEU . 10.5 ttm180 -130.69 127.28 38.54 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.484 -0.78 . . . . 4.2199999999999998 110.523 176.047 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 45.8 m . . . . . 0 C--O 1.25 1.107 0 O-C-N 124.605 1.191 . . . . 4.0099999999999998 111.859 179.161 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.831 0 CA-C-O 120.401 0.143 . . . . 6.6399999999999997 110.718 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -72.04 -45.37 0.69 Allowed 'Trans proline' 0 CA--C 1.514 -0.484 0 C-N-CA 122.578 2.186 . . . . 6.8499999999999996 109.563 176.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 6.4 p90 -126.06 165.42 18.85 Favored 'General case' 0 N--CA 1.444 -0.767 0 N-CA-C 107.189 -1.412 . . . . 6.21 107.189 169.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.412 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 48.7 mm -90.01 117.36 68.01 Favored Pre-proline 0 C--N 1.319 -0.729 0 C-N-CA 120.785 -0.366 . . . . 6.9800000000000004 110.87 -179.334 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 14.0 Cg_endo -56.94 108.69 0.37 Allowed 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.647 2.231 . . . . 4.5899999999999999 111.967 178.106 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.465 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 47.8 mtt180 -106.44 168.82 7.6 Favored Pre-proline 0 C--N 1.318 -0.8 0 CA-C-N 115.302 -0.863 . . . . 7.54 109.687 -178.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.465 ' HD2' ' HB3' ' A' ' 6' ' ' ARG . 2.1 Cg_endo -41.81 141.34 1.7 Allowed 'Trans proline' 0 C--N 1.35 0.641 0 C-N-CA 123.165 2.577 . . . . 5.6900000000000004 112.461 175.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 2.5 mp -59.93 111.14 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.82 -0.627 . . . . 4.46 110.26 -176.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -100.1 169.2 9.33 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.329 -0.85 . . . . 3.25 110.295 -174.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.518 ' C ' ' H ' ' A' ' 12' ' ' ARG . 16.9 p -91.03 -176.43 4.62 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.795 -0.639 . . . . 2.2000000000000002 111.106 -177.299 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.598 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 47.7 t -59.56 8.67 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 121.291 0.567 . . . . 1.3 111.797 177.01 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.518 ' H ' ' C ' ' A' ' 10' ' ' THR . 0.0 OUTLIER -53.28 -38.42 63.06 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.555 -0.535 . . . . 4.8099999999999996 109.555 167.84 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.466 HD12 ' HG3' ' A' ' 12' ' ' ARG . 8.6 mp -77.22 126.08 30.37 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 109.07 -0.715 . . . . 3.0499999999999998 109.07 172.075 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.598 ' HD3' ' SG ' ' A' ' 11' ' ' CYS . 17.3 mmm180 -134.31 171.75 13.83 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 113.077 0.769 . . . . 7.7800000000000002 113.077 -171.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 64.42 20.1 12.04 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 114.357 -1.292 . . . . 4.9500000000000002 110.849 -177.217 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.739 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -85.85 -51.59 3.56 Favored Glycine 0 N--CA 1.438 -1.201 0 C-N-CA 118.824 -1.655 . . . . 1.7 111.377 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.739 HG12 ' O ' ' A' ' 16' ' ' GLY . 25.5 mm -168.4 143.71 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 C-N-CA 125.903 1.681 . . . . 1.6299999999999999 107.824 157.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.6 m -109.46 99.62 8.81 Favored 'General case' 0 C--N 1.321 -0.669 0 O-C-N 121.774 -0.579 . . . . 1.28 110.084 166.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.483 ' HD1' ' SG ' ' A' ' 41' ' ' CYS . 44.8 m-85 -88.19 135.02 33.63 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.72 -0.673 . . . . 0.84999999999999998 110.938 -178.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.626 ' HB3' HD22 ' A' ' 34' ' ' ASN . 96.7 Cg_endo -88.16 97.85 0.41 Allowed 'Trans proline' 0 N--CA 1.442 -1.558 0 C-N-CA 121.452 1.435 . . . . 0.55000000000000004 109.729 164.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.55 -115.07 1.3 Allowed Glycine 0 N--CA 1.444 -0.819 0 N-CA-C 110.666 -0.973 . . . . 0.58999999999999997 110.666 -170.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 22.2 pt -146.26 152.16 13.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-O 121.277 0.56 . . . . 1.6499999999999999 111.94 179.262 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -86.27 142.52 28.49 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.219 -0.901 . . . . 1.4399999999999999 108.735 170.391 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.9 ptt180 -131.98 -39.21 1.08 Allowed 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 119.542 -0.863 . . . . 5.6399999999999997 112.251 173.218 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 4.8 mtt85 174.24 145.17 0.2 Allowed Pre-proline 0 N--CA 1.474 0.745 0 N-CA-C 112.033 0.383 . . . . 4.3700000000000001 112.033 173.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -88.41 99.47 0.22 Allowed 'Cis proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.996 -1.669 . . . . 1.6899999999999999 110.851 -9.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.601 ' CE1' HG13 ' A' ' 17' ' ' ILE . 68.7 m-85 -162.21 135.66 6.23 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.339 -0.986 . . . . 1.1100000000000001 108.339 -176.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -108.42 129.76 55.25 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.973 -0.691 . . . . 1.1499999999999999 110.194 176.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 85.4 t90 -66.81 113.45 4.9 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.684 -1.144 . . . . 0.57999999999999996 111.193 -177.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.587 ' O ' ' HB3' ' A' ' 40' ' ' CYS . 10.9 pt -121.62 92.4 2.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-N 115.548 -0.751 . . . . 1.3200000000000001 109.559 172.752 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 66.9 -171.61 30.83 Favored Glycine 0 CA--C 1.527 0.819 0 C-N-CA 121.281 -0.485 . . . . 0.51000000000000001 113.159 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.6 p -107.66 168.54 9.18 Favored 'General case' 0 CA--C 1.533 0.299 0 O-C-N 122.381 -0.482 . . . . 1.1799999999999999 111.503 -177.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.576 ' O ' ' HA3' ' A' ' 38' ' ' GLY . 42.7 t -160.38 105.31 1.47 Allowed 'General case' 0 C--N 1.334 -0.098 0 N-CA-C 110.277 -0.268 . . . . 1.0700000000000001 110.277 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.626 HD22 ' HB3' ' A' ' 20' ' ' PRO . 13.6 m-20 163.67 39.58 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.586 1.554 . . . . 1.54 109.845 176.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 57.12 37.82 28.72 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.104 -0.498 . . . . 3.2200000000000002 111.283 -175.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 136.19 -64.93 0.57 Allowed Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 111.442 -0.663 . . . . 1.4399999999999999 111.442 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.479 HG13 ' HB3' ' A' ' 34' ' ' ASN . 2.7 pt -80.27 -162.09 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.677 -0.261 . . . . 1.8700000000000001 110.339 174.533 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.576 ' HA3' ' O ' ' A' ' 33' ' ' CYS . . . 85.49 179.4 50.5 Favored Glycine 0 N--CA 1.422 -2.249 0 C-N-CA 120.497 -0.859 . . . . 1.0 111.538 177.265 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.9 m -141.25 111.9 7.04 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.015 -0.593 . . . . 1.6499999999999999 109.532 -178.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.587 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 47.2 t -79.02 111.57 15.36 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 107.26 -1.385 . . . . 0.87 107.26 175.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.483 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 2.2 m -129.2 156.5 43.85 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.815 -0.809 . . . . 1.02 108.815 -176.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.583 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -118.29 130.62 56.14 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 119.817 -0.753 . . . . 1.1799999999999999 110.301 174.008 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.503 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 1.5 tmt_? -55.12 109.86 0.59 Allowed 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 115.275 -0.875 . . . . 4.46 110.521 -177.561 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 137.4 -162.78 25.43 Favored Glycine 0 N--CA 1.442 -0.959 0 CA-C-N 115.256 -0.884 . . . . 1.54 111.85 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 31.0 t-105 -141.59 118.51 11.18 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.033 0.445 . . . . 1.98 110.597 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 12.9 ttm180 -96.68 139.55 32.58 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.032 -0.531 . . . . 4.2199999999999998 111.565 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.3 t . . . . . 0 C--O 1.247 0.943 0 CA-C-N 114.477 -1.238 . . . . 4.0099999999999998 110.976 -179.375 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.827 0 CA-C-O 120.44 0.162 . . . . 6.6399999999999997 110.87 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -77.4 -29.68 4.64 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.653 2.235 . . . . 6.8499999999999996 110.224 177.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 4.4 p90 -122.85 166.08 15.59 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 107.715 -1.217 . . . . 6.21 107.715 176.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.466 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 7.0 tp -83.45 112.11 36.74 Favored Pre-proline 0 C--N 1.321 -0.666 0 C-N-CA 120.93 -0.308 . . . . 6.9800000000000004 110.654 178.265 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.491 ' HB3' ' HA ' ' A' ' 47' ' ' SER . 2.8 Cg_endo -44.79 109.87 0.2 Allowed 'Trans proline' 0 C--N 1.356 0.957 0 C-N-CA 123.36 2.707 . . . . 4.5899999999999999 113.238 179.311 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 81.2 mtp180 -100.5 150.34 36.88 Favored Pre-proline 0 C--N 1.319 -0.744 0 CA-C-N 115.331 -0.849 . . . . 7.54 108.806 174.064 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -44.48 124.99 5.69 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 123.092 2.528 . . . . 5.6900000000000004 111.333 176.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.454 ' HA ' ' CD ' ' A' ' 46' ' ' ARG . 81.3 mt -61.64 113.04 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.524 0.678 . . . . 4.46 111.322 -174.025 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.442 ' O ' HG23 ' A' ' 30' ' ' ILE . 71.4 m-20 -81.75 165.3 21.06 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 114.843 -1.071 . . . . 3.25 111.026 -176.243 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.488 ' C ' ' H ' ' A' ' 12' ' ' ARG . 21.4 p -79.56 -175.49 4.81 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 114.949 -1.023 . . . . 2.2000000000000002 110.906 173.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.413 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 19.4 t -57.12 4.52 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 123.595 0.758 . . . . 1.3 112.617 -179.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.488 ' H ' ' C ' ' A' ' 10' ' ' THR . 34.1 ptt180 -61.27 -29.91 70.14 Favored 'General case' 0 CA--C 1.531 0.239 0 O-C-N 122.018 -0.426 . . . . 4.8099999999999996 110.86 174.08 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -88.56 97.86 11.33 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 107.319 -1.363 . . . . 3.0499999999999998 107.319 167.041 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.665 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 12.7 tpp85 -101.43 163.97 12.0 Favored 'General case' 0 N--CA 1.428 -1.538 0 N-CA-C 113.349 0.87 . . . . 7.7800000000000002 113.349 -161.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.665 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 92.9 m-20 70.34 69.61 0.21 Allowed 'General case' 0 CA--C 1.514 -0.432 0 CA-C-N 114.421 -1.263 . . . . 4.9500000000000002 112.321 168.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.665 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -125.27 -46.79 0.23 Allowed Glycine 0 N--CA 1.439 -1.154 0 C-N-CA 119.385 -1.388 . . . . 1.7 111.576 169.095 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.665 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.1 mt -168.86 131.53 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 124.523 1.129 . . . . 1.6299999999999999 109.648 156.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 1.8 m -94.04 113.09 25.0 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.908 0.385 . . . . 1.28 110.213 170.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.594 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 64.7 m-85 -95.49 140.68 22.47 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.343 -0.389 . . . . 0.84999999999999998 110.077 178.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.513 ' HA ' ' ND2' ' A' ' 34' ' ' ASN . 74.9 Cg_endo -86.71 96.39 0.5 Allowed 'Trans proline' 0 N--CA 1.443 -1.49 0 C-N-CA 121.356 1.37 . . . . 0.55000000000000004 109.787 167.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.56 -109.2 0.89 Allowed Glycine 0 N--CA 1.441 -0.968 0 CA-C-N 115.339 -0.846 . . . . 0.58999999999999997 111.523 -171.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.9 pt -146.17 145.47 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 112.386 0.513 . . . . 1.6499999999999999 112.386 -176.309 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.89 126.7 32.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.609 -0.723 . . . . 1.4399999999999999 109.195 172.634 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 37.4 ptt180 -115.98 -40.04 3.37 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 118.619 -1.232 . . . . 5.6399999999999997 112.521 176.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 172.75 152.53 0.23 Allowed Pre-proline 0 N--CA 1.473 0.691 0 CA-C-N 118.112 0.414 . . . . 4.3700000000000001 111.642 172.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -87.15 100.91 0.27 Allowed 'Cis proline' 0 C--N 1.347 0.45 0 C-N-CA 123.216 -1.577 . . . . 1.6899999999999999 110.797 -12.418 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.559 ' CE1' HD12 ' A' ' 17' ' ' ILE . 89.1 m-85 -160.88 141.92 11.72 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 108.178 -1.045 . . . . 1.1100000000000001 108.178 -175.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 7.6 p90 -107.76 128.96 55.04 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 120.437 -0.505 . . . . 1.1499999999999999 109.641 177.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 92.1 t90 -66.71 113.83 5.14 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.988 -1.005 . . . . 0.57999999999999996 110.365 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.553 ' O ' ' HB3' ' A' ' 40' ' ' CYS . 11.2 pt -120.15 93.25 2.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-N 115.271 -0.877 . . . . 1.3200000000000001 109.318 175.171 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 62.31 -172.96 8.87 Favored Glycine 0 CA--C 1.526 0.736 0 C-N-CA 121.047 -0.597 . . . . 0.51000000000000001 112.93 -176.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.4 p -102.1 165.53 11.11 Favored 'General case' 0 C--N 1.324 -0.523 0 O-C-N 122.173 -0.604 . . . . 1.1799999999999999 111.631 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 20.6 t -137.5 -178.18 5.12 Favored 'General case' 0 C--O 1.216 -0.696 0 N-CA-C 108.334 -0.988 . . . . 1.0700000000000001 108.334 178.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.513 ' ND2' ' HA ' ' A' ' 20' ' ' PRO . 87.7 m-20 67.12 1.42 2.37 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 118.28 0.491 . . . . 1.54 111.753 -177.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 49.8 m-80 65.94 85.46 0.14 Allowed 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.611 0.764 . . . . 3.2200000000000002 111.846 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 110.76 -62.46 0.29 Allowed Glycine 0 CA--C 1.511 -0.174 0 N-CA-C 111.709 -0.556 . . . . 1.4399999999999999 111.709 175.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.427 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 0.2 OUTLIER -88.76 -142.43 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.753 -0.832 . . . . 1.8700000000000001 108.753 173.424 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.427 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 60.4 175.29 1.19 Allowed Glycine 0 N--CA 1.447 -0.602 0 CA-C-O 122.009 0.783 . . . . 1.0 114.485 169.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.594 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 87.6 p -142.32 119.89 11.75 Favored 'General case' 0 N--CA 1.433 -1.278 0 N-CA-C 109.599 -0.519 . . . . 1.6499999999999999 109.599 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.553 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 46.0 t -82.63 116.8 22.18 Favored 'General case' 0 C--N 1.313 -1.018 0 N-CA-C 107.127 -1.435 . . . . 0.87 107.127 174.218 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.584 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -133.67 169.03 17.62 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 108.31 -0.996 . . . . 1.02 108.31 -178.322 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.618 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -136.73 142.14 43.05 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.669 -0.812 . . . . 1.1799999999999999 110.744 172.089 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.465 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 57.0 ttp180 -61.42 116.65 4.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 114.973 -1.012 . . . . 4.46 110.909 -176.222 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 134.24 -149.84 19.88 Favored Glycine 0 CA--C 1.497 -1.044 0 CA-C-N 115.162 -0.926 . . . . 1.54 111.658 176.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 31.4 t-105 -152.7 123.88 7.58 Favored 'General case' 0 C--N 1.317 -0.843 0 C-N-CA 120.581 -0.448 . . . . 1.98 111.189 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.454 ' CD ' ' HA ' ' A' ' 8' ' ' ILE . 21.2 ttm180 -104.79 139.91 38.88 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.912 -0.585 . . . . 4.2199999999999998 110.23 169.753 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.491 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 3.7 t . . . . . 0 C--O 1.253 1.243 0 O-C-N 124.289 0.993 . . . . 4.0099999999999998 110.538 -179.684 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.723 0 CA-C-O 120.654 0.264 . . . . 6.6399999999999997 111.525 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -76.29 -29.2 6.47 Favored 'Trans proline' 0 C--N 1.347 0.491 0 C-N-CA 122.907 2.405 . . . . 6.8499999999999996 110.269 176.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.49 ' O ' ' HD3' ' A' ' 5' ' ' PRO . 0.8 OUTLIER -121.84 164.76 16.95 Favored 'General case' 0 N--CA 1.444 -0.744 0 N-CA-C 107.575 -1.268 . . . . 6.21 107.575 172.454 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.61 110.69 18.04 Favored Pre-proline 0 C--N 1.322 -0.607 0 N-CA-C 109.656 -0.498 . . . . 6.9800000000000004 109.656 178.504 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.49 ' HD3' ' O ' ' A' ' 3' ' ' PHE . 52.1 Cg_exo -56.2 107.67 0.28 Allowed 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 122.533 2.155 . . . . 4.5899999999999999 112.058 -179.199 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.653 ' O ' ' HG2' ' A' ' 46' ' ' ARG . 22.2 mtp180 -89.15 167.53 17.72 Favored Pre-proline 0 C--N 1.32 -0.703 0 CA-C-N 115.453 -0.794 . . . . 7.54 109.602 -179.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.403 ' HD2' ' HB3' ' A' ' 6' ' ' ARG . 85.0 Cg_exo -48.26 139.08 22.3 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.387 2.058 . . . . 5.6900000000000004 112.851 176.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.588 ' HA ' ' HD3' ' A' ' 46' ' ' ARG . 3.5 mp -62.57 106.37 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.274 -0.875 . . . . 4.46 111.465 178.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -89.04 164.02 15.25 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 108.943 -0.762 . . . . 3.25 108.943 170.021 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.495 ' C ' ' H ' ' A' ' 12' ' ' ARG . 38.4 p -72.75 -175.8 1.81 Allowed 'General case' 0 C--N 1.314 -0.965 0 CA-C-N 116.504 -0.317 . . . . 2.2000000000000002 110.867 176.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.417 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 11.4 t -57.51 6.23 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 123.36 0.664 . . . . 1.3 112.054 178.816 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.495 ' H ' ' C ' ' A' ' 10' ' ' THR . 38.4 ptt180 -65.89 -33.2 75.3 Favored 'General case' 0 C--N 1.33 -0.268 0 O-C-N 122.107 -0.371 . . . . 4.8099999999999996 110.939 172.484 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -97.11 97.48 9.24 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 108.472 -0.936 . . . . 3.0499999999999998 108.472 172.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.709 ' HD3' ' SG ' ' A' ' 40' ' ' CYS . 2.7 mmm-85 -110.24 -170.71 1.7 Allowed 'General case' 0 N--CA 1.438 -1.028 0 N-CA-C 113.338 0.866 . . . . 7.7800000000000002 113.338 -166.463 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.9 m-80 69.02 53.45 0.47 Allowed 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 114.678 -1.146 . . . . 4.9500000000000002 111.154 -178.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.723 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -120.46 -50.02 0.28 Allowed Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 119.445 -1.36 . . . . 1.7 112.119 172.113 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.723 HG12 ' O ' ' A' ' 16' ' ' GLY . 25.1 mm -166.65 147.02 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 C-N-CA 125.337 1.455 . . . . 1.6299999999999999 108.149 161.112 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 31.5 t -111.12 104.03 12.52 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 121.654 -0.654 . . . . 1.28 109.426 168.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.563 ' CE1' HG23 ' A' ' 17' ' ' ILE . 17.0 m-85 -93.17 124.13 58.84 Favored Pre-proline 0 C--N 1.329 -0.287 0 N-CA-C 112.404 0.52 . . . . 0.84999999999999998 112.404 -175.809 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -82.23 97.4 0.9 Allowed 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 121.833 1.689 . . . . 0.55000000000000004 109.473 165.339 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.64 -134.0 7.12 Favored Glycine 0 N--CA 1.443 -0.84 0 N-CA-C 110.884 -0.886 . . . . 0.58999999999999997 110.884 -170.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 23.7 pt -129.17 147.8 33.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.285 0.564 . . . . 1.6499999999999999 112.006 -178.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 93.9 m -94.77 139.62 31.02 Favored 'General case' 0 N--CA 1.437 -1.094 0 CA-C-N 115.488 -0.778 . . . . 1.4399999999999999 109.797 173.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.485 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 7.1 ptt180 -143.56 -37.1 0.35 Allowed 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 118.904 -0.569 . . . . 5.6399999999999997 112.532 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.485 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 10.8 mtt180 175.54 145.68 0.24 Allowed Pre-proline 0 N--CA 1.476 0.827 0 N-CA-C 112.067 0.395 . . . . 4.3700000000000001 112.067 170.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -88.74 99.25 0.2 Allowed 'Cis proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.839 -1.734 . . . . 1.6899999999999999 110.611 -10.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.45 ' CE1' HG13 ' A' ' 17' ' ' ILE . 96.2 m-85 -161.55 138.51 8.55 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 108.919 -0.771 . . . . 1.1100000000000001 108.919 -175.405 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.506 ' CZ ' ' HB2' ' A' ' 42' ' ' ALA . 35.8 p90 -113.09 127.93 56.35 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 109.245 -0.65 . . . . 1.1499999999999999 109.245 178.001 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' TRP . . . . . 0.564 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 90.1 t90 -73.74 117.0 14.99 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.625 -0.716 . . . . 0.57999999999999996 110.971 -175.419 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.447 HG13 ' O ' ' A' ' 30' ' ' ILE . 26.6 pt -121.35 95.03 3.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 121.524 0.678 . . . . 1.3200000000000001 110.259 176.309 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 63.39 -170.97 14.86 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 121.12 -0.562 . . . . 0.51000000000000001 113.041 -178.147 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 23.2 p -108.96 148.19 31.1 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 112.928 0.714 . . . . 1.1799999999999999 112.928 -173.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.477 ' O ' ' HA3' ' A' ' 38' ' ' GLY . 18.4 t -116.74 -175.83 2.85 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.583 -1.266 . . . . 1.0700000000000001 107.583 174.308 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.428 ' HB2' ' HA3' ' A' ' 38' ' ' GLY . 84.0 m-20 64.62 -97.44 0.06 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 118.315 0.507 . . . . 1.54 111.266 179.738 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 52.0 t30 -177.05 85.77 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.762 0.315 . . . . 3.2200000000000002 110.868 -178.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 94.09 -57.42 2.11 Favored Glycine 0 CA--C 1.503 -0.695 0 N-CA-C 110.122 -1.191 . . . . 1.4399999999999999 110.122 178.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.416 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 0.8 OUTLIER -78.51 -148.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 108.063 -1.088 . . . . 1.8700000000000001 108.063 164.997 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.477 ' HA3' ' O ' ' A' ' 33' ' ' CYS . . . 76.97 111.42 0.14 Allowed Glycine 0 N--CA 1.441 -0.976 0 C-N-CA 120.245 -0.979 . . . . 1.0 113.02 173.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.5 m -90.49 99.34 12.38 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 121.162 0.506 . . . . 1.6499999999999999 109.899 176.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.709 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 40.3 t -76.05 103.35 6.06 Favored 'General case' 0 C--O 1.218 -0.597 0 N-CA-C 107.65 -1.241 . . . . 0.87 107.65 173.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.564 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 24.3 m -128.93 178.11 6.62 Favored 'General case' 0 C--N 1.311 -1.085 0 C-N-CA 120.634 -0.426 . . . . 1.02 110.473 -178.087 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.532 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -134.19 139.89 46.14 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 116.207 -0.451 . . . . 1.1799999999999999 109.983 173.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.439 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 70.9 ttt180 -62.22 111.61 2.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.659 -0.701 . . . . 4.46 111.633 -174.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.95 -153.01 20.72 Favored Glycine 0 N--CA 1.443 -0.844 0 CA-C-N 115.188 -0.915 . . . . 1.54 112.36 178.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 28.4 t-105 -144.75 118.6 9.3 Favored 'General case' 0 N--CA 1.441 -0.916 0 CA-C-O 121.143 0.497 . . . . 1.98 110.483 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.653 ' HG2' ' O ' ' A' ' 6' ' ' ARG . 1.0 OUTLIER -89.9 127.23 35.97 Favored 'General case' 0 N--CA 1.44 -0.945 0 CA-C-N 115.592 -0.731 . . . . 4.2199999999999998 110.087 176.27 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.405 ' H ' ' CB ' ' A' ' 5' ' ' PRO . 19.9 m . . . . . 0 C--O 1.252 1.196 0 O-C-N 123.865 0.728 . . . . 4.0099999999999998 110.846 -179.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . 0.422 ' HA ' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 110.672 -0.122 . . . . 6.6399999999999997 110.672 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 1' ' ' PCA . 3.2 Cg_exo -78.56 -12.09 15.39 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.799 2.333 . . . . 6.8499999999999996 110.551 -179.399 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.401 ' HE2' ' O ' ' A' ' 45' ' ' TRP . 3.6 p90 -148.04 166.36 28.0 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 107.094 -1.447 . . . . 6.21 107.094 178.52 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.478 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 6.5 tp -81.9 110.72 21.61 Favored Pre-proline 0 C--N 1.321 -0.665 0 C-N-CA 120.771 -0.372 . . . . 6.9800000000000004 110.76 178.362 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.478 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 4.0 Cg_exo -36.13 109.86 0.06 OUTLIER 'Trans proline' 0 C--N 1.362 1.241 0 C-N-CA 124.457 3.438 . . . . 4.5899999999999999 114.546 -179.069 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.484 ' O ' ' HD2' ' A' ' 46' ' ' ARG . 14.7 mtp-105 -100.96 173.01 3.95 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 114.783 -1.099 . . . . 7.54 109.905 174.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_exo -54.66 143.52 68.82 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.172 1.915 . . . . 5.6900000000000004 111.561 169.045 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.41 ' HA ' ' HG2' ' A' ' 46' ' ' ARG . 2.6 mp -61.58 128.8 23.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 115.818 -0.628 . . . . 4.46 110.674 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -110.02 164.72 12.35 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.113 0.482 . . . . 3.25 110.001 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.452 ' C ' ' H ' ' A' ' 12' ' ' ARG . 70.7 p -89.18 -175.35 4.76 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.508 -0.769 . . . . 2.2000000000000002 109.852 171.682 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.517 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 31.2 t -55.5 -1.06 0.03 OUTLIER 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.877 0.471 . . . . 1.3 112.079 178.263 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.452 ' H ' ' C ' ' A' ' 10' ' ' THR . 9.3 ptm180 -52.52 -40.52 62.54 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 122.676 0.39 . . . . 4.8099999999999996 111.615 175.011 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 10.6 mp -87.31 96.04 10.21 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 107.838 -1.171 . . . . 3.0499999999999998 107.838 170.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.718 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 8.1 tpt180 -99.97 172.11 7.42 Favored 'General case' 0 N--CA 1.431 -1.42 0 CA-C-N 116.032 -0.531 . . . . 7.7800000000000002 111.98 -165.238 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.718 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 34.0 t-20 71.18 57.5 0.2 Allowed 'General case' 0 CA--C 1.514 -0.409 0 CA-C-N 114.973 -1.012 . . . . 4.9500000000000002 110.417 170.409 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.634 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -117.04 -48.27 0.45 Allowed Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 119.389 -1.386 . . . . 1.7 111.244 171.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.634 HG13 ' O ' ' A' ' 16' ' ' GLY . 2.3 mt -170.02 133.67 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 124.571 1.149 . . . . 1.6299999999999999 109.564 154.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 11.4 m -96.8 112.36 24.14 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 120.897 -0.321 . . . . 1.28 110.19 170.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.571 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 43.3 m-85 -95.68 126.34 45.69 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.495 -0.32 . . . . 0.84999999999999998 110.24 177.068 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -80.65 96.96 1.0 Allowed 'Trans proline' 0 N--CA 1.445 -1.335 0 C-N-CA 121.027 1.151 . . . . 0.55000000000000004 109.133 166.174 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.5 -113.08 1.06 Allowed Glycine 0 N--CA 1.448 -0.527 0 N-CA-C 111.266 -0.734 . . . . 0.58999999999999997 111.266 -170.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.7 pt -142.79 156.43 18.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-O 121.062 0.458 . . . . 1.6499999999999999 111.87 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . 0.458 ' HB3' ' HB2' ' A' ' 27' ' ' TYR . 5.8 m -107.04 132.08 53.36 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 108.679 -0.86 . . . . 1.4399999999999999 108.679 172.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 10.6 ptm180 -118.12 -41.1 2.9 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 118.976 -1.09 . . . . 5.6399999999999997 111.315 175.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.512 ' HA ' ' H ' ' A' ' 27' ' ' TYR . 0.0 OUTLIER 173.78 158.61 0.31 Allowed Pre-proline 0 CA--C 1.533 0.303 0 C-N-CA 122.644 0.377 . . . . 4.3700000000000001 111.44 168.449 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.442 ' HA ' ' HB2' ' A' ' 25' ' ' ARG . 2.5 Cg_endo -86.8 99.07 0.22 Allowed 'Cis proline' 0 N--CA 1.458 -0.594 0 C-N-CA 122.652 -1.811 . . . . 1.6899999999999999 110.681 -6.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.512 ' H ' ' HA ' ' A' ' 25' ' ' ARG . 64.2 m-85 -162.9 134.75 5.19 Favored 'General case' 0 CA--C 1.504 -0.79 0 N-CA-C 108.116 -1.068 . . . . 1.1100000000000001 108.116 -175.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 13.0 p90 -108.68 128.33 54.76 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 120.289 -0.564 . . . . 1.1499999999999999 109.769 177.17 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' TRP . . . . . 0.71 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 89.2 t90 -65.0 114.73 4.77 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.053 -0.976 . . . . 0.57999999999999996 110.877 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.517 ' O ' ' HB2' ' A' ' 11' ' ' CYS . 20.7 pt -122.15 95.88 3.75 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.048 -0.978 . . . . 1.3200000000000001 109.783 173.658 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 62.84 -161.22 32.77 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 120.991 -0.623 . . . . 0.51000000000000001 113.089 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 19.7 p -117.17 170.1 8.94 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 112.842 0.682 . . . . 1.1799999999999999 112.842 -175.01 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 19.7 t -143.59 -174.98 4.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.875 -1.057 . . . . 1.0700000000000001 108.839 -175.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.449 ' O ' ' HB2' ' A' ' 35' ' ' ASN . 75.1 m-20 68.68 -85.02 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 122.692 0.397 . . . . 1.54 110.763 -178.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.449 ' HB2' ' O ' ' A' ' 34' ' ' ASN . 21.8 t-20 169.24 78.55 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.285 0 C-N-CA 123.799 0.84 . . . . 3.2200000000000002 109.212 -179.591 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 105.41 -56.47 0.53 Allowed Glycine 0 N--CA 1.453 -0.221 0 N-CA-C 111.123 -0.791 . . . . 1.4399999999999999 111.123 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.443 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 0.4 OUTLIER -84.41 -137.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.885 -0.783 . . . . 1.8700000000000001 108.885 170.503 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.443 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 67.07 115.99 0.02 OUTLIER Glycine 0 C--N 1.339 0.732 0 C-N-CA 120.881 -0.676 . . . . 1.0 114.045 175.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.571 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 77.5 p -93.64 98.91 11.46 Favored 'General case' 0 N--CA 1.434 -1.241 0 N-CA-C 109.006 -0.739 . . . . 1.6499999999999999 109.006 173.294 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 44.5 t -69.91 108.41 3.99 Favored 'General case' 0 CA--C 1.507 -0.707 0 N-CA-C 107.97 -1.122 . . . . 0.87 107.97 176.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.71 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 80.2 m -130.44 173.88 10.41 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 109.297 -0.631 . . . . 1.02 109.297 179.036 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.573 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -135.58 142.74 45.36 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 120.381 -0.528 . . . . 1.1799999999999999 110.264 172.217 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.446 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 74.4 ttt180 -62.37 112.19 2.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.259 -0.882 . . . . 4.46 111.484 -173.615 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.88 -151.71 21.06 Favored Glycine 0 N--CA 1.446 -0.649 0 CA-C-N 114.712 -1.131 . . . . 1.54 111.797 -179.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.401 ' O ' ' HE2' ' A' ' 3' ' ' PHE . 32.8 t-105 -149.43 119.86 7.39 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.045 0.45 . . . . 1.98 111.004 179.447 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.484 ' HD2' ' O ' ' A' ' 6' ' ' ARG . 0.3 OUTLIER -77.19 138.83 39.69 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.782 -0.645 . . . . 4.2199999999999998 110.015 175.55 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.424 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 31.1 p . . . . . 0 C--O 1.251 1.14 0 O-C-N 124.314 1.009 . . . . 4.0099999999999998 111.594 -178.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.753 0 CA-C-O 120.659 0.266 . . . . 6.6399999999999997 111.001 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -76.95 -46.18 0.16 Allowed 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.693 2.262 . . . . 6.8499999999999996 109.838 175.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 13.1 p90 -99.44 165.63 11.56 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.573 -1.269 . . . . 6.21 107.573 170.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.564 ' O ' ' HG3' ' A' ' 6' ' ' ARG . 51.1 mm -93.25 122.2 63.71 Favored Pre-proline 0 C--N 1.317 -0.834 0 C-N-CA 120.774 -0.37 . . . . 6.9800000000000004 110.227 178.289 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 10.0 Cg_endo -53.13 109.23 0.33 Allowed 'Trans proline' 0 C--N 1.348 0.514 0 C-N-CA 122.727 2.285 . . . . 4.5899999999999999 111.91 176.462 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.564 ' HG3' ' O ' ' A' ' 4' ' ' ILE . 67.9 mtp180 -108.02 166.47 10.88 Favored Pre-proline 0 C--N 1.319 -0.756 0 CA-C-N 115.527 -0.76 . . . . 7.54 109.328 178.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -52.1 140.4 50.45 Favored 'Trans proline' 0 C--O 1.236 0.412 0 C-N-CA 122.308 2.006 . . . . 5.6900000000000004 111.896 173.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.523 ' HA ' ' HD2' ' A' ' 46' ' ' ARG . 2.6 mp -63.2 115.72 2.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.808 -0.633 . . . . 4.46 111.02 -178.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.479 ' O ' HG23 ' A' ' 30' ' ' ILE . 65.9 m-20 -98.8 165.93 11.55 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.443 -0.798 . . . . 3.25 109.777 176.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.428 ' C ' ' H ' ' A' ' 12' ' ' ARG . 26.9 p -79.6 -175.68 4.93 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.117 -0.492 . . . . 2.2000000000000002 111.071 175.332 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.406 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 12.5 t -55.74 -0.85 0.04 OUTLIER 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 123.68 0.792 . . . . 1.3 112.209 179.552 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.428 ' H ' ' C ' ' A' ' 10' ' ' THR . 12.9 ptm180 -54.74 -41.84 70.87 Favored 'General case' 0 C--O 1.234 0.237 0 C-N-CA 122.812 0.445 . . . . 4.8099999999999996 111.446 173.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -86.29 96.41 9.95 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 106.991 -1.485 . . . . 3.0499999999999998 106.991 171.338 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.71 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 18.2 tpp85 -100.31 157.44 16.61 Favored 'General case' 0 N--CA 1.429 -1.507 0 N-CA-C 114.041 1.126 . . . . 7.7800000000000002 114.041 -157.45 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.71 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 64.7 t30 70.04 69.67 0.22 Allowed 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 113.822 -1.535 . . . . 4.9500000000000002 112.348 164.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.667 ' HA3' ' HA ' ' A' ' 42' ' ' ALA . . . -108.01 -43.82 1.26 Allowed Glycine 0 N--CA 1.432 -1.63 0 N-CA-C 109.659 -1.376 . . . . 1.7 109.659 165.055 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.613 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.1 mt -165.89 132.87 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.349 1.06 . . . . 1.6299999999999999 109.258 157.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 21.5 t -91.88 109.3 20.64 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.109 -0.33 . . . . 1.28 110.109 175.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.412 ' CD1' ' SG ' ' A' ' 23' ' ' CYS . 15.4 m-85 -96.13 122.39 58.19 Favored Pre-proline 0 CA--C 1.516 -0.346 0 N-CA-C 112.125 0.417 . . . . 0.84999999999999998 112.125 -177.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -81.92 96.47 0.91 Allowed 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 121.513 1.475 . . . . 0.55000000000000004 109.816 167.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 136.26 -119.87 2.09 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 111.067 -0.813 . . . . 0.58999999999999997 111.067 -171.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.8 pt -138.14 154.4 28.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 117.131 0.466 . . . . 1.6499999999999999 111.735 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . 0.412 ' SG ' ' CD1' ' A' ' 19' ' ' PHE . 69.0 m -101.43 139.85 36.53 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 115.622 -0.717 . . . . 1.4399999999999999 109.813 173.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.736 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 13.6 ptm180 -135.5 -39.42 0.73 Allowed 'General case' 0 C--N 1.321 -0.646 0 C-N-CA 119.733 -0.787 . . . . 5.6399999999999997 112.612 179.028 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.736 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 12.0 mmt180 176.88 140.17 0.23 Allowed Pre-proline 0 N--CA 1.476 0.86 0 C-N-CA 123.104 0.561 . . . . 4.3700000000000001 110.827 178.245 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -90.42 99.94 0.21 Allowed 'Cis proline' 0 N--CA 1.456 -0.681 0 C-N-CA 123.44 -1.483 . . . . 1.6899999999999999 110.371 -13.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.482 ' CD1' ' HA ' ' A' ' 43' ' ' ARG . 96.7 m-85 -161.01 131.4 5.15 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 108.829 -0.804 . . . . 1.1100000000000001 108.829 -176.535 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -109.2 127.51 54.28 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 109.081 -0.711 . . . . 1.1499999999999999 109.081 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' TRP . . . . . 0.594 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 86.6 t90 -70.56 117.18 11.76 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.067 -0.969 . . . . 0.57999999999999996 110.985 -175.19 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.479 HG23 ' O ' ' A' ' 9' ' ' ASP . 16.2 pt -120.75 95.6 3.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.328 -0.851 . . . . 1.3200000000000001 110.019 176.213 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 61.12 -164.64 17.9 Favored Glycine 0 CA--C 1.524 0.65 0 C-N-CA 121.284 -0.484 . . . . 0.51000000000000001 113.24 -179.574 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.2 p -111.57 151.98 28.1 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 113.073 0.768 . . . . 1.1799999999999999 113.073 -175.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 49.9 t -122.17 -177.07 3.5 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 107.154 -1.425 . . . . 1.0700000000000001 107.154 175.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 58.54 -161.44 0.25 Allowed 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 118.866 0.757 . . . . 1.54 110.506 -178.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 92.0 m-20 -109.49 78.16 1.11 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.793 0.33 . . . . 3.2200000000000002 111.104 -179.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 108.69 -52.18 0.66 Allowed Glycine 0 CA--C 1.509 -0.31 0 N-CA-C 111.149 -0.78 . . . . 1.4399999999999999 111.149 176.035 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.407 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 8.6 pt -77.46 -143.14 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 114.849 -0.676 . . . . 1.8700000000000001 109.474 170.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.407 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 76.04 103.58 0.13 Allowed Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.442 -0.885 . . . . 1.0 113.031 168.399 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 38.2 m -84.04 98.71 10.0 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.898 -0.779 . . . . 1.6499999999999999 108.898 172.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 42.7 t -72.65 106.08 4.53 Favored 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 107.884 -1.154 . . . . 0.87 107.884 175.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.594 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 37.0 m -126.9 174.56 8.72 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 121.12 0.486 . . . . 1.02 109.771 178.191 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.667 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -130.17 139.47 50.85 Favored 'General case' 0 N--CA 1.432 -1.332 0 C-N-CA 120.132 -0.627 . . . . 1.1799999999999999 109.849 172.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.482 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 61.3 ttp180 -61.34 110.96 1.57 Allowed 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.567 -0.742 . . . . 4.46 111.29 -173.349 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 135.76 -158.93 24.04 Favored Glycine 0 N--CA 1.437 -1.237 0 CA-C-N 114.771 -1.104 . . . . 1.54 111.952 -178.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.429 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 28.7 t-105 -143.71 116.98 9.0 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.867 -0.419 . . . . 1.98 109.867 -179.13 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.523 ' HD2' ' HA ' ' A' ' 8' ' ' ILE . 12.5 ttm180 -88.63 136.99 32.72 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.458 -0.337 . . . . 4.2199999999999998 110.265 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.1 t . . . . . 0 C--O 1.249 1.065 0 O-C-N 123.948 0.78 . . . . 4.0099999999999998 110.042 -177.663 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.79 0 CA-C-O 120.504 0.193 . . . . 6.6399999999999997 110.628 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -74.6 -25.14 13.04 Favored 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 122.685 2.257 . . . . 6.8499999999999996 109.888 178.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -125.92 164.13 21.45 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 107.708 -1.219 . . . . 6.21 107.708 172.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 6.2 tp -88.91 110.27 36.52 Favored Pre-proline 0 C--N 1.321 -0.67 0 N-CA-C 109.815 -0.439 . . . . 6.9800000000000004 109.815 175.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.445 ' HB3' ' H ' ' A' ' 47' ' ' SER . 70.0 Cg_exo -38.68 109.07 0.08 OUTLIER 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 123.629 2.886 . . . . 4.5899999999999999 113.964 179.547 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 38.6 mtm105 -95.02 164.98 17.94 Favored Pre-proline 0 C--N 1.321 -0.669 0 N-CA-C 108.9 -0.778 . . . . 7.54 108.9 176.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_exo -44.51 128.74 8.49 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.296 1.997 . . . . 5.6900000000000004 111.154 171.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.463 ' HA ' ' CD ' ' A' ' 46' ' ' ARG . 56.8 mt -61.6 119.48 5.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.871 -0.604 . . . . 4.46 111.678 -171.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 57.4 m-20 -84.3 163.28 19.71 Favored 'General case' 0 CA--C 1.513 -0.461 0 CA-C-N 115.462 -0.79 . . . . 3.25 109.503 177.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.464 ' C ' ' H ' ' A' ' 12' ' ' ARG . 11.2 p -84.01 -175.69 5.92 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.626 -0.715 . . . . 2.2000000000000002 110.593 176.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.426 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 37.0 t -56.05 1.62 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 122.878 0.471 . . . . 1.3 112.153 178.468 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.464 ' H ' ' C ' ' A' ' 10' ' ' THR . 14.5 ptt180 -55.79 -34.97 65.77 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 120.577 0.227 . . . . 4.8099999999999996 110.842 171.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -89.78 97.53 11.25 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 107.797 -1.186 . . . . 3.0499999999999998 107.797 168.324 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.759 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 8.3 tpt180 -109.71 171.59 7.36 Favored 'General case' 0 N--CA 1.433 -1.306 0 CA-C-O 120.971 0.415 . . . . 7.7800000000000002 112.007 -166.501 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.759 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 92.1 m-20 72.04 51.92 0.21 Allowed 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 115.215 -0.902 . . . . 4.9500000000000002 111.052 173.525 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.651 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -109.17 -47.75 0.86 Allowed Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.619 -1.277 . . . . 1.7 110.87 170.419 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.651 HG13 ' O ' ' A' ' 16' ' ' GLY . 3.3 mt -168.99 138.58 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 124.548 1.139 . . . . 1.6299999999999999 109.56 156.001 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 15.4 t -99.74 104.18 15.88 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.967 -0.382 . . . . 1.28 109.967 170.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.573 ' HD1' ' SG ' ' A' ' 23' ' ' CYS . 33.4 m-85 -92.37 131.45 34.46 Favored Pre-proline 0 CA--C 1.514 -0.424 0 CA-C-N 116.53 -0.305 . . . . 0.84999999999999998 110.903 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -87.5 96.12 0.45 Allowed 'Trans proline' 0 N--CA 1.443 -1.466 0 C-N-CA 121.171 1.247 . . . . 0.55000000000000004 109.744 165.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.75 -114.52 0.91 Allowed Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.638 -0.71 . . . . 0.58999999999999997 111.75 -173.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -140.28 141.75 32.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 121.25 0.547 . . . . 1.6499999999999999 112.111 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . 0.573 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 79.4 m -95.55 134.88 37.91 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-N 115.533 -0.758 . . . . 1.4399999999999999 109.604 172.359 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.452 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 15.0 ptm180 -136.38 -37.92 0.69 Allowed 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 120.046 -0.662 . . . . 5.6399999999999997 112.597 178.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.452 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 8.2 mtt180 176.32 146.48 0.26 Allowed Pre-proline 0 N--CA 1.47 0.573 0 N-CA-C 112.295 0.48 . . . . 4.3700000000000001 112.295 175.043 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -86.83 98.52 0.21 Allowed 'Cis proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.455 -1.894 . . . . 1.6899999999999999 110.049 -11.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.624 ' CE1' HD13 ' A' ' 17' ' ' ILE . 89.4 m-85 -162.53 133.47 4.94 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.658 -0.867 . . . . 1.1100000000000001 108.658 -174.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -109.1 127.36 54.09 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 109.229 -0.656 . . . . 1.1499999999999999 109.229 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' TRP . . . . . 0.597 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 76.4 t90 -68.66 114.24 6.86 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 114.955 -1.021 . . . . 0.57999999999999996 110.155 -178.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.426 ' O ' ' HB2' ' A' ' 11' ' ' CYS . 18.1 pt -120.98 93.71 2.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.669 0.747 . . . . 1.3200000000000001 109.981 176.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 65.08 -172.46 21.2 Favored Glycine 0 CA--C 1.524 0.621 0 CA-C-N 115.799 -0.637 . . . . 0.51000000000000001 113.049 -175.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 19.8 p -105.46 159.41 15.95 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.091 0.472 . . . . 1.1799999999999999 111.989 -174.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.407 ' SG ' ' N ' ' A' ' 34' ' ' ASN . 48.7 t -121.92 -178.37 3.83 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.36 -0.607 . . . . 1.0700000000000001 109.36 177.258 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.454 ' ND2' ' HA3' ' A' ' 38' ' ' GLY . 7.6 m-20 57.84 -145.53 0.58 Allowed 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.451 -0.574 . . . . 1.54 109.451 -172.403 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 35.0 m-80 -83.31 -1.09 52.42 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.617 0.246 . . . . 3.2200000000000002 111.11 175.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 153.63 -35.73 0.74 Allowed Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 119.817 -1.182 . . . . 1.4399999999999999 114.54 176.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -80.15 -32.34 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 113.033 0.753 . . . . 1.8700000000000001 113.033 -172.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.454 ' HA3' ' ND2' ' A' ' 34' ' ' ASN . . . -68.83 172.03 37.22 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 120.441 -0.885 . . . . 1.0 111.697 177.086 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.451 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 68.5 p -117.69 124.07 47.62 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.224 0.535 . . . . 1.6499999999999999 111.252 -174.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 42.0 t -83.9 104.26 13.84 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 107.592 -1.262 . . . . 0.87 107.592 172.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.597 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 29.6 m -127.38 174.77 8.72 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 109.852 -0.425 . . . . 1.02 109.852 178.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.623 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -136.37 143.01 43.82 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 119.923 -0.711 . . . . 1.1799999999999999 111.077 173.186 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.46 ' HD3' ' C ' ' A' ' 43' ' ' ARG . 3.4 tmt_? -61.54 112.13 2.09 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.062 -0.972 . . . . 4.46 110.466 -177.376 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 141.36 -159.33 26.7 Favored Glycine 0 N--CA 1.439 -1.116 0 CA-C-N 115.11 -0.95 . . . . 1.54 111.112 178.252 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.458 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 31.9 t-105 -148.0 119.15 7.74 Favored 'General case' 0 C--N 1.314 -0.942 0 C-N-CA 120.47 -0.492 . . . . 1.98 111.002 -179.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.463 ' CD ' ' HA ' ' A' ' 8' ' ' ILE . 23.8 ttm180 -107.63 145.62 33.07 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 115.787 -0.642 . . . . 4.2199999999999998 110.007 172.267 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.445 ' H ' ' HB3' ' A' ' 5' ' ' PRO . 17.1 t . . . . . 0 C--O 1.249 1.028 0 O-C-N 124.372 1.045 . . . . 4.0099999999999998 110.02 -176.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.808 0 CA-C-O 120.399 0.142 . . . . 6.6399999999999997 110.701 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.2 -23.67 10.14 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.805 2.336 . . . . 6.8499999999999996 110.305 177.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.0 p90 -127.83 166.1 18.88 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-N 114.212 -1.358 . . . . 6.21 107.667 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.617 ' O ' ' HG3' ' A' ' 6' ' ' ARG . 6.2 tp -95.07 113.69 62.0 Favored Pre-proline 0 C--N 1.317 -0.815 0 C-N-CA 120.528 -0.469 . . . . 6.9800000000000004 109.851 175.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.447 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 1.7 Cg_endo -44.72 124.71 5.77 Favored 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 123.006 2.471 . . . . 4.5899999999999999 112.765 176.089 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.617 ' HG3' ' O ' ' A' ' 4' ' ' ILE . 79.8 mtp180 -124.94 163.13 39.39 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-N 115.532 -0.758 . . . . 7.54 109.627 -177.147 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_exo -51.35 128.47 25.68 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.494 2.129 . . . . 5.6900000000000004 112.537 178.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 71.0 mt -82.9 116.06 26.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 CA-C-N 115.112 -0.949 . . . . 4.46 109.921 178.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -130.36 165.9 21.56 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.401 -0.363 . . . . 3.25 110.136 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 7.7 p -57.95 -176.93 0.03 OUTLIER 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 112.743 0.645 . . . . 2.2000000000000002 112.743 177.202 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.427 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 22.9 t -58.03 4.04 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.528 1.131 . . . . 1.3 113.294 -171.212 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.469 ' HG3' HD21 ' A' ' 13' ' ' LEU . 5.0 ptp180 -57.6 -31.22 65.98 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 108.735 -0.839 . . . . 4.8099999999999996 108.735 167.454 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.718 ' O ' HD11 ' A' ' 30' ' ' ILE . 3.7 mm? -88.78 122.08 31.81 Favored 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 106.789 -1.559 . . . . 3.0499999999999998 106.789 161.663 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.734 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 13.0 tpt180 -131.21 170.54 14.43 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 112.707 0.632 . . . . 7.7800000000000002 112.707 -168.737 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . 0.734 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 94.3 m-20 72.35 66.4 0.13 Allowed 'General case' 0 CA--C 1.512 -0.512 0 CA-C-N 114.775 -1.102 . . . . 4.9500000000000002 112.86 169.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.689 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -130.67 -47.91 0.13 Allowed Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 119.632 -1.27 . . . . 1.7 111.551 167.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.689 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.3 mt -169.13 133.98 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.465 1.106 . . . . 1.6299999999999999 109.9 159.663 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 6.3 t -96.94 124.04 40.81 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.978 -0.379 . . . . 1.28 109.978 172.023 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.513 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 23.3 m-85 -105.93 127.71 27.85 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 116.471 -0.331 . . . . 0.84999999999999998 111.009 179.499 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.481 ' HA ' HD22 ' A' ' 34' ' ' ASN . 57.6 Cg_endo -74.48 97.95 1.08 Allowed 'Trans proline' 0 N--CA 1.452 -0.957 0 C-N-CA 121.3 1.333 . . . . 0.55000000000000004 109.591 167.055 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.495 ' H ' ' HA2' ' A' ' 38' ' ' GLY . . . 133.04 -124.34 3.73 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.489 -0.778 . . . . 0.58999999999999997 111.259 -171.415 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -142.85 146.95 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-N 117.069 0.434 . . . . 1.6499999999999999 111.523 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . 0.45 ' SG ' ' CD1' ' A' ' 19' ' ' PHE . 22.6 m -86.18 147.19 26.24 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 115.94 -0.573 . . . . 1.4399999999999999 111.455 177.163 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.617 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 16.3 ptm180 -141.55 -37.34 0.42 Allowed 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 112.551 0.574 . . . . 5.6399999999999997 112.551 176.281 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.617 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 10.2 mmt180 177.32 142.19 0.25 Allowed Pre-proline 0 N--CA 1.478 0.96 0 C-N-CA 122.737 0.415 . . . . 4.3700000000000001 111.193 178.658 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.576 ' HD2' ' CE2' ' A' ' 27' ' ' TYR . 24.2 Cg_endo -91.35 98.35 0.16 OUTLIER 'Cis proline' 0 C--N 1.349 0.593 0 C-N-CA 122.792 -1.753 . . . . 1.6899999999999999 111.704 -10.403 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.576 ' CE2' ' HD2' ' A' ' 26' ' ' PRO . 80.9 m-85 -161.53 143.89 11.94 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.695 -0.854 . . . . 1.1100000000000001 108.695 -172.194 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 11.0 p90 -111.07 127.76 55.65 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 109.008 -0.738 . . . . 1.1499999999999999 109.008 175.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 84.6 t90 -68.5 113.35 5.96 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.144 -0.935 . . . . 0.57999999999999996 110.126 -178.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.718 HD11 ' O ' ' A' ' 13' ' ' LEU . 12.1 pt -119.27 94.35 3.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 109.242 -0.651 . . . . 1.3200000000000001 109.242 174.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 65.24 -173.2 20.21 Favored Glycine 0 CA--C 1.524 0.612 0 CA-C-N 115.962 -0.563 . . . . 0.51000000000000001 113.079 -177.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.1 p -108.57 161.78 14.75 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 122.27 -0.547 . . . . 1.1799999999999999 112.047 -176.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 39.1 t -130.98 178.97 6.27 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 116.102 -0.499 . . . . 1.0700000000000001 110.299 -177.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.481 HD22 ' HA ' ' A' ' 20' ' ' PRO . 1.7 m-20 63.8 -82.48 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.313 1.045 . . . . 1.54 110.791 -174.251 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 54.5 m-80 -151.57 26.67 0.66 Allowed 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.364 -0.606 . . . . 3.2200000000000002 109.364 -178.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 107.8 -20.34 31.75 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.752 -0.737 . . . . 1.4399999999999999 112.944 179.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.505 ' H ' HD12 ' A' ' 37' ' ' ILE . 0.2 OUTLIER -81.09 -58.4 3.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 O-C-N 122.511 -0.405 . . . . 1.8700000000000001 111.293 -177.791 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.495 ' HA2' ' H ' ' A' ' 21' ' ' GLY . . . -69.18 174.9 33.19 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.966 -0.635 . . . . 1.0 112.198 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.513 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 77.3 p -108.54 125.74 52.16 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-O 121.392 0.615 . . . . 1.6499999999999999 111.499 -173.24 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 41.4 t -82.54 113.35 20.2 Favored 'General case' 0 N--CA 1.442 -0.86 0 N-CA-C 106.67 -1.604 . . . . 0.87 106.67 169.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.48 ' HA ' HG12 ' A' ' 30' ' ' ILE . 28.2 m -132.0 177.24 7.7 Favored 'General case' 0 C--N 1.311 -1.085 0 CA-C-O 121.421 0.629 . . . . 1.02 110.703 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.617 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -135.53 137.6 42.23 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.513 -0.767 . . . . 1.1799999999999999 109.618 167.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.505 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 4.3 tmt_? -60.7 113.41 2.46 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 115.378 -0.828 . . . . 4.46 110.778 -174.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 134.62 -150.99 20.23 Favored Glycine 0 N--CA 1.438 -1.183 0 CA-C-N 115.252 -0.886 . . . . 1.54 112.072 176.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 26.0 t-105 -145.51 124.74 12.95 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.369 -0.604 . . . . 1.98 109.369 179.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 19.5 ttm180 -102.42 128.75 48.88 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 120.978 0.418 . . . . 4.2199999999999998 110.929 176.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 18.5 m . . . . . 0 C--O 1.249 1.075 0 CA-C-N 114.145 -1.388 . . . . 4.0099999999999998 112.289 178.171 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.807 0 N-CA-C 110.734 -0.098 . . . . 6.6399999999999997 110.734 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -80.44 -19.44 8.95 Favored 'Trans proline' 0 C--N 1.349 0.569 0 C-N-CA 122.722 2.281 . . . . 6.8499999999999996 110.073 175.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 14.3 p90 -136.59 163.06 31.43 Favored 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 107.297 -1.372 . . . . 6.21 107.297 175.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.436 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 6.0 tp -88.04 114.81 60.92 Favored Pre-proline 0 C--N 1.319 -0.758 0 C-N-CA 120.513 -0.475 . . . . 6.9800000000000004 110.192 176.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . 0.436 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 9.6 Cg_endo -51.47 133.76 44.07 Favored 'Trans proline' 0 C--N 1.351 0.66 0 C-N-CA 123.169 2.579 . . . . 4.5899999999999999 113.261 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.495 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 61.5 mtp180 -109.54 170.67 5.12 Favored Pre-proline 0 C--N 1.321 -0.644 0 CA-C-N 115.299 -0.864 . . . . 7.54 109.473 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.495 ' HD2' ' HB3' ' A' ' 6' ' ' ARG . 85.2 Cg_exo -43.97 132.16 8.34 Favored 'Trans proline' 0 C--N 1.352 0.755 0 C-N-CA 122.713 2.275 . . . . 5.6900000000000004 112.663 175.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.559 ' HA ' ' HD2' ' A' ' 46' ' ' ARG . 61.9 mt -69.68 120.39 17.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.595 -0.729 . . . . 4.46 111.974 -176.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 36.2 m-20 -81.14 166.15 20.93 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.19 -0.913 . . . . 3.25 109.732 174.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.525 ' C ' ' H ' ' A' ' 12' ' ' ARG . 37.0 p -85.86 -171.24 3.49 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.183 -0.673 . . . . 2.2000000000000002 109.183 174.03 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.558 ' O ' ' HG2' ' A' ' 14' ' ' ARG . 58.4 m -50.9 -1.52 0.01 OUTLIER 'General case' 0 CA--C 1.549 0.938 0 CA-C-O 121.076 0.465 . . . . 1.3 110.742 166.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.525 ' H ' ' C ' ' A' ' 10' ' ' THR . 12.0 ttt180 -32.74 -43.19 0.09 Allowed 'General case' 0 N--CA 1.463 0.176 0 C-N-CA 124.942 1.297 . . . . 4.8099999999999996 110.834 163.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 8.8 mp -114.96 111.35 21.02 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 115.184 -0.917 . . . . 3.0499999999999998 108.644 174.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.662 ' HD2' ' SG ' ' A' ' 40' ' ' CYS . 1.6 mmp_? -116.9 -171.19 1.98 Allowed 'General case' 0 CA--C 1.507 -0.682 0 N-CA-C 113.167 0.802 . . . . 7.7800000000000002 113.167 -175.438 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 70.7 42.87 0.79 Allowed 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 114.492 -1.231 . . . . 4.9500000000000002 109.63 -172.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.664 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -106.43 -51.48 0.81 Allowed Glycine 0 N--CA 1.441 -0.971 0 C-N-CA 119.233 -1.46 . . . . 1.7 111.956 173.277 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.701 HD11 ' CE1' ' A' ' 27' ' ' TYR . 2.7 mt -173.33 150.77 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 C-N-CA 125.112 1.365 . . . . 1.6299999999999999 108.914 157.14 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 9.2 t -110.89 108.28 18.02 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.263 -0.643 . . . . 1.28 109.263 166.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.618 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 46.9 m-85 -94.36 132.99 27.85 Favored Pre-proline 0 CA--C 1.513 -0.47 0 CA-C-O 120.881 0.372 . . . . 0.84999999999999998 111.184 -177.53 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -85.54 95.83 0.61 Allowed 'Trans proline' 0 N--CA 1.438 -1.793 0 N-CA-C 108.349 -1.443 . . . . 0.55000000000000004 108.349 158.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.93 -130.6 5.53 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.26 -0.882 . . . . 0.58999999999999997 110.973 -168.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.1 pt -135.87 148.48 27.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.521 0.677 . . . . 1.6499999999999999 112.606 -176.527 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -87.78 123.35 32.49 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.053 -0.976 . . . . 1.4399999999999999 109.308 169.2 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.468 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 12.3 ptm180 -123.59 -38.24 2.55 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 119.579 -0.849 . . . . 5.6399999999999997 112.335 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.468 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 11.5 mtt180 175.02 141.86 0.2 Allowed Pre-proline 0 N--CA 1.475 0.795 0 O-C-N 123.385 0.428 . . . . 4.3700000000000001 111.88 171.154 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -88.55 99.84 0.23 Allowed 'Cis proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.715 -1.785 . . . . 1.6899999999999999 110.567 -10.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.701 ' CE1' HD11 ' A' ' 17' ' ' ILE . 75.7 m-85 -161.74 128.54 3.86 Favored 'General case' 0 CA--C 1.506 -0.729 0 N-CA-C 108.883 -0.784 . . . . 1.1100000000000001 108.883 -177.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' TYR . . . . . 0.472 ' CZ ' ' HB3' ' A' ' 42' ' ' ALA . 27.0 p90 -107.83 130.13 55.01 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-O 121.208 0.528 . . . . 1.1499999999999999 110.205 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 86.4 t90 -65.67 113.82 4.53 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.49 -1.232 . . . . 0.57999999999999996 111.122 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.473 HD11 HH21 ' A' ' 14' ' ' ARG . 4.7 pt -120.32 92.68 2.21 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.852 0 CA-C-N 115.66 -0.7 . . . . 1.3200000000000001 109.383 171.728 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 66.18 -164.87 39.87 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 120.711 -0.757 . . . . 0.51000000000000001 113.292 -177.389 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -114.46 160.11 19.56 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 112.518 0.562 . . . . 1.1799999999999999 112.518 -174.693 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 49.6 t -127.92 -176.37 3.76 Favored 'General case' 0 C--O 1.22 -0.485 0 N-CA-C 107.808 -1.182 . . . . 1.0700000000000001 107.808 175.034 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.4 ' HB3' ' H ' ' A' ' 35' ' ' ASN . 92.9 m-20 61.23 -155.87 0.35 Allowed 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 118.891 0.769 . . . . 1.54 109.884 -177.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.4 ' H ' ' HB3' ' A' ' 34' ' ' ASN . 45.4 m-80 -111.05 88.54 2.81 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.806 0.336 . . . . 3.2200000000000002 111.064 179.739 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 92.04 -47.86 2.7 Favored Glycine 0 CA--C 1.506 -0.49 0 N-CA-C 110.892 -0.883 . . . . 1.4399999999999999 110.892 175.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ILE . . . . . 0.462 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 4.7 pt -77.74 -147.7 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 114.397 -0.901 . . . . 1.8700000000000001 109.79 170.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.462 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 73.44 161.76 7.01 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 121.171 -0.538 . . . . 1.0 113.459 169.211 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.772 ' HB2' ' SG ' ' A' ' 41' ' ' CYS . 4.7 p -139.74 113.2 8.43 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-O 121.928 0.87 . . . . 1.6499999999999999 111.4 177.638 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . 0.662 ' SG ' ' HD2' ' A' ' 14' ' ' ARG . 36.5 t -77.95 98.12 5.56 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 106.957 -1.497 . . . . 0.87 106.957 172.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . 0.772 ' SG ' ' HB2' ' A' ' 39' ' ' SER . 12.3 m -132.72 141.86 48.76 Favored 'General case' 0 C--N 1.32 -0.687 0 O-C-N 121.946 -0.471 . . . . 1.02 109.832 -174.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.48 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -100.69 139.8 35.87 Favored 'General case' 0 C--N 1.316 -0.848 0 C-N-CA 120.258 -0.577 . . . . 1.1799999999999999 111.495 -176.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.514 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 4.0 tmt_? -62.04 107.99 0.97 Allowed 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 115.258 -0.883 . . . . 4.46 110.245 179.11 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 138.5 -170.77 23.77 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.417 -0.81 . . . . 1.54 111.293 -178.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.525 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 23.9 t-105 -135.3 118.67 16.75 Favored 'General case' 0 N--CA 1.442 -0.842 0 C-N-CA 120.271 -0.571 . . . . 1.98 110.898 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ARG . . . . . 0.559 ' HD2' ' HA ' ' A' ' 8' ' ' ILE . 15.7 ttm180 -112.6 144.83 41.42 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 115.789 -0.641 . . . . 4.2199999999999998 110.338 176.012 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 16.3 t . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.06 -0.971 . . . . 4.0099999999999998 110.652 -179.103 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.557 HG12 ' HG3' ' A' ' 46' ' ' ARG . 41.9 mt . . . . . 0 N--CA 1.465 0.287 0 CA-C-O 121.415 0.626 . . . . 4.18 112.23 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.549 ' O ' HG22 ' A' ' 30' ' ' ILE . 17.0 m-20 -103.37 165.62 10.92 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.128 -0.942 . . . . 3.25 110.069 175.5 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.407 ' C ' ' H ' ' A' ' 12' ' ' ARG . 25.0 p -83.53 -176.34 6.25 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.843 -0.617 . . . . 1.72 110.375 173.167 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.578 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 25.4 t -58.01 1.58 0.05 OUTLIER 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 122.789 0.436 . . . . 1.04 112.081 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.43 HH11 ' HD2' ' A' ' 12' ' ' ARG . 8.3 ptt180 -54.56 -35.44 63.26 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 109.86 -0.422 . . . . 4.23 109.86 170.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.417 ' O ' HD12 ' A' ' 30' ' ' ILE . 11.1 mp -85.41 97.82 10.22 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 107.278 -1.379 . . . . 2.66 107.278 165.69 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.608 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 19.0 tpt180 -107.41 168.57 9.14 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 112.22 0.452 . . . . 7.01 112.22 -164.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.608 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 6.1 t30 72.57 69.63 0.13 Allowed 'General case' 0 CA--C 1.513 -0.48 0 CA-C-N 114.859 -1.064 . . . . 4.38 111.219 172.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.721 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -130.45 -47.17 0.14 Allowed Glycine 0 N--CA 1.435 -1.369 0 C-N-CA 119.891 -1.147 . . . . 1.7 111.273 167.146 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.721 HG12 ' O ' ' A' ' 16' ' ' GLY . 15.9 mm -164.86 146.51 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 124.415 1.086 . . . . 1.05 108.685 164.162 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -113.92 111.4 21.64 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.32 -0.622 . . . . 1.28 109.32 165.148 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.453 ' CE1' HG21 ' A' ' 17' ' ' ILE . 44.3 m-85 -94.27 139.91 22.62 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 116.38 -0.373 . . . . 0.67 111.17 -176.754 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -84.98 98.52 0.68 Allowed 'Trans proline' 0 N--CA 1.445 -1.356 0 C-N-CA 121.819 1.68 . . . . 0.48 109.139 163.569 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 123.51 -131.13 7.97 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 110.373 -1.091 . . . . 0.59 110.373 -166.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 36.4 pt -136.95 156.67 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.532 0.682 . . . . 1.2 112.228 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 29' ' ' TRP . 0.2 OUTLIER -81.17 130.59 35.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.876 -1.057 . . . . 1.44 110.428 174.73 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.734 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 14.8 ptp180 -119.14 -39.98 2.87 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 119.461 -0.896 . . . . 5.09 112.701 176.494 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.734 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 12.9 mmt180 176.43 140.45 0.22 Allowed Pre-proline 0 N--CA 1.482 1.158 0 C-N-CA 123.32 0.648 . . . . 3.77 110.557 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.426 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 1.7 Cg_endo -91.24 100.46 0.22 Allowed 'Cis proline' 0 N--CA 1.455 -0.765 0 C-N-CA 123.646 -1.398 . . . . 1.34 109.968 -13.715 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.594 ' CE1' HG13 ' A' ' 17' ' ' ILE . 83.7 m-85 -160.84 133.03 5.98 Favored 'General case' 0 CA--C 1.503 -0.834 0 N-CA-C 108.816 -0.809 . . . . 0.64 108.816 -174.065 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.523 ' CD1' ' HB3' ' A' ' 46' ' ' ARG . 19.1 p90 -108.3 129.54 55.22 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.003 -0.544 . . . . 0.71 109.582 -179.019 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' TRP . . . . . 0.526 ' HB2' ' SG ' ' A' ' 23' ' ' CYS . 90.0 t90 -66.8 112.77 4.43 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.34 -0.845 . . . . 0.54 110.746 -178.538 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.578 ' O ' ' HB2' ' A' ' 11' ' ' CYS . 5.3 pt -119.2 93.41 2.53 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 115.021 -0.99 . . . . 0.72 108.985 173.013 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 68.7 177.22 13.52 Favored Glycine 0 C--N 1.316 -0.544 0 C-N-CA 120.821 -0.704 . . . . 0.47 112.715 -179.129 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.5 HG22 ' O ' ' A' ' 38' ' ' GLY . 0.1 OUTLIER -97.71 164.53 12.37 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 122.323 -0.516 . . . . 0.62 111.19 -175.99 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 10.5 t -136.26 179.57 6.27 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.355 -0.98 . . . . 1.07 108.355 175.654 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.43 ' HB2' ' H ' ' A' ' 38' ' ' GLY . 13.8 m120 53.34 27.65 6.49 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 120.722 0.296 . . . . 1.54 111.106 -175.072 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 2.8 t30 64.54 22.16 12.61 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 123.36 0.664 . . . . 2.54 111.586 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 136.3 -36.04 2.05 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 119.911 -1.137 . . . . 1.12 114.021 175.096 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.424 HG13 ' CB ' ' A' ' 34' ' ' ASN . 0.9 OUTLIER -82.57 -23.55 8.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 112.597 0.591 . . . . 1.87 112.597 -175.835 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.5 ' O ' HG22 ' A' ' 32' ' ' THR . . . -103.53 -167.93 25.54 Favored Glycine 0 N--CA 1.426 -1.991 0 N-CA-C 110.37 -1.092 . . . . 0.79 110.37 -177.794 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.534 ' HB2' ' SG ' ' A' ' 41' ' ' CYS . 23.6 p -144.77 119.87 10.09 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.478 0.656 . . . . 1.25 111.75 -173.412 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.482 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 41.8 t -74.42 104.2 5.06 Favored 'General case' 0 N--CA 1.442 -0.86 0 N-CA-C 107.073 -1.454 . . . . 0.87 107.073 172.076 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.534 ' SG ' ' HB2' ' A' ' 39' ' ' SER . 14.1 m -139.26 111.16 7.27 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.361 -0.607 . . . . 1.02 109.361 -176.854 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.568 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -80.7 143.39 33.03 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.871 0.367 . . . . 0.55 110.87 -172.768 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.566 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 39.7 ttm180 -62.53 114.07 3.33 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.432 -0.804 . . . . 3.86 111.096 -176.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 139.17 -152.56 22.38 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 114.676 -1.147 . . . . 1.54 111.263 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 38.3 t-105 -145.12 130.39 18.6 Favored 'General case' 0 N--CA 1.443 -0.806 0 C-N-CA 119.957 -0.697 . . . . 1.55 112.048 179.451 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.557 ' HG3' HG12 ' A' ' 8' ' ' ILE . 1.9 tpp180 -125.33 117.32 23.49 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 115.092 -0.958 . . . . 3.53 110.312 174.093 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.489 ' HB2' HD11 ' A' ' 8' ' ' ILE . 44.4 m . . . . . 0 C--O 1.248 1.014 0 CA-C-N 114.067 -1.424 . . . . 4.01 111.704 -176.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 2.2 mp . . . . . 0 N--CA 1.453 -0.277 0 CA-C-O 121.296 0.57 . . . . 4.18 111.259 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -91.37 165.24 13.52 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.295 -0.866 . . . . 3.25 109.464 177.675 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.403 ' C ' ' H ' ' A' ' 12' ' ' ARG . 6.5 p -89.27 -175.83 4.89 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 116.264 -0.426 . . . . 1.72 110.825 176.07 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.511 ' H ' ' HA3' ' A' ' 31' ' ' GLY . 19.0 t -64.41 11.37 0.05 OUTLIER 'General case' 0 N--CA 1.47 0.549 0 CA-C-O 121.317 0.58 . . . . 1.04 112.088 -172.242 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 12' ' ' ARG . 18.3 ptt85 -57.96 -25.69 61.32 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.851 -0.796 . . . . 4.23 108.851 161.526 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.612 HD21 ' NH2' ' A' ' 46' ' ' ARG . 5.4 mp -74.71 153.19 38.97 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 115.554 -0.748 . . . . 2.66 109.518 169.378 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.66 98.99 6.41 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 114.611 1.337 . . . . 7.01 114.611 -167.156 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 66.5 t30 31.18 61.74 0.24 Allowed 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 124.181 0.992 . . . . 4.38 113.335 156.325 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.664 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -77.24 -43.54 16.01 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 118.811 -1.661 . . . . 1.7 112.824 -172.176 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.664 HG12 ' O ' ' A' ' 16' ' ' GLY . 20.3 mm -163.18 128.33 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 124.896 1.278 . . . . 1.05 108.273 165.685 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 8.2 m -94.89 110.54 22.41 Favored 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 120.407 -0.517 . . . . 1.28 110.785 173.333 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.531 ' CZ ' HG21 ' A' ' 17' ' ' ILE . 43.8 m-85 -102.52 131.68 22.16 Favored Pre-proline 0 CA--C 1.51 -0.59 0 CA-C-N 116.036 -0.529 . . . . 0.67 110.82 177.764 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -74.48 97.8 1.07 Allowed 'Trans proline' 0 N--CA 1.448 -1.165 0 C-N-CA 121.104 1.202 . . . . 0.48 109.316 169.03 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.478 ' H ' ' HA2' ' A' ' 38' ' ' GLY . . . 128.92 -122.56 3.96 Favored Glycine 0 N--CA 1.442 -0.927 0 CA-C-N 115.217 -0.901 . . . . 0.59 111.204 -169.155 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -146.6 147.15 18.2 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 121.115 0.483 . . . . 1.2 111.567 -178.333 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' CYS . . . . . 0.508 ' HB3' ' HB2' ' A' ' 27' ' ' TYR . 0.0 OUTLIER -71.65 127.69 33.39 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.367 -0.833 . . . . 1.44 110.424 173.759 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.698 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 25.8 ptt180 -116.09 -38.11 3.69 Favored 'General case' 0 C--N 1.322 -0.628 0 C-N-CA 120.14 -0.624 . . . . 5.09 111.537 175.555 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.698 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 14.7 mmt180 175.7 143.93 0.23 Allowed Pre-proline 0 N--CA 1.477 0.899 0 C-N-CA 123.361 0.664 . . . . 3.77 110.932 177.218 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 1.2 Cg_endo -93.94 100.4 0.18 OUTLIER 'Cis proline' 0 N--CA 1.457 -0.62 0 C-N-CA 123.878 -1.301 . . . . 1.34 110.756 -14.464 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.628 ' CE1' HG13 ' A' ' 17' ' ' ILE . 63.1 m-85 -161.5 139.56 9.29 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.726 -0.842 . . . . 0.64 108.726 -175.203 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.418 ' CZ ' ' HB3' ' A' ' 42' ' ' ALA . 26.1 p90 -107.85 131.74 54.17 Favored 'General case' 0 C--N 1.312 -1.027 0 C-N-CA 120.306 -0.558 . . . . 0.71 110.348 177.689 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 86.9 t90 -67.02 112.58 4.44 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.642 -1.163 . . . . 0.54 110.92 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.567 HG12 ' O ' ' A' ' 40' ' ' CYS . 0.6 OUTLIER -120.11 93.62 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 CA-C-O 121.957 0.884 . . . . 0.72 109.404 170.398 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.511 ' HA3' ' H ' ' A' ' 11' ' ' CYS . . . 70.75 178.63 26.72 Favored Glycine 0 CA--C 1.523 0.559 0 CA-C-N 115.544 -0.753 . . . . 0.47 113.482 -177.789 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.539 HG22 ' O ' ' A' ' 38' ' ' GLY . 0.0 OUTLIER -97.87 162.9 13.02 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.066 0.46 . . . . 0.62 111.137 -177.534 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 15.7 t -135.36 -177.22 4.56 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.374 -0.973 . . . . 1.07 108.374 175.639 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 12.8 m120 59.63 -160.82 0.28 Allowed 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 109.905 -0.406 . . . . 1.54 109.905 -173.138 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -83.21 42.21 0.8 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.113 0.482 . . . . 2.54 110.113 174.512 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 89.72 11.61 63.58 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 121.069 -0.586 . . . . 1.12 112.487 -178.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 8.1 pt -120.25 14.09 6.51 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.351 0 CA-C-O 121.219 0.533 . . . . 1.87 112.013 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.539 ' O ' HG22 ' A' ' 32' ' ' THR . . . -133.12 170.4 22.21 Favored Glycine 0 N--CA 1.424 -2.109 0 N-CA-C 110.082 -1.207 . . . . 0.79 110.082 178.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 57.2 p -120.51 126.04 49.38 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 121.022 0.439 . . . . 1.25 110.584 -177.253 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.567 ' O ' HG12 ' A' ' 30' ' ' ILE . 38.5 t -82.67 91.05 6.91 Favored 'General case' 0 C--O 1.211 -0.967 0 N-CA-C 107.346 -1.353 . . . . 0.87 107.346 175.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.433 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 3.0 m -100.66 -176.52 3.21 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.791 -0.818 . . . . 1.02 108.791 -177.859 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.633 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -142.32 138.76 31.5 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.909 -0.316 . . . . 0.55 110.479 166.018 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.485 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 34.8 ttp180 -59.81 110.4 1.15 Allowed 'General case' 0 C--O 1.234 0.287 0 O-C-N 123.957 0.786 . . . . 3.86 110.876 -178.822 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 138.65 -154.86 23.34 Favored Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 114.909 -1.041 . . . . 1.54 111.215 -177.485 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 32.5 t-105 -145.25 146.03 31.52 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 121.222 0.534 . . . . 1.55 111.353 177.813 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.612 ' NH2' HD21 ' A' ' 13' ' ' LEU . 10.5 ttm180 -130.69 127.28 38.54 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.484 -0.78 . . . . 3.53 110.523 176.047 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 45.8 m . . . . . 0 C--O 1.25 1.107 0 O-C-N 124.605 1.191 . . . . 4.01 111.859 179.161 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.419 ' N ' HD12 ' A' ' 8' ' ' ILE . 2.5 mp . . . . . 0 N--CA 1.454 -0.231 0 CA-C-O 121.302 0.572 . . . . 4.18 110.26 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -100.1 169.2 9.33 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.329 -0.85 . . . . 3.25 110.295 -174.771 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 12' ' ' ARG . 16.9 p -91.03 -176.43 4.62 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.795 -0.639 . . . . 1.72 111.106 -177.299 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.618 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 47.7 t -59.56 8.67 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 121.291 0.567 . . . . 1.04 111.797 177.01 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.505 ' HG3' HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -53.28 -38.42 63.06 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.555 -0.535 . . . . 4.23 109.555 167.84 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.505 HD12 ' HG3' ' A' ' 12' ' ' ARG . 8.6 mp -77.22 126.08 30.37 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 109.07 -0.715 . . . . 2.66 109.07 172.075 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.618 ' HD3' ' SG ' ' A' ' 11' ' ' CYS . 17.3 mmm180 -134.31 171.75 13.83 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 113.077 0.769 . . . . 7.01 113.077 -171.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 64.42 20.1 12.04 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 114.357 -1.292 . . . . 4.38 110.849 -177.217 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.735 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -85.85 -51.59 3.56 Favored Glycine 0 N--CA 1.438 -1.201 0 C-N-CA 118.824 -1.655 . . . . 1.7 111.377 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.735 HG12 ' O ' ' A' ' 16' ' ' GLY . 25.5 mm -168.4 143.71 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 C-N-CA 125.903 1.681 . . . . 1.05 107.824 157.532 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.6 m -109.46 99.62 8.81 Favored 'General case' 0 C--N 1.321 -0.669 0 O-C-N 121.774 -0.579 . . . . 1.28 110.084 166.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.483 ' HD1' ' SG ' ' A' ' 41' ' ' CYS . 44.8 m-85 -88.19 135.02 33.63 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.72 -0.673 . . . . 0.67 110.938 -178.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -88.16 97.85 0.41 Allowed 'Trans proline' 0 N--CA 1.442 -1.558 0 C-N-CA 121.452 1.435 . . . . 0.48 109.729 164.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.55 -115.07 1.3 Allowed Glycine 0 N--CA 1.444 -0.819 0 N-CA-C 110.666 -0.973 . . . . 0.59 110.666 -170.563 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 22.2 pt -146.26 152.16 13.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-O 121.277 0.56 . . . . 1.2 111.94 179.262 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -86.27 142.52 28.49 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.219 -0.901 . . . . 1.44 108.735 170.391 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.9 ptt180 -131.98 -39.21 1.08 Allowed 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 119.542 -0.863 . . . . 5.09 112.251 173.218 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.408 HH11 ' HD2' ' A' ' 25' ' ' ARG . 4.8 mtt85 174.24 145.17 0.2 Allowed Pre-proline 0 N--CA 1.474 0.745 0 N-CA-C 112.033 0.383 . . . . 3.77 112.033 173.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -88.41 99.47 0.22 Allowed 'Cis proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.996 -1.669 . . . . 1.34 110.851 -9.53 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.624 ' CE1' HG13 ' A' ' 17' ' ' ILE . 68.7 m-85 -162.21 135.66 6.23 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.339 -0.986 . . . . 0.64 108.339 -176.77 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -108.42 129.76 55.25 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.973 -0.691 . . . . 0.71 110.194 176.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 85.4 t90 -66.81 113.45 4.9 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.684 -1.144 . . . . 0.54 111.193 -177.04 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.58 ' O ' ' HB3' ' A' ' 40' ' ' CYS . 10.9 pt -121.62 92.4 2.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-N 115.548 -0.751 . . . . 0.72 109.559 172.752 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 66.9 -171.61 30.83 Favored Glycine 0 CA--C 1.527 0.819 0 C-N-CA 121.281 -0.485 . . . . 0.47 113.159 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.6 p -107.66 168.54 9.18 Favored 'General case' 0 CA--C 1.533 0.299 0 O-C-N 122.381 -0.482 . . . . 0.62 111.503 -177.02 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.587 ' O ' ' HA3' ' A' ' 38' ' ' GLY . 42.7 t -160.38 105.31 1.47 Allowed 'General case' 0 C--N 1.334 -0.098 0 N-CA-C 110.277 -0.268 . . . . 1.07 110.277 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.522 ' HB3' HG13 ' A' ' 37' ' ' ILE . 0.7 OUTLIER 163.67 39.58 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.586 1.554 . . . . 1.54 109.845 176.798 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 57.12 37.82 28.72 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.104 -0.498 . . . . 2.54 111.283 -175.708 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 136.19 -64.93 0.57 Allowed Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 111.442 -0.663 . . . . 1.12 111.442 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.522 HG13 ' HB3' ' A' ' 34' ' ' ASN . 2.7 pt -80.27 -162.09 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.677 -0.261 . . . . 1.87 110.339 174.533 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.587 ' HA3' ' O ' ' A' ' 33' ' ' CYS . . . 85.49 179.4 50.5 Favored Glycine 0 N--CA 1.422 -2.249 0 C-N-CA 120.497 -0.859 . . . . 0.79 111.538 177.265 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.9 m -141.25 111.9 7.04 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.015 -0.593 . . . . 1.25 109.532 -178.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.58 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 47.2 t -79.02 111.57 15.36 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 107.26 -1.385 . . . . 0.87 107.26 175.828 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.483 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 2.2 m -129.2 156.5 43.85 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.815 -0.809 . . . . 1.02 108.815 -176.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.622 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -118.29 130.62 56.14 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 119.817 -0.753 . . . . 0.55 110.301 174.008 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.503 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 1.5 tmt_? -55.12 109.86 0.59 Allowed 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 115.275 -0.875 . . . . 3.86 110.521 -177.561 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 137.4 -162.78 25.43 Favored Glycine 0 N--CA 1.442 -0.959 0 CA-C-N 115.256 -0.884 . . . . 1.54 111.85 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 31.0 t-105 -141.59 118.51 11.18 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.033 0.445 . . . . 1.55 110.597 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 12.9 ttm180 -96.68 139.55 32.58 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.032 -0.531 . . . . 3.53 111.565 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.3 t . . . . . 0 C--O 1.247 0.943 0 CA-C-N 114.477 -1.238 . . . . 4.01 110.976 -179.375 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.461 ' HA ' ' CD ' ' A' ' 46' ' ' ARG . 81.3 mt . . . . . 0 N--CA 1.45 -0.451 0 CA-C-O 121.524 0.678 . . . . 4.18 111.322 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.466 ' O ' HG22 ' A' ' 30' ' ' ILE . 71.4 m-20 -81.75 165.3 21.06 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 114.843 -1.071 . . . . 3.25 111.026 -176.243 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.447 ' C ' ' H ' ' A' ' 12' ' ' ARG . 21.4 p -79.56 -175.49 4.81 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 114.949 -1.023 . . . . 1.72 110.906 173.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.417 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 19.4 t -57.12 4.52 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 123.595 0.758 . . . . 1.04 112.617 -179.335 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.447 ' H ' ' C ' ' A' ' 10' ' ' THR . 34.1 ptt180 -61.27 -29.91 70.14 Favored 'General case' 0 CA--C 1.531 0.239 0 O-C-N 122.018 -0.426 . . . . 4.23 110.86 174.08 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.403 ' O ' HD12 ' A' ' 30' ' ' ILE . 4.4 mm? -88.56 97.86 11.33 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 107.319 -1.363 . . . . 2.66 107.319 167.041 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.635 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 12.7 tpp85 -101.43 163.97 12.0 Favored 'General case' 0 N--CA 1.428 -1.538 0 N-CA-C 113.349 0.87 . . . . 7.01 113.349 -161.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.635 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 92.9 m-20 70.34 69.61 0.21 Allowed 'General case' 0 CA--C 1.514 -0.432 0 CA-C-N 114.421 -1.263 . . . . 4.38 112.321 168.755 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.684 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -125.27 -46.79 0.23 Allowed Glycine 0 N--CA 1.439 -1.154 0 C-N-CA 119.385 -1.388 . . . . 1.7 111.576 169.095 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.684 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.1 mt -168.86 131.53 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 124.523 1.129 . . . . 1.05 109.648 156.843 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 1.8 m -94.04 113.09 25.0 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.908 0.385 . . . . 1.28 110.213 170.861 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.615 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 64.7 m-85 -95.49 140.68 22.47 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.343 -0.389 . . . . 0.67 110.077 178.464 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_endo -86.71 96.39 0.5 Allowed 'Trans proline' 0 N--CA 1.443 -1.49 0 C-N-CA 121.356 1.37 . . . . 0.48 109.787 167.229 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.56 -109.2 0.89 Allowed Glycine 0 N--CA 1.441 -0.968 0 CA-C-N 115.339 -0.846 . . . . 0.59 111.523 -171.61 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.9 pt -146.17 145.47 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 112.386 0.513 . . . . 1.2 112.386 -176.309 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.89 126.7 32.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.609 -0.723 . . . . 1.44 109.195 172.634 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 37.4 ptt180 -115.98 -40.04 3.37 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 118.619 -1.232 . . . . 5.09 112.521 176.697 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 172.75 152.53 0.23 Allowed Pre-proline 0 N--CA 1.473 0.691 0 CA-C-N 118.112 0.414 . . . . 3.77 111.642 172.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -87.15 100.91 0.27 Allowed 'Cis proline' 0 C--N 1.347 0.45 0 C-N-CA 123.216 -1.577 . . . . 1.34 110.797 -12.418 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.57 ' CE1' HD12 ' A' ' 17' ' ' ILE . 89.1 m-85 -160.88 141.92 11.72 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 108.178 -1.045 . . . . 0.64 108.178 -175.662 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 7.6 p90 -107.76 128.96 55.04 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 120.437 -0.505 . . . . 0.71 109.641 177.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 92.1 t90 -66.71 113.83 5.14 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.988 -1.005 . . . . 0.54 110.365 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.544 ' O ' ' HB3' ' A' ' 40' ' ' CYS . 11.2 pt -120.15 93.25 2.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-N 115.271 -0.877 . . . . 0.72 109.318 175.171 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 62.31 -172.96 8.87 Favored Glycine 0 CA--C 1.526 0.736 0 C-N-CA 121.047 -0.597 . . . . 0.47 112.93 -176.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.4 p -102.1 165.53 11.11 Favored 'General case' 0 C--N 1.324 -0.523 0 O-C-N 122.173 -0.604 . . . . 0.62 111.631 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 20.6 t -137.5 -178.18 5.12 Favored 'General case' 0 C--O 1.216 -0.696 0 N-CA-C 108.334 -0.988 . . . . 1.07 108.334 178.348 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 12.2 m120 67.12 1.42 2.37 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 118.28 0.491 . . . . 1.54 111.753 -177.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 49.8 m-80 65.94 85.46 0.14 Allowed 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.611 0.764 . . . . 2.54 111.846 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 110.76 -62.46 0.29 Allowed Glycine 0 CA--C 1.511 -0.174 0 N-CA-C 111.709 -0.556 . . . . 1.12 111.709 175.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.454 ' H ' HD12 ' A' ' 37' ' ' ILE . 0.2 OUTLIER -88.76 -142.43 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.753 -0.832 . . . . 1.87 108.753 173.424 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.4 175.29 1.19 Allowed Glycine 0 N--CA 1.447 -0.602 0 CA-C-O 122.009 0.783 . . . . 0.79 114.485 169.797 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.615 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 87.6 p -142.32 119.89 11.75 Favored 'General case' 0 N--CA 1.433 -1.278 0 N-CA-C 109.599 -0.519 . . . . 1.25 109.599 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.544 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 46.0 t -82.63 116.8 22.18 Favored 'General case' 0 C--N 1.313 -1.018 0 N-CA-C 107.127 -1.435 . . . . 0.87 107.127 174.218 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.586 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -133.67 169.03 17.62 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 108.31 -0.996 . . . . 1.02 108.31 -178.322 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.659 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -136.73 142.14 43.05 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.669 -0.812 . . . . 0.55 110.744 172.089 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.477 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 57.0 ttp180 -61.42 116.65 4.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 114.973 -1.012 . . . . 3.86 110.909 -176.222 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 134.24 -149.84 19.88 Favored Glycine 0 CA--C 1.497 -1.044 0 CA-C-N 115.162 -0.926 . . . . 1.54 111.658 176.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 31.4 t-105 -152.7 123.88 7.58 Favored 'General case' 0 C--N 1.317 -0.843 0 C-N-CA 120.581 -0.448 . . . . 1.55 111.189 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.461 ' CD ' ' HA ' ' A' ' 8' ' ' ILE . 21.2 ttm180 -104.79 139.91 38.88 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.912 -0.585 . . . . 3.53 110.23 169.753 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.7 t . . . . . 0 C--O 1.253 1.243 0 O-C-N 124.289 0.993 . . . . 4.01 110.538 -179.684 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.619 ' HA ' ' HD3' ' A' ' 46' ' ' ARG . 3.5 mp . . . . . 0 C--O 1.235 0.297 0 CA-C-O 121.194 0.521 . . . . 4.18 111.465 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -89.04 164.02 15.25 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 108.943 -0.762 . . . . 3.25 108.943 170.021 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.495 ' C ' ' H ' ' A' ' 12' ' ' ARG . 38.4 p -72.75 -175.8 1.81 Allowed 'General case' 0 C--N 1.314 -0.965 0 CA-C-N 116.504 -0.317 . . . . 1.72 110.867 176.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.42 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 11.4 t -57.51 6.23 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 123.36 0.664 . . . . 1.04 112.054 178.816 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.495 ' H ' ' C ' ' A' ' 10' ' ' THR . 38.4 ptt180 -65.89 -33.2 75.3 Favored 'General case' 0 C--N 1.33 -0.268 0 O-C-N 122.107 -0.371 . . . . 4.23 110.939 172.484 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.406 ' CD2' ' HG3' ' A' ' 12' ' ' ARG . 4.5 mm? -97.11 97.48 9.24 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 108.472 -0.936 . . . . 2.66 108.472 172.086 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.725 ' HD3' ' SG ' ' A' ' 40' ' ' CYS . 2.7 mmm-85 -110.24 -170.71 1.7 Allowed 'General case' 0 N--CA 1.438 -1.028 0 N-CA-C 113.338 0.866 . . . . 7.01 113.338 -166.463 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.9 m-80 69.02 53.45 0.47 Allowed 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 114.678 -1.146 . . . . 4.38 111.154 -178.686 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.717 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -120.46 -50.02 0.28 Allowed Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 119.445 -1.36 . . . . 1.7 112.119 172.113 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.717 HG12 ' O ' ' A' ' 16' ' ' GLY . 25.1 mm -166.65 147.02 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 C-N-CA 125.337 1.455 . . . . 1.05 108.149 161.112 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 31.5 t -111.12 104.03 12.52 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 121.654 -0.654 . . . . 1.28 109.426 168.788 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.554 ' CE1' HG21 ' A' ' 17' ' ' ILE . 17.0 m-85 -93.17 124.13 58.84 Favored Pre-proline 0 C--N 1.329 -0.287 0 N-CA-C 112.404 0.52 . . . . 0.67 112.404 -175.809 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -82.23 97.4 0.9 Allowed 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 121.833 1.689 . . . . 0.48 109.473 165.339 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.64 -134.0 7.12 Favored Glycine 0 N--CA 1.443 -0.84 0 N-CA-C 110.884 -0.886 . . . . 0.59 110.884 -170.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 23.7 pt -129.17 147.8 33.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.285 0.564 . . . . 1.2 112.006 -178.46 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 93.9 m -94.77 139.62 31.02 Favored 'General case' 0 N--CA 1.437 -1.094 0 CA-C-N 115.488 -0.778 . . . . 1.44 109.797 173.51 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.48 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 7.1 ptt180 -143.56 -37.1 0.35 Allowed 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 118.904 -0.569 . . . . 5.09 112.532 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.48 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 10.8 mtt180 175.54 145.68 0.24 Allowed Pre-proline 0 N--CA 1.476 0.827 0 N-CA-C 112.067 0.395 . . . . 3.77 112.067 170.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -88.74 99.25 0.2 Allowed 'Cis proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.839 -1.734 . . . . 1.34 110.611 -10.604 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.475 ' CE1' HG13 ' A' ' 17' ' ' ILE . 96.2 m-85 -161.55 138.51 8.55 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 108.919 -0.771 . . . . 0.64 108.919 -175.405 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.512 ' CZ ' ' HB3' ' A' ' 42' ' ' ALA . 35.8 p90 -113.09 127.93 56.35 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 109.245 -0.65 . . . . 0.71 109.245 178.001 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' TRP . . . . . 0.562 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 90.1 t90 -73.74 117.0 14.99 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.625 -0.716 . . . . 0.54 110.971 -175.419 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.463 ' O ' HG13 ' A' ' 30' ' ' ILE . 26.6 pt -121.35 95.03 3.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 121.524 0.678 . . . . 0.72 110.259 176.309 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 63.39 -170.97 14.86 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 121.12 -0.562 . . . . 0.47 113.041 -178.147 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 23.2 p -108.96 148.19 31.1 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 112.928 0.714 . . . . 0.62 112.928 -173.203 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.481 ' O ' ' HA3' ' A' ' 38' ' ' GLY . 18.4 t -116.74 -175.83 2.85 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.583 -1.266 . . . . 1.07 107.583 174.308 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.436 ' HB2' ' HA3' ' A' ' 38' ' ' GLY . 84.0 m-20 64.62 -97.44 0.06 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 118.315 0.507 . . . . 1.54 111.266 179.738 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 52.0 t30 -177.05 85.77 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.762 0.315 . . . . 2.54 110.868 -178.168 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 94.09 -57.42 2.11 Favored Glycine 0 CA--C 1.503 -0.695 0 N-CA-C 110.122 -1.191 . . . . 1.12 110.122 178.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.455 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 0.8 OUTLIER -78.51 -148.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 108.063 -1.088 . . . . 1.87 108.063 164.997 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.481 ' HA3' ' O ' ' A' ' 33' ' ' CYS . . . 76.97 111.42 0.14 Allowed Glycine 0 N--CA 1.441 -0.976 0 C-N-CA 120.245 -0.979 . . . . 0.79 113.02 173.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.5 m -90.49 99.34 12.38 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 121.162 0.506 . . . . 1.25 109.899 176.708 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.725 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 40.3 t -76.05 103.35 6.06 Favored 'General case' 0 C--O 1.218 -0.597 0 N-CA-C 107.65 -1.241 . . . . 0.87 107.65 173.596 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.562 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 24.3 m -128.93 178.11 6.62 Favored 'General case' 0 C--N 1.311 -1.085 0 C-N-CA 120.634 -0.426 . . . . 1.02 110.473 -178.087 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.571 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -134.19 139.89 46.14 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 116.207 -0.451 . . . . 0.55 109.983 173.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.451 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 70.9 ttt180 -62.22 111.61 2.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.659 -0.701 . . . . 3.86 111.633 -174.154 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.95 -153.01 20.72 Favored Glycine 0 N--CA 1.443 -0.844 0 CA-C-N 115.188 -0.915 . . . . 1.54 112.36 178.15 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 28.4 t-105 -144.75 118.6 9.3 Favored 'General case' 0 N--CA 1.441 -0.916 0 CA-C-O 121.143 0.497 . . . . 1.55 110.483 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.619 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 1.0 OUTLIER -89.9 127.23 35.97 Favored 'General case' 0 N--CA 1.44 -0.945 0 CA-C-N 115.592 -0.731 . . . . 3.53 110.087 176.27 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 19.9 m . . . . . 0 C--O 1.252 1.196 0 O-C-N 123.865 0.728 . . . . 4.01 110.846 -179.271 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.437 ' HA ' ' HG2' ' A' ' 46' ' ' ARG . 2.6 mp . . . . . 0 N--CA 1.456 -0.172 0 CA-C-O 120.708 0.29 . . . . 4.18 110.674 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -110.02 164.72 12.35 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.113 0.482 . . . . 3.25 110.001 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.446 ' C ' ' H ' ' A' ' 12' ' ' ARG . 70.7 p -89.18 -175.35 4.76 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.508 -0.769 . . . . 1.72 109.852 171.682 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 31.2 t -55.5 -1.06 0.03 OUTLIER 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.877 0.471 . . . . 1.04 112.079 178.263 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.446 ' H ' ' C ' ' A' ' 10' ' ' THR . 9.3 ptm180 -52.52 -40.52 62.54 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 122.676 0.39 . . . . 4.23 111.615 175.011 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 10.6 mp -87.31 96.04 10.21 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 107.838 -1.171 . . . . 2.66 107.838 170.742 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.692 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 8.1 tpt180 -99.97 172.11 7.42 Favored 'General case' 0 N--CA 1.431 -1.42 0 CA-C-N 116.032 -0.531 . . . . 7.01 111.98 -165.238 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.692 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 34.0 t-20 71.18 57.5 0.2 Allowed 'General case' 0 CA--C 1.514 -0.409 0 CA-C-N 114.973 -1.012 . . . . 4.38 110.417 170.409 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.652 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -117.04 -48.27 0.45 Allowed Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 119.389 -1.386 . . . . 1.7 111.244 171.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.652 HG13 ' O ' ' A' ' 16' ' ' GLY . 2.3 mt -170.02 133.67 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 124.571 1.149 . . . . 1.05 109.564 154.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 11.4 m -96.8 112.36 24.14 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 120.897 -0.321 . . . . 1.28 110.19 170.571 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.6 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 43.3 m-85 -95.68 126.34 45.69 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.495 -0.32 . . . . 0.67 110.24 177.068 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -80.65 96.96 1.0 Allowed 'Trans proline' 0 N--CA 1.445 -1.335 0 C-N-CA 121.027 1.151 . . . . 0.48 109.133 166.174 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.5 -113.08 1.06 Allowed Glycine 0 N--CA 1.448 -0.527 0 N-CA-C 111.266 -0.734 . . . . 0.59 111.266 -170.253 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.7 pt -142.79 156.43 18.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-O 121.062 0.458 . . . . 1.2 111.87 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' CYS . . . . . 0.5 ' HB3' ' HB2' ' A' ' 27' ' ' TYR . 5.8 m -107.04 132.08 53.36 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 108.679 -0.86 . . . . 1.44 108.679 172.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 10.6 ptm180 -118.12 -41.1 2.9 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 118.976 -1.09 . . . . 5.09 111.315 175.171 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.508 ' HA ' ' H ' ' A' ' 27' ' ' TYR . 0.0 OUTLIER 173.78 158.61 0.31 Allowed Pre-proline 0 CA--C 1.533 0.303 0 C-N-CA 122.644 0.377 . . . . 3.77 111.44 168.449 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.432 ' HA ' ' HB2' ' A' ' 25' ' ' ARG . 2.5 Cg_endo -86.8 99.07 0.22 Allowed 'Cis proline' 0 N--CA 1.458 -0.594 0 C-N-CA 122.652 -1.811 . . . . 1.34 110.681 -6.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.52 ' CE1' HD12 ' A' ' 17' ' ' ILE . 64.2 m-85 -162.9 134.75 5.19 Favored 'General case' 0 CA--C 1.504 -0.79 0 N-CA-C 108.116 -1.068 . . . . 0.64 108.116 -175.859 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 13.0 p90 -108.68 128.33 54.76 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 120.289 -0.564 . . . . 0.71 109.769 177.17 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' TRP . . . . . 0.711 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 89.2 t90 -65.0 114.73 4.77 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.053 -0.976 . . . . 0.54 110.877 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.513 ' O ' ' HB2' ' A' ' 11' ' ' CYS . 20.7 pt -122.15 95.88 3.75 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.048 -0.978 . . . . 0.72 109.783 173.658 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 62.84 -161.22 32.77 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 120.991 -0.623 . . . . 0.47 113.089 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 19.7 p -117.17 170.1 8.94 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 112.842 0.682 . . . . 0.62 112.842 -175.01 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 19.7 t -143.59 -174.98 4.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.875 -1.057 . . . . 1.07 108.839 -175.425 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.458 ' O ' ' HB2' ' A' ' 35' ' ' ASN . 9.9 m120 68.68 -85.02 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 122.692 0.397 . . . . 1.54 110.763 -178.545 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.458 ' HB2' ' O ' ' A' ' 34' ' ' ASN . 21.8 t-20 169.24 78.55 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.285 0 C-N-CA 123.799 0.84 . . . . 2.54 109.212 -179.591 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 105.41 -56.47 0.53 Allowed Glycine 0 N--CA 1.453 -0.221 0 N-CA-C 111.123 -0.791 . . . . 1.12 111.123 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.513 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 0.4 OUTLIER -84.41 -137.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.885 -0.783 . . . . 1.87 108.885 170.503 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.513 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 67.07 115.99 0.02 OUTLIER Glycine 0 C--N 1.339 0.732 0 C-N-CA 120.881 -0.676 . . . . 0.79 114.045 175.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.6 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 77.5 p -93.64 98.91 11.46 Favored 'General case' 0 N--CA 1.434 -1.241 0 N-CA-C 109.006 -0.739 . . . . 1.25 109.006 173.294 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 44.5 t -69.91 108.41 3.99 Favored 'General case' 0 CA--C 1.507 -0.707 0 N-CA-C 107.97 -1.122 . . . . 0.87 107.97 176.244 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.711 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 80.2 m -130.44 173.88 10.41 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 109.297 -0.631 . . . . 1.02 109.297 179.036 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.612 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -135.58 142.74 45.36 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 120.381 -0.528 . . . . 0.55 110.264 172.217 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.445 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 74.4 ttt180 -62.37 112.19 2.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.259 -0.882 . . . . 3.86 111.484 -173.615 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.88 -151.71 21.06 Favored Glycine 0 N--CA 1.446 -0.649 0 CA-C-N 114.712 -1.131 . . . . 1.54 111.797 -179.24 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 32.8 t-105 -149.43 119.86 7.39 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.045 0.45 . . . . 1.55 111.004 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.437 ' HG2' ' HA ' ' A' ' 8' ' ' ILE . 0.3 OUTLIER -77.19 138.83 39.69 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.782 -0.645 . . . . 3.53 110.015 175.55 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 31.1 p . . . . . 0 C--O 1.251 1.14 0 O-C-N 124.314 1.009 . . . . 4.01 111.594 -178.267 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.57 ' HA ' ' HD2' ' A' ' 46' ' ' ARG . 2.6 mp . . . . . 0 N--CA 1.453 -0.309 0 CA-C-O 121.035 0.445 . . . . 4.18 111.02 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.481 ' O ' HG22 ' A' ' 30' ' ' ILE . 65.9 m-20 -98.8 165.93 11.55 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.443 -0.798 . . . . 3.25 109.777 176.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.422 ' C ' ' H ' ' A' ' 12' ' ' ARG . 26.9 p -79.6 -175.68 4.93 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.117 -0.492 . . . . 1.72 111.071 175.332 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.405 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 12.5 t -55.74 -0.85 0.04 OUTLIER 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 123.68 0.792 . . . . 1.04 112.209 179.552 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.422 ' H ' ' C ' ' A' ' 10' ' ' THR . 12.9 ptm180 -54.74 -41.84 70.87 Favored 'General case' 0 C--O 1.234 0.237 0 C-N-CA 122.812 0.445 . . . . 4.23 111.446 173.673 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -86.29 96.41 9.95 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 106.991 -1.485 . . . . 2.66 106.991 171.338 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.664 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 18.2 tpp85 -100.31 157.44 16.61 Favored 'General case' 0 N--CA 1.429 -1.507 0 N-CA-C 114.041 1.126 . . . . 7.01 114.041 -157.45 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.664 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 64.7 t30 70.04 69.67 0.22 Allowed 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 113.822 -1.535 . . . . 4.38 112.348 164.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.722 ' HA3' ' HA ' ' A' ' 42' ' ' ALA . . . -108.01 -43.82 1.26 Allowed Glycine 0 N--CA 1.432 -1.63 0 N-CA-C 109.659 -1.376 . . . . 1.7 109.659 165.055 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.634 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.1 mt -165.89 132.87 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.349 1.06 . . . . 1.05 109.258 157.863 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 21.5 t -91.88 109.3 20.64 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.109 -0.33 . . . . 1.28 110.109 175.168 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.412 ' CD1' ' SG ' ' A' ' 23' ' ' CYS . 15.4 m-85 -96.13 122.39 58.19 Favored Pre-proline 0 CA--C 1.516 -0.346 0 N-CA-C 112.125 0.417 . . . . 0.67 112.125 -177.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -81.92 96.47 0.91 Allowed 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 121.513 1.475 . . . . 0.48 109.816 167.11 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 136.26 -119.87 2.09 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 111.067 -0.813 . . . . 0.59 111.067 -171.502 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.8 pt -138.14 154.4 28.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 117.131 0.466 . . . . 1.2 111.735 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' CYS . . . . . 0.412 ' SG ' ' CD1' ' A' ' 19' ' ' PHE . 69.0 m -101.43 139.85 36.53 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 115.622 -0.717 . . . . 1.44 109.813 173.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.733 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 13.6 ptm180 -135.5 -39.42 0.73 Allowed 'General case' 0 C--N 1.321 -0.646 0 C-N-CA 119.733 -0.787 . . . . 5.09 112.612 179.028 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.733 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 12.0 mmt180 176.88 140.17 0.23 Allowed Pre-proline 0 N--CA 1.476 0.86 0 C-N-CA 123.104 0.561 . . . . 3.77 110.827 178.245 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 4.1 Cg_exo -90.42 99.94 0.21 Allowed 'Cis proline' 0 N--CA 1.456 -0.681 0 C-N-CA 123.44 -1.483 . . . . 1.34 110.371 -13.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.488 ' CD1' ' HA ' ' A' ' 43' ' ' ARG . 96.7 m-85 -161.01 131.4 5.15 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 108.829 -0.804 . . . . 0.64 108.829 -176.535 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -109.2 127.51 54.28 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 109.081 -0.711 . . . . 0.71 109.081 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' TRP . . . . . 0.584 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 86.6 t90 -70.56 117.18 11.76 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.067 -0.969 . . . . 0.54 110.985 -175.19 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.481 HG22 ' O ' ' A' ' 9' ' ' ASP . 16.2 pt -120.75 95.6 3.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.328 -0.851 . . . . 0.72 110.019 176.213 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 61.12 -164.64 17.9 Favored Glycine 0 CA--C 1.524 0.65 0 C-N-CA 121.284 -0.484 . . . . 0.47 113.24 -179.574 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.2 p -111.57 151.98 28.1 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 113.073 0.768 . . . . 0.62 113.073 -175.128 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.408 ' HB2' ' HB2' ' A' ' 40' ' ' CYS . 49.9 t -122.17 -177.07 3.5 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 107.154 -1.425 . . . . 1.07 107.154 175.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 58.54 -161.44 0.25 Allowed 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 118.866 0.757 . . . . 1.54 110.506 -178.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 92.0 m-20 -109.49 78.16 1.11 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.793 0.33 . . . . 2.54 111.104 -179.571 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 108.69 -52.18 0.66 Allowed Glycine 0 CA--C 1.509 -0.31 0 N-CA-C 111.149 -0.78 . . . . 1.12 111.149 176.035 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.413 HG12 ' H ' ' A' ' 37' ' ' ILE . 8.6 pt -77.46 -143.14 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 114.849 -0.676 . . . . 1.87 109.474 170.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.407 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 76.04 103.58 0.13 Allowed Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.442 -0.885 . . . . 0.79 113.031 168.399 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 38.2 m -84.04 98.71 10.0 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.898 -0.779 . . . . 1.25 108.898 172.604 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.408 ' HB2' ' HB2' ' A' ' 33' ' ' CYS . 42.7 t -72.65 106.08 4.53 Favored 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 107.884 -1.154 . . . . 0.87 107.884 175.441 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.584 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 37.0 m -126.9 174.56 8.72 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 121.12 0.486 . . . . 1.02 109.771 178.191 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.722 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -130.17 139.47 50.85 Favored 'General case' 0 N--CA 1.432 -1.332 0 C-N-CA 120.132 -0.627 . . . . 0.55 109.849 172.168 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.488 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 61.3 ttp180 -61.34 110.96 1.57 Allowed 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.567 -0.742 . . . . 3.86 111.29 -173.349 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 135.76 -158.93 24.04 Favored Glycine 0 N--CA 1.437 -1.237 0 CA-C-N 114.771 -1.104 . . . . 1.54 111.952 -178.489 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.431 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 28.7 t-105 -143.71 116.98 9.0 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.867 -0.419 . . . . 1.55 109.867 -179.13 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.57 ' HD2' ' HA ' ' A' ' 8' ' ' ILE . 12.5 ttm180 -88.63 136.99 32.72 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.458 -0.337 . . . . 3.53 110.265 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.1 t . . . . . 0 C--O 1.249 1.065 0 O-C-N 123.948 0.78 . . . . 4.01 110.042 -177.663 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.471 ' HA ' ' CD ' ' A' ' 46' ' ' ARG . 56.8 mt . . . . . 0 N--CA 1.451 -0.399 0 CA-C-O 121.292 0.568 . . . . 4.18 111.678 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 57.4 m-20 -84.3 163.28 19.71 Favored 'General case' 0 CA--C 1.513 -0.461 0 CA-C-N 115.462 -0.79 . . . . 3.25 109.503 177.449 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.444 ' C ' ' H ' ' A' ' 12' ' ' ARG . 11.2 p -84.01 -175.69 5.92 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.626 -0.715 . . . . 1.72 110.593 176.628 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.453 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 37.0 t -56.05 1.62 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 122.878 0.471 . . . . 1.04 112.153 178.468 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.444 ' H ' ' C ' ' A' ' 10' ' ' THR . 14.5 ptt180 -55.79 -34.97 65.77 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 120.577 0.227 . . . . 4.23 110.842 171.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -89.78 97.53 11.25 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 107.797 -1.186 . . . . 2.66 107.797 168.324 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.72 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 8.3 tpt180 -109.71 171.59 7.36 Favored 'General case' 0 N--CA 1.433 -1.306 0 CA-C-O 120.971 0.415 . . . . 7.01 112.007 -166.501 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.72 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 92.1 m-20 72.04 51.92 0.21 Allowed 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 115.215 -0.902 . . . . 4.38 111.052 173.525 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.67 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -109.17 -47.75 0.86 Allowed Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.619 -1.277 . . . . 1.7 110.87 170.419 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.67 HG13 ' O ' ' A' ' 16' ' ' GLY . 3.3 mt -168.99 138.58 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 124.548 1.139 . . . . 1.05 109.56 156.001 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 15.4 t -99.74 104.18 15.88 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.967 -0.382 . . . . 1.28 109.967 170.632 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.566 ' HD1' ' SG ' ' A' ' 23' ' ' CYS . 33.4 m-85 -92.37 131.45 34.46 Favored Pre-proline 0 CA--C 1.514 -0.424 0 CA-C-N 116.53 -0.305 . . . . 0.67 110.903 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -87.5 96.12 0.45 Allowed 'Trans proline' 0 N--CA 1.443 -1.466 0 C-N-CA 121.171 1.247 . . . . 0.48 109.744 165.317 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.75 -114.52 0.91 Allowed Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.638 -0.71 . . . . 0.59 111.75 -173.548 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -140.28 141.75 32.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 121.25 0.547 . . . . 1.2 112.111 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' CYS . . . . . 0.566 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 79.4 m -95.55 134.88 37.91 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-N 115.533 -0.758 . . . . 1.44 109.604 172.359 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.447 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 15.0 ptm180 -136.38 -37.92 0.69 Allowed 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 120.046 -0.662 . . . . 5.09 112.597 178.856 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.447 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 8.2 mtt180 176.32 146.48 0.26 Allowed Pre-proline 0 N--CA 1.47 0.573 0 N-CA-C 112.295 0.48 . . . . 3.77 112.295 175.043 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -86.83 98.52 0.21 Allowed 'Cis proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.455 -1.894 . . . . 1.34 110.049 -11.445 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.64 ' CE1' HD12 ' A' ' 17' ' ' ILE . 89.4 m-85 -162.53 133.47 4.94 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.658 -0.867 . . . . 0.64 108.658 -174.799 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -109.1 127.36 54.09 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 109.229 -0.656 . . . . 0.71 109.229 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' TRP . . . . . 0.6 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 76.4 t90 -68.66 114.24 6.86 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 114.955 -1.021 . . . . 0.54 110.155 -178.16 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.457 HG12 ' HA ' ' A' ' 41' ' ' CYS . 18.1 pt -120.98 93.71 2.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.669 0.747 . . . . 0.72 109.981 176.16 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 65.08 -172.46 21.2 Favored Glycine 0 CA--C 1.524 0.621 0 CA-C-N 115.799 -0.637 . . . . 0.47 113.049 -175.444 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 19.8 p -105.46 159.41 15.95 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.091 0.472 . . . . 0.62 111.989 -174.653 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.407 ' SG ' ' N ' ' A' ' 34' ' ' ASN . 48.7 t -121.92 -178.37 3.83 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.36 -0.607 . . . . 1.07 109.36 177.258 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.407 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 2.5 m120 57.84 -145.53 0.58 Allowed 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.451 -0.574 . . . . 1.54 109.451 -172.403 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 35.0 m-80 -83.31 -1.09 52.42 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.617 0.246 . . . . 2.54 111.11 175.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 153.63 -35.73 0.74 Allowed Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 119.817 -1.182 . . . . 1.12 114.54 176.479 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -80.15 -32.34 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 113.033 0.753 . . . . 1.87 113.033 -172.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.83 172.03 37.22 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 120.441 -0.885 . . . . 0.79 111.697 177.086 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.477 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 68.5 p -117.69 124.07 47.62 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.224 0.535 . . . . 1.25 111.252 -174.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 42.0 t -83.9 104.26 13.84 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 107.592 -1.262 . . . . 0.87 107.592 172.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.6 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 29.6 m -127.38 174.77 8.72 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 109.852 -0.425 . . . . 1.02 109.852 178.862 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.655 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -136.37 143.01 43.82 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 119.923 -0.711 . . . . 0.55 111.077 173.186 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.468 ' C ' ' HD3' ' A' ' 43' ' ' ARG . 3.4 tmt_? -61.54 112.13 2.09 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.062 -0.972 . . . . 3.86 110.466 -177.376 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 141.36 -159.33 26.7 Favored Glycine 0 N--CA 1.439 -1.116 0 CA-C-N 115.11 -0.95 . . . . 1.54 111.112 178.252 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.46 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 31.9 t-105 -148.0 119.15 7.74 Favored 'General case' 0 C--N 1.314 -0.942 0 C-N-CA 120.47 -0.492 . . . . 1.55 111.002 -179.434 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.471 ' CD ' ' HA ' ' A' ' 8' ' ' ILE . 23.8 ttm180 -107.63 145.62 33.07 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 115.787 -0.642 . . . . 3.53 110.007 172.267 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 17.1 t . . . . . 0 C--O 1.249 1.028 0 O-C-N 124.372 1.045 . . . . 4.01 110.02 -176.342 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 71.0 mt . . . . . 0 N--CA 1.447 -0.58 0 N-CA-C 109.921 -0.4 . . . . 4.18 109.921 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -130.36 165.9 21.56 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.401 -0.363 . . . . 3.25 110.136 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 7.7 p -57.95 -176.93 0.03 OUTLIER 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 112.743 0.645 . . . . 1.72 112.743 177.202 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.454 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 22.9 t -58.03 4.04 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.528 1.131 . . . . 1.04 113.294 -171.212 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.522 ' HG3' HD22 ' A' ' 13' ' ' LEU . 5.0 ptp180 -57.6 -31.22 65.98 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 108.735 -0.839 . . . . 4.23 108.735 167.454 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.726 ' O ' HD12 ' A' ' 30' ' ' ILE . 3.7 mm? -88.78 122.08 31.81 Favored 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 106.789 -1.559 . . . . 2.66 106.789 161.663 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.689 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 13.0 tpt180 -131.21 170.54 14.43 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 112.707 0.632 . . . . 7.01 112.707 -168.737 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ASN . . . . . 0.689 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 94.3 m-20 72.35 66.4 0.13 Allowed 'General case' 0 CA--C 1.512 -0.512 0 CA-C-N 114.775 -1.102 . . . . 4.38 112.86 169.022 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.706 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -130.67 -47.91 0.13 Allowed Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 119.632 -1.27 . . . . 1.7 111.551 167.509 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.706 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.3 mt -169.13 133.98 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.465 1.106 . . . . 1.05 109.9 159.663 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 6.3 t -96.94 124.04 40.81 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.978 -0.379 . . . . 1.28 109.978 172.023 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.537 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 23.3 m-85 -105.93 127.71 27.85 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 116.471 -0.331 . . . . 0.67 111.009 179.499 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -74.48 97.95 1.08 Allowed 'Trans proline' 0 N--CA 1.452 -0.957 0 C-N-CA 121.3 1.333 . . . . 0.48 109.591 167.055 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.585 ' H ' ' HA2' ' A' ' 38' ' ' GLY . . . 133.04 -124.34 3.73 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.489 -0.778 . . . . 0.59 111.259 -171.415 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -142.85 146.95 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-N 117.069 0.434 . . . . 1.2 111.523 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' CYS . . . . . 0.45 ' SG ' ' CD1' ' A' ' 19' ' ' PHE . 22.6 m -86.18 147.19 26.24 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 115.94 -0.573 . . . . 1.44 111.455 177.163 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.61 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 16.3 ptm180 -141.55 -37.34 0.42 Allowed 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 112.551 0.574 . . . . 5.09 112.551 176.281 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.61 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 10.2 mmt180 177.32 142.19 0.25 Allowed Pre-proline 0 N--CA 1.478 0.96 0 C-N-CA 122.737 0.415 . . . . 3.77 111.193 178.658 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.569 ' HD2' ' CE2' ' A' ' 27' ' ' TYR . 24.2 Cg_endo -91.35 98.35 0.16 OUTLIER 'Cis proline' 0 C--N 1.349 0.593 0 C-N-CA 122.792 -1.753 . . . . 1.34 111.704 -10.403 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.569 ' CE2' ' HD2' ' A' ' 26' ' ' PRO . 80.9 m-85 -161.53 143.89 11.94 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.695 -0.854 . . . . 0.64 108.695 -172.194 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 11.0 p90 -111.07 127.76 55.65 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 109.008 -0.738 . . . . 0.71 109.008 175.671 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 84.6 t90 -68.5 113.35 5.96 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.144 -0.935 . . . . 0.54 110.126 -178.047 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.726 HD12 ' O ' ' A' ' 13' ' ' LEU . 12.1 pt -119.27 94.35 3.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 109.242 -0.651 . . . . 0.72 109.242 174.777 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 65.24 -173.2 20.21 Favored Glycine 0 CA--C 1.524 0.612 0 CA-C-N 115.962 -0.563 . . . . 0.47 113.079 -177.599 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.1 p -108.57 161.78 14.75 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 122.27 -0.547 . . . . 0.62 112.047 -176.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 39.1 t -130.98 178.97 6.27 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 116.102 -0.499 . . . . 1.07 110.299 -177.63 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 63.8 -82.48 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.313 1.045 . . . . 1.54 110.791 -174.251 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 54.5 m-80 -151.57 26.67 0.66 Allowed 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.364 -0.606 . . . . 2.54 109.364 -178.677 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 107.8 -20.34 31.75 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.752 -0.737 . . . . 1.12 112.944 179.685 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.586 ' H ' HD12 ' A' ' 37' ' ' ILE . 0.2 OUTLIER -81.09 -58.4 3.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 O-C-N 122.511 -0.405 . . . . 1.87 111.293 -177.791 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.585 ' HA2' ' H ' ' A' ' 21' ' ' GLY . . . -69.18 174.9 33.19 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.966 -0.635 . . . . 0.79 112.198 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.537 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 77.3 p -108.54 125.74 52.16 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-O 121.392 0.615 . . . . 1.25 111.499 -173.24 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 41.4 t -82.54 113.35 20.2 Favored 'General case' 0 N--CA 1.442 -0.86 0 N-CA-C 106.67 -1.604 . . . . 0.87 106.67 169.282 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.537 ' HA ' HG12 ' A' ' 30' ' ' ILE . 28.2 m -132.0 177.24 7.7 Favored 'General case' 0 C--N 1.311 -1.085 0 CA-C-O 121.421 0.629 . . . . 1.02 110.703 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.671 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -135.53 137.6 42.23 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.513 -0.767 . . . . 0.55 109.618 167.789 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.508 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 4.3 tmt_? -60.7 113.41 2.46 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 115.378 -0.828 . . . . 3.86 110.778 -174.741 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 134.62 -150.99 20.23 Favored Glycine 0 N--CA 1.438 -1.183 0 CA-C-N 115.252 -0.886 . . . . 1.54 112.072 176.542 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 26.0 t-105 -145.51 124.74 12.95 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.369 -0.604 . . . . 1.55 109.369 179.711 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 19.5 ttm180 -102.42 128.75 48.88 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 120.978 0.418 . . . . 3.53 110.929 176.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 18.5 m . . . . . 0 C--O 1.249 1.075 0 CA-C-N 114.145 -1.388 . . . . 4.01 112.289 178.171 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.592 ' HA ' ' HD2' ' A' ' 46' ' ' ARG . 61.9 mt . . . . . 0 N--CA 1.451 -0.425 0 CA-C-O 121.203 0.525 . . . . 4.18 111.974 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 36.2 m-20 -81.14 166.15 20.93 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.19 -0.913 . . . . 3.25 109.732 174.755 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.51 ' C ' ' H ' ' A' ' 12' ' ' ARG . 37.0 p -85.86 -171.24 3.49 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.183 -0.673 . . . . 1.72 109.183 174.03 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.583 ' O ' ' HG2' ' A' ' 14' ' ' ARG . 58.4 m -50.9 -1.52 0.01 OUTLIER 'General case' 0 CA--C 1.549 0.938 0 CA-C-O 121.076 0.465 . . . . 1.04 110.742 166.727 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.51 ' H ' ' C ' ' A' ' 10' ' ' THR . 12.0 ttt180 -32.74 -43.19 0.09 Allowed 'General case' 0 N--CA 1.463 0.176 0 C-N-CA 124.942 1.297 . . . . 4.23 110.834 163.715 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 8.8 mp -114.96 111.35 21.02 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 115.184 -0.917 . . . . 2.66 108.644 174.23 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ARG . . . . . 0.667 ' HD2' ' SG ' ' A' ' 40' ' ' CYS . 1.6 mmp_? -116.9 -171.19 1.98 Allowed 'General case' 0 CA--C 1.507 -0.682 0 N-CA-C 113.167 0.802 . . . . 7.01 113.167 -175.438 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 70.7 42.87 0.79 Allowed 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 114.492 -1.231 . . . . 4.38 109.63 -172.611 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.675 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -106.43 -51.48 0.81 Allowed Glycine 0 N--CA 1.441 -0.971 0 C-N-CA 119.233 -1.46 . . . . 1.7 111.956 173.277 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.716 HD12 ' CE1' ' A' ' 27' ' ' TYR . 2.7 mt -173.33 150.77 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 C-N-CA 125.112 1.365 . . . . 1.05 108.914 157.14 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 9.2 t -110.89 108.28 18.02 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.263 -0.643 . . . . 1.28 109.263 166.155 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.643 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 46.9 m-85 -94.36 132.99 27.85 Favored Pre-proline 0 CA--C 1.513 -0.47 0 CA-C-O 120.881 0.372 . . . . 0.67 111.184 -177.53 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -85.54 95.83 0.61 Allowed 'Trans proline' 0 N--CA 1.438 -1.793 0 N-CA-C 108.349 -1.443 . . . . 0.48 108.349 158.478 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.93 -130.6 5.53 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.26 -0.882 . . . . 0.59 110.973 -168.806 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.1 pt -135.87 148.48 27.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.521 0.677 . . . . 1.2 112.606 -176.527 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -87.78 123.35 32.49 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.053 -0.976 . . . . 1.44 109.308 169.2 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.464 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 12.3 ptm180 -123.59 -38.24 2.55 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 119.579 -0.849 . . . . 5.09 112.335 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.464 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 11.5 mtt180 175.02 141.86 0.2 Allowed Pre-proline 0 N--CA 1.475 0.795 0 O-C-N 123.385 0.428 . . . . 3.77 111.88 171.154 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 3.9 Cg_exo -88.55 99.84 0.23 Allowed 'Cis proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.715 -1.785 . . . . 1.34 110.567 -10.012 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.716 ' CE1' HD12 ' A' ' 17' ' ' ILE . 75.7 m-85 -161.74 128.54 3.86 Favored 'General case' 0 CA--C 1.506 -0.729 0 N-CA-C 108.883 -0.784 . . . . 0.64 108.883 -177.65 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' TYR . . . . . 0.458 ' CZ ' ' HB3' ' A' ' 42' ' ' ALA . 27.0 p90 -107.83 130.13 55.01 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-O 121.208 0.528 . . . . 0.71 110.205 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 86.4 t90 -65.67 113.82 4.53 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.49 -1.232 . . . . 0.54 111.122 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.487 HD11 HH21 ' A' ' 14' ' ' ARG . 4.7 pt -120.32 92.68 2.21 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.852 0 CA-C-N 115.66 -0.7 . . . . 0.72 109.383 171.728 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 66.18 -164.87 39.87 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 120.711 -0.757 . . . . 0.47 113.292 -177.389 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -114.46 160.11 19.56 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 112.518 0.562 . . . . 0.62 112.518 -174.693 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 49.6 t -127.92 -176.37 3.76 Favored 'General case' 0 C--O 1.22 -0.485 0 N-CA-C 107.808 -1.182 . . . . 1.07 107.808 175.034 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 61.23 -155.87 0.35 Allowed 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 118.891 0.769 . . . . 1.54 109.884 -177.708 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 -111.05 88.54 2.81 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.806 0.336 . . . . 2.54 111.064 179.739 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 92.04 -47.86 2.7 Favored Glycine 0 CA--C 1.506 -0.49 0 N-CA-C 110.892 -0.883 . . . . 1.12 110.892 175.296 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ILE . . . . . 0.474 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 4.7 pt -77.74 -147.7 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 114.397 -0.901 . . . . 1.87 109.79 170.424 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.474 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 73.44 161.76 7.01 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 121.171 -0.538 . . . . 0.79 113.459 169.211 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.777 ' HB2' ' SG ' ' A' ' 41' ' ' CYS . 4.7 p -139.74 113.2 8.43 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-O 121.928 0.87 . . . . 1.25 111.4 177.638 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' CYS . . . . . 0.667 ' SG ' ' HD2' ' A' ' 14' ' ' ARG . 36.5 t -77.95 98.12 5.56 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 106.957 -1.497 . . . . 0.87 106.957 172.837 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' CYS . . . . . 0.777 ' SG ' ' HB2' ' A' ' 39' ' ' SER . 12.3 m -132.72 141.86 48.76 Favored 'General case' 0 C--N 1.32 -0.687 0 O-C-N 121.946 -0.471 . . . . 1.02 109.832 -174.294 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.497 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -100.69 139.8 35.87 Favored 'General case' 0 C--N 1.316 -0.848 0 C-N-CA 120.258 -0.577 . . . . 0.55 111.495 -176.79 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.509 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 4.0 tmt_? -62.04 107.99 0.97 Allowed 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 115.258 -0.883 . . . . 3.86 110.245 179.11 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 138.5 -170.77 23.77 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.417 -0.81 . . . . 1.54 111.293 -178.846 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.527 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 23.9 t-105 -135.3 118.67 16.75 Favored 'General case' 0 N--CA 1.442 -0.842 0 C-N-CA 120.271 -0.571 . . . . 1.55 110.898 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ARG . . . . . 0.592 ' HD2' ' HA ' ' A' ' 8' ' ' ILE . 15.7 ttm180 -112.6 144.83 41.42 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 115.789 -0.641 . . . . 3.53 110.338 176.012 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 16.3 t . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.06 -0.971 . . . . 4.01 110.652 -179.103 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.683 0 CA-C-O 120.392 0.139 . . . . 6.64 111.262 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.1 -45.3 0.22 Allowed 'Trans proline' 0 N--CA 1.461 -0.431 0 C-N-CA 122.447 2.098 . . . . 6.85 109.681 173.255 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.564 ' O ' ' HD3' ' A' ' 5' ' ' PRO . 5.5 p90 -81.39 164.99 21.71 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 114.834 -1.075 . . . . 5.56 108.488 171.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.429 HG23 ' O ' ' A' ' 4' ' ' ILE . 6.7 tp -86.22 108.64 18.25 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-O 120.94 0.4 . . . . 6.59 110.254 176.091 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.634 ' HB3' ' H ' ' A' ' 47' ' ' SER . 87.5 Cg_exo -50.03 114.54 1.43 Allowed 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 122.602 2.202 . . . . 4.3 113.055 178.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.525 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 21.4 mmm180 -79.4 178.42 2.32 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 115.083 -0.962 . . . . 7.04 108.605 176.37 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.525 ' HD2' ' HB3' ' A' ' 6' ' ' ARG . 98.1 Cg_exo -46.61 135.34 16.64 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 121.936 1.757 . . . . 5.21 112.329 174.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.557 HG12 ' HG3' ' A' ' 46' ' ' ARG . 41.9 mt -60.29 129.47 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 121.415 0.626 . . . . 4.18 112.23 -177.157 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.549 ' O ' HG22 ' A' ' 30' ' ' ILE . 17.0 m-20 -103.37 165.62 10.92 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.128 -0.942 . . . . 3.25 110.069 175.5 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.407 ' C ' ' H ' ' A' ' 12' ' ' ARG . 25.0 p -83.53 -176.34 6.25 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.843 -0.617 . . . . 1.72 110.375 173.167 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.578 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 25.4 t -58.01 1.58 0.05 OUTLIER 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 122.789 0.436 . . . . 1.04 112.081 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.43 HH11 ' HD2' ' A' ' 12' ' ' ARG . 8.3 ptt180 -54.56 -35.44 63.26 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 109.86 -0.422 . . . . 4.23 109.86 170.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.417 ' O ' HD12 ' A' ' 30' ' ' ILE . 11.1 mp -85.41 97.82 10.22 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 107.278 -1.379 . . . . 2.66 107.278 165.69 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.608 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 19.0 tpt180 -107.41 168.57 9.14 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 112.22 0.452 . . . . 7.01 112.22 -164.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.608 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 6.1 t30 72.57 69.63 0.13 Allowed 'General case' 0 CA--C 1.513 -0.48 0 CA-C-N 114.859 -1.064 . . . . 4.38 111.219 172.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.721 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -130.45 -47.17 0.14 Allowed Glycine 0 N--CA 1.435 -1.369 0 C-N-CA 119.891 -1.147 . . . . 1.7 111.273 167.146 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.721 HG12 ' O ' ' A' ' 16' ' ' GLY . 15.9 mm -164.86 146.51 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 124.415 1.086 . . . . 1.05 108.685 164.162 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -113.92 111.4 21.64 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.32 -0.622 . . . . 1.28 109.32 165.148 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.453 ' CE1' HG21 ' A' ' 17' ' ' ILE . 44.3 m-85 -94.27 139.91 22.62 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 116.38 -0.373 . . . . 0.67 111.17 -176.754 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -84.98 98.52 0.68 Allowed 'Trans proline' 0 N--CA 1.445 -1.356 0 C-N-CA 121.819 1.68 . . . . 0.48 109.139 163.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 123.51 -131.13 7.97 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 110.373 -1.091 . . . . 0.59 110.373 -166.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 36.4 pt -136.95 156.67 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.532 0.682 . . . . 1.2 112.228 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 29' ' ' TRP . 0.2 OUTLIER -81.17 130.59 35.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.876 -1.057 . . . . 1.44 110.428 174.73 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.734 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 14.8 ptp180 -119.14 -39.98 2.87 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 119.461 -0.896 . . . . 5.09 112.701 176.494 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.734 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 12.9 mmt180 176.43 140.45 0.22 Allowed Pre-proline 0 N--CA 1.482 1.158 0 C-N-CA 123.32 0.648 . . . . 3.77 110.557 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.426 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 1.7 Cg_endo -91.24 100.46 0.22 Allowed 'Cis proline' 0 N--CA 1.455 -0.765 0 C-N-CA 123.646 -1.398 . . . . 1.34 109.968 -13.715 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.594 ' CE1' HG13 ' A' ' 17' ' ' ILE . 83.7 m-85 -160.84 133.03 5.98 Favored 'General case' 0 CA--C 1.503 -0.834 0 N-CA-C 108.816 -0.809 . . . . 0.64 108.816 -174.065 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.523 ' CD1' ' HB3' ' A' ' 46' ' ' ARG . 19.1 p90 -108.3 129.54 55.22 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.003 -0.544 . . . . 0.71 109.582 -179.019 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' TRP . . . . . 0.526 ' HB2' ' SG ' ' A' ' 23' ' ' CYS . 90.0 t90 -66.8 112.77 4.43 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.34 -0.845 . . . . 0.54 110.746 -178.538 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.578 ' O ' ' HB2' ' A' ' 11' ' ' CYS . 5.3 pt -119.2 93.41 2.53 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 115.021 -0.99 . . . . 0.72 108.985 173.013 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 68.7 177.22 13.52 Favored Glycine 0 C--N 1.316 -0.544 0 C-N-CA 120.821 -0.704 . . . . 0.47 112.715 -179.129 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.5 HG22 ' O ' ' A' ' 38' ' ' GLY . 0.1 OUTLIER -97.71 164.53 12.37 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 122.323 -0.516 . . . . 0.62 111.19 -175.99 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 10.5 t -136.26 179.57 6.27 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.355 -0.98 . . . . 1.07 108.355 175.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.43 ' HB2' ' H ' ' A' ' 38' ' ' GLY . 13.8 m120 53.34 27.65 6.49 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 120.722 0.296 . . . . 1.54 111.106 -175.072 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 2.8 t30 64.54 22.16 12.61 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 123.36 0.664 . . . . 2.54 111.586 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 136.3 -36.04 2.05 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 119.911 -1.137 . . . . 1.12 114.021 175.096 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.424 HG13 ' CB ' ' A' ' 34' ' ' ASN . 0.9 OUTLIER -82.57 -23.55 8.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 112.597 0.591 . . . . 1.87 112.597 -175.835 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.5 ' O ' HG22 ' A' ' 32' ' ' THR . . . -103.53 -167.93 25.54 Favored Glycine 0 N--CA 1.426 -1.991 0 N-CA-C 110.37 -1.092 . . . . 0.79 110.37 -177.794 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.534 ' HB2' ' SG ' ' A' ' 41' ' ' CYS . 23.6 p -144.77 119.87 10.09 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.478 0.656 . . . . 1.25 111.75 -173.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.482 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 41.8 t -74.42 104.2 5.06 Favored 'General case' 0 N--CA 1.442 -0.86 0 N-CA-C 107.073 -1.454 . . . . 0.87 107.073 172.076 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.534 ' SG ' ' HB2' ' A' ' 39' ' ' SER . 14.1 m -139.26 111.16 7.27 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.361 -0.607 . . . . 1.02 109.361 -176.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.568 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -80.7 143.39 33.03 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.871 0.367 . . . . 0.55 110.87 -172.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.566 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 39.7 ttm180 -62.53 114.07 3.33 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.432 -0.804 . . . . 3.86 111.096 -176.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 139.17 -152.56 22.38 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 114.676 -1.147 . . . . 1.54 111.263 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 38.3 t-105 -145.12 130.39 18.6 Favored 'General case' 0 N--CA 1.443 -0.806 0 C-N-CA 119.957 -0.697 . . . . 1.55 112.048 179.451 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.557 ' HG3' HG12 ' A' ' 8' ' ' ILE . 1.9 tpp180 -125.33 117.32 23.49 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 115.092 -0.958 . . . . 3.53 110.312 174.093 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.634 ' H ' ' HB3' ' A' ' 5' ' ' PRO . 44.4 m . . . . . 0 C--O 1.248 1.014 0 CA-C-N 114.067 -1.424 . . . . 4.01 111.704 -176.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.795 0 CA-C-O 120.39 0.138 . . . . 6.64 110.906 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -76.4 -29.46 6.09 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.581 2.187 . . . . 6.85 109.991 175.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 4.0 p90 -119.1 165.18 14.48 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-N 114.463 -1.244 . . . . 5.56 107.973 173.527 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.442 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 7.0 tp -83.35 112.39 38.73 Favored Pre-proline 0 C--N 1.322 -0.6 0 C-N-CA 121.069 -0.252 . . . . 6.59 110.634 178.374 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.442 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 6.5 Cg_endo -48.9 111.18 0.43 Allowed 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 123.332 2.688 . . . . 4.3 113.409 -178.758 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.486 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 13.4 mtm180 -106.94 167.49 9.4 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 115.348 -0.842 . . . . 7.04 108.908 176.405 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.486 ' HD2' ' HB3' ' A' ' 6' ' ' ARG . 3.5 Cg_endo -48.55 140.53 21.56 Favored 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.103 1.869 . . . . 5.21 110.586 171.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 2.2 mp -60.01 119.18 3.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.296 0.57 . . . . 4.18 111.259 -172.324 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -91.37 165.24 13.52 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.295 -0.866 . . . . 3.25 109.464 177.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.403 ' C ' ' H ' ' A' ' 12' ' ' ARG . 6.5 p -89.27 -175.83 4.89 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 116.264 -0.426 . . . . 1.72 110.825 176.07 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.511 ' H ' ' HA3' ' A' ' 31' ' ' GLY . 19.0 t -64.41 11.37 0.05 OUTLIER 'General case' 0 N--CA 1.47 0.549 0 CA-C-O 121.317 0.58 . . . . 1.04 112.088 -172.242 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 12' ' ' ARG . 18.3 ptt85 -57.96 -25.69 61.32 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.851 -0.796 . . . . 4.23 108.851 161.526 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.612 HD21 ' NH2' ' A' ' 46' ' ' ARG . 5.4 mp -74.71 153.19 38.97 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 115.554 -0.748 . . . . 2.66 109.518 169.378 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.66 98.99 6.41 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 114.611 1.337 . . . . 7.01 114.611 -167.156 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 66.5 t30 31.18 61.74 0.24 Allowed 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 124.181 0.992 . . . . 4.38 113.335 156.325 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.664 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -77.24 -43.54 16.01 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 118.811 -1.661 . . . . 1.7 112.824 -172.176 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.664 HG12 ' O ' ' A' ' 16' ' ' GLY . 20.3 mm -163.18 128.33 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 124.896 1.278 . . . . 1.05 108.273 165.685 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 8.2 m -94.89 110.54 22.41 Favored 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 120.407 -0.517 . . . . 1.28 110.785 173.333 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.531 ' CZ ' HG21 ' A' ' 17' ' ' ILE . 43.8 m-85 -102.52 131.68 22.16 Favored Pre-proline 0 CA--C 1.51 -0.59 0 CA-C-N 116.036 -0.529 . . . . 0.67 110.82 177.764 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -74.48 97.8 1.07 Allowed 'Trans proline' 0 N--CA 1.448 -1.165 0 C-N-CA 121.104 1.202 . . . . 0.48 109.316 169.03 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.478 ' H ' ' HA2' ' A' ' 38' ' ' GLY . . . 128.92 -122.56 3.96 Favored Glycine 0 N--CA 1.442 -0.927 0 CA-C-N 115.217 -0.901 . . . . 0.59 111.204 -169.155 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -146.6 147.15 18.2 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 121.115 0.483 . . . . 1.2 111.567 -178.333 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' CYS . . . . . 0.508 ' HB3' ' HB2' ' A' ' 27' ' ' TYR . 0.0 OUTLIER -71.65 127.69 33.39 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.367 -0.833 . . . . 1.44 110.424 173.759 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.698 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 25.8 ptt180 -116.09 -38.11 3.69 Favored 'General case' 0 C--N 1.322 -0.628 0 C-N-CA 120.14 -0.624 . . . . 5.09 111.537 175.555 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.698 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 14.7 mmt180 175.7 143.93 0.23 Allowed Pre-proline 0 N--CA 1.477 0.899 0 C-N-CA 123.361 0.664 . . . . 3.77 110.932 177.218 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 1.2 Cg_endo -93.94 100.4 0.18 OUTLIER 'Cis proline' 0 N--CA 1.457 -0.62 0 C-N-CA 123.878 -1.301 . . . . 1.34 110.756 -14.464 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.628 ' CE1' HG13 ' A' ' 17' ' ' ILE . 63.1 m-85 -161.5 139.56 9.29 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.726 -0.842 . . . . 0.64 108.726 -175.203 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.418 ' CZ ' ' HB3' ' A' ' 42' ' ' ALA . 26.1 p90 -107.85 131.74 54.17 Favored 'General case' 0 C--N 1.312 -1.027 0 C-N-CA 120.306 -0.558 . . . . 0.71 110.348 177.689 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 86.9 t90 -67.02 112.58 4.44 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.642 -1.163 . . . . 0.54 110.92 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.567 HG12 ' O ' ' A' ' 40' ' ' CYS . 0.6 OUTLIER -120.11 93.62 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 CA-C-O 121.957 0.884 . . . . 0.72 109.404 170.398 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.511 ' HA3' ' H ' ' A' ' 11' ' ' CYS . . . 70.75 178.63 26.72 Favored Glycine 0 CA--C 1.523 0.559 0 CA-C-N 115.544 -0.753 . . . . 0.47 113.482 -177.789 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.539 HG22 ' O ' ' A' ' 38' ' ' GLY . 0.0 OUTLIER -97.87 162.9 13.02 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.066 0.46 . . . . 0.62 111.137 -177.534 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 15.7 t -135.36 -177.22 4.56 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.374 -0.973 . . . . 1.07 108.374 175.639 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 12.8 m120 59.63 -160.82 0.28 Allowed 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 109.905 -0.406 . . . . 1.54 109.905 -173.138 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -83.21 42.21 0.8 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.113 0.482 . . . . 2.54 110.113 174.512 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 89.72 11.61 63.58 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 121.069 -0.586 . . . . 1.12 112.487 -178.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 8.1 pt -120.25 14.09 6.51 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.351 0 CA-C-O 121.219 0.533 . . . . 1.87 112.013 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.539 ' O ' HG22 ' A' ' 32' ' ' THR . . . -133.12 170.4 22.21 Favored Glycine 0 N--CA 1.424 -2.109 0 N-CA-C 110.082 -1.207 . . . . 0.79 110.082 178.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 57.2 p -120.51 126.04 49.38 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 121.022 0.439 . . . . 1.25 110.584 -177.253 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.567 ' O ' HG12 ' A' ' 30' ' ' ILE . 38.5 t -82.67 91.05 6.91 Favored 'General case' 0 C--O 1.211 -0.967 0 N-CA-C 107.346 -1.353 . . . . 0.87 107.346 175.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.433 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 3.0 m -100.66 -176.52 3.21 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.791 -0.818 . . . . 1.02 108.791 -177.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.633 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -142.32 138.76 31.5 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.909 -0.316 . . . . 0.55 110.479 166.018 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.485 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 34.8 ttp180 -59.81 110.4 1.15 Allowed 'General case' 0 C--O 1.234 0.287 0 O-C-N 123.957 0.786 . . . . 3.86 110.876 -178.822 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 138.65 -154.86 23.34 Favored Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 114.909 -1.041 . . . . 1.54 111.215 -177.485 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 32.5 t-105 -145.25 146.03 31.52 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 121.222 0.534 . . . . 1.55 111.353 177.813 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.612 ' NH2' HD21 ' A' ' 13' ' ' LEU . 10.5 ttm180 -130.69 127.28 38.54 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.484 -0.78 . . . . 3.53 110.523 176.047 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 45.8 m . . . . . 0 C--O 1.25 1.107 0 O-C-N 124.605 1.191 . . . . 4.01 111.859 179.161 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.831 0 CA-C-O 120.401 0.143 . . . . 6.64 110.718 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -72.04 -45.37 0.69 Allowed 'Trans proline' 0 CA--C 1.514 -0.484 0 C-N-CA 122.578 2.186 . . . . 6.85 109.563 176.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 6.4 p90 -126.06 165.42 18.85 Favored 'General case' 0 N--CA 1.444 -0.767 0 N-CA-C 107.189 -1.412 . . . . 5.56 107.189 169.768 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.426 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 48.7 mm -90.01 117.36 68.01 Favored Pre-proline 0 C--N 1.319 -0.729 0 C-N-CA 120.785 -0.366 . . . . 6.59 110.87 -179.334 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.426 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 14.0 Cg_endo -56.94 108.69 0.37 Allowed 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.647 2.231 . . . . 4.3 111.967 178.106 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.46 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 47.8 mtt180 -106.44 168.82 7.6 Favored Pre-proline 0 C--N 1.318 -0.8 0 CA-C-N 115.302 -0.863 . . . . 7.04 109.687 -178.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.46 ' HD2' ' HB3' ' A' ' 6' ' ' ARG . 2.1 Cg_endo -41.81 141.34 1.7 Allowed 'Trans proline' 0 C--N 1.35 0.641 0 C-N-CA 123.165 2.577 . . . . 5.21 112.461 175.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.419 ' N ' HD12 ' A' ' 8' ' ' ILE . 2.5 mp -59.93 111.14 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.82 -0.627 . . . . 4.18 110.26 -176.407 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -100.1 169.2 9.33 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.329 -0.85 . . . . 3.25 110.295 -174.771 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 12' ' ' ARG . 16.9 p -91.03 -176.43 4.62 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.795 -0.639 . . . . 1.72 111.106 -177.299 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.618 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 47.7 t -59.56 8.67 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 121.291 0.567 . . . . 1.04 111.797 177.01 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.505 ' HG3' HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -53.28 -38.42 63.06 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.555 -0.535 . . . . 4.23 109.555 167.84 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.505 HD12 ' HG3' ' A' ' 12' ' ' ARG . 8.6 mp -77.22 126.08 30.37 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 109.07 -0.715 . . . . 2.66 109.07 172.075 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.618 ' HD3' ' SG ' ' A' ' 11' ' ' CYS . 17.3 mmm180 -134.31 171.75 13.83 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 113.077 0.769 . . . . 7.01 113.077 -171.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 64.42 20.1 12.04 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 114.357 -1.292 . . . . 4.38 110.849 -177.217 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.735 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -85.85 -51.59 3.56 Favored Glycine 0 N--CA 1.438 -1.201 0 C-N-CA 118.824 -1.655 . . . . 1.7 111.377 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.735 HG12 ' O ' ' A' ' 16' ' ' GLY . 25.5 mm -168.4 143.71 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 C-N-CA 125.903 1.681 . . . . 1.05 107.824 157.532 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.6 m -109.46 99.62 8.81 Favored 'General case' 0 C--N 1.321 -0.669 0 O-C-N 121.774 -0.579 . . . . 1.28 110.084 166.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.483 ' HD1' ' SG ' ' A' ' 41' ' ' CYS . 44.8 m-85 -88.19 135.02 33.63 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.72 -0.673 . . . . 0.67 110.938 -178.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -88.16 97.85 0.41 Allowed 'Trans proline' 0 N--CA 1.442 -1.558 0 C-N-CA 121.452 1.435 . . . . 0.48 109.729 164.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.55 -115.07 1.3 Allowed Glycine 0 N--CA 1.444 -0.819 0 N-CA-C 110.666 -0.973 . . . . 0.59 110.666 -170.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 22.2 pt -146.26 152.16 13.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-O 121.277 0.56 . . . . 1.2 111.94 179.262 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -86.27 142.52 28.49 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.219 -0.901 . . . . 1.44 108.735 170.391 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.9 ptt180 -131.98 -39.21 1.08 Allowed 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 119.542 -0.863 . . . . 5.09 112.251 173.218 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.408 HH11 ' HD2' ' A' ' 25' ' ' ARG . 4.8 mtt85 174.24 145.17 0.2 Allowed Pre-proline 0 N--CA 1.474 0.745 0 N-CA-C 112.033 0.383 . . . . 3.77 112.033 173.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -88.41 99.47 0.22 Allowed 'Cis proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.996 -1.669 . . . . 1.34 110.851 -9.53 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.624 ' CE1' HG13 ' A' ' 17' ' ' ILE . 68.7 m-85 -162.21 135.66 6.23 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.339 -0.986 . . . . 0.64 108.339 -176.77 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -108.42 129.76 55.25 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.973 -0.691 . . . . 0.71 110.194 176.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 85.4 t90 -66.81 113.45 4.9 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.684 -1.144 . . . . 0.54 111.193 -177.04 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.58 ' O ' ' HB3' ' A' ' 40' ' ' CYS . 10.9 pt -121.62 92.4 2.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-N 115.548 -0.751 . . . . 0.72 109.559 172.752 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 66.9 -171.61 30.83 Favored Glycine 0 CA--C 1.527 0.819 0 C-N-CA 121.281 -0.485 . . . . 0.47 113.159 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.6 p -107.66 168.54 9.18 Favored 'General case' 0 CA--C 1.533 0.299 0 O-C-N 122.381 -0.482 . . . . 0.62 111.503 -177.02 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.587 ' O ' ' HA3' ' A' ' 38' ' ' GLY . 42.7 t -160.38 105.31 1.47 Allowed 'General case' 0 C--N 1.334 -0.098 0 N-CA-C 110.277 -0.268 . . . . 1.07 110.277 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.522 ' HB3' HG13 ' A' ' 37' ' ' ILE . 0.7 OUTLIER 163.67 39.58 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.586 1.554 . . . . 1.54 109.845 176.798 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 57.12 37.82 28.72 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.104 -0.498 . . . . 2.54 111.283 -175.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 136.19 -64.93 0.57 Allowed Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 111.442 -0.663 . . . . 1.12 111.442 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.522 HG13 ' HB3' ' A' ' 34' ' ' ASN . 2.7 pt -80.27 -162.09 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.677 -0.261 . . . . 1.87 110.339 174.533 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.587 ' HA3' ' O ' ' A' ' 33' ' ' CYS . . . 85.49 179.4 50.5 Favored Glycine 0 N--CA 1.422 -2.249 0 C-N-CA 120.497 -0.859 . . . . 0.79 111.538 177.265 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.9 m -141.25 111.9 7.04 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.015 -0.593 . . . . 1.25 109.532 -178.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.58 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 47.2 t -79.02 111.57 15.36 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 107.26 -1.385 . . . . 0.87 107.26 175.828 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.483 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 2.2 m -129.2 156.5 43.85 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.815 -0.809 . . . . 1.02 108.815 -176.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.622 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -118.29 130.62 56.14 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 119.817 -0.753 . . . . 0.55 110.301 174.008 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.503 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 1.5 tmt_? -55.12 109.86 0.59 Allowed 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 115.275 -0.875 . . . . 3.86 110.521 -177.561 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 137.4 -162.78 25.43 Favored Glycine 0 N--CA 1.442 -0.959 0 CA-C-N 115.256 -0.884 . . . . 1.54 111.85 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 31.0 t-105 -141.59 118.51 11.18 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.033 0.445 . . . . 1.55 110.597 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 12.9 ttm180 -96.68 139.55 32.58 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.032 -0.531 . . . . 3.53 111.565 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.3 t . . . . . 0 C--O 1.247 0.943 0 CA-C-N 114.477 -1.238 . . . . 4.01 110.976 -179.375 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.427 ' HA ' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.476 0.827 0 CA-C-O 120.44 0.162 . . . . 6.64 110.87 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 1' ' ' PCA . 4.8 Cg_exo -77.4 -29.68 4.64 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.653 2.235 . . . . 6.85 110.224 177.471 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 4.4 p90 -122.85 166.08 15.59 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 107.715 -1.217 . . . . 5.56 107.715 176.115 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.497 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 7.0 tp -83.45 112.11 36.74 Favored Pre-proline 0 C--N 1.321 -0.666 0 C-N-CA 120.93 -0.308 . . . . 6.59 110.654 178.265 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.508 ' HB3' ' HA ' ' A' ' 47' ' ' SER . 2.8 Cg_endo -44.79 109.87 0.2 Allowed 'Trans proline' 0 C--N 1.356 0.957 0 C-N-CA 123.36 2.707 . . . . 4.3 113.238 179.311 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 81.2 mtp180 -100.5 150.34 36.88 Favored Pre-proline 0 C--N 1.319 -0.744 0 CA-C-N 115.331 -0.849 . . . . 7.04 108.806 174.064 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -44.48 124.99 5.69 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 123.092 2.528 . . . . 5.21 111.333 176.652 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.461 ' HA ' ' CD ' ' A' ' 46' ' ' ARG . 81.3 mt -61.64 113.04 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.524 0.678 . . . . 4.18 111.322 -174.025 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.466 ' O ' HG22 ' A' ' 30' ' ' ILE . 71.4 m-20 -81.75 165.3 21.06 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 114.843 -1.071 . . . . 3.25 111.026 -176.243 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.447 ' C ' ' H ' ' A' ' 12' ' ' ARG . 21.4 p -79.56 -175.49 4.81 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 114.949 -1.023 . . . . 1.72 110.906 173.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.417 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 19.4 t -57.12 4.52 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 123.595 0.758 . . . . 1.04 112.617 -179.335 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.447 ' H ' ' C ' ' A' ' 10' ' ' THR . 34.1 ptt180 -61.27 -29.91 70.14 Favored 'General case' 0 CA--C 1.531 0.239 0 O-C-N 122.018 -0.426 . . . . 4.23 110.86 174.08 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.403 ' O ' HD12 ' A' ' 30' ' ' ILE . 4.4 mm? -88.56 97.86 11.33 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 107.319 -1.363 . . . . 2.66 107.319 167.041 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.635 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 12.7 tpp85 -101.43 163.97 12.0 Favored 'General case' 0 N--CA 1.428 -1.538 0 N-CA-C 113.349 0.87 . . . . 7.01 113.349 -161.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.635 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 92.9 m-20 70.34 69.61 0.21 Allowed 'General case' 0 CA--C 1.514 -0.432 0 CA-C-N 114.421 -1.263 . . . . 4.38 112.321 168.755 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.684 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -125.27 -46.79 0.23 Allowed Glycine 0 N--CA 1.439 -1.154 0 C-N-CA 119.385 -1.388 . . . . 1.7 111.576 169.095 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.684 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.1 mt -168.86 131.53 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 124.523 1.129 . . . . 1.05 109.648 156.843 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 1.8 m -94.04 113.09 25.0 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.908 0.385 . . . . 1.28 110.213 170.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.615 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 64.7 m-85 -95.49 140.68 22.47 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.343 -0.389 . . . . 0.67 110.077 178.464 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_endo -86.71 96.39 0.5 Allowed 'Trans proline' 0 N--CA 1.443 -1.49 0 C-N-CA 121.356 1.37 . . . . 0.48 109.787 167.229 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.56 -109.2 0.89 Allowed Glycine 0 N--CA 1.441 -0.968 0 CA-C-N 115.339 -0.846 . . . . 0.59 111.523 -171.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.9 pt -146.17 145.47 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 112.386 0.513 . . . . 1.2 112.386 -176.309 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.89 126.7 32.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.609 -0.723 . . . . 1.44 109.195 172.634 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 37.4 ptt180 -115.98 -40.04 3.37 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 118.619 -1.232 . . . . 5.09 112.521 176.697 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 172.75 152.53 0.23 Allowed Pre-proline 0 N--CA 1.473 0.691 0 CA-C-N 118.112 0.414 . . . . 3.77 111.642 172.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -87.15 100.91 0.27 Allowed 'Cis proline' 0 C--N 1.347 0.45 0 C-N-CA 123.216 -1.577 . . . . 1.34 110.797 -12.418 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.57 ' CE1' HD12 ' A' ' 17' ' ' ILE . 89.1 m-85 -160.88 141.92 11.72 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 108.178 -1.045 . . . . 0.64 108.178 -175.662 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 7.6 p90 -107.76 128.96 55.04 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 120.437 -0.505 . . . . 0.71 109.641 177.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 92.1 t90 -66.71 113.83 5.14 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.988 -1.005 . . . . 0.54 110.365 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.544 ' O ' ' HB3' ' A' ' 40' ' ' CYS . 11.2 pt -120.15 93.25 2.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-N 115.271 -0.877 . . . . 0.72 109.318 175.171 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 62.31 -172.96 8.87 Favored Glycine 0 CA--C 1.526 0.736 0 C-N-CA 121.047 -0.597 . . . . 0.47 112.93 -176.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.4 p -102.1 165.53 11.11 Favored 'General case' 0 C--N 1.324 -0.523 0 O-C-N 122.173 -0.604 . . . . 0.62 111.631 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 20.6 t -137.5 -178.18 5.12 Favored 'General case' 0 C--O 1.216 -0.696 0 N-CA-C 108.334 -0.988 . . . . 1.07 108.334 178.348 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 12.2 m120 67.12 1.42 2.37 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 118.28 0.491 . . . . 1.54 111.753 -177.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 49.8 m-80 65.94 85.46 0.14 Allowed 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.611 0.764 . . . . 2.54 111.846 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 110.76 -62.46 0.29 Allowed Glycine 0 CA--C 1.511 -0.174 0 N-CA-C 111.709 -0.556 . . . . 1.12 111.709 175.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.454 ' H ' HD12 ' A' ' 37' ' ' ILE . 0.2 OUTLIER -88.76 -142.43 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.753 -0.832 . . . . 1.87 108.753 173.424 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.4 175.29 1.19 Allowed Glycine 0 N--CA 1.447 -0.602 0 CA-C-O 122.009 0.783 . . . . 0.79 114.485 169.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.615 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 87.6 p -142.32 119.89 11.75 Favored 'General case' 0 N--CA 1.433 -1.278 0 N-CA-C 109.599 -0.519 . . . . 1.25 109.599 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.544 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 46.0 t -82.63 116.8 22.18 Favored 'General case' 0 C--N 1.313 -1.018 0 N-CA-C 107.127 -1.435 . . . . 0.87 107.127 174.218 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.586 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -133.67 169.03 17.62 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 108.31 -0.996 . . . . 1.02 108.31 -178.322 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.659 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -136.73 142.14 43.05 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.669 -0.812 . . . . 0.55 110.744 172.089 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.477 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 57.0 ttp180 -61.42 116.65 4.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 114.973 -1.012 . . . . 3.86 110.909 -176.222 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 134.24 -149.84 19.88 Favored Glycine 0 CA--C 1.497 -1.044 0 CA-C-N 115.162 -0.926 . . . . 1.54 111.658 176.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 31.4 t-105 -152.7 123.88 7.58 Favored 'General case' 0 C--N 1.317 -0.843 0 C-N-CA 120.581 -0.448 . . . . 1.55 111.189 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.461 ' CD ' ' HA ' ' A' ' 8' ' ' ILE . 21.2 ttm180 -104.79 139.91 38.88 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.912 -0.585 . . . . 3.53 110.23 169.753 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.508 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 3.7 t . . . . . 0 C--O 1.253 1.243 0 O-C-N 124.289 0.993 . . . . 4.01 110.538 -179.684 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.414 ' HA ' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.473 0.723 0 CA-C-O 120.654 0.264 . . . . 6.64 111.525 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 1' ' ' PCA . 2.9 Cg_exo -76.29 -29.2 6.47 Favored 'Trans proline' 0 C--N 1.347 0.491 0 C-N-CA 122.907 2.405 . . . . 6.85 110.269 176.657 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.488 ' O ' ' HD3' ' A' ' 5' ' ' PRO . 0.8 OUTLIER -121.84 164.76 16.95 Favored 'General case' 0 N--CA 1.444 -0.744 0 N-CA-C 107.575 -1.268 . . . . 5.56 107.575 172.454 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.61 110.69 18.04 Favored Pre-proline 0 C--N 1.322 -0.607 0 N-CA-C 109.656 -0.498 . . . . 6.59 109.656 178.504 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.488 ' HD3' ' O ' ' A' ' 3' ' ' PHE . 52.1 Cg_exo -56.2 107.67 0.28 Allowed 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 122.533 2.155 . . . . 4.3 112.058 -179.199 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.643 ' O ' ' HG2' ' A' ' 46' ' ' ARG . 22.2 mtp180 -89.15 167.53 17.72 Favored Pre-proline 0 C--N 1.32 -0.703 0 CA-C-N 115.453 -0.794 . . . . 7.04 109.602 -179.749 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.424 ' HD2' ' HB3' ' A' ' 6' ' ' ARG . 85.0 Cg_exo -48.26 139.08 22.3 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.387 2.058 . . . . 5.21 112.851 176.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.619 ' HA ' ' HD3' ' A' ' 46' ' ' ARG . 3.5 mp -62.57 106.37 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.274 -0.875 . . . . 4.18 111.465 178.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -89.04 164.02 15.25 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 108.943 -0.762 . . . . 3.25 108.943 170.021 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.495 ' C ' ' H ' ' A' ' 12' ' ' ARG . 38.4 p -72.75 -175.8 1.81 Allowed 'General case' 0 C--N 1.314 -0.965 0 CA-C-N 116.504 -0.317 . . . . 1.72 110.867 176.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.42 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 11.4 t -57.51 6.23 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 123.36 0.664 . . . . 1.04 112.054 178.816 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.495 ' H ' ' C ' ' A' ' 10' ' ' THR . 38.4 ptt180 -65.89 -33.2 75.3 Favored 'General case' 0 C--N 1.33 -0.268 0 O-C-N 122.107 -0.371 . . . . 4.23 110.939 172.484 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.406 ' CD2' ' HG3' ' A' ' 12' ' ' ARG . 4.5 mm? -97.11 97.48 9.24 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 108.472 -0.936 . . . . 2.66 108.472 172.086 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.725 ' HD3' ' SG ' ' A' ' 40' ' ' CYS . 2.7 mmm-85 -110.24 -170.71 1.7 Allowed 'General case' 0 N--CA 1.438 -1.028 0 N-CA-C 113.338 0.866 . . . . 7.01 113.338 -166.463 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.9 m-80 69.02 53.45 0.47 Allowed 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 114.678 -1.146 . . . . 4.38 111.154 -178.686 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.717 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -120.46 -50.02 0.28 Allowed Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 119.445 -1.36 . . . . 1.7 112.119 172.113 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.717 HG12 ' O ' ' A' ' 16' ' ' GLY . 25.1 mm -166.65 147.02 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 C-N-CA 125.337 1.455 . . . . 1.05 108.149 161.112 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 31.5 t -111.12 104.03 12.52 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 121.654 -0.654 . . . . 1.28 109.426 168.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.554 ' CE1' HG21 ' A' ' 17' ' ' ILE . 17.0 m-85 -93.17 124.13 58.84 Favored Pre-proline 0 C--N 1.329 -0.287 0 N-CA-C 112.404 0.52 . . . . 0.67 112.404 -175.809 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -82.23 97.4 0.9 Allowed 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 121.833 1.689 . . . . 0.48 109.473 165.339 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.64 -134.0 7.12 Favored Glycine 0 N--CA 1.443 -0.84 0 N-CA-C 110.884 -0.886 . . . . 0.59 110.884 -170.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 23.7 pt -129.17 147.8 33.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.285 0.564 . . . . 1.2 112.006 -178.46 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 93.9 m -94.77 139.62 31.02 Favored 'General case' 0 N--CA 1.437 -1.094 0 CA-C-N 115.488 -0.778 . . . . 1.44 109.797 173.51 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.48 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 7.1 ptt180 -143.56 -37.1 0.35 Allowed 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 118.904 -0.569 . . . . 5.09 112.532 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.48 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 10.8 mtt180 175.54 145.68 0.24 Allowed Pre-proline 0 N--CA 1.476 0.827 0 N-CA-C 112.067 0.395 . . . . 3.77 112.067 170.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -88.74 99.25 0.2 Allowed 'Cis proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.839 -1.734 . . . . 1.34 110.611 -10.604 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.475 ' CE1' HG13 ' A' ' 17' ' ' ILE . 96.2 m-85 -161.55 138.51 8.55 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 108.919 -0.771 . . . . 0.64 108.919 -175.405 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.512 ' CZ ' ' HB3' ' A' ' 42' ' ' ALA . 35.8 p90 -113.09 127.93 56.35 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 109.245 -0.65 . . . . 0.71 109.245 178.001 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' TRP . . . . . 0.562 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 90.1 t90 -73.74 117.0 14.99 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.625 -0.716 . . . . 0.54 110.971 -175.419 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.463 ' O ' HG13 ' A' ' 30' ' ' ILE . 26.6 pt -121.35 95.03 3.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 121.524 0.678 . . . . 0.72 110.259 176.309 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 63.39 -170.97 14.86 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 121.12 -0.562 . . . . 0.47 113.041 -178.147 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 23.2 p -108.96 148.19 31.1 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 112.928 0.714 . . . . 0.62 112.928 -173.203 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.481 ' O ' ' HA3' ' A' ' 38' ' ' GLY . 18.4 t -116.74 -175.83 2.85 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.583 -1.266 . . . . 1.07 107.583 174.308 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.436 ' HB2' ' HA3' ' A' ' 38' ' ' GLY . 84.0 m-20 64.62 -97.44 0.06 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 118.315 0.507 . . . . 1.54 111.266 179.738 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 52.0 t30 -177.05 85.77 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.762 0.315 . . . . 2.54 110.868 -178.168 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 94.09 -57.42 2.11 Favored Glycine 0 CA--C 1.503 -0.695 0 N-CA-C 110.122 -1.191 . . . . 1.12 110.122 178.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.455 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 0.8 OUTLIER -78.51 -148.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 108.063 -1.088 . . . . 1.87 108.063 164.997 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.481 ' HA3' ' O ' ' A' ' 33' ' ' CYS . . . 76.97 111.42 0.14 Allowed Glycine 0 N--CA 1.441 -0.976 0 C-N-CA 120.245 -0.979 . . . . 0.79 113.02 173.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.5 m -90.49 99.34 12.38 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 121.162 0.506 . . . . 1.25 109.899 176.708 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.725 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 40.3 t -76.05 103.35 6.06 Favored 'General case' 0 C--O 1.218 -0.597 0 N-CA-C 107.65 -1.241 . . . . 0.87 107.65 173.596 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.562 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 24.3 m -128.93 178.11 6.62 Favored 'General case' 0 C--N 1.311 -1.085 0 C-N-CA 120.634 -0.426 . . . . 1.02 110.473 -178.087 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.571 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -134.19 139.89 46.14 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 116.207 -0.451 . . . . 0.55 109.983 173.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.451 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 70.9 ttt180 -62.22 111.61 2.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.659 -0.701 . . . . 3.86 111.633 -174.154 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.95 -153.01 20.72 Favored Glycine 0 N--CA 1.443 -0.844 0 CA-C-N 115.188 -0.915 . . . . 1.54 112.36 178.15 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 28.4 t-105 -144.75 118.6 9.3 Favored 'General case' 0 N--CA 1.441 -0.916 0 CA-C-O 121.143 0.497 . . . . 1.55 110.483 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.643 ' HG2' ' O ' ' A' ' 6' ' ' ARG . 1.0 OUTLIER -89.9 127.23 35.97 Favored 'General case' 0 N--CA 1.44 -0.945 0 CA-C-N 115.592 -0.731 . . . . 3.53 110.087 176.27 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.432 ' H ' ' CB ' ' A' ' 5' ' ' PRO . 19.9 m . . . . . 0 C--O 1.252 1.196 0 O-C-N 123.865 0.728 . . . . 4.01 110.846 -179.271 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.455 ' HA ' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 110.672 -0.122 . . . . 6.64 110.672 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 1' ' ' PCA . 3.2 Cg_exo -78.56 -12.09 15.39 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.799 2.333 . . . . 6.85 110.551 -179.399 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 3.6 p90 -148.04 166.36 28.0 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 107.094 -1.447 . . . . 5.56 107.094 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.5 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 6.5 tp -81.9 110.72 21.61 Favored Pre-proline 0 C--N 1.321 -0.665 0 C-N-CA 120.771 -0.372 . . . . 6.59 110.76 178.362 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.5 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 4.0 Cg_exo -36.13 109.86 0.06 OUTLIER 'Trans proline' 0 C--N 1.362 1.241 0 C-N-CA 124.457 3.438 . . . . 4.3 114.546 -179.069 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.508 ' O ' ' HD2' ' A' ' 46' ' ' ARG . 14.7 mtp-105 -100.96 173.01 3.95 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 114.783 -1.099 . . . . 7.04 109.905 174.718 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_exo -54.66 143.52 68.82 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.172 1.915 . . . . 5.21 111.561 169.045 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.437 ' HA ' ' HG2' ' A' ' 46' ' ' ARG . 2.6 mp -61.58 128.8 23.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 115.818 -0.628 . . . . 4.18 110.674 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -110.02 164.72 12.35 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.113 0.482 . . . . 3.25 110.001 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.446 ' C ' ' H ' ' A' ' 12' ' ' ARG . 70.7 p -89.18 -175.35 4.76 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.508 -0.769 . . . . 1.72 109.852 171.682 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 31.2 t -55.5 -1.06 0.03 OUTLIER 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.877 0.471 . . . . 1.04 112.079 178.263 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.446 ' H ' ' C ' ' A' ' 10' ' ' THR . 9.3 ptm180 -52.52 -40.52 62.54 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 122.676 0.39 . . . . 4.23 111.615 175.011 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 10.6 mp -87.31 96.04 10.21 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 107.838 -1.171 . . . . 2.66 107.838 170.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.692 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 8.1 tpt180 -99.97 172.11 7.42 Favored 'General case' 0 N--CA 1.431 -1.42 0 CA-C-N 116.032 -0.531 . . . . 7.01 111.98 -165.238 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.692 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 34.0 t-20 71.18 57.5 0.2 Allowed 'General case' 0 CA--C 1.514 -0.409 0 CA-C-N 114.973 -1.012 . . . . 4.38 110.417 170.409 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.652 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -117.04 -48.27 0.45 Allowed Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 119.389 -1.386 . . . . 1.7 111.244 171.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.652 HG13 ' O ' ' A' ' 16' ' ' GLY . 2.3 mt -170.02 133.67 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 124.571 1.149 . . . . 1.05 109.564 154.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 11.4 m -96.8 112.36 24.14 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 120.897 -0.321 . . . . 1.28 110.19 170.571 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.6 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 43.3 m-85 -95.68 126.34 45.69 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.495 -0.32 . . . . 0.67 110.24 177.068 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -80.65 96.96 1.0 Allowed 'Trans proline' 0 N--CA 1.445 -1.335 0 C-N-CA 121.027 1.151 . . . . 0.48 109.133 166.174 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.5 -113.08 1.06 Allowed Glycine 0 N--CA 1.448 -0.527 0 N-CA-C 111.266 -0.734 . . . . 0.59 111.266 -170.253 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.7 pt -142.79 156.43 18.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-O 121.062 0.458 . . . . 1.2 111.87 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' CYS . . . . . 0.5 ' HB3' ' HB2' ' A' ' 27' ' ' TYR . 5.8 m -107.04 132.08 53.36 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 108.679 -0.86 . . . . 1.44 108.679 172.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 10.6 ptm180 -118.12 -41.1 2.9 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 118.976 -1.09 . . . . 5.09 111.315 175.171 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.508 ' HA ' ' H ' ' A' ' 27' ' ' TYR . 0.0 OUTLIER 173.78 158.61 0.31 Allowed Pre-proline 0 CA--C 1.533 0.303 0 C-N-CA 122.644 0.377 . . . . 3.77 111.44 168.449 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.432 ' HA ' ' HB2' ' A' ' 25' ' ' ARG . 2.5 Cg_endo -86.8 99.07 0.22 Allowed 'Cis proline' 0 N--CA 1.458 -0.594 0 C-N-CA 122.652 -1.811 . . . . 1.34 110.681 -6.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.52 ' CE1' HD12 ' A' ' 17' ' ' ILE . 64.2 m-85 -162.9 134.75 5.19 Favored 'General case' 0 CA--C 1.504 -0.79 0 N-CA-C 108.116 -1.068 . . . . 0.64 108.116 -175.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 13.0 p90 -108.68 128.33 54.76 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 120.289 -0.564 . . . . 0.71 109.769 177.17 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' TRP . . . . . 0.711 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 89.2 t90 -65.0 114.73 4.77 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.053 -0.976 . . . . 0.54 110.877 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.513 ' O ' ' HB2' ' A' ' 11' ' ' CYS . 20.7 pt -122.15 95.88 3.75 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.048 -0.978 . . . . 0.72 109.783 173.658 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 62.84 -161.22 32.77 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 120.991 -0.623 . . . . 0.47 113.089 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 19.7 p -117.17 170.1 8.94 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 112.842 0.682 . . . . 0.62 112.842 -175.01 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 19.7 t -143.59 -174.98 4.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.875 -1.057 . . . . 1.07 108.839 -175.425 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.458 ' O ' ' HB2' ' A' ' 35' ' ' ASN . 9.9 m120 68.68 -85.02 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 122.692 0.397 . . . . 1.54 110.763 -178.545 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.458 ' HB2' ' O ' ' A' ' 34' ' ' ASN . 21.8 t-20 169.24 78.55 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.285 0 C-N-CA 123.799 0.84 . . . . 2.54 109.212 -179.591 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 105.41 -56.47 0.53 Allowed Glycine 0 N--CA 1.453 -0.221 0 N-CA-C 111.123 -0.791 . . . . 1.12 111.123 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.513 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 0.4 OUTLIER -84.41 -137.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.885 -0.783 . . . . 1.87 108.885 170.503 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.513 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 67.07 115.99 0.02 OUTLIER Glycine 0 C--N 1.339 0.732 0 C-N-CA 120.881 -0.676 . . . . 0.79 114.045 175.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.6 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 77.5 p -93.64 98.91 11.46 Favored 'General case' 0 N--CA 1.434 -1.241 0 N-CA-C 109.006 -0.739 . . . . 1.25 109.006 173.294 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 44.5 t -69.91 108.41 3.99 Favored 'General case' 0 CA--C 1.507 -0.707 0 N-CA-C 107.97 -1.122 . . . . 0.87 107.97 176.244 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.711 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 80.2 m -130.44 173.88 10.41 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 109.297 -0.631 . . . . 1.02 109.297 179.036 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.612 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -135.58 142.74 45.36 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 120.381 -0.528 . . . . 0.55 110.264 172.217 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.445 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 74.4 ttt180 -62.37 112.19 2.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.259 -0.882 . . . . 3.86 111.484 -173.615 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.88 -151.71 21.06 Favored Glycine 0 N--CA 1.446 -0.649 0 CA-C-N 114.712 -1.131 . . . . 1.54 111.797 -179.24 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 32.8 t-105 -149.43 119.86 7.39 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.045 0.45 . . . . 1.55 111.004 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.508 ' HD2' ' O ' ' A' ' 6' ' ' ARG . 0.3 OUTLIER -77.19 138.83 39.69 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.782 -0.645 . . . . 3.53 110.015 175.55 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.441 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 31.1 p . . . . . 0 C--O 1.251 1.14 0 O-C-N 124.314 1.009 . . . . 4.01 111.594 -178.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.418 ' HA ' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.474 0.753 0 CA-C-O 120.659 0.266 . . . . 6.64 111.001 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 1' ' ' PCA . 5.8 Cg_exo -76.95 -46.18 0.16 Allowed 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.693 2.262 . . . . 6.85 109.838 175.701 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 13.1 p90 -99.44 165.63 11.56 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.573 -1.269 . . . . 5.56 107.573 170.527 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.577 ' O ' ' HG3' ' A' ' 6' ' ' ARG . 51.1 mm -93.25 122.2 63.71 Favored Pre-proline 0 C--N 1.317 -0.834 0 C-N-CA 120.774 -0.37 . . . . 6.59 110.227 178.289 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 10.0 Cg_endo -53.13 109.23 0.33 Allowed 'Trans proline' 0 C--N 1.348 0.514 0 C-N-CA 122.727 2.285 . . . . 4.3 111.91 176.462 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.577 ' HG3' ' O ' ' A' ' 4' ' ' ILE . 67.9 mtp180 -108.02 166.47 10.88 Favored Pre-proline 0 C--N 1.319 -0.756 0 CA-C-N 115.527 -0.76 . . . . 7.04 109.328 178.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -52.1 140.4 50.45 Favored 'Trans proline' 0 C--O 1.236 0.412 0 C-N-CA 122.308 2.006 . . . . 5.21 111.896 173.671 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.57 ' HA ' ' HD2' ' A' ' 46' ' ' ARG . 2.6 mp -63.2 115.72 2.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.808 -0.633 . . . . 4.18 111.02 -178.262 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.481 ' O ' HG22 ' A' ' 30' ' ' ILE . 65.9 m-20 -98.8 165.93 11.55 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.443 -0.798 . . . . 3.25 109.777 176.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.422 ' C ' ' H ' ' A' ' 12' ' ' ARG . 26.9 p -79.6 -175.68 4.93 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.117 -0.492 . . . . 1.72 111.071 175.332 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.405 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 12.5 t -55.74 -0.85 0.04 OUTLIER 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 123.68 0.792 . . . . 1.04 112.209 179.552 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.422 ' H ' ' C ' ' A' ' 10' ' ' THR . 12.9 ptm180 -54.74 -41.84 70.87 Favored 'General case' 0 C--O 1.234 0.237 0 C-N-CA 122.812 0.445 . . . . 4.23 111.446 173.673 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -86.29 96.41 9.95 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 106.991 -1.485 . . . . 2.66 106.991 171.338 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.664 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 18.2 tpp85 -100.31 157.44 16.61 Favored 'General case' 0 N--CA 1.429 -1.507 0 N-CA-C 114.041 1.126 . . . . 7.01 114.041 -157.45 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.664 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 64.7 t30 70.04 69.67 0.22 Allowed 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 113.822 -1.535 . . . . 4.38 112.348 164.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.722 ' HA3' ' HA ' ' A' ' 42' ' ' ALA . . . -108.01 -43.82 1.26 Allowed Glycine 0 N--CA 1.432 -1.63 0 N-CA-C 109.659 -1.376 . . . . 1.7 109.659 165.055 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.634 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.1 mt -165.89 132.87 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.349 1.06 . . . . 1.05 109.258 157.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 21.5 t -91.88 109.3 20.64 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.109 -0.33 . . . . 1.28 110.109 175.168 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.412 ' CD1' ' SG ' ' A' ' 23' ' ' CYS . 15.4 m-85 -96.13 122.39 58.19 Favored Pre-proline 0 CA--C 1.516 -0.346 0 N-CA-C 112.125 0.417 . . . . 0.67 112.125 -177.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -81.92 96.47 0.91 Allowed 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 121.513 1.475 . . . . 0.48 109.816 167.11 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 136.26 -119.87 2.09 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 111.067 -0.813 . . . . 0.59 111.067 -171.502 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.8 pt -138.14 154.4 28.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 117.131 0.466 . . . . 1.2 111.735 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' CYS . . . . . 0.412 ' SG ' ' CD1' ' A' ' 19' ' ' PHE . 69.0 m -101.43 139.85 36.53 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 115.622 -0.717 . . . . 1.44 109.813 173.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.733 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 13.6 ptm180 -135.5 -39.42 0.73 Allowed 'General case' 0 C--N 1.321 -0.646 0 C-N-CA 119.733 -0.787 . . . . 5.09 112.612 179.028 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.733 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 12.0 mmt180 176.88 140.17 0.23 Allowed Pre-proline 0 N--CA 1.476 0.86 0 C-N-CA 123.104 0.561 . . . . 3.77 110.827 178.245 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 4.1 Cg_exo -90.42 99.94 0.21 Allowed 'Cis proline' 0 N--CA 1.456 -0.681 0 C-N-CA 123.44 -1.483 . . . . 1.34 110.371 -13.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.488 ' CD1' ' HA ' ' A' ' 43' ' ' ARG . 96.7 m-85 -161.01 131.4 5.15 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 108.829 -0.804 . . . . 0.64 108.829 -176.535 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -109.2 127.51 54.28 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 109.081 -0.711 . . . . 0.71 109.081 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' TRP . . . . . 0.584 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 86.6 t90 -70.56 117.18 11.76 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.067 -0.969 . . . . 0.54 110.985 -175.19 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.481 HG22 ' O ' ' A' ' 9' ' ' ASP . 16.2 pt -120.75 95.6 3.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.328 -0.851 . . . . 0.72 110.019 176.213 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 61.12 -164.64 17.9 Favored Glycine 0 CA--C 1.524 0.65 0 C-N-CA 121.284 -0.484 . . . . 0.47 113.24 -179.574 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.2 p -111.57 151.98 28.1 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 113.073 0.768 . . . . 0.62 113.073 -175.128 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.408 ' HB2' ' HB2' ' A' ' 40' ' ' CYS . 49.9 t -122.17 -177.07 3.5 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 107.154 -1.425 . . . . 1.07 107.154 175.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 58.54 -161.44 0.25 Allowed 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 118.866 0.757 . . . . 1.54 110.506 -178.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 92.0 m-20 -109.49 78.16 1.11 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.793 0.33 . . . . 2.54 111.104 -179.571 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 108.69 -52.18 0.66 Allowed Glycine 0 CA--C 1.509 -0.31 0 N-CA-C 111.149 -0.78 . . . . 1.12 111.149 176.035 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.413 HG12 ' H ' ' A' ' 37' ' ' ILE . 8.6 pt -77.46 -143.14 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 114.849 -0.676 . . . . 1.87 109.474 170.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.407 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 76.04 103.58 0.13 Allowed Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.442 -0.885 . . . . 0.79 113.031 168.399 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 38.2 m -84.04 98.71 10.0 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.898 -0.779 . . . . 1.25 108.898 172.604 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.408 ' HB2' ' HB2' ' A' ' 33' ' ' CYS . 42.7 t -72.65 106.08 4.53 Favored 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 107.884 -1.154 . . . . 0.87 107.884 175.441 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.584 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 37.0 m -126.9 174.56 8.72 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 121.12 0.486 . . . . 1.02 109.771 178.191 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.722 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -130.17 139.47 50.85 Favored 'General case' 0 N--CA 1.432 -1.332 0 C-N-CA 120.132 -0.627 . . . . 0.55 109.849 172.168 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.488 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 61.3 ttp180 -61.34 110.96 1.57 Allowed 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.567 -0.742 . . . . 3.86 111.29 -173.349 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 135.76 -158.93 24.04 Favored Glycine 0 N--CA 1.437 -1.237 0 CA-C-N 114.771 -1.104 . . . . 1.54 111.952 -178.489 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.431 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 28.7 t-105 -143.71 116.98 9.0 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.867 -0.419 . . . . 1.55 109.867 -179.13 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.57 ' HD2' ' HA ' ' A' ' 8' ' ' ILE . 12.5 ttm180 -88.63 136.99 32.72 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.458 -0.337 . . . . 3.53 110.265 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.1 t . . . . . 0 C--O 1.249 1.065 0 O-C-N 123.948 0.78 . . . . 4.01 110.042 -177.663 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.404 ' HA ' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.475 0.79 0 CA-C-O 120.504 0.193 . . . . 6.64 110.628 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 1' ' ' PCA . 3.2 Cg_exo -74.6 -25.14 13.04 Favored 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 122.685 2.257 . . . . 6.85 109.888 178.736 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -125.92 164.13 21.45 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 107.708 -1.219 . . . . 5.56 107.708 172.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 6.2 tp -88.91 110.27 36.52 Favored Pre-proline 0 C--N 1.321 -0.67 0 N-CA-C 109.815 -0.439 . . . . 6.59 109.815 175.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.538 ' HB3' ' H ' ' A' ' 47' ' ' SER . 70.0 Cg_exo -38.68 109.07 0.08 OUTLIER 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 123.629 2.886 . . . . 4.3 113.964 179.547 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 38.6 mtm105 -95.02 164.98 17.94 Favored Pre-proline 0 C--N 1.321 -0.669 0 N-CA-C 108.9 -0.778 . . . . 7.04 108.9 176.449 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_exo -44.51 128.74 8.49 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.296 1.997 . . . . 5.21 111.154 171.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.471 ' HA ' ' CD ' ' A' ' 46' ' ' ARG . 56.8 mt -61.6 119.48 5.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.871 -0.604 . . . . 4.18 111.678 -171.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 57.4 m-20 -84.3 163.28 19.71 Favored 'General case' 0 CA--C 1.513 -0.461 0 CA-C-N 115.462 -0.79 . . . . 3.25 109.503 177.449 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.444 ' C ' ' H ' ' A' ' 12' ' ' ARG . 11.2 p -84.01 -175.69 5.92 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.626 -0.715 . . . . 1.72 110.593 176.628 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.453 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 37.0 t -56.05 1.62 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 122.878 0.471 . . . . 1.04 112.153 178.468 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.444 ' H ' ' C ' ' A' ' 10' ' ' THR . 14.5 ptt180 -55.79 -34.97 65.77 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 120.577 0.227 . . . . 4.23 110.842 171.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -89.78 97.53 11.25 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 107.797 -1.186 . . . . 2.66 107.797 168.324 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.72 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 8.3 tpt180 -109.71 171.59 7.36 Favored 'General case' 0 N--CA 1.433 -1.306 0 CA-C-O 120.971 0.415 . . . . 7.01 112.007 -166.501 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.72 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 92.1 m-20 72.04 51.92 0.21 Allowed 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 115.215 -0.902 . . . . 4.38 111.052 173.525 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.67 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -109.17 -47.75 0.86 Allowed Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.619 -1.277 . . . . 1.7 110.87 170.419 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.67 HG13 ' O ' ' A' ' 16' ' ' GLY . 3.3 mt -168.99 138.58 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 124.548 1.139 . . . . 1.05 109.56 156.001 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 15.4 t -99.74 104.18 15.88 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.967 -0.382 . . . . 1.28 109.967 170.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.566 ' HD1' ' SG ' ' A' ' 23' ' ' CYS . 33.4 m-85 -92.37 131.45 34.46 Favored Pre-proline 0 CA--C 1.514 -0.424 0 CA-C-N 116.53 -0.305 . . . . 0.67 110.903 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -87.5 96.12 0.45 Allowed 'Trans proline' 0 N--CA 1.443 -1.466 0 C-N-CA 121.171 1.247 . . . . 0.48 109.744 165.317 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.75 -114.52 0.91 Allowed Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.638 -0.71 . . . . 0.59 111.75 -173.548 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -140.28 141.75 32.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 121.25 0.547 . . . . 1.2 112.111 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' CYS . . . . . 0.566 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 79.4 m -95.55 134.88 37.91 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-N 115.533 -0.758 . . . . 1.44 109.604 172.359 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.447 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 15.0 ptm180 -136.38 -37.92 0.69 Allowed 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 120.046 -0.662 . . . . 5.09 112.597 178.856 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.447 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 8.2 mtt180 176.32 146.48 0.26 Allowed Pre-proline 0 N--CA 1.47 0.573 0 N-CA-C 112.295 0.48 . . . . 3.77 112.295 175.043 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -86.83 98.52 0.21 Allowed 'Cis proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.455 -1.894 . . . . 1.34 110.049 -11.445 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.64 ' CE1' HD12 ' A' ' 17' ' ' ILE . 89.4 m-85 -162.53 133.47 4.94 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.658 -0.867 . . . . 0.64 108.658 -174.799 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -109.1 127.36 54.09 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 109.229 -0.656 . . . . 0.71 109.229 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' TRP . . . . . 0.6 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 76.4 t90 -68.66 114.24 6.86 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 114.955 -1.021 . . . . 0.54 110.155 -178.16 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.457 HG12 ' HA ' ' A' ' 41' ' ' CYS . 18.1 pt -120.98 93.71 2.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.669 0.747 . . . . 0.72 109.981 176.16 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 65.08 -172.46 21.2 Favored Glycine 0 CA--C 1.524 0.621 0 CA-C-N 115.799 -0.637 . . . . 0.47 113.049 -175.444 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 19.8 p -105.46 159.41 15.95 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.091 0.472 . . . . 0.62 111.989 -174.653 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.407 ' SG ' ' N ' ' A' ' 34' ' ' ASN . 48.7 t -121.92 -178.37 3.83 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.36 -0.607 . . . . 1.07 109.36 177.258 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.407 ' N ' ' SG ' ' A' ' 33' ' ' CYS . 2.5 m120 57.84 -145.53 0.58 Allowed 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.451 -0.574 . . . . 1.54 109.451 -172.403 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 35.0 m-80 -83.31 -1.09 52.42 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.617 0.246 . . . . 2.54 111.11 175.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 153.63 -35.73 0.74 Allowed Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 119.817 -1.182 . . . . 1.12 114.54 176.479 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -80.15 -32.34 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 113.033 0.753 . . . . 1.87 113.033 -172.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -68.83 172.03 37.22 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 120.441 -0.885 . . . . 0.79 111.697 177.086 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.477 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 68.5 p -117.69 124.07 47.62 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.224 0.535 . . . . 1.25 111.252 -174.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 42.0 t -83.9 104.26 13.84 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 107.592 -1.262 . . . . 0.87 107.592 172.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.6 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 29.6 m -127.38 174.77 8.72 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 109.852 -0.425 . . . . 1.02 109.852 178.862 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.655 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -136.37 143.01 43.82 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 119.923 -0.711 . . . . 0.55 111.077 173.186 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.468 ' C ' ' HD3' ' A' ' 43' ' ' ARG . 3.4 tmt_? -61.54 112.13 2.09 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.062 -0.972 . . . . 3.86 110.466 -177.376 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 141.36 -159.33 26.7 Favored Glycine 0 N--CA 1.439 -1.116 0 CA-C-N 115.11 -0.95 . . . . 1.54 111.112 178.252 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.46 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 31.9 t-105 -148.0 119.15 7.74 Favored 'General case' 0 C--N 1.314 -0.942 0 C-N-CA 120.47 -0.492 . . . . 1.55 111.002 -179.434 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.471 ' CD ' ' HA ' ' A' ' 8' ' ' ILE . 23.8 ttm180 -107.63 145.62 33.07 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 115.787 -0.642 . . . . 3.53 110.007 172.267 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.538 ' H ' ' HB3' ' A' ' 5' ' ' PRO . 17.1 t . . . . . 0 C--O 1.249 1.028 0 O-C-N 124.372 1.045 . . . . 4.01 110.02 -176.342 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.405 ' HA ' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.475 0.808 0 CA-C-O 120.399 0.142 . . . . 6.64 110.701 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 1' ' ' PCA . 6.2 Cg_exo -77.2 -23.67 10.14 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.805 2.336 . . . . 6.85 110.305 177.458 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.0 p90 -127.83 166.1 18.88 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-N 114.212 -1.358 . . . . 5.56 107.667 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.629 ' O ' ' HG3' ' A' ' 6' ' ' ARG . 6.2 tp -95.07 113.69 62.0 Favored Pre-proline 0 C--N 1.317 -0.815 0 C-N-CA 120.528 -0.469 . . . . 6.59 109.851 175.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.464 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 1.7 Cg_endo -44.72 124.71 5.77 Favored 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 123.006 2.471 . . . . 4.3 112.765 176.089 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.629 ' HG3' ' O ' ' A' ' 4' ' ' ILE . 79.8 mtp180 -124.94 163.13 39.39 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-N 115.532 -0.758 . . . . 7.04 109.627 -177.147 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_exo -51.35 128.47 25.68 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.494 2.129 . . . . 5.21 112.537 178.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 71.0 mt -82.9 116.06 26.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 CA-C-N 115.112 -0.949 . . . . 4.18 109.921 178.737 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -130.36 165.9 21.56 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.401 -0.363 . . . . 3.25 110.136 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 7.7 p -57.95 -176.93 0.03 OUTLIER 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 112.743 0.645 . . . . 1.72 112.743 177.202 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.454 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 22.9 t -58.03 4.04 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.528 1.131 . . . . 1.04 113.294 -171.212 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.522 ' HG3' HD22 ' A' ' 13' ' ' LEU . 5.0 ptp180 -57.6 -31.22 65.98 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 108.735 -0.839 . . . . 4.23 108.735 167.454 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.726 ' O ' HD12 ' A' ' 30' ' ' ILE . 3.7 mm? -88.78 122.08 31.81 Favored 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 106.789 -1.559 . . . . 2.66 106.789 161.663 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.689 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 13.0 tpt180 -131.21 170.54 14.43 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 112.707 0.632 . . . . 7.01 112.707 -168.737 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASN . . . . . 0.689 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 94.3 m-20 72.35 66.4 0.13 Allowed 'General case' 0 CA--C 1.512 -0.512 0 CA-C-N 114.775 -1.102 . . . . 4.38 112.86 169.022 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.706 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -130.67 -47.91 0.13 Allowed Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 119.632 -1.27 . . . . 1.7 111.551 167.509 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.706 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.3 mt -169.13 133.98 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.465 1.106 . . . . 1.05 109.9 159.663 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 6.3 t -96.94 124.04 40.81 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.978 -0.379 . . . . 1.28 109.978 172.023 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.537 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 23.3 m-85 -105.93 127.71 27.85 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 116.471 -0.331 . . . . 0.67 111.009 179.499 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -74.48 97.95 1.08 Allowed 'Trans proline' 0 N--CA 1.452 -0.957 0 C-N-CA 121.3 1.333 . . . . 0.48 109.591 167.055 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.585 ' H ' ' HA2' ' A' ' 38' ' ' GLY . . . 133.04 -124.34 3.73 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.489 -0.778 . . . . 0.59 111.259 -171.415 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -142.85 146.95 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-N 117.069 0.434 . . . . 1.2 111.523 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' CYS . . . . . 0.45 ' SG ' ' CD1' ' A' ' 19' ' ' PHE . 22.6 m -86.18 147.19 26.24 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 115.94 -0.573 . . . . 1.44 111.455 177.163 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.61 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 16.3 ptm180 -141.55 -37.34 0.42 Allowed 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 112.551 0.574 . . . . 5.09 112.551 176.281 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.61 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 10.2 mmt180 177.32 142.19 0.25 Allowed Pre-proline 0 N--CA 1.478 0.96 0 C-N-CA 122.737 0.415 . . . . 3.77 111.193 178.658 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.569 ' HD2' ' CE2' ' A' ' 27' ' ' TYR . 24.2 Cg_endo -91.35 98.35 0.16 OUTLIER 'Cis proline' 0 C--N 1.349 0.593 0 C-N-CA 122.792 -1.753 . . . . 1.34 111.704 -10.403 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.569 ' CE2' ' HD2' ' A' ' 26' ' ' PRO . 80.9 m-85 -161.53 143.89 11.94 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.695 -0.854 . . . . 0.64 108.695 -172.194 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 11.0 p90 -111.07 127.76 55.65 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 109.008 -0.738 . . . . 0.71 109.008 175.671 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 84.6 t90 -68.5 113.35 5.96 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.144 -0.935 . . . . 0.54 110.126 -178.047 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.726 HD12 ' O ' ' A' ' 13' ' ' LEU . 12.1 pt -119.27 94.35 3.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 109.242 -0.651 . . . . 0.72 109.242 174.777 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 65.24 -173.2 20.21 Favored Glycine 0 CA--C 1.524 0.612 0 CA-C-N 115.962 -0.563 . . . . 0.47 113.079 -177.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.1 p -108.57 161.78 14.75 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 122.27 -0.547 . . . . 0.62 112.047 -176.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 39.1 t -130.98 178.97 6.27 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 116.102 -0.499 . . . . 1.07 110.299 -177.63 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 63.8 -82.48 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.313 1.045 . . . . 1.54 110.791 -174.251 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 54.5 m-80 -151.57 26.67 0.66 Allowed 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.364 -0.606 . . . . 2.54 109.364 -178.677 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 107.8 -20.34 31.75 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.752 -0.737 . . . . 1.12 112.944 179.685 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.586 ' H ' HD12 ' A' ' 37' ' ' ILE . 0.2 OUTLIER -81.09 -58.4 3.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 O-C-N 122.511 -0.405 . . . . 1.87 111.293 -177.791 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.585 ' HA2' ' H ' ' A' ' 21' ' ' GLY . . . -69.18 174.9 33.19 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.966 -0.635 . . . . 0.79 112.198 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.537 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 77.3 p -108.54 125.74 52.16 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-O 121.392 0.615 . . . . 1.25 111.499 -173.24 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 41.4 t -82.54 113.35 20.2 Favored 'General case' 0 N--CA 1.442 -0.86 0 N-CA-C 106.67 -1.604 . . . . 0.87 106.67 169.282 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.537 ' HA ' HG12 ' A' ' 30' ' ' ILE . 28.2 m -132.0 177.24 7.7 Favored 'General case' 0 C--N 1.311 -1.085 0 CA-C-O 121.421 0.629 . . . . 1.02 110.703 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.671 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -135.53 137.6 42.23 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.513 -0.767 . . . . 0.55 109.618 167.789 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.508 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 4.3 tmt_? -60.7 113.41 2.46 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 115.378 -0.828 . . . . 3.86 110.778 -174.741 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 134.62 -150.99 20.23 Favored Glycine 0 N--CA 1.438 -1.183 0 CA-C-N 115.252 -0.886 . . . . 1.54 112.072 176.542 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 26.0 t-105 -145.51 124.74 12.95 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.369 -0.604 . . . . 1.55 109.369 179.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 19.5 ttm180 -102.42 128.75 48.88 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 120.978 0.418 . . . . 3.53 110.929 176.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 18.5 m . . . . . 0 C--O 1.249 1.075 0 CA-C-N 114.145 -1.388 . . . . 4.01 112.289 178.171 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' PCA . . . . . 0.422 ' HA ' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.475 0.807 0 N-CA-C 110.734 -0.098 . . . . 6.64 110.734 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 1' ' ' PCA . 3.2 Cg_exo -80.44 -19.44 8.95 Favored 'Trans proline' 0 C--N 1.349 0.569 0 C-N-CA 122.722 2.281 . . . . 6.85 110.073 175.401 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 14.3 p90 -136.59 163.06 31.43 Favored 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 107.297 -1.372 . . . . 5.56 107.297 175.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.461 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 6.0 tp -88.04 114.81 60.92 Favored Pre-proline 0 C--N 1.319 -0.758 0 C-N-CA 120.513 -0.475 . . . . 6.59 110.192 176.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' PRO . . . . . 0.461 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 9.6 Cg_endo -51.47 133.76 44.07 Favored 'Trans proline' 0 C--N 1.351 0.66 0 C-N-CA 123.169 2.579 . . . . 4.3 113.261 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.514 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 61.5 mtp180 -109.54 170.67 5.12 Favored Pre-proline 0 C--N 1.321 -0.644 0 CA-C-N 115.299 -0.864 . . . . 7.04 109.473 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.514 ' HD2' ' HB3' ' A' ' 6' ' ' ARG . 85.2 Cg_exo -43.97 132.16 8.34 Favored 'Trans proline' 0 C--N 1.352 0.755 0 C-N-CA 122.713 2.275 . . . . 5.21 112.663 175.648 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.592 ' HA ' ' HD2' ' A' ' 46' ' ' ARG . 61.9 mt -69.68 120.39 17.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.595 -0.729 . . . . 4.18 111.974 -176.75 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 36.2 m-20 -81.14 166.15 20.93 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.19 -0.913 . . . . 3.25 109.732 174.755 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.51 ' C ' ' H ' ' A' ' 12' ' ' ARG . 37.0 p -85.86 -171.24 3.49 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.183 -0.673 . . . . 1.72 109.183 174.03 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.583 ' O ' ' HG2' ' A' ' 14' ' ' ARG . 58.4 m -50.9 -1.52 0.01 OUTLIER 'General case' 0 CA--C 1.549 0.938 0 CA-C-O 121.076 0.465 . . . . 1.04 110.742 166.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.51 ' H ' ' C ' ' A' ' 10' ' ' THR . 12.0 ttt180 -32.74 -43.19 0.09 Allowed 'General case' 0 N--CA 1.463 0.176 0 C-N-CA 124.942 1.297 . . . . 4.23 110.834 163.715 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 8.8 mp -114.96 111.35 21.02 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 115.184 -0.917 . . . . 2.66 108.644 174.23 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.667 ' HD2' ' SG ' ' A' ' 40' ' ' CYS . 1.6 mmp_? -116.9 -171.19 1.98 Allowed 'General case' 0 CA--C 1.507 -0.682 0 N-CA-C 113.167 0.802 . . . . 7.01 113.167 -175.438 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 70.7 42.87 0.79 Allowed 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 114.492 -1.231 . . . . 4.38 109.63 -172.611 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.675 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -106.43 -51.48 0.81 Allowed Glycine 0 N--CA 1.441 -0.971 0 C-N-CA 119.233 -1.46 . . . . 1.7 111.956 173.277 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.716 HD12 ' CE1' ' A' ' 27' ' ' TYR . 2.7 mt -173.33 150.77 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 C-N-CA 125.112 1.365 . . . . 1.05 108.914 157.14 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 9.2 t -110.89 108.28 18.02 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.263 -0.643 . . . . 1.28 109.263 166.155 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.643 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 46.9 m-85 -94.36 132.99 27.85 Favored Pre-proline 0 CA--C 1.513 -0.47 0 CA-C-O 120.881 0.372 . . . . 0.67 111.184 -177.53 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -85.54 95.83 0.61 Allowed 'Trans proline' 0 N--CA 1.438 -1.793 0 N-CA-C 108.349 -1.443 . . . . 0.48 108.349 158.478 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.93 -130.6 5.53 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.26 -0.882 . . . . 0.59 110.973 -168.806 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.1 pt -135.87 148.48 27.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.521 0.677 . . . . 1.2 112.606 -176.527 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -87.78 123.35 32.49 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.053 -0.976 . . . . 1.44 109.308 169.2 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.464 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 12.3 ptm180 -123.59 -38.24 2.55 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 119.579 -0.849 . . . . 5.09 112.335 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.464 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 11.5 mtt180 175.02 141.86 0.2 Allowed Pre-proline 0 N--CA 1.475 0.795 0 O-C-N 123.385 0.428 . . . . 3.77 111.88 171.154 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 3.9 Cg_exo -88.55 99.84 0.23 Allowed 'Cis proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.715 -1.785 . . . . 1.34 110.567 -10.012 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.716 ' CE1' HD12 ' A' ' 17' ' ' ILE . 75.7 m-85 -161.74 128.54 3.86 Favored 'General case' 0 CA--C 1.506 -0.729 0 N-CA-C 108.883 -0.784 . . . . 0.64 108.883 -177.65 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' TYR . . . . . 0.458 ' CZ ' ' HB3' ' A' ' 42' ' ' ALA . 27.0 p90 -107.83 130.13 55.01 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-O 121.208 0.528 . . . . 0.71 110.205 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 86.4 t90 -65.67 113.82 4.53 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.49 -1.232 . . . . 0.54 111.122 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.487 HD11 HH21 ' A' ' 14' ' ' ARG . 4.7 pt -120.32 92.68 2.21 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.852 0 CA-C-N 115.66 -0.7 . . . . 0.72 109.383 171.728 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 66.18 -164.87 39.87 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 120.711 -0.757 . . . . 0.47 113.292 -177.389 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -114.46 160.11 19.56 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 112.518 0.562 . . . . 0.62 112.518 -174.693 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 49.6 t -127.92 -176.37 3.76 Favored 'General case' 0 C--O 1.22 -0.485 0 N-CA-C 107.808 -1.182 . . . . 1.07 107.808 175.034 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 61.23 -155.87 0.35 Allowed 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 118.891 0.769 . . . . 1.54 109.884 -177.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 -111.05 88.54 2.81 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.806 0.336 . . . . 2.54 111.064 179.739 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 92.04 -47.86 2.7 Favored Glycine 0 CA--C 1.506 -0.49 0 N-CA-C 110.892 -0.883 . . . . 1.12 110.892 175.296 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ILE . . . . . 0.474 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 4.7 pt -77.74 -147.7 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 114.397 -0.901 . . . . 1.87 109.79 170.424 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.474 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 73.44 161.76 7.01 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 121.171 -0.538 . . . . 0.79 113.459 169.211 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.777 ' HB2' ' SG ' ' A' ' 41' ' ' CYS . 4.7 p -139.74 113.2 8.43 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-O 121.928 0.87 . . . . 1.25 111.4 177.638 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' CYS . . . . . 0.667 ' SG ' ' HD2' ' A' ' 14' ' ' ARG . 36.5 t -77.95 98.12 5.56 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 106.957 -1.497 . . . . 0.87 106.957 172.837 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' CYS . . . . . 0.777 ' SG ' ' HB2' ' A' ' 39' ' ' SER . 12.3 m -132.72 141.86 48.76 Favored 'General case' 0 C--N 1.32 -0.687 0 O-C-N 121.946 -0.471 . . . . 1.02 109.832 -174.294 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.497 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -100.69 139.8 35.87 Favored 'General case' 0 C--N 1.316 -0.848 0 C-N-CA 120.258 -0.577 . . . . 0.55 111.495 -176.79 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.509 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 4.0 tmt_? -62.04 107.99 0.97 Allowed 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 115.258 -0.883 . . . . 3.86 110.245 179.11 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 138.5 -170.77 23.77 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.417 -0.81 . . . . 1.54 111.293 -178.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.527 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 23.9 t-105 -135.3 118.67 16.75 Favored 'General case' 0 N--CA 1.442 -0.842 0 C-N-CA 120.271 -0.571 . . . . 1.55 110.898 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ARG . . . . . 0.592 ' HD2' ' HA ' ' A' ' 8' ' ' ILE . 15.7 ttm180 -112.6 144.83 41.42 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 115.789 -0.641 . . . . 3.53 110.338 176.012 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.439 ' H ' ' HB3' ' A' ' 5' ' ' PRO . 16.3 t . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.06 -0.971 . . . . 4.01 110.652 -179.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.557 HG12 ' HG3' ' A' ' 46' ' ' ARG . 41.9 mt . . . . . 0 N--CA 1.465 0.287 0 CA-C-O 121.415 0.626 . . . . 4.18 112.23 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.549 ' O ' HG22 ' A' ' 30' ' ' ILE . 17.0 m-20 -103.37 165.62 10.92 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.128 -0.942 . . . . 3.25 110.069 175.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.407 ' C ' ' H ' ' A' ' 12' ' ' ARG . 25.0 p -83.53 -176.34 6.25 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.843 -0.617 . . . . 1.72 110.375 173.167 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.578 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 25.4 t -58.01 1.58 0.05 OUTLIER 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 122.789 0.436 . . . . 1.04 112.081 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.43 HH11 ' HD2' ' A' ' 12' ' ' ARG . 8.3 ptt180 -54.56 -35.44 63.26 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 109.86 -0.422 . . . . 4.23 109.86 170.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.417 ' O ' HD12 ' A' ' 30' ' ' ILE . 11.1 mp -85.41 97.82 10.22 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 107.278 -1.379 . . . . 2.66 107.278 165.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.608 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 19.0 tpt180 -107.41 168.57 9.14 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 112.22 0.452 . . . . 7.01 112.22 -164.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.608 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 6.1 t30 72.57 69.63 0.13 Allowed 'General case' 0 CA--C 1.513 -0.48 0 CA-C-N 114.859 -1.064 . . . . 4.38 111.219 172.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.721 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -130.45 -47.17 0.14 Allowed Glycine 0 N--CA 1.435 -1.369 0 C-N-CA 119.891 -1.147 . . . . 1.7 111.273 167.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.721 HG12 ' O ' ' A' ' 16' ' ' GLY . 15.9 mm -164.86 146.51 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 124.415 1.086 . . . . 1.05 108.685 164.162 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -113.92 111.4 21.64 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.32 -0.622 . . . . 1.28 109.32 165.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.453 ' CE1' HG21 ' A' ' 17' ' ' ILE . 44.3 m-85 -94.27 139.91 22.62 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 116.38 -0.373 . . . . 0.67 111.17 -176.754 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -84.98 98.52 0.68 Allowed 'Trans proline' 0 N--CA 1.445 -1.356 0 C-N-CA 121.819 1.68 . . . . 0.48 109.139 163.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 123.51 -131.13 7.97 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 110.373 -1.091 . . . . 0.59 110.373 -166.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 36.4 pt -136.95 156.67 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.532 0.682 . . . . 1.2 112.228 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 29' ' ' TRP . 0.2 OUTLIER -81.17 130.59 35.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.876 -1.057 . . . . 1.44 110.428 174.73 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.734 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 14.8 ptp180 -119.14 -39.98 2.87 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 119.461 -0.896 . . . . 5.09 112.701 176.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.734 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 12.9 mmt180 176.43 140.45 0.22 Allowed Pre-proline 0 N--CA 1.482 1.158 0 C-N-CA 123.32 0.648 . . . . 3.77 110.557 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.426 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 1.7 Cg_endo -91.24 100.46 0.22 Allowed 'Cis proline' 0 N--CA 1.455 -0.765 0 C-N-CA 123.646 -1.398 . . . . 1.34 109.968 -13.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.594 ' CE1' HG13 ' A' ' 17' ' ' ILE . 83.7 m-85 -160.84 133.03 5.98 Favored 'General case' 0 CA--C 1.503 -0.834 0 N-CA-C 108.816 -0.809 . . . . 0.64 108.816 -174.065 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.523 ' CD1' ' HB3' ' A' ' 46' ' ' ARG . 19.1 p90 -108.3 129.54 55.22 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.003 -0.544 . . . . 0.71 109.582 -179.019 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' TRP . . . . . 0.526 ' HB2' ' SG ' ' A' ' 23' ' ' CYS . 90.0 t90 -66.8 112.77 4.43 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.34 -0.845 . . . . 0.54 110.746 -178.538 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.578 ' O ' ' HB2' ' A' ' 11' ' ' CYS . 5.3 pt -119.2 93.41 2.53 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 115.021 -0.99 . . . . 0.72 108.985 173.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 68.7 177.22 13.52 Favored Glycine 0 C--N 1.316 -0.544 0 C-N-CA 120.821 -0.704 . . . . 0.47 112.715 -179.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.5 HG22 ' O ' ' A' ' 38' ' ' GLY . 0.1 OUTLIER -97.71 164.53 12.37 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 122.323 -0.516 . . . . 0.62 111.19 -175.99 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 10.5 t -136.26 179.57 6.27 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.355 -0.98 . . . . 1.07 108.355 175.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.438 ' ND2' ' HA3' ' A' ' 38' ' ' GLY . 83.9 m-20 53.34 27.65 6.49 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 120.722 0.296 . . . . 1.54 111.106 -175.072 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 2.8 t30 64.54 22.16 12.61 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 123.36 0.664 . . . . 2.54 111.586 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 136.3 -36.04 2.05 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 119.911 -1.137 . . . . 1.12 114.021 175.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.424 HG13 ' CB ' ' A' ' 34' ' ' ASN . 0.9 OUTLIER -82.57 -23.55 8.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 112.597 0.591 . . . . 1.87 112.597 -175.835 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.5 ' O ' HG22 ' A' ' 32' ' ' THR . . . -103.53 -167.93 25.54 Favored Glycine 0 N--CA 1.426 -1.991 0 N-CA-C 110.37 -1.092 . . . . 0.79 110.37 -177.794 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.534 ' HB2' ' SG ' ' A' ' 41' ' ' CYS . 23.6 p -144.77 119.87 10.09 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.478 0.656 . . . . 1.25 111.75 -173.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.482 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 41.8 t -74.42 104.2 5.06 Favored 'General case' 0 N--CA 1.442 -0.86 0 N-CA-C 107.073 -1.454 . . . . 0.87 107.073 172.076 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.534 ' SG ' ' HB2' ' A' ' 39' ' ' SER . 14.1 m -139.26 111.16 7.27 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.361 -0.607 . . . . 1.02 109.361 -176.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.568 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -80.7 143.39 33.03 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.871 0.367 . . . . 0.55 110.87 -172.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.566 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 39.7 ttm180 -62.53 114.07 3.33 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.432 -0.804 . . . . 3.86 111.096 -176.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 139.17 -152.56 22.38 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 114.676 -1.147 . . . . 1.54 111.263 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 38.3 t-105 -145.12 130.39 18.6 Favored 'General case' 0 N--CA 1.443 -0.806 0 C-N-CA 119.957 -0.697 . . . . 1.55 112.048 179.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.557 ' HG3' HG12 ' A' ' 8' ' ' ILE . 1.9 tpp180 -125.33 117.32 23.49 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 115.092 -0.958 . . . . 3.53 110.312 174.093 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.489 ' HB2' HD11 ' A' ' 8' ' ' ILE . 44.4 m . . . . . 0 C--O 1.248 1.014 0 CA-C-N 114.067 -1.424 . . . . 4.01 111.704 -176.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 2.2 mp . . . . . 0 N--CA 1.453 -0.277 0 CA-C-O 121.296 0.57 . . . . 4.18 111.259 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -91.37 165.24 13.52 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.295 -0.866 . . . . 3.25 109.464 177.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.403 ' C ' ' H ' ' A' ' 12' ' ' ARG . 6.5 p -89.27 -175.83 4.89 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 116.264 -0.426 . . . . 1.72 110.825 176.07 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.511 ' H ' ' HA3' ' A' ' 31' ' ' GLY . 19.0 t -64.41 11.37 0.05 OUTLIER 'General case' 0 N--CA 1.47 0.549 0 CA-C-O 121.317 0.58 . . . . 1.04 112.088 -172.242 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 12' ' ' ARG . 18.3 ptt85 -57.96 -25.69 61.32 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.851 -0.796 . . . . 4.23 108.851 161.526 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.612 HD21 ' NH2' ' A' ' 46' ' ' ARG . 5.4 mp -74.71 153.19 38.97 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 115.554 -0.748 . . . . 2.66 109.518 169.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.66 98.99 6.41 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 114.611 1.337 . . . . 7.01 114.611 -167.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 66.5 t30 31.18 61.74 0.24 Allowed 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 124.181 0.992 . . . . 4.38 113.335 156.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.664 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -77.24 -43.54 16.01 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 118.811 -1.661 . . . . 1.7 112.824 -172.176 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.664 HG12 ' O ' ' A' ' 16' ' ' GLY . 20.3 mm -163.18 128.33 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 124.896 1.278 . . . . 1.05 108.273 165.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 8.2 m -94.89 110.54 22.41 Favored 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 120.407 -0.517 . . . . 1.28 110.785 173.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.531 ' CZ ' HG21 ' A' ' 17' ' ' ILE . 43.8 m-85 -102.52 131.68 22.16 Favored Pre-proline 0 CA--C 1.51 -0.59 0 CA-C-N 116.036 -0.529 . . . . 0.67 110.82 177.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -74.48 97.8 1.07 Allowed 'Trans proline' 0 N--CA 1.448 -1.165 0 C-N-CA 121.104 1.202 . . . . 0.48 109.316 169.03 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.478 ' H ' ' HA2' ' A' ' 38' ' ' GLY . . . 128.92 -122.56 3.96 Favored Glycine 0 N--CA 1.442 -0.927 0 CA-C-N 115.217 -0.901 . . . . 0.59 111.204 -169.155 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -146.6 147.15 18.2 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 121.115 0.483 . . . . 1.2 111.567 -178.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . 0.508 ' HB3' ' HB2' ' A' ' 27' ' ' TYR . 0.0 OUTLIER -71.65 127.69 33.39 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.367 -0.833 . . . . 1.44 110.424 173.759 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.698 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 25.8 ptt180 -116.09 -38.11 3.69 Favored 'General case' 0 C--N 1.322 -0.628 0 C-N-CA 120.14 -0.624 . . . . 5.09 111.537 175.555 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.698 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 14.7 mmt180 175.7 143.93 0.23 Allowed Pre-proline 0 N--CA 1.477 0.899 0 C-N-CA 123.361 0.664 . . . . 3.77 110.932 177.218 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 1.2 Cg_endo -93.94 100.4 0.18 OUTLIER 'Cis proline' 0 N--CA 1.457 -0.62 0 C-N-CA 123.878 -1.301 . . . . 1.34 110.756 -14.464 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.628 ' CE1' HG13 ' A' ' 17' ' ' ILE . 63.1 m-85 -161.5 139.56 9.29 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.726 -0.842 . . . . 0.64 108.726 -175.203 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.418 ' CZ ' ' HB3' ' A' ' 42' ' ' ALA . 26.1 p90 -107.85 131.74 54.17 Favored 'General case' 0 C--N 1.312 -1.027 0 C-N-CA 120.306 -0.558 . . . . 0.71 110.348 177.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 86.9 t90 -67.02 112.58 4.44 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.642 -1.163 . . . . 0.54 110.92 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.567 HG12 ' O ' ' A' ' 40' ' ' CYS . 0.6 OUTLIER -120.11 93.62 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 CA-C-O 121.957 0.884 . . . . 0.72 109.404 170.398 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.511 ' HA3' ' H ' ' A' ' 11' ' ' CYS . . . 70.75 178.63 26.72 Favored Glycine 0 CA--C 1.523 0.559 0 CA-C-N 115.544 -0.753 . . . . 0.47 113.482 -177.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.539 HG22 ' O ' ' A' ' 38' ' ' GLY . 0.0 OUTLIER -97.87 162.9 13.02 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.066 0.46 . . . . 0.62 111.137 -177.534 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 15.7 t -135.36 -177.22 4.56 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.374 -0.973 . . . . 1.07 108.374 175.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.433 ' ND2' ' HA3' ' A' ' 38' ' ' GLY . 92.5 m-20 59.63 -160.82 0.28 Allowed 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 109.905 -0.406 . . . . 1.54 109.905 -173.138 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -83.21 42.21 0.8 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.113 0.482 . . . . 2.54 110.113 174.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 89.72 11.61 63.58 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 121.069 -0.586 . . . . 1.12 112.487 -178.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 8.1 pt -120.25 14.09 6.51 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.351 0 CA-C-O 121.219 0.533 . . . . 1.87 112.013 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.539 ' O ' HG22 ' A' ' 32' ' ' THR . . . -133.12 170.4 22.21 Favored Glycine 0 N--CA 1.424 -2.109 0 N-CA-C 110.082 -1.207 . . . . 0.79 110.082 178.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 57.2 p -120.51 126.04 49.38 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 121.022 0.439 . . . . 1.25 110.584 -177.253 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.567 ' O ' HG12 ' A' ' 30' ' ' ILE . 38.5 t -82.67 91.05 6.91 Favored 'General case' 0 C--O 1.211 -0.967 0 N-CA-C 107.346 -1.353 . . . . 0.87 107.346 175.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.433 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 3.0 m -100.66 -176.52 3.21 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.791 -0.818 . . . . 1.02 108.791 -177.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.633 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -142.32 138.76 31.5 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.909 -0.316 . . . . 0.55 110.479 166.018 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.485 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 34.8 ttp180 -59.81 110.4 1.15 Allowed 'General case' 0 C--O 1.234 0.287 0 O-C-N 123.957 0.786 . . . . 3.86 110.876 -178.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 138.65 -154.86 23.34 Favored Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 114.909 -1.041 . . . . 1.54 111.215 -177.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 32.5 t-105 -145.25 146.03 31.52 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 121.222 0.534 . . . . 1.55 111.353 177.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.612 ' NH2' HD21 ' A' ' 13' ' ' LEU . 10.5 ttm180 -130.69 127.28 38.54 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.484 -0.78 . . . . 3.53 110.523 176.047 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 45.8 m . . . . . 0 C--O 1.25 1.107 0 O-C-N 124.605 1.191 . . . . 4.01 111.859 179.161 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.419 ' N ' HD12 ' A' ' 8' ' ' ILE . 2.5 mp . . . . . 0 N--CA 1.454 -0.231 0 CA-C-O 121.302 0.572 . . . . 4.18 110.26 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -100.1 169.2 9.33 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.329 -0.85 . . . . 3.25 110.295 -174.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 12' ' ' ARG . 16.9 p -91.03 -176.43 4.62 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.795 -0.639 . . . . 1.72 111.106 -177.299 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.618 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 47.7 t -59.56 8.67 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 121.291 0.567 . . . . 1.04 111.797 177.01 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.505 ' HG3' HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -53.28 -38.42 63.06 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.555 -0.535 . . . . 4.23 109.555 167.84 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.505 HD12 ' HG3' ' A' ' 12' ' ' ARG . 8.6 mp -77.22 126.08 30.37 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 109.07 -0.715 . . . . 2.66 109.07 172.075 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.618 ' HD3' ' SG ' ' A' ' 11' ' ' CYS . 17.3 mmm180 -134.31 171.75 13.83 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 113.077 0.769 . . . . 7.01 113.077 -171.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 64.42 20.1 12.04 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 114.357 -1.292 . . . . 4.38 110.849 -177.217 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.735 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -85.85 -51.59 3.56 Favored Glycine 0 N--CA 1.438 -1.201 0 C-N-CA 118.824 -1.655 . . . . 1.7 111.377 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.735 HG12 ' O ' ' A' ' 16' ' ' GLY . 25.5 mm -168.4 143.71 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 C-N-CA 125.903 1.681 . . . . 1.05 107.824 157.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.6 m -109.46 99.62 8.81 Favored 'General case' 0 C--N 1.321 -0.669 0 O-C-N 121.774 -0.579 . . . . 1.28 110.084 166.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.483 ' HD1' ' SG ' ' A' ' 41' ' ' CYS . 44.8 m-85 -88.19 135.02 33.63 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.72 -0.673 . . . . 0.67 110.938 -178.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.628 ' HB3' HD21 ' A' ' 34' ' ' ASN . 96.7 Cg_endo -88.16 97.85 0.41 Allowed 'Trans proline' 0 N--CA 1.442 -1.558 0 C-N-CA 121.452 1.435 . . . . 0.48 109.729 164.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.55 -115.07 1.3 Allowed Glycine 0 N--CA 1.444 -0.819 0 N-CA-C 110.666 -0.973 . . . . 0.59 110.666 -170.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 22.2 pt -146.26 152.16 13.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-O 121.277 0.56 . . . . 1.2 111.94 179.262 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -86.27 142.52 28.49 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.219 -0.901 . . . . 1.44 108.735 170.391 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.9 ptt180 -131.98 -39.21 1.08 Allowed 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 119.542 -0.863 . . . . 5.09 112.251 173.218 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.408 HH11 ' HD2' ' A' ' 25' ' ' ARG . 4.8 mtt85 174.24 145.17 0.2 Allowed Pre-proline 0 N--CA 1.474 0.745 0 N-CA-C 112.033 0.383 . . . . 3.77 112.033 173.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -88.41 99.47 0.22 Allowed 'Cis proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.996 -1.669 . . . . 1.34 110.851 -9.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.624 ' CE1' HG13 ' A' ' 17' ' ' ILE . 68.7 m-85 -162.21 135.66 6.23 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.339 -0.986 . . . . 0.64 108.339 -176.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -108.42 129.76 55.25 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.973 -0.691 . . . . 0.71 110.194 176.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 85.4 t90 -66.81 113.45 4.9 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.684 -1.144 . . . . 0.54 111.193 -177.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.58 ' O ' ' HB3' ' A' ' 40' ' ' CYS . 10.9 pt -121.62 92.4 2.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-N 115.548 -0.751 . . . . 0.72 109.559 172.752 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 66.9 -171.61 30.83 Favored Glycine 0 CA--C 1.527 0.819 0 C-N-CA 121.281 -0.485 . . . . 0.47 113.159 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.6 p -107.66 168.54 9.18 Favored 'General case' 0 CA--C 1.533 0.299 0 O-C-N 122.381 -0.482 . . . . 0.62 111.503 -177.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.587 ' O ' ' HA3' ' A' ' 38' ' ' GLY . 42.7 t -160.38 105.31 1.47 Allowed 'General case' 0 C--N 1.334 -0.098 0 N-CA-C 110.277 -0.268 . . . . 1.07 110.277 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.628 HD21 ' HB3' ' A' ' 20' ' ' PRO . 13.6 m-20 163.67 39.58 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.586 1.554 . . . . 1.54 109.845 176.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 57.12 37.82 28.72 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.104 -0.498 . . . . 2.54 111.283 -175.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 136.19 -64.93 0.57 Allowed Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 111.442 -0.663 . . . . 1.12 111.442 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.522 HG13 ' HB3' ' A' ' 34' ' ' ASN . 2.7 pt -80.27 -162.09 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.677 -0.261 . . . . 1.87 110.339 174.533 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.587 ' HA3' ' O ' ' A' ' 33' ' ' CYS . . . 85.49 179.4 50.5 Favored Glycine 0 N--CA 1.422 -2.249 0 C-N-CA 120.497 -0.859 . . . . 0.79 111.538 177.265 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.9 m -141.25 111.9 7.04 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.015 -0.593 . . . . 1.25 109.532 -178.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.58 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 47.2 t -79.02 111.57 15.36 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 107.26 -1.385 . . . . 0.87 107.26 175.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.483 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 2.2 m -129.2 156.5 43.85 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.815 -0.809 . . . . 1.02 108.815 -176.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.622 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -118.29 130.62 56.14 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 119.817 -0.753 . . . . 0.55 110.301 174.008 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.503 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 1.5 tmt_? -55.12 109.86 0.59 Allowed 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 115.275 -0.875 . . . . 3.86 110.521 -177.561 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 137.4 -162.78 25.43 Favored Glycine 0 N--CA 1.442 -0.959 0 CA-C-N 115.256 -0.884 . . . . 1.54 111.85 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 31.0 t-105 -141.59 118.51 11.18 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.033 0.445 . . . . 1.55 110.597 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 12.9 ttm180 -96.68 139.55 32.58 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.032 -0.531 . . . . 3.53 111.565 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.3 t . . . . . 0 C--O 1.247 0.943 0 CA-C-N 114.477 -1.238 . . . . 4.01 110.976 -179.375 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.461 ' HA ' ' CD ' ' A' ' 46' ' ' ARG . 81.3 mt . . . . . 0 N--CA 1.45 -0.451 0 CA-C-O 121.524 0.678 . . . . 4.18 111.322 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.466 ' O ' HG22 ' A' ' 30' ' ' ILE . 71.4 m-20 -81.75 165.3 21.06 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 114.843 -1.071 . . . . 3.25 111.026 -176.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.447 ' C ' ' H ' ' A' ' 12' ' ' ARG . 21.4 p -79.56 -175.49 4.81 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 114.949 -1.023 . . . . 1.72 110.906 173.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.417 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 19.4 t -57.12 4.52 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 123.595 0.758 . . . . 1.04 112.617 -179.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.447 ' H ' ' C ' ' A' ' 10' ' ' THR . 34.1 ptt180 -61.27 -29.91 70.14 Favored 'General case' 0 CA--C 1.531 0.239 0 O-C-N 122.018 -0.426 . . . . 4.23 110.86 174.08 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.403 ' O ' HD12 ' A' ' 30' ' ' ILE . 4.4 mm? -88.56 97.86 11.33 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 107.319 -1.363 . . . . 2.66 107.319 167.041 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.635 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 12.7 tpp85 -101.43 163.97 12.0 Favored 'General case' 0 N--CA 1.428 -1.538 0 N-CA-C 113.349 0.87 . . . . 7.01 113.349 -161.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.635 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 92.9 m-20 70.34 69.61 0.21 Allowed 'General case' 0 CA--C 1.514 -0.432 0 CA-C-N 114.421 -1.263 . . . . 4.38 112.321 168.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.684 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -125.27 -46.79 0.23 Allowed Glycine 0 N--CA 1.439 -1.154 0 C-N-CA 119.385 -1.388 . . . . 1.7 111.576 169.095 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.684 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.1 mt -168.86 131.53 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 124.523 1.129 . . . . 1.05 109.648 156.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 1.8 m -94.04 113.09 25.0 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.908 0.385 . . . . 1.28 110.213 170.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.615 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 64.7 m-85 -95.49 140.68 22.47 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.343 -0.389 . . . . 0.67 110.077 178.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.469 ' HA ' ' ND2' ' A' ' 34' ' ' ASN . 74.9 Cg_endo -86.71 96.39 0.5 Allowed 'Trans proline' 0 N--CA 1.443 -1.49 0 C-N-CA 121.356 1.37 . . . . 0.48 109.787 167.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.56 -109.2 0.89 Allowed Glycine 0 N--CA 1.441 -0.968 0 CA-C-N 115.339 -0.846 . . . . 0.59 111.523 -171.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.9 pt -146.17 145.47 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 112.386 0.513 . . . . 1.2 112.386 -176.309 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.89 126.7 32.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.609 -0.723 . . . . 1.44 109.195 172.634 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 37.4 ptt180 -115.98 -40.04 3.37 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 118.619 -1.232 . . . . 5.09 112.521 176.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 172.75 152.53 0.23 Allowed Pre-proline 0 N--CA 1.473 0.691 0 CA-C-N 118.112 0.414 . . . . 3.77 111.642 172.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -87.15 100.91 0.27 Allowed 'Cis proline' 0 C--N 1.347 0.45 0 C-N-CA 123.216 -1.577 . . . . 1.34 110.797 -12.418 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.57 ' CE1' HD12 ' A' ' 17' ' ' ILE . 89.1 m-85 -160.88 141.92 11.72 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 108.178 -1.045 . . . . 0.64 108.178 -175.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 7.6 p90 -107.76 128.96 55.04 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 120.437 -0.505 . . . . 0.71 109.641 177.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 92.1 t90 -66.71 113.83 5.14 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.988 -1.005 . . . . 0.54 110.365 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.544 ' O ' ' HB3' ' A' ' 40' ' ' CYS . 11.2 pt -120.15 93.25 2.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-N 115.271 -0.877 . . . . 0.72 109.318 175.171 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 62.31 -172.96 8.87 Favored Glycine 0 CA--C 1.526 0.736 0 C-N-CA 121.047 -0.597 . . . . 0.47 112.93 -176.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.4 p -102.1 165.53 11.11 Favored 'General case' 0 C--N 1.324 -0.523 0 O-C-N 122.173 -0.604 . . . . 0.62 111.631 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 20.6 t -137.5 -178.18 5.12 Favored 'General case' 0 C--O 1.216 -0.696 0 N-CA-C 108.334 -0.988 . . . . 1.07 108.334 178.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.469 ' ND2' ' HA ' ' A' ' 20' ' ' PRO . 87.7 m-20 67.12 1.42 2.37 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 118.28 0.491 . . . . 1.54 111.753 -177.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 49.8 m-80 65.94 85.46 0.14 Allowed 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.611 0.764 . . . . 2.54 111.846 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 110.76 -62.46 0.29 Allowed Glycine 0 CA--C 1.511 -0.174 0 N-CA-C 111.709 -0.556 . . . . 1.12 111.709 175.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.454 ' H ' HD12 ' A' ' 37' ' ' ILE . 0.2 OUTLIER -88.76 -142.43 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.753 -0.832 . . . . 1.87 108.753 173.424 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.4 175.29 1.19 Allowed Glycine 0 N--CA 1.447 -0.602 0 CA-C-O 122.009 0.783 . . . . 0.79 114.485 169.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.615 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 87.6 p -142.32 119.89 11.75 Favored 'General case' 0 N--CA 1.433 -1.278 0 N-CA-C 109.599 -0.519 . . . . 1.25 109.599 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.544 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 46.0 t -82.63 116.8 22.18 Favored 'General case' 0 C--N 1.313 -1.018 0 N-CA-C 107.127 -1.435 . . . . 0.87 107.127 174.218 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.586 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -133.67 169.03 17.62 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 108.31 -0.996 . . . . 1.02 108.31 -178.322 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.659 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -136.73 142.14 43.05 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.669 -0.812 . . . . 0.55 110.744 172.089 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.477 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 57.0 ttp180 -61.42 116.65 4.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 114.973 -1.012 . . . . 3.86 110.909 -176.222 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 134.24 -149.84 19.88 Favored Glycine 0 CA--C 1.497 -1.044 0 CA-C-N 115.162 -0.926 . . . . 1.54 111.658 176.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 31.4 t-105 -152.7 123.88 7.58 Favored 'General case' 0 C--N 1.317 -0.843 0 C-N-CA 120.581 -0.448 . . . . 1.55 111.189 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.461 ' CD ' ' HA ' ' A' ' 8' ' ' ILE . 21.2 ttm180 -104.79 139.91 38.88 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.912 -0.585 . . . . 3.53 110.23 169.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.7 t . . . . . 0 C--O 1.253 1.243 0 O-C-N 124.289 0.993 . . . . 4.01 110.538 -179.684 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.619 ' HA ' ' HD3' ' A' ' 46' ' ' ARG . 3.5 mp . . . . . 0 C--O 1.235 0.297 0 CA-C-O 121.194 0.521 . . . . 4.18 111.465 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -89.04 164.02 15.25 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 108.943 -0.762 . . . . 3.25 108.943 170.021 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.495 ' C ' ' H ' ' A' ' 12' ' ' ARG . 38.4 p -72.75 -175.8 1.81 Allowed 'General case' 0 C--N 1.314 -0.965 0 CA-C-N 116.504 -0.317 . . . . 1.72 110.867 176.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.42 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 11.4 t -57.51 6.23 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 123.36 0.664 . . . . 1.04 112.054 178.816 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.495 ' H ' ' C ' ' A' ' 10' ' ' THR . 38.4 ptt180 -65.89 -33.2 75.3 Favored 'General case' 0 C--N 1.33 -0.268 0 O-C-N 122.107 -0.371 . . . . 4.23 110.939 172.484 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.406 ' CD2' ' HG3' ' A' ' 12' ' ' ARG . 4.5 mm? -97.11 97.48 9.24 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 108.472 -0.936 . . . . 2.66 108.472 172.086 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.725 ' HD3' ' SG ' ' A' ' 40' ' ' CYS . 2.7 mmm-85 -110.24 -170.71 1.7 Allowed 'General case' 0 N--CA 1.438 -1.028 0 N-CA-C 113.338 0.866 . . . . 7.01 113.338 -166.463 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.9 m-80 69.02 53.45 0.47 Allowed 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 114.678 -1.146 . . . . 4.38 111.154 -178.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.717 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -120.46 -50.02 0.28 Allowed Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 119.445 -1.36 . . . . 1.7 112.119 172.113 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.717 HG12 ' O ' ' A' ' 16' ' ' GLY . 25.1 mm -166.65 147.02 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 C-N-CA 125.337 1.455 . . . . 1.05 108.149 161.112 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 31.5 t -111.12 104.03 12.52 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 121.654 -0.654 . . . . 1.28 109.426 168.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.554 ' CE1' HG21 ' A' ' 17' ' ' ILE . 17.0 m-85 -93.17 124.13 58.84 Favored Pre-proline 0 C--N 1.329 -0.287 0 N-CA-C 112.404 0.52 . . . . 0.67 112.404 -175.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -82.23 97.4 0.9 Allowed 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 121.833 1.689 . . . . 0.48 109.473 165.339 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.64 -134.0 7.12 Favored Glycine 0 N--CA 1.443 -0.84 0 N-CA-C 110.884 -0.886 . . . . 0.59 110.884 -170.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 23.7 pt -129.17 147.8 33.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.285 0.564 . . . . 1.2 112.006 -178.46 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 93.9 m -94.77 139.62 31.02 Favored 'General case' 0 N--CA 1.437 -1.094 0 CA-C-N 115.488 -0.778 . . . . 1.44 109.797 173.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.48 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 7.1 ptt180 -143.56 -37.1 0.35 Allowed 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 118.904 -0.569 . . . . 5.09 112.532 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.48 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 10.8 mtt180 175.54 145.68 0.24 Allowed Pre-proline 0 N--CA 1.476 0.827 0 N-CA-C 112.067 0.395 . . . . 3.77 112.067 170.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -88.74 99.25 0.2 Allowed 'Cis proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.839 -1.734 . . . . 1.34 110.611 -10.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.475 ' CE1' HG13 ' A' ' 17' ' ' ILE . 96.2 m-85 -161.55 138.51 8.55 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 108.919 -0.771 . . . . 0.64 108.919 -175.405 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.512 ' CZ ' ' HB3' ' A' ' 42' ' ' ALA . 35.8 p90 -113.09 127.93 56.35 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 109.245 -0.65 . . . . 0.71 109.245 178.001 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' TRP . . . . . 0.562 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 90.1 t90 -73.74 117.0 14.99 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.625 -0.716 . . . . 0.54 110.971 -175.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.463 ' O ' HG13 ' A' ' 30' ' ' ILE . 26.6 pt -121.35 95.03 3.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 121.524 0.678 . . . . 0.72 110.259 176.309 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 63.39 -170.97 14.86 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 121.12 -0.562 . . . . 0.47 113.041 -178.147 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 23.2 p -108.96 148.19 31.1 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 112.928 0.714 . . . . 0.62 112.928 -173.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.481 ' O ' ' HA3' ' A' ' 38' ' ' GLY . 18.4 t -116.74 -175.83 2.85 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.583 -1.266 . . . . 1.07 107.583 174.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.436 ' HB2' ' HA3' ' A' ' 38' ' ' GLY . 84.0 m-20 64.62 -97.44 0.06 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 118.315 0.507 . . . . 1.54 111.266 179.738 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 52.0 t30 -177.05 85.77 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.762 0.315 . . . . 2.54 110.868 -178.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 94.09 -57.42 2.11 Favored Glycine 0 CA--C 1.503 -0.695 0 N-CA-C 110.122 -1.191 . . . . 1.12 110.122 178.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.455 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 0.8 OUTLIER -78.51 -148.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 108.063 -1.088 . . . . 1.87 108.063 164.997 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.481 ' HA3' ' O ' ' A' ' 33' ' ' CYS . . . 76.97 111.42 0.14 Allowed Glycine 0 N--CA 1.441 -0.976 0 C-N-CA 120.245 -0.979 . . . . 0.79 113.02 173.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.5 m -90.49 99.34 12.38 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 121.162 0.506 . . . . 1.25 109.899 176.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.725 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 40.3 t -76.05 103.35 6.06 Favored 'General case' 0 C--O 1.218 -0.597 0 N-CA-C 107.65 -1.241 . . . . 0.87 107.65 173.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.562 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 24.3 m -128.93 178.11 6.62 Favored 'General case' 0 C--N 1.311 -1.085 0 C-N-CA 120.634 -0.426 . . . . 1.02 110.473 -178.087 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.571 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -134.19 139.89 46.14 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 116.207 -0.451 . . . . 0.55 109.983 173.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.451 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 70.9 ttt180 -62.22 111.61 2.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.659 -0.701 . . . . 3.86 111.633 -174.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.95 -153.01 20.72 Favored Glycine 0 N--CA 1.443 -0.844 0 CA-C-N 115.188 -0.915 . . . . 1.54 112.36 178.15 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 28.4 t-105 -144.75 118.6 9.3 Favored 'General case' 0 N--CA 1.441 -0.916 0 CA-C-O 121.143 0.497 . . . . 1.55 110.483 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.619 ' HD3' ' HA ' ' A' ' 8' ' ' ILE . 1.0 OUTLIER -89.9 127.23 35.97 Favored 'General case' 0 N--CA 1.44 -0.945 0 CA-C-N 115.592 -0.731 . . . . 3.53 110.087 176.27 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 19.9 m . . . . . 0 C--O 1.252 1.196 0 O-C-N 123.865 0.728 . . . . 4.01 110.846 -179.271 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.437 ' HA ' ' HG2' ' A' ' 46' ' ' ARG . 2.6 mp . . . . . 0 N--CA 1.456 -0.172 0 CA-C-O 120.708 0.29 . . . . 4.18 110.674 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -110.02 164.72 12.35 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.113 0.482 . . . . 3.25 110.001 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.446 ' C ' ' H ' ' A' ' 12' ' ' ARG . 70.7 p -89.18 -175.35 4.76 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.508 -0.769 . . . . 1.72 109.852 171.682 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 31.2 t -55.5 -1.06 0.03 OUTLIER 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.877 0.471 . . . . 1.04 112.079 178.263 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.446 ' H ' ' C ' ' A' ' 10' ' ' THR . 9.3 ptm180 -52.52 -40.52 62.54 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 122.676 0.39 . . . . 4.23 111.615 175.011 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 10.6 mp -87.31 96.04 10.21 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 107.838 -1.171 . . . . 2.66 107.838 170.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.692 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 8.1 tpt180 -99.97 172.11 7.42 Favored 'General case' 0 N--CA 1.431 -1.42 0 CA-C-N 116.032 -0.531 . . . . 7.01 111.98 -165.238 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.692 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 34.0 t-20 71.18 57.5 0.2 Allowed 'General case' 0 CA--C 1.514 -0.409 0 CA-C-N 114.973 -1.012 . . . . 4.38 110.417 170.409 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.652 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -117.04 -48.27 0.45 Allowed Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 119.389 -1.386 . . . . 1.7 111.244 171.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.652 HG13 ' O ' ' A' ' 16' ' ' GLY . 2.3 mt -170.02 133.67 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 124.571 1.149 . . . . 1.05 109.564 154.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 11.4 m -96.8 112.36 24.14 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 120.897 -0.321 . . . . 1.28 110.19 170.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.6 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 43.3 m-85 -95.68 126.34 45.69 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.495 -0.32 . . . . 0.67 110.24 177.068 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -80.65 96.96 1.0 Allowed 'Trans proline' 0 N--CA 1.445 -1.335 0 C-N-CA 121.027 1.151 . . . . 0.48 109.133 166.174 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.5 -113.08 1.06 Allowed Glycine 0 N--CA 1.448 -0.527 0 N-CA-C 111.266 -0.734 . . . . 0.59 111.266 -170.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.7 pt -142.79 156.43 18.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-O 121.062 0.458 . . . . 1.2 111.87 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . 0.5 ' HB3' ' HB2' ' A' ' 27' ' ' TYR . 5.8 m -107.04 132.08 53.36 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 108.679 -0.86 . . . . 1.44 108.679 172.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 10.6 ptm180 -118.12 -41.1 2.9 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 118.976 -1.09 . . . . 5.09 111.315 175.171 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.508 ' HA ' ' H ' ' A' ' 27' ' ' TYR . 0.0 OUTLIER 173.78 158.61 0.31 Allowed Pre-proline 0 CA--C 1.533 0.303 0 C-N-CA 122.644 0.377 . . . . 3.77 111.44 168.449 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.432 ' HA ' ' HB2' ' A' ' 25' ' ' ARG . 2.5 Cg_endo -86.8 99.07 0.22 Allowed 'Cis proline' 0 N--CA 1.458 -0.594 0 C-N-CA 122.652 -1.811 . . . . 1.34 110.681 -6.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.52 ' CE1' HD12 ' A' ' 17' ' ' ILE . 64.2 m-85 -162.9 134.75 5.19 Favored 'General case' 0 CA--C 1.504 -0.79 0 N-CA-C 108.116 -1.068 . . . . 0.64 108.116 -175.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 13.0 p90 -108.68 128.33 54.76 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 120.289 -0.564 . . . . 0.71 109.769 177.17 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' TRP . . . . . 0.711 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 89.2 t90 -65.0 114.73 4.77 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.053 -0.976 . . . . 0.54 110.877 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.513 ' O ' ' HB2' ' A' ' 11' ' ' CYS . 20.7 pt -122.15 95.88 3.75 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.048 -0.978 . . . . 0.72 109.783 173.658 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 62.84 -161.22 32.77 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 120.991 -0.623 . . . . 0.47 113.089 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 19.7 p -117.17 170.1 8.94 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 112.842 0.682 . . . . 0.62 112.842 -175.01 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 19.7 t -143.59 -174.98 4.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.875 -1.057 . . . . 1.07 108.839 -175.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.458 ' O ' ' HB2' ' A' ' 35' ' ' ASN . 75.1 m-20 68.68 -85.02 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 122.692 0.397 . . . . 1.54 110.763 -178.545 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.458 ' HB2' ' O ' ' A' ' 34' ' ' ASN . 21.8 t-20 169.24 78.55 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.285 0 C-N-CA 123.799 0.84 . . . . 2.54 109.212 -179.591 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 105.41 -56.47 0.53 Allowed Glycine 0 N--CA 1.453 -0.221 0 N-CA-C 111.123 -0.791 . . . . 1.12 111.123 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.513 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 0.4 OUTLIER -84.41 -137.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.885 -0.783 . . . . 1.87 108.885 170.503 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.513 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 67.07 115.99 0.02 OUTLIER Glycine 0 C--N 1.339 0.732 0 C-N-CA 120.881 -0.676 . . . . 0.79 114.045 175.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.6 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 77.5 p -93.64 98.91 11.46 Favored 'General case' 0 N--CA 1.434 -1.241 0 N-CA-C 109.006 -0.739 . . . . 1.25 109.006 173.294 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 44.5 t -69.91 108.41 3.99 Favored 'General case' 0 CA--C 1.507 -0.707 0 N-CA-C 107.97 -1.122 . . . . 0.87 107.97 176.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.711 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 80.2 m -130.44 173.88 10.41 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 109.297 -0.631 . . . . 1.02 109.297 179.036 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.612 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -135.58 142.74 45.36 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 120.381 -0.528 . . . . 0.55 110.264 172.217 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.445 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 74.4 ttt180 -62.37 112.19 2.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.259 -0.882 . . . . 3.86 111.484 -173.615 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.88 -151.71 21.06 Favored Glycine 0 N--CA 1.446 -0.649 0 CA-C-N 114.712 -1.131 . . . . 1.54 111.797 -179.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 32.8 t-105 -149.43 119.86 7.39 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.045 0.45 . . . . 1.55 111.004 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.437 ' HG2' ' HA ' ' A' ' 8' ' ' ILE . 0.3 OUTLIER -77.19 138.83 39.69 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.782 -0.645 . . . . 3.53 110.015 175.55 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 31.1 p . . . . . 0 C--O 1.251 1.14 0 O-C-N 124.314 1.009 . . . . 4.01 111.594 -178.267 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.57 ' HA ' ' HD2' ' A' ' 46' ' ' ARG . 2.6 mp . . . . . 0 N--CA 1.453 -0.309 0 CA-C-O 121.035 0.445 . . . . 4.18 111.02 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.481 ' O ' HG22 ' A' ' 30' ' ' ILE . 65.9 m-20 -98.8 165.93 11.55 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.443 -0.798 . . . . 3.25 109.777 176.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.422 ' C ' ' H ' ' A' ' 12' ' ' ARG . 26.9 p -79.6 -175.68 4.93 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.117 -0.492 . . . . 1.72 111.071 175.332 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.405 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 12.5 t -55.74 -0.85 0.04 OUTLIER 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 123.68 0.792 . . . . 1.04 112.209 179.552 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.422 ' H ' ' C ' ' A' ' 10' ' ' THR . 12.9 ptm180 -54.74 -41.84 70.87 Favored 'General case' 0 C--O 1.234 0.237 0 C-N-CA 122.812 0.445 . . . . 4.23 111.446 173.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -86.29 96.41 9.95 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 106.991 -1.485 . . . . 2.66 106.991 171.338 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.664 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 18.2 tpp85 -100.31 157.44 16.61 Favored 'General case' 0 N--CA 1.429 -1.507 0 N-CA-C 114.041 1.126 . . . . 7.01 114.041 -157.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.664 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 64.7 t30 70.04 69.67 0.22 Allowed 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 113.822 -1.535 . . . . 4.38 112.348 164.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.722 ' HA3' ' HA ' ' A' ' 42' ' ' ALA . . . -108.01 -43.82 1.26 Allowed Glycine 0 N--CA 1.432 -1.63 0 N-CA-C 109.659 -1.376 . . . . 1.7 109.659 165.055 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.634 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.1 mt -165.89 132.87 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.349 1.06 . . . . 1.05 109.258 157.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 21.5 t -91.88 109.3 20.64 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.109 -0.33 . . . . 1.28 110.109 175.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.412 ' CD1' ' SG ' ' A' ' 23' ' ' CYS . 15.4 m-85 -96.13 122.39 58.19 Favored Pre-proline 0 CA--C 1.516 -0.346 0 N-CA-C 112.125 0.417 . . . . 0.67 112.125 -177.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -81.92 96.47 0.91 Allowed 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 121.513 1.475 . . . . 0.48 109.816 167.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 136.26 -119.87 2.09 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 111.067 -0.813 . . . . 0.59 111.067 -171.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.8 pt -138.14 154.4 28.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 117.131 0.466 . . . . 1.2 111.735 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . 0.412 ' SG ' ' CD1' ' A' ' 19' ' ' PHE . 69.0 m -101.43 139.85 36.53 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 115.622 -0.717 . . . . 1.44 109.813 173.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.733 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 13.6 ptm180 -135.5 -39.42 0.73 Allowed 'General case' 0 C--N 1.321 -0.646 0 C-N-CA 119.733 -0.787 . . . . 5.09 112.612 179.028 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.733 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 12.0 mmt180 176.88 140.17 0.23 Allowed Pre-proline 0 N--CA 1.476 0.86 0 C-N-CA 123.104 0.561 . . . . 3.77 110.827 178.245 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 4.1 Cg_exo -90.42 99.94 0.21 Allowed 'Cis proline' 0 N--CA 1.456 -0.681 0 C-N-CA 123.44 -1.483 . . . . 1.34 110.371 -13.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.488 ' CD1' ' HA ' ' A' ' 43' ' ' ARG . 96.7 m-85 -161.01 131.4 5.15 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 108.829 -0.804 . . . . 0.64 108.829 -176.535 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -109.2 127.51 54.28 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 109.081 -0.711 . . . . 0.71 109.081 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' TRP . . . . . 0.584 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 86.6 t90 -70.56 117.18 11.76 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.067 -0.969 . . . . 0.54 110.985 -175.19 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.481 HG22 ' O ' ' A' ' 9' ' ' ASP . 16.2 pt -120.75 95.6 3.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.328 -0.851 . . . . 0.72 110.019 176.213 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 61.12 -164.64 17.9 Favored Glycine 0 CA--C 1.524 0.65 0 C-N-CA 121.284 -0.484 . . . . 0.47 113.24 -179.574 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.2 p -111.57 151.98 28.1 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 113.073 0.768 . . . . 0.62 113.073 -175.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.408 ' HB2' ' HB2' ' A' ' 40' ' ' CYS . 49.9 t -122.17 -177.07 3.5 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 107.154 -1.425 . . . . 1.07 107.154 175.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 58.54 -161.44 0.25 Allowed 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 118.866 0.757 . . . . 1.54 110.506 -178.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 92.0 m-20 -109.49 78.16 1.11 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.793 0.33 . . . . 2.54 111.104 -179.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 108.69 -52.18 0.66 Allowed Glycine 0 CA--C 1.509 -0.31 0 N-CA-C 111.149 -0.78 . . . . 1.12 111.149 176.035 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.413 HG12 ' H ' ' A' ' 37' ' ' ILE . 8.6 pt -77.46 -143.14 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 114.849 -0.676 . . . . 1.87 109.474 170.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.407 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 76.04 103.58 0.13 Allowed Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.442 -0.885 . . . . 0.79 113.031 168.399 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 38.2 m -84.04 98.71 10.0 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.898 -0.779 . . . . 1.25 108.898 172.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.408 ' HB2' ' HB2' ' A' ' 33' ' ' CYS . 42.7 t -72.65 106.08 4.53 Favored 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 107.884 -1.154 . . . . 0.87 107.884 175.441 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.584 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 37.0 m -126.9 174.56 8.72 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 121.12 0.486 . . . . 1.02 109.771 178.191 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.722 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -130.17 139.47 50.85 Favored 'General case' 0 N--CA 1.432 -1.332 0 C-N-CA 120.132 -0.627 . . . . 0.55 109.849 172.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.488 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 61.3 ttp180 -61.34 110.96 1.57 Allowed 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.567 -0.742 . . . . 3.86 111.29 -173.349 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 135.76 -158.93 24.04 Favored Glycine 0 N--CA 1.437 -1.237 0 CA-C-N 114.771 -1.104 . . . . 1.54 111.952 -178.489 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.431 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 28.7 t-105 -143.71 116.98 9.0 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.867 -0.419 . . . . 1.55 109.867 -179.13 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.57 ' HD2' ' HA ' ' A' ' 8' ' ' ILE . 12.5 ttm180 -88.63 136.99 32.72 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.458 -0.337 . . . . 3.53 110.265 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.1 t . . . . . 0 C--O 1.249 1.065 0 O-C-N 123.948 0.78 . . . . 4.01 110.042 -177.663 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.471 ' HA ' ' CD ' ' A' ' 46' ' ' ARG . 56.8 mt . . . . . 0 N--CA 1.451 -0.399 0 CA-C-O 121.292 0.568 . . . . 4.18 111.678 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 57.4 m-20 -84.3 163.28 19.71 Favored 'General case' 0 CA--C 1.513 -0.461 0 CA-C-N 115.462 -0.79 . . . . 3.25 109.503 177.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.444 ' C ' ' H ' ' A' ' 12' ' ' ARG . 11.2 p -84.01 -175.69 5.92 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.626 -0.715 . . . . 1.72 110.593 176.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.453 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 37.0 t -56.05 1.62 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 122.878 0.471 . . . . 1.04 112.153 178.468 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.444 ' H ' ' C ' ' A' ' 10' ' ' THR . 14.5 ptt180 -55.79 -34.97 65.77 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 120.577 0.227 . . . . 4.23 110.842 171.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -89.78 97.53 11.25 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 107.797 -1.186 . . . . 2.66 107.797 168.324 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.72 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 8.3 tpt180 -109.71 171.59 7.36 Favored 'General case' 0 N--CA 1.433 -1.306 0 CA-C-O 120.971 0.415 . . . . 7.01 112.007 -166.501 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.72 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 92.1 m-20 72.04 51.92 0.21 Allowed 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 115.215 -0.902 . . . . 4.38 111.052 173.525 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.67 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -109.17 -47.75 0.86 Allowed Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.619 -1.277 . . . . 1.7 110.87 170.419 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.67 HG13 ' O ' ' A' ' 16' ' ' GLY . 3.3 mt -168.99 138.58 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 124.548 1.139 . . . . 1.05 109.56 156.001 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 15.4 t -99.74 104.18 15.88 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.967 -0.382 . . . . 1.28 109.967 170.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.566 ' HD1' ' SG ' ' A' ' 23' ' ' CYS . 33.4 m-85 -92.37 131.45 34.46 Favored Pre-proline 0 CA--C 1.514 -0.424 0 CA-C-N 116.53 -0.305 . . . . 0.67 110.903 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -87.5 96.12 0.45 Allowed 'Trans proline' 0 N--CA 1.443 -1.466 0 C-N-CA 121.171 1.247 . . . . 0.48 109.744 165.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.75 -114.52 0.91 Allowed Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.638 -0.71 . . . . 0.59 111.75 -173.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -140.28 141.75 32.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 121.25 0.547 . . . . 1.2 112.111 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . 0.566 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 79.4 m -95.55 134.88 37.91 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-N 115.533 -0.758 . . . . 1.44 109.604 172.359 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.447 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 15.0 ptm180 -136.38 -37.92 0.69 Allowed 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 120.046 -0.662 . . . . 5.09 112.597 178.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.447 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 8.2 mtt180 176.32 146.48 0.26 Allowed Pre-proline 0 N--CA 1.47 0.573 0 N-CA-C 112.295 0.48 . . . . 3.77 112.295 175.043 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -86.83 98.52 0.21 Allowed 'Cis proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.455 -1.894 . . . . 1.34 110.049 -11.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.64 ' CE1' HD12 ' A' ' 17' ' ' ILE . 89.4 m-85 -162.53 133.47 4.94 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.658 -0.867 . . . . 0.64 108.658 -174.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -109.1 127.36 54.09 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 109.229 -0.656 . . . . 0.71 109.229 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' TRP . . . . . 0.6 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 76.4 t90 -68.66 114.24 6.86 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 114.955 -1.021 . . . . 0.54 110.155 -178.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.457 HG12 ' HA ' ' A' ' 41' ' ' CYS . 18.1 pt -120.98 93.71 2.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.669 0.747 . . . . 0.72 109.981 176.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 65.08 -172.46 21.2 Favored Glycine 0 CA--C 1.524 0.621 0 CA-C-N 115.799 -0.637 . . . . 0.47 113.049 -175.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 19.8 p -105.46 159.41 15.95 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.091 0.472 . . . . 0.62 111.989 -174.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.407 ' SG ' ' N ' ' A' ' 34' ' ' ASN . 48.7 t -121.92 -178.37 3.83 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.36 -0.607 . . . . 1.07 109.36 177.258 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.461 ' ND2' ' HA3' ' A' ' 38' ' ' GLY . 7.6 m-20 57.84 -145.53 0.58 Allowed 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.451 -0.574 . . . . 1.54 109.451 -172.403 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 35.0 m-80 -83.31 -1.09 52.42 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.617 0.246 . . . . 2.54 111.11 175.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 153.63 -35.73 0.74 Allowed Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 119.817 -1.182 . . . . 1.12 114.54 176.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -80.15 -32.34 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 113.033 0.753 . . . . 1.87 113.033 -172.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.461 ' HA3' ' ND2' ' A' ' 34' ' ' ASN . . . -68.83 172.03 37.22 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 120.441 -0.885 . . . . 0.79 111.697 177.086 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.477 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 68.5 p -117.69 124.07 47.62 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.224 0.535 . . . . 1.25 111.252 -174.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 42.0 t -83.9 104.26 13.84 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 107.592 -1.262 . . . . 0.87 107.592 172.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.6 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 29.6 m -127.38 174.77 8.72 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 109.852 -0.425 . . . . 1.02 109.852 178.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.655 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -136.37 143.01 43.82 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 119.923 -0.711 . . . . 0.55 111.077 173.186 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.468 ' C ' ' HD3' ' A' ' 43' ' ' ARG . 3.4 tmt_? -61.54 112.13 2.09 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.062 -0.972 . . . . 3.86 110.466 -177.376 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 141.36 -159.33 26.7 Favored Glycine 0 N--CA 1.439 -1.116 0 CA-C-N 115.11 -0.95 . . . . 1.54 111.112 178.252 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.46 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 31.9 t-105 -148.0 119.15 7.74 Favored 'General case' 0 C--N 1.314 -0.942 0 C-N-CA 120.47 -0.492 . . . . 1.55 111.002 -179.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.471 ' CD ' ' HA ' ' A' ' 8' ' ' ILE . 23.8 ttm180 -107.63 145.62 33.07 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 115.787 -0.642 . . . . 3.53 110.007 172.267 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 17.1 t . . . . . 0 C--O 1.249 1.028 0 O-C-N 124.372 1.045 . . . . 4.01 110.02 -176.342 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 71.0 mt . . . . . 0 N--CA 1.447 -0.58 0 N-CA-C 109.921 -0.4 . . . . 4.18 109.921 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -130.36 165.9 21.56 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.401 -0.363 . . . . 3.25 110.136 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 7.7 p -57.95 -176.93 0.03 OUTLIER 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 112.743 0.645 . . . . 1.72 112.743 177.202 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.454 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 22.9 t -58.03 4.04 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.528 1.131 . . . . 1.04 113.294 -171.212 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.522 ' HG3' HD22 ' A' ' 13' ' ' LEU . 5.0 ptp180 -57.6 -31.22 65.98 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 108.735 -0.839 . . . . 4.23 108.735 167.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.726 ' O ' HD12 ' A' ' 30' ' ' ILE . 3.7 mm? -88.78 122.08 31.81 Favored 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 106.789 -1.559 . . . . 2.66 106.789 161.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.689 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 13.0 tpt180 -131.21 170.54 14.43 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 112.707 0.632 . . . . 7.01 112.707 -168.737 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . 0.689 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 94.3 m-20 72.35 66.4 0.13 Allowed 'General case' 0 CA--C 1.512 -0.512 0 CA-C-N 114.775 -1.102 . . . . 4.38 112.86 169.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.706 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -130.67 -47.91 0.13 Allowed Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 119.632 -1.27 . . . . 1.7 111.551 167.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.706 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.3 mt -169.13 133.98 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.465 1.106 . . . . 1.05 109.9 159.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 6.3 t -96.94 124.04 40.81 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.978 -0.379 . . . . 1.28 109.978 172.023 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.537 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 23.3 m-85 -105.93 127.71 27.85 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 116.471 -0.331 . . . . 0.67 111.009 179.499 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.521 ' HA ' HD21 ' A' ' 34' ' ' ASN . 57.6 Cg_endo -74.48 97.95 1.08 Allowed 'Trans proline' 0 N--CA 1.452 -0.957 0 C-N-CA 121.3 1.333 . . . . 0.48 109.591 167.055 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.585 ' H ' ' HA2' ' A' ' 38' ' ' GLY . . . 133.04 -124.34 3.73 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.489 -0.778 . . . . 0.59 111.259 -171.415 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -142.85 146.95 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-N 117.069 0.434 . . . . 1.2 111.523 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . 0.45 ' SG ' ' CD1' ' A' ' 19' ' ' PHE . 22.6 m -86.18 147.19 26.24 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 115.94 -0.573 . . . . 1.44 111.455 177.163 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.61 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 16.3 ptm180 -141.55 -37.34 0.42 Allowed 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 112.551 0.574 . . . . 5.09 112.551 176.281 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.61 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 10.2 mmt180 177.32 142.19 0.25 Allowed Pre-proline 0 N--CA 1.478 0.96 0 C-N-CA 122.737 0.415 . . . . 3.77 111.193 178.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.569 ' HD2' ' CE2' ' A' ' 27' ' ' TYR . 24.2 Cg_endo -91.35 98.35 0.16 OUTLIER 'Cis proline' 0 C--N 1.349 0.593 0 C-N-CA 122.792 -1.753 . . . . 1.34 111.704 -10.403 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.569 ' CE2' ' HD2' ' A' ' 26' ' ' PRO . 80.9 m-85 -161.53 143.89 11.94 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.695 -0.854 . . . . 0.64 108.695 -172.194 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 11.0 p90 -111.07 127.76 55.65 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 109.008 -0.738 . . . . 0.71 109.008 175.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 84.6 t90 -68.5 113.35 5.96 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.144 -0.935 . . . . 0.54 110.126 -178.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.726 HD12 ' O ' ' A' ' 13' ' ' LEU . 12.1 pt -119.27 94.35 3.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 109.242 -0.651 . . . . 0.72 109.242 174.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 65.24 -173.2 20.21 Favored Glycine 0 CA--C 1.524 0.612 0 CA-C-N 115.962 -0.563 . . . . 0.47 113.079 -177.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.1 p -108.57 161.78 14.75 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 122.27 -0.547 . . . . 0.62 112.047 -176.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 39.1 t -130.98 178.97 6.27 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 116.102 -0.499 . . . . 1.07 110.299 -177.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.521 HD21 ' HA ' ' A' ' 20' ' ' PRO . 1.7 m-20 63.8 -82.48 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.313 1.045 . . . . 1.54 110.791 -174.251 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 54.5 m-80 -151.57 26.67 0.66 Allowed 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.364 -0.606 . . . . 2.54 109.364 -178.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 107.8 -20.34 31.75 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.752 -0.737 . . . . 1.12 112.944 179.685 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.586 ' H ' HD12 ' A' ' 37' ' ' ILE . 0.2 OUTLIER -81.09 -58.4 3.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 O-C-N 122.511 -0.405 . . . . 1.87 111.293 -177.791 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.585 ' HA2' ' H ' ' A' ' 21' ' ' GLY . . . -69.18 174.9 33.19 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.966 -0.635 . . . . 0.79 112.198 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.537 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 77.3 p -108.54 125.74 52.16 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-O 121.392 0.615 . . . . 1.25 111.499 -173.24 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 41.4 t -82.54 113.35 20.2 Favored 'General case' 0 N--CA 1.442 -0.86 0 N-CA-C 106.67 -1.604 . . . . 0.87 106.67 169.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.537 ' HA ' HG12 ' A' ' 30' ' ' ILE . 28.2 m -132.0 177.24 7.7 Favored 'General case' 0 C--N 1.311 -1.085 0 CA-C-O 121.421 0.629 . . . . 1.02 110.703 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.671 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -135.53 137.6 42.23 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.513 -0.767 . . . . 0.55 109.618 167.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.508 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 4.3 tmt_? -60.7 113.41 2.46 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 115.378 -0.828 . . . . 3.86 110.778 -174.741 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 134.62 -150.99 20.23 Favored Glycine 0 N--CA 1.438 -1.183 0 CA-C-N 115.252 -0.886 . . . . 1.54 112.072 176.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 26.0 t-105 -145.51 124.74 12.95 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.369 -0.604 . . . . 1.55 109.369 179.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 19.5 ttm180 -102.42 128.75 48.88 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 120.978 0.418 . . . . 3.53 110.929 176.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 18.5 m . . . . . 0 C--O 1.249 1.075 0 CA-C-N 114.145 -1.388 . . . . 4.01 112.289 178.171 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.592 ' HA ' ' HD2' ' A' ' 46' ' ' ARG . 61.9 mt . . . . . 0 N--CA 1.451 -0.425 0 CA-C-O 121.203 0.525 . . . . 4.18 111.974 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 36.2 m-20 -81.14 166.15 20.93 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.19 -0.913 . . . . 3.25 109.732 174.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.51 ' C ' ' H ' ' A' ' 12' ' ' ARG . 37.0 p -85.86 -171.24 3.49 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.183 -0.673 . . . . 1.72 109.183 174.03 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.583 ' O ' ' HG2' ' A' ' 14' ' ' ARG . 58.4 m -50.9 -1.52 0.01 OUTLIER 'General case' 0 CA--C 1.549 0.938 0 CA-C-O 121.076 0.465 . . . . 1.04 110.742 166.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.51 ' H ' ' C ' ' A' ' 10' ' ' THR . 12.0 ttt180 -32.74 -43.19 0.09 Allowed 'General case' 0 N--CA 1.463 0.176 0 C-N-CA 124.942 1.297 . . . . 4.23 110.834 163.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 8.8 mp -114.96 111.35 21.02 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 115.184 -0.917 . . . . 2.66 108.644 174.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ARG . . . . . 0.667 ' HD2' ' SG ' ' A' ' 40' ' ' CYS . 1.6 mmp_? -116.9 -171.19 1.98 Allowed 'General case' 0 CA--C 1.507 -0.682 0 N-CA-C 113.167 0.802 . . . . 7.01 113.167 -175.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 70.7 42.87 0.79 Allowed 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 114.492 -1.231 . . . . 4.38 109.63 -172.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.675 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -106.43 -51.48 0.81 Allowed Glycine 0 N--CA 1.441 -0.971 0 C-N-CA 119.233 -1.46 . . . . 1.7 111.956 173.277 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.716 HD12 ' CE1' ' A' ' 27' ' ' TYR . 2.7 mt -173.33 150.77 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 C-N-CA 125.112 1.365 . . . . 1.05 108.914 157.14 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 9.2 t -110.89 108.28 18.02 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.263 -0.643 . . . . 1.28 109.263 166.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.643 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 46.9 m-85 -94.36 132.99 27.85 Favored Pre-proline 0 CA--C 1.513 -0.47 0 CA-C-O 120.881 0.372 . . . . 0.67 111.184 -177.53 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -85.54 95.83 0.61 Allowed 'Trans proline' 0 N--CA 1.438 -1.793 0 N-CA-C 108.349 -1.443 . . . . 0.48 108.349 158.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.93 -130.6 5.53 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.26 -0.882 . . . . 0.59 110.973 -168.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.1 pt -135.87 148.48 27.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.521 0.677 . . . . 1.2 112.606 -176.527 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -87.78 123.35 32.49 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.053 -0.976 . . . . 1.44 109.308 169.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.464 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 12.3 ptm180 -123.59 -38.24 2.55 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 119.579 -0.849 . . . . 5.09 112.335 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.464 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 11.5 mtt180 175.02 141.86 0.2 Allowed Pre-proline 0 N--CA 1.475 0.795 0 O-C-N 123.385 0.428 . . . . 3.77 111.88 171.154 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 3.9 Cg_exo -88.55 99.84 0.23 Allowed 'Cis proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.715 -1.785 . . . . 1.34 110.567 -10.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.716 ' CE1' HD12 ' A' ' 17' ' ' ILE . 75.7 m-85 -161.74 128.54 3.86 Favored 'General case' 0 CA--C 1.506 -0.729 0 N-CA-C 108.883 -0.784 . . . . 0.64 108.883 -177.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' TYR . . . . . 0.458 ' CZ ' ' HB3' ' A' ' 42' ' ' ALA . 27.0 p90 -107.83 130.13 55.01 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-O 121.208 0.528 . . . . 0.71 110.205 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 86.4 t90 -65.67 113.82 4.53 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.49 -1.232 . . . . 0.54 111.122 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.487 HD11 HH21 ' A' ' 14' ' ' ARG . 4.7 pt -120.32 92.68 2.21 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.852 0 CA-C-N 115.66 -0.7 . . . . 0.72 109.383 171.728 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 66.18 -164.87 39.87 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 120.711 -0.757 . . . . 0.47 113.292 -177.389 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -114.46 160.11 19.56 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 112.518 0.562 . . . . 0.62 112.518 -174.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 49.6 t -127.92 -176.37 3.76 Favored 'General case' 0 C--O 1.22 -0.485 0 N-CA-C 107.808 -1.182 . . . . 1.07 107.808 175.034 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 61.23 -155.87 0.35 Allowed 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 118.891 0.769 . . . . 1.54 109.884 -177.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 -111.05 88.54 2.81 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.806 0.336 . . . . 2.54 111.064 179.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 92.04 -47.86 2.7 Favored Glycine 0 CA--C 1.506 -0.49 0 N-CA-C 110.892 -0.883 . . . . 1.12 110.892 175.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ILE . . . . . 0.474 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 4.7 pt -77.74 -147.7 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 114.397 -0.901 . . . . 1.87 109.79 170.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.474 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 73.44 161.76 7.01 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 121.171 -0.538 . . . . 0.79 113.459 169.211 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.777 ' HB2' ' SG ' ' A' ' 41' ' ' CYS . 4.7 p -139.74 113.2 8.43 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-O 121.928 0.87 . . . . 1.25 111.4 177.638 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' CYS . . . . . 0.667 ' SG ' ' HD2' ' A' ' 14' ' ' ARG . 36.5 t -77.95 98.12 5.56 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 106.957 -1.497 . . . . 0.87 106.957 172.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . 0.777 ' SG ' ' HB2' ' A' ' 39' ' ' SER . 12.3 m -132.72 141.86 48.76 Favored 'General case' 0 C--N 1.32 -0.687 0 O-C-N 121.946 -0.471 . . . . 1.02 109.832 -174.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.497 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -100.69 139.8 35.87 Favored 'General case' 0 C--N 1.316 -0.848 0 C-N-CA 120.258 -0.577 . . . . 0.55 111.495 -176.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.509 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 4.0 tmt_? -62.04 107.99 0.97 Allowed 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 115.258 -0.883 . . . . 3.86 110.245 179.11 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 138.5 -170.77 23.77 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.417 -0.81 . . . . 1.54 111.293 -178.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.527 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 23.9 t-105 -135.3 118.67 16.75 Favored 'General case' 0 N--CA 1.442 -0.842 0 C-N-CA 120.271 -0.571 . . . . 1.55 110.898 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ARG . . . . . 0.592 ' HD2' ' HA ' ' A' ' 8' ' ' ILE . 15.7 ttm180 -112.6 144.83 41.42 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 115.789 -0.641 . . . . 3.53 110.338 176.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 16.3 t . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.06 -0.971 . . . . 4.01 110.652 -179.103 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.683 0 CA-C-O 120.392 0.139 . . . . 6.64 111.262 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -76.1 -45.3 0.22 Allowed 'Trans proline' 0 N--CA 1.461 -0.431 0 C-N-CA 122.447 2.098 . . . . 6.85 109.681 173.255 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.564 ' O ' ' HD3' ' A' ' 5' ' ' PRO . 5.5 p90 -81.39 164.99 21.71 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 114.834 -1.075 . . . . 5.56 108.488 171.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.429 HG23 ' O ' ' A' ' 4' ' ' ILE . 6.7 tp -86.22 108.64 18.25 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-O 120.94 0.4 . . . . 6.59 110.254 176.091 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.634 ' HB3' ' H ' ' A' ' 47' ' ' SER . 87.5 Cg_exo -50.03 114.54 1.43 Allowed 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 122.602 2.202 . . . . 4.3 113.055 178.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.525 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 21.4 mmm180 -79.4 178.42 2.32 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-N 115.083 -0.962 . . . . 7.04 108.605 176.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.525 ' HD2' ' HB3' ' A' ' 6' ' ' ARG . 98.1 Cg_exo -46.61 135.34 16.64 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 121.936 1.757 . . . . 5.21 112.329 174.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.557 HG12 ' HG3' ' A' ' 46' ' ' ARG . 41.9 mt -60.29 129.47 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 121.415 0.626 . . . . 4.18 112.23 -177.157 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.549 ' O ' HG22 ' A' ' 30' ' ' ILE . 17.0 m-20 -103.37 165.62 10.92 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.128 -0.942 . . . . 3.25 110.069 175.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.407 ' C ' ' H ' ' A' ' 12' ' ' ARG . 25.0 p -83.53 -176.34 6.25 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.843 -0.617 . . . . 1.72 110.375 173.167 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.578 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 25.4 t -58.01 1.58 0.05 OUTLIER 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 122.789 0.436 . . . . 1.04 112.081 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.43 HH11 ' HD2' ' A' ' 12' ' ' ARG . 8.3 ptt180 -54.56 -35.44 63.26 Favored 'General case' 0 CA--C 1.533 0.306 0 N-CA-C 109.86 -0.422 . . . . 4.23 109.86 170.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.417 ' O ' HD12 ' A' ' 30' ' ' ILE . 11.1 mp -85.41 97.82 10.22 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 107.278 -1.379 . . . . 2.66 107.278 165.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.608 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 19.0 tpt180 -107.41 168.57 9.14 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 112.22 0.452 . . . . 7.01 112.22 -164.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.608 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 6.1 t30 72.57 69.63 0.13 Allowed 'General case' 0 CA--C 1.513 -0.48 0 CA-C-N 114.859 -1.064 . . . . 4.38 111.219 172.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.721 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -130.45 -47.17 0.14 Allowed Glycine 0 N--CA 1.435 -1.369 0 C-N-CA 119.891 -1.147 . . . . 1.7 111.273 167.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.721 HG12 ' O ' ' A' ' 16' ' ' GLY . 15.9 mm -164.86 146.51 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 124.415 1.086 . . . . 1.05 108.685 164.162 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -113.92 111.4 21.64 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.32 -0.622 . . . . 1.28 109.32 165.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.453 ' CE1' HG21 ' A' ' 17' ' ' ILE . 44.3 m-85 -94.27 139.91 22.62 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 116.38 -0.373 . . . . 0.67 111.17 -176.754 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -84.98 98.52 0.68 Allowed 'Trans proline' 0 N--CA 1.445 -1.356 0 C-N-CA 121.819 1.68 . . . . 0.48 109.139 163.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 123.51 -131.13 7.97 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 110.373 -1.091 . . . . 0.59 110.373 -166.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 36.4 pt -136.95 156.67 34.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.532 0.682 . . . . 1.2 112.228 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 29' ' ' TRP . 0.2 OUTLIER -81.17 130.59 35.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.876 -1.057 . . . . 1.44 110.428 174.73 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.734 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 14.8 ptp180 -119.14 -39.98 2.87 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 119.461 -0.896 . . . . 5.09 112.701 176.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.734 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 12.9 mmt180 176.43 140.45 0.22 Allowed Pre-proline 0 N--CA 1.482 1.158 0 C-N-CA 123.32 0.648 . . . . 3.77 110.557 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.426 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 1.7 Cg_endo -91.24 100.46 0.22 Allowed 'Cis proline' 0 N--CA 1.455 -0.765 0 C-N-CA 123.646 -1.398 . . . . 1.34 109.968 -13.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.594 ' CE1' HG13 ' A' ' 17' ' ' ILE . 83.7 m-85 -160.84 133.03 5.98 Favored 'General case' 0 CA--C 1.503 -0.834 0 N-CA-C 108.816 -0.809 . . . . 0.64 108.816 -174.065 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.523 ' CD1' ' HB3' ' A' ' 46' ' ' ARG . 19.1 p90 -108.3 129.54 55.22 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 116.003 -0.544 . . . . 0.71 109.582 -179.019 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' TRP . . . . . 0.526 ' HB2' ' SG ' ' A' ' 23' ' ' CYS . 90.0 t90 -66.8 112.77 4.43 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.34 -0.845 . . . . 0.54 110.746 -178.538 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.578 ' O ' ' HB2' ' A' ' 11' ' ' CYS . 5.3 pt -119.2 93.41 2.53 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.844 0 CA-C-N 115.021 -0.99 . . . . 0.72 108.985 173.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 68.7 177.22 13.52 Favored Glycine 0 C--N 1.316 -0.544 0 C-N-CA 120.821 -0.704 . . . . 0.47 112.715 -179.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.5 HG22 ' O ' ' A' ' 38' ' ' GLY . 0.1 OUTLIER -97.71 164.53 12.37 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 122.323 -0.516 . . . . 0.62 111.19 -175.99 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 10.5 t -136.26 179.57 6.27 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.355 -0.98 . . . . 1.07 108.355 175.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.438 ' ND2' ' HA3' ' A' ' 38' ' ' GLY . 83.9 m-20 53.34 27.65 6.49 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 120.722 0.296 . . . . 1.54 111.106 -175.072 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 2.8 t30 64.54 22.16 12.61 Favored 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 123.36 0.664 . . . . 2.54 111.586 179.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 136.3 -36.04 2.05 Favored Glycine 0 CA--C 1.519 0.311 0 C-N-CA 119.911 -1.137 . . . . 1.12 114.021 175.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.424 HG13 ' CB ' ' A' ' 34' ' ' ASN . 0.9 OUTLIER -82.57 -23.55 8.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 112.597 0.591 . . . . 1.87 112.597 -175.835 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.5 ' O ' HG22 ' A' ' 32' ' ' THR . . . -103.53 -167.93 25.54 Favored Glycine 0 N--CA 1.426 -1.991 0 N-CA-C 110.37 -1.092 . . . . 0.79 110.37 -177.794 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.534 ' HB2' ' SG ' ' A' ' 41' ' ' CYS . 23.6 p -144.77 119.87 10.09 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.478 0.656 . . . . 1.25 111.75 -173.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.482 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 41.8 t -74.42 104.2 5.06 Favored 'General case' 0 N--CA 1.442 -0.86 0 N-CA-C 107.073 -1.454 . . . . 0.87 107.073 172.076 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.534 ' SG ' ' HB2' ' A' ' 39' ' ' SER . 14.1 m -139.26 111.16 7.27 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 109.361 -0.607 . . . . 1.02 109.361 -176.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.568 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -80.7 143.39 33.03 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.871 0.367 . . . . 0.55 110.87 -172.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.566 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 39.7 ttm180 -62.53 114.07 3.33 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.432 -0.804 . . . . 3.86 111.096 -176.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 139.17 -152.56 22.38 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 114.676 -1.147 . . . . 1.54 111.263 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 38.3 t-105 -145.12 130.39 18.6 Favored 'General case' 0 N--CA 1.443 -0.806 0 C-N-CA 119.957 -0.697 . . . . 1.55 112.048 179.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.557 ' HG3' HG12 ' A' ' 8' ' ' ILE . 1.9 tpp180 -125.33 117.32 23.49 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 115.092 -0.958 . . . . 3.53 110.312 174.093 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.634 ' H ' ' HB3' ' A' ' 5' ' ' PRO . 44.4 m . . . . . 0 C--O 1.248 1.014 0 CA-C-N 114.067 -1.424 . . . . 4.01 111.704 -176.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.795 0 CA-C-O 120.39 0.138 . . . . 6.64 110.906 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -76.4 -29.46 6.09 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.581 2.187 . . . . 6.85 109.991 175.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 4.0 p90 -119.1 165.18 14.48 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-N 114.463 -1.244 . . . . 5.56 107.973 173.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.442 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 7.0 tp -83.35 112.39 38.73 Favored Pre-proline 0 C--N 1.322 -0.6 0 C-N-CA 121.069 -0.252 . . . . 6.59 110.634 178.374 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.442 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 6.5 Cg_endo -48.9 111.18 0.43 Allowed 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 123.332 2.688 . . . . 4.3 113.409 -178.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.486 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 13.4 mtm180 -106.94 167.49 9.4 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 115.348 -0.842 . . . . 7.04 108.908 176.405 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.486 ' HD2' ' HB3' ' A' ' 6' ' ' ARG . 3.5 Cg_endo -48.55 140.53 21.56 Favored 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.103 1.869 . . . . 5.21 110.586 171.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 2.2 mp -60.01 119.18 3.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.296 0.57 . . . . 4.18 111.259 -172.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -91.37 165.24 13.52 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.295 -0.866 . . . . 3.25 109.464 177.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.403 ' C ' ' H ' ' A' ' 12' ' ' ARG . 6.5 p -89.27 -175.83 4.89 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 116.264 -0.426 . . . . 1.72 110.825 176.07 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.511 ' H ' ' HA3' ' A' ' 31' ' ' GLY . 19.0 t -64.41 11.37 0.05 OUTLIER 'General case' 0 N--CA 1.47 0.549 0 CA-C-O 121.317 0.58 . . . . 1.04 112.088 -172.242 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.415 HH11 ' HD2' ' A' ' 12' ' ' ARG . 18.3 ptt85 -57.96 -25.69 61.32 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.851 -0.796 . . . . 4.23 108.851 161.526 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.612 HD21 ' NH2' ' A' ' 46' ' ' ARG . 5.4 mp -74.71 153.19 38.97 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 115.554 -0.748 . . . . 2.66 109.518 169.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -78.66 98.99 6.41 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 114.611 1.337 . . . . 7.01 114.611 -167.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 66.5 t30 31.18 61.74 0.24 Allowed 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 124.181 0.992 . . . . 4.38 113.335 156.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.664 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -77.24 -43.54 16.01 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 118.811 -1.661 . . . . 1.7 112.824 -172.176 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.664 HG12 ' O ' ' A' ' 16' ' ' GLY . 20.3 mm -163.18 128.33 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 C-N-CA 124.896 1.278 . . . . 1.05 108.273 165.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 8.2 m -94.89 110.54 22.41 Favored 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 120.407 -0.517 . . . . 1.28 110.785 173.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.531 ' CZ ' HG21 ' A' ' 17' ' ' ILE . 43.8 m-85 -102.52 131.68 22.16 Favored Pre-proline 0 CA--C 1.51 -0.59 0 CA-C-N 116.036 -0.529 . . . . 0.67 110.82 177.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -74.48 97.8 1.07 Allowed 'Trans proline' 0 N--CA 1.448 -1.165 0 C-N-CA 121.104 1.202 . . . . 0.48 109.316 169.03 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.478 ' H ' ' HA2' ' A' ' 38' ' ' GLY . . . 128.92 -122.56 3.96 Favored Glycine 0 N--CA 1.442 -0.927 0 CA-C-N 115.217 -0.901 . . . . 0.59 111.204 -169.155 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -146.6 147.15 18.2 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 121.115 0.483 . . . . 1.2 111.567 -178.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . 0.508 ' HB3' ' HB2' ' A' ' 27' ' ' TYR . 0.0 OUTLIER -71.65 127.69 33.39 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.367 -0.833 . . . . 1.44 110.424 173.759 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.698 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 25.8 ptt180 -116.09 -38.11 3.69 Favored 'General case' 0 C--N 1.322 -0.628 0 C-N-CA 120.14 -0.624 . . . . 5.09 111.537 175.555 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.698 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 14.7 mmt180 175.7 143.93 0.23 Allowed Pre-proline 0 N--CA 1.477 0.899 0 C-N-CA 123.361 0.664 . . . . 3.77 110.932 177.218 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 1.2 Cg_endo -93.94 100.4 0.18 OUTLIER 'Cis proline' 0 N--CA 1.457 -0.62 0 C-N-CA 123.878 -1.301 . . . . 1.34 110.756 -14.464 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.628 ' CE1' HG13 ' A' ' 17' ' ' ILE . 63.1 m-85 -161.5 139.56 9.29 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.726 -0.842 . . . . 0.64 108.726 -175.203 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.418 ' CZ ' ' HB3' ' A' ' 42' ' ' ALA . 26.1 p90 -107.85 131.74 54.17 Favored 'General case' 0 C--N 1.312 -1.027 0 C-N-CA 120.306 -0.558 . . . . 0.71 110.348 177.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 86.9 t90 -67.02 112.58 4.44 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.642 -1.163 . . . . 0.54 110.92 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.567 HG12 ' O ' ' A' ' 40' ' ' CYS . 0.6 OUTLIER -120.11 93.62 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 CA-C-O 121.957 0.884 . . . . 0.72 109.404 170.398 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.511 ' HA3' ' H ' ' A' ' 11' ' ' CYS . . . 70.75 178.63 26.72 Favored Glycine 0 CA--C 1.523 0.559 0 CA-C-N 115.544 -0.753 . . . . 0.47 113.482 -177.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.539 HG22 ' O ' ' A' ' 38' ' ' GLY . 0.0 OUTLIER -97.87 162.9 13.02 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.066 0.46 . . . . 0.62 111.137 -177.534 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 15.7 t -135.36 -177.22 4.56 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.374 -0.973 . . . . 1.07 108.374 175.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.433 ' ND2' ' HA3' ' A' ' 38' ' ' GLY . 92.5 m-20 59.63 -160.82 0.28 Allowed 'General case' 0 N--CA 1.464 0.236 0 N-CA-C 109.905 -0.406 . . . . 1.54 109.905 -173.138 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -83.21 42.21 0.8 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.113 0.482 . . . . 2.54 110.113 174.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 89.72 11.61 63.58 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 121.069 -0.586 . . . . 1.12 112.487 -178.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 8.1 pt -120.25 14.09 6.51 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.351 0 CA-C-O 121.219 0.533 . . . . 1.87 112.013 -179.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.539 ' O ' HG22 ' A' ' 32' ' ' THR . . . -133.12 170.4 22.21 Favored Glycine 0 N--CA 1.424 -2.109 0 N-CA-C 110.082 -1.207 . . . . 0.79 110.082 178.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 57.2 p -120.51 126.04 49.38 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 121.022 0.439 . . . . 1.25 110.584 -177.253 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.567 ' O ' HG12 ' A' ' 30' ' ' ILE . 38.5 t -82.67 91.05 6.91 Favored 'General case' 0 C--O 1.211 -0.967 0 N-CA-C 107.346 -1.353 . . . . 0.87 107.346 175.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.433 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 3.0 m -100.66 -176.52 3.21 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.791 -0.818 . . . . 1.02 108.791 -177.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.633 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -142.32 138.76 31.5 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 120.909 -0.316 . . . . 0.55 110.479 166.018 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.485 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 34.8 ttp180 -59.81 110.4 1.15 Allowed 'General case' 0 C--O 1.234 0.287 0 O-C-N 123.957 0.786 . . . . 3.86 110.876 -178.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 138.65 -154.86 23.34 Favored Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 114.909 -1.041 . . . . 1.54 111.215 -177.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 32.5 t-105 -145.25 146.03 31.52 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 121.222 0.534 . . . . 1.55 111.353 177.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.612 ' NH2' HD21 ' A' ' 13' ' ' LEU . 10.5 ttm180 -130.69 127.28 38.54 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.484 -0.78 . . . . 3.53 110.523 176.047 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 45.8 m . . . . . 0 C--O 1.25 1.107 0 O-C-N 124.605 1.191 . . . . 4.01 111.859 179.161 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.831 0 CA-C-O 120.401 0.143 . . . . 6.64 110.718 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -72.04 -45.37 0.69 Allowed 'Trans proline' 0 CA--C 1.514 -0.484 0 C-N-CA 122.578 2.186 . . . . 6.85 109.563 176.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 6.4 p90 -126.06 165.42 18.85 Favored 'General case' 0 N--CA 1.444 -0.767 0 N-CA-C 107.189 -1.412 . . . . 5.56 107.189 169.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.426 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 48.7 mm -90.01 117.36 68.01 Favored Pre-proline 0 C--N 1.319 -0.729 0 C-N-CA 120.785 -0.366 . . . . 6.59 110.87 -179.334 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.426 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 14.0 Cg_endo -56.94 108.69 0.37 Allowed 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.647 2.231 . . . . 4.3 111.967 178.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.46 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 47.8 mtt180 -106.44 168.82 7.6 Favored Pre-proline 0 C--N 1.318 -0.8 0 CA-C-N 115.302 -0.863 . . . . 7.04 109.687 -178.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.46 ' HD2' ' HB3' ' A' ' 6' ' ' ARG . 2.1 Cg_endo -41.81 141.34 1.7 Allowed 'Trans proline' 0 C--N 1.35 0.641 0 C-N-CA 123.165 2.577 . . . . 5.21 112.461 175.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.419 ' N ' HD12 ' A' ' 8' ' ' ILE . 2.5 mp -59.93 111.14 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.82 -0.627 . . . . 4.18 110.26 -176.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -100.1 169.2 9.33 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.329 -0.85 . . . . 3.25 110.295 -174.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 12' ' ' ARG . 16.9 p -91.03 -176.43 4.62 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.795 -0.639 . . . . 1.72 111.106 -177.299 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.618 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 47.7 t -59.56 8.67 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 121.291 0.567 . . . . 1.04 111.797 177.01 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.505 ' HG3' HD12 ' A' ' 13' ' ' LEU . 0.0 OUTLIER -53.28 -38.42 63.06 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.555 -0.535 . . . . 4.23 109.555 167.84 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.505 HD12 ' HG3' ' A' ' 12' ' ' ARG . 8.6 mp -77.22 126.08 30.37 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 109.07 -0.715 . . . . 2.66 109.07 172.075 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.618 ' HD3' ' SG ' ' A' ' 11' ' ' CYS . 17.3 mmm180 -134.31 171.75 13.83 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 113.077 0.769 . . . . 7.01 113.077 -171.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 64.42 20.1 12.04 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 114.357 -1.292 . . . . 4.38 110.849 -177.217 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.735 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -85.85 -51.59 3.56 Favored Glycine 0 N--CA 1.438 -1.201 0 C-N-CA 118.824 -1.655 . . . . 1.7 111.377 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.735 HG12 ' O ' ' A' ' 16' ' ' GLY . 25.5 mm -168.4 143.71 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.787 0 C-N-CA 125.903 1.681 . . . . 1.05 107.824 157.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.6 m -109.46 99.62 8.81 Favored 'General case' 0 C--N 1.321 -0.669 0 O-C-N 121.774 -0.579 . . . . 1.28 110.084 166.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.483 ' HD1' ' SG ' ' A' ' 41' ' ' CYS . 44.8 m-85 -88.19 135.02 33.63 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.72 -0.673 . . . . 0.67 110.938 -178.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.628 ' HB3' HD21 ' A' ' 34' ' ' ASN . 96.7 Cg_endo -88.16 97.85 0.41 Allowed 'Trans proline' 0 N--CA 1.442 -1.558 0 C-N-CA 121.452 1.435 . . . . 0.48 109.729 164.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.55 -115.07 1.3 Allowed Glycine 0 N--CA 1.444 -0.819 0 N-CA-C 110.666 -0.973 . . . . 0.59 110.666 -170.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 22.2 pt -146.26 152.16 13.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 CA-C-O 121.277 0.56 . . . . 1.2 111.94 179.262 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -86.27 142.52 28.49 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.219 -0.901 . . . . 1.44 108.735 170.391 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.9 ptt180 -131.98 -39.21 1.08 Allowed 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 119.542 -0.863 . . . . 5.09 112.251 173.218 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.408 HH11 ' HD2' ' A' ' 25' ' ' ARG . 4.8 mtt85 174.24 145.17 0.2 Allowed Pre-proline 0 N--CA 1.474 0.745 0 N-CA-C 112.033 0.383 . . . . 3.77 112.033 173.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -88.41 99.47 0.22 Allowed 'Cis proline' 0 N--CA 1.459 -0.515 0 C-N-CA 122.996 -1.669 . . . . 1.34 110.851 -9.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.624 ' CE1' HG13 ' A' ' 17' ' ' ILE . 68.7 m-85 -162.21 135.66 6.23 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.339 -0.986 . . . . 0.64 108.339 -176.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 20.4 p90 -108.42 129.76 55.25 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.973 -0.691 . . . . 0.71 110.194 176.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 85.4 t90 -66.81 113.45 4.9 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 114.684 -1.144 . . . . 0.54 111.193 -177.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.58 ' O ' ' HB3' ' A' ' 40' ' ' CYS . 10.9 pt -121.62 92.4 2.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-N 115.548 -0.751 . . . . 0.72 109.559 172.752 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 66.9 -171.61 30.83 Favored Glycine 0 CA--C 1.527 0.819 0 C-N-CA 121.281 -0.485 . . . . 0.47 113.159 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.6 p -107.66 168.54 9.18 Favored 'General case' 0 CA--C 1.533 0.299 0 O-C-N 122.381 -0.482 . . . . 0.62 111.503 -177.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.587 ' O ' ' HA3' ' A' ' 38' ' ' GLY . 42.7 t -160.38 105.31 1.47 Allowed 'General case' 0 C--N 1.334 -0.098 0 N-CA-C 110.277 -0.268 . . . . 1.07 110.277 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.628 HD21 ' HB3' ' A' ' 20' ' ' PRO . 13.6 m-20 163.67 39.58 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 125.586 1.554 . . . . 1.54 109.845 176.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 57.12 37.82 28.72 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.104 -0.498 . . . . 2.54 111.283 -175.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 136.19 -64.93 0.57 Allowed Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 111.442 -0.663 . . . . 1.12 111.442 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.522 HG13 ' HB3' ' A' ' 34' ' ' ASN . 2.7 pt -80.27 -162.09 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.677 -0.261 . . . . 1.87 110.339 174.533 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.587 ' HA3' ' O ' ' A' ' 33' ' ' CYS . . . 85.49 179.4 50.5 Favored Glycine 0 N--CA 1.422 -2.249 0 C-N-CA 120.497 -0.859 . . . . 0.79 111.538 177.265 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.9 m -141.25 111.9 7.04 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.015 -0.593 . . . . 1.25 109.532 -178.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.58 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 47.2 t -79.02 111.57 15.36 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 107.26 -1.385 . . . . 0.87 107.26 175.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.483 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 2.2 m -129.2 156.5 43.85 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.815 -0.809 . . . . 1.02 108.815 -176.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.622 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -118.29 130.62 56.14 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 119.817 -0.753 . . . . 0.55 110.301 174.008 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.503 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 1.5 tmt_? -55.12 109.86 0.59 Allowed 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 115.275 -0.875 . . . . 3.86 110.521 -177.561 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 137.4 -162.78 25.43 Favored Glycine 0 N--CA 1.442 -0.959 0 CA-C-N 115.256 -0.884 . . . . 1.54 111.85 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 31.0 t-105 -141.59 118.51 11.18 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.033 0.445 . . . . 1.55 110.597 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 12.9 ttm180 -96.68 139.55 32.58 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.032 -0.531 . . . . 3.53 111.565 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.3 t . . . . . 0 C--O 1.247 0.943 0 CA-C-N 114.477 -1.238 . . . . 4.01 110.976 -179.375 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.427 ' HA ' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.476 0.827 0 CA-C-O 120.44 0.162 . . . . 6.64 110.87 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 1' ' ' PCA . 4.8 Cg_exo -77.4 -29.68 4.64 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.653 2.235 . . . . 6.85 110.224 177.471 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 4.4 p90 -122.85 166.08 15.59 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 107.715 -1.217 . . . . 5.56 107.715 176.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.497 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 7.0 tp -83.45 112.11 36.74 Favored Pre-proline 0 C--N 1.321 -0.666 0 C-N-CA 120.93 -0.308 . . . . 6.59 110.654 178.265 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.508 ' HB3' ' HA ' ' A' ' 47' ' ' SER . 2.8 Cg_endo -44.79 109.87 0.2 Allowed 'Trans proline' 0 C--N 1.356 0.957 0 C-N-CA 123.36 2.707 . . . . 4.3 113.238 179.311 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 81.2 mtp180 -100.5 150.34 36.88 Favored Pre-proline 0 C--N 1.319 -0.744 0 CA-C-N 115.331 -0.849 . . . . 7.04 108.806 174.064 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -44.48 124.99 5.69 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 123.092 2.528 . . . . 5.21 111.333 176.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.461 ' HA ' ' CD ' ' A' ' 46' ' ' ARG . 81.3 mt -61.64 113.04 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.524 0.678 . . . . 4.18 111.322 -174.025 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.466 ' O ' HG22 ' A' ' 30' ' ' ILE . 71.4 m-20 -81.75 165.3 21.06 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 114.843 -1.071 . . . . 3.25 111.026 -176.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.447 ' C ' ' H ' ' A' ' 12' ' ' ARG . 21.4 p -79.56 -175.49 4.81 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 114.949 -1.023 . . . . 1.72 110.906 173.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.417 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 19.4 t -57.12 4.52 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 123.595 0.758 . . . . 1.04 112.617 -179.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.447 ' H ' ' C ' ' A' ' 10' ' ' THR . 34.1 ptt180 -61.27 -29.91 70.14 Favored 'General case' 0 CA--C 1.531 0.239 0 O-C-N 122.018 -0.426 . . . . 4.23 110.86 174.08 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.403 ' O ' HD12 ' A' ' 30' ' ' ILE . 4.4 mm? -88.56 97.86 11.33 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 107.319 -1.363 . . . . 2.66 107.319 167.041 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.635 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 12.7 tpp85 -101.43 163.97 12.0 Favored 'General case' 0 N--CA 1.428 -1.538 0 N-CA-C 113.349 0.87 . . . . 7.01 113.349 -161.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.635 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 92.9 m-20 70.34 69.61 0.21 Allowed 'General case' 0 CA--C 1.514 -0.432 0 CA-C-N 114.421 -1.263 . . . . 4.38 112.321 168.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.684 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -125.27 -46.79 0.23 Allowed Glycine 0 N--CA 1.439 -1.154 0 C-N-CA 119.385 -1.388 . . . . 1.7 111.576 169.095 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.684 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.1 mt -168.86 131.53 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 124.523 1.129 . . . . 1.05 109.648 156.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 1.8 m -94.04 113.09 25.0 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.908 0.385 . . . . 1.28 110.213 170.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.615 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 64.7 m-85 -95.49 140.68 22.47 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.343 -0.389 . . . . 0.67 110.077 178.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.469 ' HA ' ' ND2' ' A' ' 34' ' ' ASN . 74.9 Cg_endo -86.71 96.39 0.5 Allowed 'Trans proline' 0 N--CA 1.443 -1.49 0 C-N-CA 121.356 1.37 . . . . 0.48 109.787 167.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.56 -109.2 0.89 Allowed Glycine 0 N--CA 1.441 -0.968 0 CA-C-N 115.339 -0.846 . . . . 0.59 111.523 -171.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 9.9 pt -146.17 145.47 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 112.386 0.513 . . . . 1.2 112.386 -176.309 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.89 126.7 32.76 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.609 -0.723 . . . . 1.44 109.195 172.634 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 37.4 ptt180 -115.98 -40.04 3.37 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 118.619 -1.232 . . . . 5.09 112.521 176.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 172.75 152.53 0.23 Allowed Pre-proline 0 N--CA 1.473 0.691 0 CA-C-N 118.112 0.414 . . . . 3.77 111.642 172.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -87.15 100.91 0.27 Allowed 'Cis proline' 0 C--N 1.347 0.45 0 C-N-CA 123.216 -1.577 . . . . 1.34 110.797 -12.418 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.57 ' CE1' HD12 ' A' ' 17' ' ' ILE . 89.1 m-85 -160.88 141.92 11.72 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 108.178 -1.045 . . . . 0.64 108.178 -175.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 7.6 p90 -107.76 128.96 55.04 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 120.437 -0.505 . . . . 0.71 109.641 177.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 92.1 t90 -66.71 113.83 5.14 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.988 -1.005 . . . . 0.54 110.365 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.544 ' O ' ' HB3' ' A' ' 40' ' ' CYS . 11.2 pt -120.15 93.25 2.43 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-N 115.271 -0.877 . . . . 0.72 109.318 175.171 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 62.31 -172.96 8.87 Favored Glycine 0 CA--C 1.526 0.736 0 C-N-CA 121.047 -0.597 . . . . 0.47 112.93 -176.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.4 p -102.1 165.53 11.11 Favored 'General case' 0 C--N 1.324 -0.523 0 O-C-N 122.173 -0.604 . . . . 0.62 111.631 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 20.6 t -137.5 -178.18 5.12 Favored 'General case' 0 C--O 1.216 -0.696 0 N-CA-C 108.334 -0.988 . . . . 1.07 108.334 178.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.469 ' ND2' ' HA ' ' A' ' 20' ' ' PRO . 87.7 m-20 67.12 1.42 2.37 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 118.28 0.491 . . . . 1.54 111.753 -177.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 49.8 m-80 65.94 85.46 0.14 Allowed 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 123.611 0.764 . . . . 2.54 111.846 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 110.76 -62.46 0.29 Allowed Glycine 0 CA--C 1.511 -0.174 0 N-CA-C 111.709 -0.556 . . . . 1.12 111.709 175.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.454 ' H ' HD12 ' A' ' 37' ' ' ILE . 0.2 OUTLIER -88.76 -142.43 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 108.753 -0.832 . . . . 1.87 108.753 173.424 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.4 175.29 1.19 Allowed Glycine 0 N--CA 1.447 -0.602 0 CA-C-O 122.009 0.783 . . . . 0.79 114.485 169.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.615 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 87.6 p -142.32 119.89 11.75 Favored 'General case' 0 N--CA 1.433 -1.278 0 N-CA-C 109.599 -0.519 . . . . 1.25 109.599 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.544 ' HB3' ' O ' ' A' ' 30' ' ' ILE . 46.0 t -82.63 116.8 22.18 Favored 'General case' 0 C--N 1.313 -1.018 0 N-CA-C 107.127 -1.435 . . . . 0.87 107.127 174.218 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.586 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -133.67 169.03 17.62 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 108.31 -0.996 . . . . 1.02 108.31 -178.322 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.659 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -136.73 142.14 43.05 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.669 -0.812 . . . . 0.55 110.744 172.089 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.477 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 57.0 ttp180 -61.42 116.65 4.85 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 114.973 -1.012 . . . . 3.86 110.909 -176.222 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 134.24 -149.84 19.88 Favored Glycine 0 CA--C 1.497 -1.044 0 CA-C-N 115.162 -0.926 . . . . 1.54 111.658 176.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 31.4 t-105 -152.7 123.88 7.58 Favored 'General case' 0 C--N 1.317 -0.843 0 C-N-CA 120.581 -0.448 . . . . 1.55 111.189 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.461 ' CD ' ' HA ' ' A' ' 8' ' ' ILE . 21.2 ttm180 -104.79 139.91 38.88 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.912 -0.585 . . . . 3.53 110.23 169.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.508 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 3.7 t . . . . . 0 C--O 1.253 1.243 0 O-C-N 124.289 0.993 . . . . 4.01 110.538 -179.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.414 ' HA ' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.473 0.723 0 CA-C-O 120.654 0.264 . . . . 6.64 111.525 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 1' ' ' PCA . 2.9 Cg_exo -76.29 -29.2 6.47 Favored 'Trans proline' 0 C--N 1.347 0.491 0 C-N-CA 122.907 2.405 . . . . 6.85 110.269 176.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.488 ' O ' ' HD3' ' A' ' 5' ' ' PRO . 0.8 OUTLIER -121.84 164.76 16.95 Favored 'General case' 0 N--CA 1.444 -0.744 0 N-CA-C 107.575 -1.268 . . . . 5.56 107.575 172.454 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.61 110.69 18.04 Favored Pre-proline 0 C--N 1.322 -0.607 0 N-CA-C 109.656 -0.498 . . . . 6.59 109.656 178.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.488 ' HD3' ' O ' ' A' ' 3' ' ' PHE . 52.1 Cg_exo -56.2 107.67 0.28 Allowed 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 122.533 2.155 . . . . 4.3 112.058 -179.199 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.643 ' O ' ' HG2' ' A' ' 46' ' ' ARG . 22.2 mtp180 -89.15 167.53 17.72 Favored Pre-proline 0 C--N 1.32 -0.703 0 CA-C-N 115.453 -0.794 . . . . 7.04 109.602 -179.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.424 ' HD2' ' HB3' ' A' ' 6' ' ' ARG . 85.0 Cg_exo -48.26 139.08 22.3 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.387 2.058 . . . . 5.21 112.851 176.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.619 ' HA ' ' HD3' ' A' ' 46' ' ' ARG . 3.5 mp -62.57 106.37 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.274 -0.875 . . . . 4.18 111.465 178.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -89.04 164.02 15.25 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 108.943 -0.762 . . . . 3.25 108.943 170.021 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.495 ' C ' ' H ' ' A' ' 12' ' ' ARG . 38.4 p -72.75 -175.8 1.81 Allowed 'General case' 0 C--N 1.314 -0.965 0 CA-C-N 116.504 -0.317 . . . . 1.72 110.867 176.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.42 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 11.4 t -57.51 6.23 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 123.36 0.664 . . . . 1.04 112.054 178.816 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.495 ' H ' ' C ' ' A' ' 10' ' ' THR . 38.4 ptt180 -65.89 -33.2 75.3 Favored 'General case' 0 C--N 1.33 -0.268 0 O-C-N 122.107 -0.371 . . . . 4.23 110.939 172.484 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.406 ' CD2' ' HG3' ' A' ' 12' ' ' ARG . 4.5 mm? -97.11 97.48 9.24 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 108.472 -0.936 . . . . 2.66 108.472 172.086 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.725 ' HD3' ' SG ' ' A' ' 40' ' ' CYS . 2.7 mmm-85 -110.24 -170.71 1.7 Allowed 'General case' 0 N--CA 1.438 -1.028 0 N-CA-C 113.338 0.866 . . . . 7.01 113.338 -166.463 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.9 m-80 69.02 53.45 0.47 Allowed 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 114.678 -1.146 . . . . 4.38 111.154 -178.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.717 ' O ' HG12 ' A' ' 17' ' ' ILE . . . -120.46 -50.02 0.28 Allowed Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 119.445 -1.36 . . . . 1.7 112.119 172.113 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.717 HG12 ' O ' ' A' ' 16' ' ' GLY . 25.1 mm -166.65 147.02 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 C-N-CA 125.337 1.455 . . . . 1.05 108.149 161.112 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 31.5 t -111.12 104.03 12.52 Favored 'General case' 0 C--N 1.324 -0.524 0 O-C-N 121.654 -0.654 . . . . 1.28 109.426 168.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.554 ' CE1' HG21 ' A' ' 17' ' ' ILE . 17.0 m-85 -93.17 124.13 58.84 Favored Pre-proline 0 C--N 1.329 -0.287 0 N-CA-C 112.404 0.52 . . . . 0.67 112.404 -175.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -82.23 97.4 0.9 Allowed 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 121.833 1.689 . . . . 0.48 109.473 165.339 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.64 -134.0 7.12 Favored Glycine 0 N--CA 1.443 -0.84 0 N-CA-C 110.884 -0.886 . . . . 0.59 110.884 -170.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 23.7 pt -129.17 147.8 33.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.285 0.564 . . . . 1.2 112.006 -178.46 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 93.9 m -94.77 139.62 31.02 Favored 'General case' 0 N--CA 1.437 -1.094 0 CA-C-N 115.488 -0.778 . . . . 1.44 109.797 173.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.48 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 7.1 ptt180 -143.56 -37.1 0.35 Allowed 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 118.904 -0.569 . . . . 5.09 112.532 -179.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.48 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 10.8 mtt180 175.54 145.68 0.24 Allowed Pre-proline 0 N--CA 1.476 0.827 0 N-CA-C 112.067 0.395 . . . . 3.77 112.067 170.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -88.74 99.25 0.2 Allowed 'Cis proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.839 -1.734 . . . . 1.34 110.611 -10.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.475 ' CE1' HG13 ' A' ' 17' ' ' ILE . 96.2 m-85 -161.55 138.51 8.55 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 108.919 -0.771 . . . . 0.64 108.919 -175.405 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.512 ' CZ ' ' HB3' ' A' ' 42' ' ' ALA . 35.8 p90 -113.09 127.93 56.35 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 109.245 -0.65 . . . . 0.71 109.245 178.001 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' TRP . . . . . 0.562 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 90.1 t90 -73.74 117.0 14.99 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.625 -0.716 . . . . 0.54 110.971 -175.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.463 ' O ' HG13 ' A' ' 30' ' ' ILE . 26.6 pt -121.35 95.03 3.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-O 121.524 0.678 . . . . 0.72 110.259 176.309 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 63.39 -170.97 14.86 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 121.12 -0.562 . . . . 0.47 113.041 -178.147 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 23.2 p -108.96 148.19 31.1 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 112.928 0.714 . . . . 0.62 112.928 -173.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.481 ' O ' ' HA3' ' A' ' 38' ' ' GLY . 18.4 t -116.74 -175.83 2.85 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.583 -1.266 . . . . 1.07 107.583 174.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.436 ' HB2' ' HA3' ' A' ' 38' ' ' GLY . 84.0 m-20 64.62 -97.44 0.06 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 118.315 0.507 . . . . 1.54 111.266 179.738 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 52.0 t30 -177.05 85.77 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.762 0.315 . . . . 2.54 110.868 -178.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 94.09 -57.42 2.11 Favored Glycine 0 CA--C 1.503 -0.695 0 N-CA-C 110.122 -1.191 . . . . 1.12 110.122 178.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.455 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 0.8 OUTLIER -78.51 -148.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 108.063 -1.088 . . . . 1.87 108.063 164.997 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.481 ' HA3' ' O ' ' A' ' 33' ' ' CYS . . . 76.97 111.42 0.14 Allowed Glycine 0 N--CA 1.441 -0.976 0 C-N-CA 120.245 -0.979 . . . . 0.79 113.02 173.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.5 m -90.49 99.34 12.38 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 121.162 0.506 . . . . 1.25 109.899 176.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.725 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 40.3 t -76.05 103.35 6.06 Favored 'General case' 0 C--O 1.218 -0.597 0 N-CA-C 107.65 -1.241 . . . . 0.87 107.65 173.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.562 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 24.3 m -128.93 178.11 6.62 Favored 'General case' 0 C--N 1.311 -1.085 0 C-N-CA 120.634 -0.426 . . . . 1.02 110.473 -178.087 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.571 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -134.19 139.89 46.14 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 116.207 -0.451 . . . . 0.55 109.983 173.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.451 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 70.9 ttt180 -62.22 111.61 2.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.659 -0.701 . . . . 3.86 111.633 -174.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.95 -153.01 20.72 Favored Glycine 0 N--CA 1.443 -0.844 0 CA-C-N 115.188 -0.915 . . . . 1.54 112.36 178.15 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 28.4 t-105 -144.75 118.6 9.3 Favored 'General case' 0 N--CA 1.441 -0.916 0 CA-C-O 121.143 0.497 . . . . 1.55 110.483 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.643 ' HG2' ' O ' ' A' ' 6' ' ' ARG . 1.0 OUTLIER -89.9 127.23 35.97 Favored 'General case' 0 N--CA 1.44 -0.945 0 CA-C-N 115.592 -0.731 . . . . 3.53 110.087 176.27 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.432 ' H ' ' CB ' ' A' ' 5' ' ' PRO . 19.9 m . . . . . 0 C--O 1.252 1.196 0 O-C-N 123.865 0.728 . . . . 4.01 110.846 -179.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.455 ' HA ' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 110.672 -0.122 . . . . 6.64 110.672 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 1' ' ' PCA . 3.2 Cg_exo -78.56 -12.09 15.39 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.799 2.333 . . . . 6.85 110.551 -179.399 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 3.6 p90 -148.04 166.36 28.0 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 107.094 -1.447 . . . . 5.56 107.094 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.5 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 6.5 tp -81.9 110.72 21.61 Favored Pre-proline 0 C--N 1.321 -0.665 0 C-N-CA 120.771 -0.372 . . . . 6.59 110.76 178.362 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.5 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 4.0 Cg_exo -36.13 109.86 0.06 OUTLIER 'Trans proline' 0 C--N 1.362 1.241 0 C-N-CA 124.457 3.438 . . . . 4.3 114.546 -179.069 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.508 ' O ' ' HD2' ' A' ' 46' ' ' ARG . 14.7 mtp-105 -100.96 173.01 3.95 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 114.783 -1.099 . . . . 7.04 109.905 174.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_exo -54.66 143.52 68.82 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.172 1.915 . . . . 5.21 111.561 169.045 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.437 ' HA ' ' HG2' ' A' ' 46' ' ' ARG . 2.6 mp -61.58 128.8 23.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 115.818 -0.628 . . . . 4.18 110.674 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -110.02 164.72 12.35 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.113 0.482 . . . . 3.25 110.001 -179.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.446 ' C ' ' H ' ' A' ' 12' ' ' ARG . 70.7 p -89.18 -175.35 4.76 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.508 -0.769 . . . . 1.72 109.852 171.682 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 31.2 t -55.5 -1.06 0.03 OUTLIER 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.877 0.471 . . . . 1.04 112.079 178.263 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.446 ' H ' ' C ' ' A' ' 10' ' ' THR . 9.3 ptm180 -52.52 -40.52 62.54 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 122.676 0.39 . . . . 4.23 111.615 175.011 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 10.6 mp -87.31 96.04 10.21 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 107.838 -1.171 . . . . 2.66 107.838 170.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.692 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 8.1 tpt180 -99.97 172.11 7.42 Favored 'General case' 0 N--CA 1.431 -1.42 0 CA-C-N 116.032 -0.531 . . . . 7.01 111.98 -165.238 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.692 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 34.0 t-20 71.18 57.5 0.2 Allowed 'General case' 0 CA--C 1.514 -0.409 0 CA-C-N 114.973 -1.012 . . . . 4.38 110.417 170.409 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.652 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -117.04 -48.27 0.45 Allowed Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 119.389 -1.386 . . . . 1.7 111.244 171.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.652 HG13 ' O ' ' A' ' 16' ' ' GLY . 2.3 mt -170.02 133.67 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 124.571 1.149 . . . . 1.05 109.564 154.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 11.4 m -96.8 112.36 24.14 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 120.897 -0.321 . . . . 1.28 110.19 170.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.6 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 43.3 m-85 -95.68 126.34 45.69 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.495 -0.32 . . . . 0.67 110.24 177.068 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -80.65 96.96 1.0 Allowed 'Trans proline' 0 N--CA 1.445 -1.335 0 C-N-CA 121.027 1.151 . . . . 0.48 109.133 166.174 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 135.5 -113.08 1.06 Allowed Glycine 0 N--CA 1.448 -0.527 0 N-CA-C 111.266 -0.734 . . . . 0.59 111.266 -170.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.7 pt -142.79 156.43 18.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-O 121.062 0.458 . . . . 1.2 111.87 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . 0.5 ' HB3' ' HB2' ' A' ' 27' ' ' TYR . 5.8 m -107.04 132.08 53.36 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 108.679 -0.86 . . . . 1.44 108.679 172.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 10.6 ptm180 -118.12 -41.1 2.9 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 118.976 -1.09 . . . . 5.09 111.315 175.171 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.508 ' HA ' ' H ' ' A' ' 27' ' ' TYR . 0.0 OUTLIER 173.78 158.61 0.31 Allowed Pre-proline 0 CA--C 1.533 0.303 0 C-N-CA 122.644 0.377 . . . . 3.77 111.44 168.449 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.432 ' HA ' ' HB2' ' A' ' 25' ' ' ARG . 2.5 Cg_endo -86.8 99.07 0.22 Allowed 'Cis proline' 0 N--CA 1.458 -0.594 0 C-N-CA 122.652 -1.811 . . . . 1.34 110.681 -6.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.52 ' CE1' HD12 ' A' ' 17' ' ' ILE . 64.2 m-85 -162.9 134.75 5.19 Favored 'General case' 0 CA--C 1.504 -0.79 0 N-CA-C 108.116 -1.068 . . . . 0.64 108.116 -175.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 13.0 p90 -108.68 128.33 54.76 Favored 'General case' 0 C--N 1.301 -1.507 0 C-N-CA 120.289 -0.564 . . . . 0.71 109.769 177.17 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' TRP . . . . . 0.711 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 89.2 t90 -65.0 114.73 4.77 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.053 -0.976 . . . . 0.54 110.877 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.513 ' O ' ' HB2' ' A' ' 11' ' ' CYS . 20.7 pt -122.15 95.88 3.75 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 115.048 -0.978 . . . . 0.72 109.783 173.658 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 62.84 -161.22 32.77 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 120.991 -0.623 . . . . 0.47 113.089 -179.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 19.7 p -117.17 170.1 8.94 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 112.842 0.682 . . . . 0.62 112.842 -175.01 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 19.7 t -143.59 -174.98 4.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.875 -1.057 . . . . 1.07 108.839 -175.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.458 ' O ' ' HB2' ' A' ' 35' ' ' ASN . 75.1 m-20 68.68 -85.02 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 122.692 0.397 . . . . 1.54 110.763 -178.545 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.458 ' HB2' ' O ' ' A' ' 34' ' ' ASN . 21.8 t-20 169.24 78.55 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.285 0 C-N-CA 123.799 0.84 . . . . 2.54 109.212 -179.591 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 105.41 -56.47 0.53 Allowed Glycine 0 N--CA 1.453 -0.221 0 N-CA-C 111.123 -0.791 . . . . 1.12 111.123 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.513 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 0.4 OUTLIER -84.41 -137.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 N-CA-C 108.885 -0.783 . . . . 1.87 108.885 170.503 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.513 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 67.07 115.99 0.02 OUTLIER Glycine 0 C--N 1.339 0.732 0 C-N-CA 120.881 -0.676 . . . . 0.79 114.045 175.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.6 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 77.5 p -93.64 98.91 11.46 Favored 'General case' 0 N--CA 1.434 -1.241 0 N-CA-C 109.006 -0.739 . . . . 1.25 109.006 173.294 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 44.5 t -69.91 108.41 3.99 Favored 'General case' 0 CA--C 1.507 -0.707 0 N-CA-C 107.97 -1.122 . . . . 0.87 107.97 176.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.711 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 80.2 m -130.44 173.88 10.41 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 109.297 -0.631 . . . . 1.02 109.297 179.036 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.612 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -135.58 142.74 45.36 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 120.381 -0.528 . . . . 0.55 110.264 172.217 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.445 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 74.4 ttt180 -62.37 112.19 2.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.259 -0.882 . . . . 3.86 111.484 -173.615 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.88 -151.71 21.06 Favored Glycine 0 N--CA 1.446 -0.649 0 CA-C-N 114.712 -1.131 . . . . 1.54 111.797 -179.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 32.8 t-105 -149.43 119.86 7.39 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.045 0.45 . . . . 1.55 111.004 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.508 ' HD2' ' O ' ' A' ' 6' ' ' ARG . 0.3 OUTLIER -77.19 138.83 39.69 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.782 -0.645 . . . . 3.53 110.015 175.55 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.441 ' HA ' ' HB3' ' A' ' 5' ' ' PRO . 31.1 p . . . . . 0 C--O 1.251 1.14 0 O-C-N 124.314 1.009 . . . . 4.01 111.594 -178.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.418 ' HA ' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.474 0.753 0 CA-C-O 120.659 0.266 . . . . 6.64 111.001 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 1' ' ' PCA . 5.8 Cg_exo -76.95 -46.18 0.16 Allowed 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.693 2.262 . . . . 6.85 109.838 175.701 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 13.1 p90 -99.44 165.63 11.56 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.573 -1.269 . . . . 5.56 107.573 170.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.577 ' O ' ' HG3' ' A' ' 6' ' ' ARG . 51.1 mm -93.25 122.2 63.71 Favored Pre-proline 0 C--N 1.317 -0.834 0 C-N-CA 120.774 -0.37 . . . . 6.59 110.227 178.289 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 10.0 Cg_endo -53.13 109.23 0.33 Allowed 'Trans proline' 0 C--N 1.348 0.514 0 C-N-CA 122.727 2.285 . . . . 4.3 111.91 176.462 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.577 ' HG3' ' O ' ' A' ' 4' ' ' ILE . 67.9 mtp180 -108.02 166.47 10.88 Favored Pre-proline 0 C--N 1.319 -0.756 0 CA-C-N 115.527 -0.76 . . . . 7.04 109.328 178.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -52.1 140.4 50.45 Favored 'Trans proline' 0 C--O 1.236 0.412 0 C-N-CA 122.308 2.006 . . . . 5.21 111.896 173.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.57 ' HA ' ' HD2' ' A' ' 46' ' ' ARG . 2.6 mp -63.2 115.72 2.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.808 -0.633 . . . . 4.18 111.02 -178.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.481 ' O ' HG22 ' A' ' 30' ' ' ILE . 65.9 m-20 -98.8 165.93 11.55 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.443 -0.798 . . . . 3.25 109.777 176.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.422 ' C ' ' H ' ' A' ' 12' ' ' ARG . 26.9 p -79.6 -175.68 4.93 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.117 -0.492 . . . . 1.72 111.071 175.332 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.405 ' HB2' ' O ' ' A' ' 30' ' ' ILE . 12.5 t -55.74 -0.85 0.04 OUTLIER 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 123.68 0.792 . . . . 1.04 112.209 179.552 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.422 ' H ' ' C ' ' A' ' 10' ' ' THR . 12.9 ptm180 -54.74 -41.84 70.87 Favored 'General case' 0 C--O 1.234 0.237 0 C-N-CA 122.812 0.445 . . . . 4.23 111.446 173.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -86.29 96.41 9.95 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 106.991 -1.485 . . . . 2.66 106.991 171.338 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.664 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 18.2 tpp85 -100.31 157.44 16.61 Favored 'General case' 0 N--CA 1.429 -1.507 0 N-CA-C 114.041 1.126 . . . . 7.01 114.041 -157.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.664 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 64.7 t30 70.04 69.67 0.22 Allowed 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 113.822 -1.535 . . . . 4.38 112.348 164.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.722 ' HA3' ' HA ' ' A' ' 42' ' ' ALA . . . -108.01 -43.82 1.26 Allowed Glycine 0 N--CA 1.432 -1.63 0 N-CA-C 109.659 -1.376 . . . . 1.7 109.659 165.055 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.634 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.1 mt -165.89 132.87 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 C-N-CA 124.349 1.06 . . . . 1.05 109.258 157.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 21.5 t -91.88 109.3 20.64 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.109 -0.33 . . . . 1.28 110.109 175.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.412 ' CD1' ' SG ' ' A' ' 23' ' ' CYS . 15.4 m-85 -96.13 122.39 58.19 Favored Pre-proline 0 CA--C 1.516 -0.346 0 N-CA-C 112.125 0.417 . . . . 0.67 112.125 -177.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -81.92 96.47 0.91 Allowed 'Trans proline' 0 N--CA 1.448 -1.185 0 C-N-CA 121.513 1.475 . . . . 0.48 109.816 167.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 136.26 -119.87 2.09 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 111.067 -0.813 . . . . 0.59 111.067 -171.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.8 pt -138.14 154.4 28.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 117.131 0.466 . . . . 1.2 111.735 -179.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . 0.412 ' SG ' ' CD1' ' A' ' 19' ' ' PHE . 69.0 m -101.43 139.85 36.53 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 115.622 -0.717 . . . . 1.44 109.813 173.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.733 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 13.6 ptm180 -135.5 -39.42 0.73 Allowed 'General case' 0 C--N 1.321 -0.646 0 C-N-CA 119.733 -0.787 . . . . 5.09 112.612 179.028 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.733 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 12.0 mmt180 176.88 140.17 0.23 Allowed Pre-proline 0 N--CA 1.476 0.86 0 C-N-CA 123.104 0.561 . . . . 3.77 110.827 178.245 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.433 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 4.1 Cg_exo -90.42 99.94 0.21 Allowed 'Cis proline' 0 N--CA 1.456 -0.681 0 C-N-CA 123.44 -1.483 . . . . 1.34 110.371 -13.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.488 ' CD1' ' HA ' ' A' ' 43' ' ' ARG . 96.7 m-85 -161.01 131.4 5.15 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 108.829 -0.804 . . . . 0.64 108.829 -176.535 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -109.2 127.51 54.28 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 109.081 -0.711 . . . . 0.71 109.081 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' TRP . . . . . 0.584 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 86.6 t90 -70.56 117.18 11.76 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.067 -0.969 . . . . 0.54 110.985 -175.19 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.481 HG22 ' O ' ' A' ' 9' ' ' ASP . 16.2 pt -120.75 95.6 3.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.328 -0.851 . . . . 0.72 110.019 176.213 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 61.12 -164.64 17.9 Favored Glycine 0 CA--C 1.524 0.65 0 C-N-CA 121.284 -0.484 . . . . 0.47 113.24 -179.574 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.2 p -111.57 151.98 28.1 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 113.073 0.768 . . . . 0.62 113.073 -175.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.408 ' HB2' ' HB2' ' A' ' 40' ' ' CYS . 49.9 t -122.17 -177.07 3.5 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 107.154 -1.425 . . . . 1.07 107.154 175.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 58.54 -161.44 0.25 Allowed 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 118.866 0.757 . . . . 1.54 110.506 -178.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 92.0 m-20 -109.49 78.16 1.11 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.793 0.33 . . . . 2.54 111.104 -179.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 108.69 -52.18 0.66 Allowed Glycine 0 CA--C 1.509 -0.31 0 N-CA-C 111.149 -0.78 . . . . 1.12 111.149 176.035 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.413 HG12 ' H ' ' A' ' 37' ' ' ILE . 8.6 pt -77.46 -143.14 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 114.849 -0.676 . . . . 1.87 109.474 170.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.407 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 76.04 103.58 0.13 Allowed Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.442 -0.885 . . . . 0.79 113.031 168.399 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 38.2 m -84.04 98.71 10.0 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.898 -0.779 . . . . 1.25 108.898 172.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.408 ' HB2' ' HB2' ' A' ' 33' ' ' CYS . 42.7 t -72.65 106.08 4.53 Favored 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 107.884 -1.154 . . . . 0.87 107.884 175.441 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.584 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 37.0 m -126.9 174.56 8.72 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 121.12 0.486 . . . . 1.02 109.771 178.191 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.722 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -130.17 139.47 50.85 Favored 'General case' 0 N--CA 1.432 -1.332 0 C-N-CA 120.132 -0.627 . . . . 0.55 109.849 172.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.488 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 61.3 ttp180 -61.34 110.96 1.57 Allowed 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 115.567 -0.742 . . . . 3.86 111.29 -173.349 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 135.76 -158.93 24.04 Favored Glycine 0 N--CA 1.437 -1.237 0 CA-C-N 114.771 -1.104 . . . . 1.54 111.952 -178.489 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.431 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 28.7 t-105 -143.71 116.98 9.0 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.867 -0.419 . . . . 1.55 109.867 -179.13 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.57 ' HD2' ' HA ' ' A' ' 8' ' ' ILE . 12.5 ttm180 -88.63 136.99 32.72 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.458 -0.337 . . . . 3.53 110.265 179.408 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 8.1 t . . . . . 0 C--O 1.249 1.065 0 O-C-N 123.948 0.78 . . . . 4.01 110.042 -177.663 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.404 ' HA ' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.475 0.79 0 CA-C-O 120.504 0.193 . . . . 6.64 110.628 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 1' ' ' PCA . 3.2 Cg_exo -74.6 -25.14 13.04 Favored 'Trans proline' 0 C--N 1.347 0.477 0 C-N-CA 122.685 2.257 . . . . 6.85 109.888 178.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -125.92 164.13 21.45 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 107.708 -1.219 . . . . 5.56 107.708 172.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 6.2 tp -88.91 110.27 36.52 Favored Pre-proline 0 C--N 1.321 -0.67 0 N-CA-C 109.815 -0.439 . . . . 6.59 109.815 175.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.538 ' HB3' ' H ' ' A' ' 47' ' ' SER . 70.0 Cg_exo -38.68 109.07 0.08 OUTLIER 'Trans proline' 0 C--N 1.354 0.859 0 C-N-CA 123.629 2.886 . . . . 4.3 113.964 179.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 38.6 mtm105 -95.02 164.98 17.94 Favored Pre-proline 0 C--N 1.321 -0.669 0 N-CA-C 108.9 -0.778 . . . . 7.04 108.9 176.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 96.8 Cg_exo -44.51 128.74 8.49 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.296 1.997 . . . . 5.21 111.154 171.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.471 ' HA ' ' CD ' ' A' ' 46' ' ' ARG . 56.8 mt -61.6 119.48 5.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.871 -0.604 . . . . 4.18 111.678 -171.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 57.4 m-20 -84.3 163.28 19.71 Favored 'General case' 0 CA--C 1.513 -0.461 0 CA-C-N 115.462 -0.79 . . . . 3.25 109.503 177.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.444 ' C ' ' H ' ' A' ' 12' ' ' ARG . 11.2 p -84.01 -175.69 5.92 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.626 -0.715 . . . . 1.72 110.593 176.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.453 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 37.0 t -56.05 1.62 0.02 OUTLIER 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 122.878 0.471 . . . . 1.04 112.153 178.468 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.444 ' H ' ' C ' ' A' ' 10' ' ' THR . 14.5 ptt180 -55.79 -34.97 65.77 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 120.577 0.227 . . . . 4.23 110.842 171.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -89.78 97.53 11.25 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 107.797 -1.186 . . . . 2.66 107.797 168.324 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.72 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 8.3 tpt180 -109.71 171.59 7.36 Favored 'General case' 0 N--CA 1.433 -1.306 0 CA-C-O 120.971 0.415 . . . . 7.01 112.007 -166.501 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.72 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 92.1 m-20 72.04 51.92 0.21 Allowed 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 115.215 -0.902 . . . . 4.38 111.052 173.525 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.67 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -109.17 -47.75 0.86 Allowed Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.619 -1.277 . . . . 1.7 110.87 170.419 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.67 HG13 ' O ' ' A' ' 16' ' ' GLY . 3.3 mt -168.99 138.58 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 124.548 1.139 . . . . 1.05 109.56 156.001 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 15.4 t -99.74 104.18 15.88 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.967 -0.382 . . . . 1.28 109.967 170.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.566 ' HD1' ' SG ' ' A' ' 23' ' ' CYS . 33.4 m-85 -92.37 131.45 34.46 Favored Pre-proline 0 CA--C 1.514 -0.424 0 CA-C-N 116.53 -0.305 . . . . 0.67 110.903 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -87.5 96.12 0.45 Allowed 'Trans proline' 0 N--CA 1.443 -1.466 0 C-N-CA 121.171 1.247 . . . . 0.48 109.744 165.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.75 -114.52 0.91 Allowed Glycine 0 N--CA 1.446 -0.658 0 CA-C-N 115.638 -0.71 . . . . 0.59 111.75 -173.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -140.28 141.75 32.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 121.25 0.547 . . . . 1.2 112.111 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . 0.566 ' SG ' ' HD1' ' A' ' 19' ' ' PHE . 79.4 m -95.55 134.88 37.91 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-N 115.533 -0.758 . . . . 1.44 109.604 172.359 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.447 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 15.0 ptm180 -136.38 -37.92 0.69 Allowed 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 120.046 -0.662 . . . . 5.09 112.597 178.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.447 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 8.2 mtt180 176.32 146.48 0.26 Allowed Pre-proline 0 N--CA 1.47 0.573 0 N-CA-C 112.295 0.48 . . . . 3.77 112.295 175.043 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -86.83 98.52 0.21 Allowed 'Cis proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.455 -1.894 . . . . 1.34 110.049 -11.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.64 ' CE1' HD12 ' A' ' 17' ' ' ILE . 89.4 m-85 -162.53 133.47 4.94 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.658 -0.867 . . . . 0.64 108.658 -174.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -109.1 127.36 54.09 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 109.229 -0.656 . . . . 0.71 109.229 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' TRP . . . . . 0.6 ' HA ' ' SG ' ' A' ' 41' ' ' CYS . 76.4 t90 -68.66 114.24 6.86 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 114.955 -1.021 . . . . 0.54 110.155 -178.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.457 HG12 ' HA ' ' A' ' 41' ' ' CYS . 18.1 pt -120.98 93.71 2.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 121.669 0.747 . . . . 0.72 109.981 176.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 65.08 -172.46 21.2 Favored Glycine 0 CA--C 1.524 0.621 0 CA-C-N 115.799 -0.637 . . . . 0.47 113.049 -175.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 19.8 p -105.46 159.41 15.95 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.091 0.472 . . . . 0.62 111.989 -174.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.407 ' SG ' ' N ' ' A' ' 34' ' ' ASN . 48.7 t -121.92 -178.37 3.83 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.36 -0.607 . . . . 1.07 109.36 177.258 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.461 ' ND2' ' HA3' ' A' ' 38' ' ' GLY . 7.6 m-20 57.84 -145.53 0.58 Allowed 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.451 -0.574 . . . . 1.54 109.451 -172.403 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 35.0 m-80 -83.31 -1.09 52.42 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 120.617 0.246 . . . . 2.54 111.11 175.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 153.63 -35.73 0.74 Allowed Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 119.817 -1.182 . . . . 1.12 114.54 176.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -80.15 -32.34 13.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 113.033 0.753 . . . . 1.87 113.033 -172.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.461 ' HA3' ' ND2' ' A' ' 34' ' ' ASN . . . -68.83 172.03 37.22 Favored Glycine 0 N--CA 1.442 -0.947 0 C-N-CA 120.441 -0.885 . . . . 0.79 111.697 177.086 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.477 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 68.5 p -117.69 124.07 47.62 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.224 0.535 . . . . 1.25 111.252 -174.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 42.0 t -83.9 104.26 13.84 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 107.592 -1.262 . . . . 0.87 107.592 172.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.6 ' SG ' ' HA ' ' A' ' 29' ' ' TRP . 29.6 m -127.38 174.77 8.72 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 109.852 -0.425 . . . . 1.02 109.852 178.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.655 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -136.37 143.01 43.82 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 119.923 -0.711 . . . . 0.55 111.077 173.186 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.468 ' C ' ' HD3' ' A' ' 43' ' ' ARG . 3.4 tmt_? -61.54 112.13 2.09 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-N 115.062 -0.972 . . . . 3.86 110.466 -177.376 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 141.36 -159.33 26.7 Favored Glycine 0 N--CA 1.439 -1.116 0 CA-C-N 115.11 -0.95 . . . . 1.54 111.112 178.252 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.46 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 31.9 t-105 -148.0 119.15 7.74 Favored 'General case' 0 C--N 1.314 -0.942 0 C-N-CA 120.47 -0.492 . . . . 1.55 111.002 -179.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.471 ' CD ' ' HA ' ' A' ' 8' ' ' ILE . 23.8 ttm180 -107.63 145.62 33.07 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 115.787 -0.642 . . . . 3.53 110.007 172.267 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.538 ' H ' ' HB3' ' A' ' 5' ' ' PRO . 17.1 t . . . . . 0 C--O 1.249 1.028 0 O-C-N 124.372 1.045 . . . . 4.01 110.02 -176.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.405 ' HA ' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.475 0.808 0 CA-C-O 120.399 0.142 . . . . 6.64 110.701 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 1' ' ' PCA . 6.2 Cg_exo -77.2 -23.67 10.14 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.805 2.336 . . . . 6.85 110.305 177.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 9.0 p90 -127.83 166.1 18.88 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-N 114.212 -1.358 . . . . 5.56 107.667 175.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.629 ' O ' ' HG3' ' A' ' 6' ' ' ARG . 6.2 tp -95.07 113.69 62.0 Favored Pre-proline 0 C--N 1.317 -0.815 0 C-N-CA 120.528 -0.469 . . . . 6.59 109.851 175.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.464 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 1.7 Cg_endo -44.72 124.71 5.77 Favored 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 123.006 2.471 . . . . 4.3 112.765 176.089 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.629 ' HG3' ' O ' ' A' ' 4' ' ' ILE . 79.8 mtp180 -124.94 163.13 39.39 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-N 115.532 -0.758 . . . . 7.04 109.627 -177.147 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_exo -51.35 128.47 25.68 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.494 2.129 . . . . 5.21 112.537 178.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 71.0 mt -82.9 116.06 26.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 CA-C-N 115.112 -0.949 . . . . 4.18 109.921 178.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -130.36 165.9 21.56 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.401 -0.363 . . . . 3.25 110.136 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 7.7 p -57.95 -176.93 0.03 OUTLIER 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 112.743 0.645 . . . . 1.72 112.743 177.202 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.454 ' SG ' ' HD3' ' A' ' 14' ' ' ARG . 22.9 t -58.03 4.04 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.528 1.131 . . . . 1.04 113.294 -171.212 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.522 ' HG3' HD22 ' A' ' 13' ' ' LEU . 5.0 ptp180 -57.6 -31.22 65.98 Favored 'General case' 0 CA--C 1.534 0.364 0 N-CA-C 108.735 -0.839 . . . . 4.23 108.735 167.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.726 ' O ' HD12 ' A' ' 30' ' ' ILE . 3.7 mm? -88.78 122.08 31.81 Favored 'General case' 0 N--CA 1.451 -0.401 0 N-CA-C 106.789 -1.559 . . . . 2.66 106.789 161.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.689 ' HG3' ' N ' ' A' ' 15' ' ' ASN . 13.0 tpt180 -131.21 170.54 14.43 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 112.707 0.632 . . . . 7.01 112.707 -168.737 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . 0.689 ' N ' ' HG3' ' A' ' 14' ' ' ARG . 94.3 m-20 72.35 66.4 0.13 Allowed 'General case' 0 CA--C 1.512 -0.512 0 CA-C-N 114.775 -1.102 . . . . 4.38 112.86 169.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.706 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -130.67 -47.91 0.13 Allowed Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 119.632 -1.27 . . . . 1.7 111.551 167.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.706 HG13 ' O ' ' A' ' 16' ' ' GLY . 4.3 mt -169.13 133.98 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.465 1.106 . . . . 1.05 109.9 159.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 6.3 t -96.94 124.04 40.81 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.978 -0.379 . . . . 1.28 109.978 172.023 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.537 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 23.3 m-85 -105.93 127.71 27.85 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 116.471 -0.331 . . . . 0.67 111.009 179.499 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.521 ' HA ' HD21 ' A' ' 34' ' ' ASN . 57.6 Cg_endo -74.48 97.95 1.08 Allowed 'Trans proline' 0 N--CA 1.452 -0.957 0 C-N-CA 121.3 1.333 . . . . 0.48 109.591 167.055 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.585 ' H ' ' HA2' ' A' ' 38' ' ' GLY . . . 133.04 -124.34 3.73 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.489 -0.778 . . . . 0.59 111.259 -171.415 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 16.0 pt -142.85 146.95 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-N 117.069 0.434 . . . . 1.2 111.523 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . 0.45 ' SG ' ' CD1' ' A' ' 19' ' ' PHE . 22.6 m -86.18 147.19 26.24 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 115.94 -0.573 . . . . 1.44 111.455 177.163 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.61 ' O ' ' HG2' ' A' ' 25' ' ' ARG . 16.3 ptm180 -141.55 -37.34 0.42 Allowed 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 112.551 0.574 . . . . 5.09 112.551 176.281 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.61 ' HG2' ' O ' ' A' ' 24' ' ' ARG . 10.2 mmt180 177.32 142.19 0.25 Allowed Pre-proline 0 N--CA 1.478 0.96 0 C-N-CA 122.737 0.415 . . . . 3.77 111.193 178.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.569 ' HD2' ' CE2' ' A' ' 27' ' ' TYR . 24.2 Cg_endo -91.35 98.35 0.16 OUTLIER 'Cis proline' 0 C--N 1.349 0.593 0 C-N-CA 122.792 -1.753 . . . . 1.34 111.704 -10.403 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.569 ' CE2' ' HD2' ' A' ' 26' ' ' PRO . 80.9 m-85 -161.53 143.89 11.94 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.695 -0.854 . . . . 0.64 108.695 -172.194 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . . . . . . . . . 11.0 p90 -111.07 127.76 55.65 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 109.008 -0.738 . . . . 0.71 109.008 175.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 84.6 t90 -68.5 113.35 5.96 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 115.144 -0.935 . . . . 0.54 110.126 -178.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.726 HD12 ' O ' ' A' ' 13' ' ' LEU . 12.1 pt -119.27 94.35 3.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 109.242 -0.651 . . . . 0.72 109.242 174.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 65.24 -173.2 20.21 Favored Glycine 0 CA--C 1.524 0.612 0 CA-C-N 115.962 -0.563 . . . . 0.47 113.079 -177.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.1 p -108.57 161.78 14.75 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 122.27 -0.547 . . . . 0.62 112.047 -176.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 39.1 t -130.98 178.97 6.27 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 116.102 -0.499 . . . . 1.07 110.299 -177.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.521 HD21 ' HA ' ' A' ' 20' ' ' PRO . 1.7 m-20 63.8 -82.48 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.313 1.045 . . . . 1.54 110.791 -174.251 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 54.5 m-80 -151.57 26.67 0.66 Allowed 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.364 -0.606 . . . . 2.54 109.364 -178.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 107.8 -20.34 31.75 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.752 -0.737 . . . . 1.12 112.944 179.685 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.586 ' H ' HD12 ' A' ' 37' ' ' ILE . 0.2 OUTLIER -81.09 -58.4 3.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 O-C-N 122.511 -0.405 . . . . 1.87 111.293 -177.791 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.585 ' HA2' ' H ' ' A' ' 21' ' ' GLY . . . -69.18 174.9 33.19 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.966 -0.635 . . . . 0.79 112.198 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.537 ' OG ' ' HB2' ' A' ' 19' ' ' PHE . 77.3 p -108.54 125.74 52.16 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-O 121.392 0.615 . . . . 1.25 111.499 -173.24 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 41.4 t -82.54 113.35 20.2 Favored 'General case' 0 N--CA 1.442 -0.86 0 N-CA-C 106.67 -1.604 . . . . 0.87 106.67 169.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.537 ' HA ' HG12 ' A' ' 30' ' ' ILE . 28.2 m -132.0 177.24 7.7 Favored 'General case' 0 C--N 1.311 -1.085 0 CA-C-O 121.421 0.629 . . . . 1.02 110.703 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.671 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -135.53 137.6 42.23 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.513 -0.767 . . . . 0.55 109.618 167.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.508 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 4.3 tmt_? -60.7 113.41 2.46 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 115.378 -0.828 . . . . 3.86 110.778 -174.741 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 134.62 -150.99 20.23 Favored Glycine 0 N--CA 1.438 -1.183 0 CA-C-N 115.252 -0.886 . . . . 1.54 112.072 176.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 26.0 t-105 -145.51 124.74 12.95 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.369 -0.604 . . . . 1.55 109.369 179.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . . . . . . . . . 19.5 ttm180 -102.42 128.75 48.88 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 120.978 0.418 . . . . 3.53 110.929 176.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 18.5 m . . . . . 0 C--O 1.249 1.075 0 CA-C-N 114.145 -1.388 . . . . 4.01 112.289 178.171 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' PCA . . . . . 0.422 ' HA ' ' HD3' ' A' ' 2' ' ' PRO . . . . . . . . 0 N--CA 1.475 0.807 0 N-CA-C 110.734 -0.098 . . . . 6.64 110.734 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 1' ' ' PCA . 3.2 Cg_exo -80.44 -19.44 8.95 Favored 'Trans proline' 0 C--N 1.349 0.569 0 C-N-CA 122.722 2.281 . . . . 6.85 110.073 175.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 14.3 p90 -136.59 163.06 31.43 Favored 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 107.297 -1.372 . . . . 5.56 107.297 175.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.461 ' HA ' ' HD2' ' A' ' 5' ' ' PRO . 6.0 tp -88.04 114.81 60.92 Favored Pre-proline 0 C--N 1.319 -0.758 0 C-N-CA 120.513 -0.475 . . . . 6.59 110.192 176.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . 0.461 ' HD2' ' HA ' ' A' ' 4' ' ' ILE . 9.6 Cg_endo -51.47 133.76 44.07 Favored 'Trans proline' 0 C--N 1.351 0.66 0 C-N-CA 123.169 2.579 . . . . 4.3 113.261 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.514 ' HB3' ' HD2' ' A' ' 7' ' ' PRO . 61.5 mtp180 -109.54 170.67 5.12 Favored Pre-proline 0 C--N 1.321 -0.644 0 CA-C-N 115.299 -0.864 . . . . 7.04 109.473 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.514 ' HD2' ' HB3' ' A' ' 6' ' ' ARG . 85.2 Cg_exo -43.97 132.16 8.34 Favored 'Trans proline' 0 C--N 1.352 0.755 0 C-N-CA 122.713 2.275 . . . . 5.21 112.663 175.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.592 ' HA ' ' HD2' ' A' ' 46' ' ' ARG . 61.9 mt -69.68 120.39 17.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.595 -0.729 . . . . 4.18 111.974 -176.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 36.2 m-20 -81.14 166.15 20.93 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.19 -0.913 . . . . 3.25 109.732 174.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.51 ' C ' ' H ' ' A' ' 12' ' ' ARG . 37.0 p -85.86 -171.24 3.49 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.183 -0.673 . . . . 1.72 109.183 174.03 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.583 ' O ' ' HG2' ' A' ' 14' ' ' ARG . 58.4 m -50.9 -1.52 0.01 OUTLIER 'General case' 0 CA--C 1.549 0.938 0 CA-C-O 121.076 0.465 . . . . 1.04 110.742 166.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.51 ' H ' ' C ' ' A' ' 10' ' ' THR . 12.0 ttt180 -32.74 -43.19 0.09 Allowed 'General case' 0 N--CA 1.463 0.176 0 C-N-CA 124.942 1.297 . . . . 4.23 110.834 163.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 8.8 mp -114.96 111.35 21.02 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 115.184 -0.917 . . . . 2.66 108.644 174.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.667 ' HD2' ' SG ' ' A' ' 40' ' ' CYS . 1.6 mmp_? -116.9 -171.19 1.98 Allowed 'General case' 0 CA--C 1.507 -0.682 0 N-CA-C 113.167 0.802 . . . . 7.01 113.167 -175.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 70.7 42.87 0.79 Allowed 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 114.492 -1.231 . . . . 4.38 109.63 -172.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.675 ' O ' HG13 ' A' ' 17' ' ' ILE . . . -106.43 -51.48 0.81 Allowed Glycine 0 N--CA 1.441 -0.971 0 C-N-CA 119.233 -1.46 . . . . 1.7 111.956 173.277 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.716 HD12 ' CE1' ' A' ' 27' ' ' TYR . 2.7 mt -173.33 150.77 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 C-N-CA 125.112 1.365 . . . . 1.05 108.914 157.14 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 9.2 t -110.89 108.28 18.02 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.263 -0.643 . . . . 1.28 109.263 166.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.643 ' HB2' ' OG ' ' A' ' 39' ' ' SER . 46.9 m-85 -94.36 132.99 27.85 Favored Pre-proline 0 CA--C 1.513 -0.47 0 CA-C-O 120.881 0.372 . . . . 0.67 111.184 -177.53 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -85.54 95.83 0.61 Allowed 'Trans proline' 0 N--CA 1.438 -1.793 0 N-CA-C 108.349 -1.443 . . . . 0.48 108.349 158.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 134.93 -130.6 5.53 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.26 -0.882 . . . . 0.59 110.973 -168.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 25.1 pt -135.87 148.48 27.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 121.521 0.677 . . . . 1.2 112.606 -176.527 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -87.78 123.35 32.49 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.053 -0.976 . . . . 1.44 109.308 169.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.464 ' O ' ' HG3' ' A' ' 25' ' ' ARG . 12.3 ptm180 -123.59 -38.24 2.55 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 119.579 -0.849 . . . . 5.09 112.335 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.464 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 11.5 mtt180 175.02 141.86 0.2 Allowed Pre-proline 0 N--CA 1.475 0.795 0 O-C-N 123.385 0.428 . . . . 3.77 111.88 171.154 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 25' ' ' ARG . 3.9 Cg_exo -88.55 99.84 0.23 Allowed 'Cis proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.715 -1.785 . . . . 1.34 110.567 -10.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.716 ' CE1' HD12 ' A' ' 17' ' ' ILE . 75.7 m-85 -161.74 128.54 3.86 Favored 'General case' 0 CA--C 1.506 -0.729 0 N-CA-C 108.883 -0.784 . . . . 0.64 108.883 -177.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' TYR . . . . . 0.458 ' CZ ' ' HB3' ' A' ' 42' ' ' ALA . 27.0 p90 -107.83 130.13 55.01 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-O 121.208 0.528 . . . . 0.71 110.205 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' TRP . . . . . . . . . . . . . 86.4 t90 -65.67 113.82 4.53 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.49 -1.232 . . . . 0.54 111.122 -178.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.487 HD11 HH21 ' A' ' 14' ' ' ARG . 4.7 pt -120.32 92.68 2.21 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.852 0 CA-C-N 115.66 -0.7 . . . . 0.72 109.383 171.728 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 66.18 -164.87 39.87 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 120.711 -0.757 . . . . 0.47 113.292 -177.389 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -114.46 160.11 19.56 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 112.518 0.562 . . . . 0.62 112.518 -174.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . . . . . . . . . 49.6 t -127.92 -176.37 3.76 Favored 'General case' 0 C--O 1.22 -0.485 0 N-CA-C 107.808 -1.182 . . . . 1.07 107.808 175.034 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 61.23 -155.87 0.35 Allowed 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 118.891 0.769 . . . . 1.54 109.884 -177.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 -111.05 88.54 2.81 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.806 0.336 . . . . 2.54 111.064 179.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 92.04 -47.86 2.7 Favored Glycine 0 CA--C 1.506 -0.49 0 N-CA-C 110.892 -0.883 . . . . 1.12 110.892 175.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ILE . . . . . 0.474 ' HB ' ' H ' ' A' ' 38' ' ' GLY . 4.7 pt -77.74 -147.7 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 114.397 -0.901 . . . . 1.87 109.79 170.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.474 ' H ' ' HB ' ' A' ' 37' ' ' ILE . . . 73.44 161.76 7.01 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 121.171 -0.538 . . . . 0.79 113.459 169.211 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.777 ' HB2' ' SG ' ' A' ' 41' ' ' CYS . 4.7 p -139.74 113.2 8.43 Favored 'General case' 0 N--CA 1.436 -1.171 0 CA-C-O 121.928 0.87 . . . . 1.25 111.4 177.638 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . 0.667 ' SG ' ' HD2' ' A' ' 14' ' ' ARG . 36.5 t -77.95 98.12 5.56 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 106.957 -1.497 . . . . 0.87 106.957 172.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . 0.777 ' SG ' ' HB2' ' A' ' 39' ' ' SER . 12.3 m -132.72 141.86 48.76 Favored 'General case' 0 C--N 1.32 -0.687 0 O-C-N 121.946 -0.471 . . . . 1.02 109.832 -174.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.497 ' HA ' ' HA3' ' A' ' 16' ' ' GLY . . . -100.69 139.8 35.87 Favored 'General case' 0 C--N 1.316 -0.848 0 C-N-CA 120.258 -0.577 . . . . 0.55 111.495 -176.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.509 ' HA ' ' CD1' ' A' ' 27' ' ' TYR . 4.0 tmt_? -62.04 107.99 0.97 Allowed 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 115.258 -0.883 . . . . 3.86 110.245 179.11 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 138.5 -170.77 23.77 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.417 -0.81 . . . . 1.54 111.293 -178.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.527 ' HZ3' ' O ' ' A' ' 27' ' ' TYR . 23.9 t-105 -135.3 118.67 16.75 Favored 'General case' 0 N--CA 1.442 -0.842 0 C-N-CA 120.271 -0.571 . . . . 1.55 110.898 -179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ARG . . . . . 0.592 ' HD2' ' HA ' ' A' ' 8' ' ' ILE . 15.7 ttm180 -112.6 144.83 41.42 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 115.789 -0.641 . . . . 3.53 110.338 176.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.439 ' H ' ' HB3' ' A' ' 5' ' ' PRO . 16.3 t . . . . . 0 C--O 1.247 0.941 0 CA-C-O 118.06 -0.971 . . . . 4.01 110.652 -179.103 . . . . . . . . 1 1 . 1 stop_ save_